1 | (+)-(S)-2-(6-methoxynaphthalen-2-yl) propanoic acid | 1件: Propanoic acid Propanoic acid | - | - | - | 1件: 271 271 💬 |
2 | (-)-3-(4-Aminophenyl)-2-methoxypropionic acid | - | - | - | - | 1件: 97 97 💬 |
3 | (1R,3S,5R)-2-(2-(3-acetyl-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl)acetyl)-N-(6-bromo-3-methylpyridin-2-yl)-5-methyl-2-azabicyclo[3.1.0]hexane-3-carboxamide | - | - | - | - | 1件: 11 11 💬 |
4 | (2-chloro-5-[11C]methoxy-N-(((3s,5s,7s)-3,5,7-trifluoroadamantan-1-yl)methyl) benzamide) | - | - | - | - | 1件: 6 6 💬 |
5 | (2S)-2-[(4R)-2-oxo-4-propylpyrrolidin-1-y1] butanamide | - | - | - | - | 1件: 309 309 💬 |
6 | (2S)-2-[(4R)-2-oxo-4-propylpyrrolidin-1-yl] butanamide | - | - | - | - | 1件: 309 309 💬 |
7 | (3R,4R)-4-methyl-3-(methyl-1H-pyrrolo [2,3-d]pyrimidin-4-ylamino)-beta-oxo-1- | - | - | - | - | 1件: 46 46 💬 |
8 | (3R,4R)-4-methyl-3-(methyl-1H-pyrrolo [2,3-d]pyrimidin-4-ylamino)-beta-oxo-1-piperidinepropanenitrile, | - | - | - | - | 1件: 46 46 💬 |
9 | (3R,4R)-4-methyl-3-(methyl-1H-pyrrolo [2,3-d]pyrimidin-4-ylamino)-ß-oxo-1- | - | - | - | - | 1件: 46 46 💬 |
10 | (3R,4R)-4-methyl-3-(methyl-1H-pyrrolo [2,3-d]pyrimidin-4-ylamino)-ß-oxo-1-piperidinepropanenitrile, | - | - | - | - | 1件: 46 46 💬 |
11 | (3R,4R)-4-metil-3-(metil-1H-pirrolo [2,3-d]pirimidin-4-ilamino)-beta-oxo-1- | - | - | - | - | 1件: 46 46 💬 |
12 | (3R,4R)-4-metil-3-(metil-1H-pirrolo [2,3-d]pirimidin-4-ilamino)-ß-oxo-1- | - | - | - | - | 1件: 46 46 💬 |
13 | (4S)-4-[4-cyano-2-(methylsulfonyl)phenyl]-3,6-dimethyl-2-oxo-1-[3-(trifluoromethyl)phenyl]-1,2,3,4-tetrahydropyrimidine-5-carbonitrile | - | - | - | - | 1件: 231 231 💬 |
14 | (4S,5R)-5-[3,5-bis(trifluoromethyl)phenyl]-3-{[4’- | - | - | - | - | 1件: 79 79 💬 |
15 | (6R)-4, 5, 6, 7 - tetrahydro-N6-propyl-2,6-benzothiazolidiamine dihydrochloride monohydrate | - | - | - | - | 1件: 2 2 💬 |
16 | (6S)-6-{propyl-[2-[2-thienyl]ethyl]amino}-5,6,7,8-tetrahydro-1-naphtalenol | - | - | - | - | 1件: 6 6 💬 |
17 | (7R,8R,9R)-2.3-Dimethyl-8-hydroxy-7(2-methoxyethoxy)- 9-phenyl-7.8.9.10-tetrahydro-imidazo-[1.2-h].[1.7].- naphthyridine | - | - | - | - | 1件: 301 301 💬 |
18 | (E)-1-(4-((1R,2S,3R)-1,2,3,4-tetrahydroxybutyl)-1H-imidazol-2-yl)ethanone oxime | - | - | - | - | 1件: 161 161 💬 |
19 | (minus)-L-alpha-hydrazino-3,4-dihydroxy-alpha-methylbenzenepropanoic acid monohydrate | - | - | - | - | 1件: 6 6 💬 |
20 | (R) 3-(5-Dimethylcarbamoyl-pent-1-enyl)-N-(2-hydroxy-1- methylethyl) benzamide | - | - | - | - | 1件: 13 13 💬 |
21 | (R)-(1-(4-FLUOROPHENYL)-6-((1-METHYL-1H-PYRAZOL-4- | 1件: Pyrazole Pyrazole | - | - | - | 1件: 75 75 💬 |
22 | (R)-(1-(4-FLUOROPHENYL)-6-((1-METHYL-1H-PYRAZOL-4-YL)SULFONYL)-4,4A,5,6,7,8-HEXAHYDRO-1H-PYRAZOLO[3,4-G]ISOQUINOLIN-4A-YL)(4-(TRIFLUOROMETHYL)PYRIDIN-2-YL)METHANONE | 1件: Pyrazole Pyrazole | - | - | - | 1件: 75 75 💬 |
23 | (R)-(1-(4-FLUOROPHENYL)-6-((1-METHYL-1H-PYRAZOL-4-YL)SULFONYL)4,4A,5,6,7,8-HEXAHYDRO-1H-PYRAZOLO[3,4-G]ISOQUINOLIN-4A-YL)(4(TRIFLUOROMETHYL)PYRIDIN-2-YL)METHANONE | 1件: Pyrazole Pyrazole | - | - | - | 1件: 75 75 💬 |
24 | (R)-(1-(4-FLUOROPHENYL)-6-((1-METHYL-1H-PYRAZOL-4YL)SULFONYL)4,4A,5,6,7,8HEXAHYDRO-1H-PYRAZOLO[3,4-G]ISOQUINOLIN4AYL)(4(TRIFLUOROMETHYL)PYRIDIN-2-YL)METHANONE | 1件: Pyrazole Pyrazole | - | - | - | 1件: 75 75 💬 |
25 | (R)-3-(1-oxo-propoxy)-4-(N,N,N-trimethyl amonium chloride)-butanoic acid | 2件: Butyric Acid Butyric Acid, Chloride ion | - | - | - | 1件: 97 97 💬 |
26 | (R)-[N-metil-11C1-PK11195(PK) | - | - | - | - | 1件: 127 127 💬 |
27 | (R)-N-(5-(5-ETHYL-1,2,4-OXADIAZOL-3-YL)-2,3-DIHYDRO-1H-INDEN-1-YL)-1-METHYL-1H-PYRAZOLE-4-CARBOXAMIDE | 1件: Pyrazole Pyrazole | - | - | - | 1件: 58 58 💬 |
28 | (R)-N-(5-(5-ETHYL-1,2,4-OXADIAZOL-3-YL)-2,3-DIHYDRO-1H-INDEN-1-YL)-1METHYL-1H-PYRAZOLE-4-CARBOXAMIDE | 1件: Pyrazole Pyrazole | - | - | - | 1件: 58 58 💬 |
29 | (R)-N-(5-(5-ETHYL-1,2,4-OXADIAZOL-3-YL)-2,3-DIHYDRO-1H-INDEN-1-YL)-1METHYL-1HPYRAZOLE-4-CARBOXAMIDE | - | - | - | - | 1件: 58 58 💬 |
30 | (R)-tetrahydrofuran-3-yl 4-(6-(5-(4-ethoxy-1-isopropylpiperidin-4- yl)pyridine-2-yl)pyrrolo[1,2-b]pyridazin-4-yl)piperazine-1-carboxylate sesquisuccinate | 1件: Piperazine Piperazine | 1件: Piperazine
Piperazine
💬 | - | - | 1件: 272 272 💬 |
31 | (R)-tetrahydrofuran-3-yl 4-(6-(5-(4-ethoxy-1-isopropylpiperidin-4- yl)pyridine-2yl)pyrrolo[1,2-b]pyridazin-4-yl)piperazine-1-carboxylate | 1件: Piperazine Piperazine | 1件: Piperazine
Piperazine
💬 | - | - | 1件: 272 272 💬 |
32 | (RS)-baclofen, naltrexone hydrochloride and D-sorbitol | 3件: Baclofen Baclofen, Naltrexone, Sorbitol | 3件: Sorbitol solution
Sorbitol solution
,
Baclofen
,
Naltrexone
💬 | 5件: GABBR1 GABBR1, GABBR2, OPRD1, OPRK1, OPRM1 💬 | 9件: Estrogen signaling pathway Estrogen signaling pathway, GABAergic synapse, GnRH secretion, Morphine addiction, Neuroactive ligand-receptor interaction, Sphingolipid signaling pathway, Taste transduction, cAMP signaling pathway, cGMP-PKG signaling pathway 💬 | 1件: 10 10 💬 |
33 | (S)- 2- Amino- 4,5,6,7- tetrahydro- 6- (propylamino)benzothiazol | - | - | - | - | 1件: 6 6 💬 |
34 | (S)-(+)-2-(4-(3-fluorobenzyl)oxybenzyl)aminopropanamide methanesulfonate | - | - | - | - | 1件: 6 6 💬 |
35 | (S)-(-)-3-(4-Aminophenyl)-2-methoxypropionic Acid | - | - | - | - | 1件: 97 97 💬 |
36 | (S)-2-(4,6-dimethylpyrimidin-2-yloxy)-3-methoxy-3,3-diphenylpropanoic acid | - | - | - | - | 1件: 86 86 💬 |
37 | (S)-2-amino-6-(2-hydroxypropanoyl)-7,8-dihydropteridin-4(3H)-one | - | - | - | - | 1件: 240 240 💬 |
38 | (S)-3-((3-(1-((6-(3,4-DIMETHOXYPHENYL)PRYAZIN-2- YL)AMINO)ETHYL)PHENYL)CARBAMOYL)-5-METHYLPRIDIN-1-IUM | - | - | - | - | 1件: 86 86 💬 |
39 | (S)-3-((3-(1-((6-(3,4-DIMETHOXYPHENYL)PRYAZIN-2-YL)AMINO)ETHYL)PHENYL)CARBAMOYL)-5-METHYLPRIDIN-1-IUM | - | - | - | - | 1件: 86 86 💬 |
40 | (S)-4,5-dihydro-2-[2-hydroxy-3-(3,6,9-trioxadecyloxy)phenyl]-4-methyl-4-thiazo | - | - | - | - | 1件: 284 284 💬 |
41 | (S)-4,5-dihydro-2-[2-hydroxy-3-(3,6,9-trioxadecyloxy)phenyl]-4-methyl-4-thiazolecarboxylate magnesium hydroxide | 3件: Hydroxide ion Hydroxide ion, Magnesium, Magnesium hydroxide | 1件: Magnesium hydroxide
Magnesium hydroxide
💬 | - | - | 1件: 284 284 💬 |
42 | (S)-4,5-dihydro-2[hydroxy-3-(3,6,9-trioxadecyloxy)phenyl]-4-m | - | - | - | - | 1件: 284 284 💬 |
43 | (S)-4,5-dihydro-2[hydroxy-3-(3,6,9-trioxadecyloxy)phenyl]-4-methyl-4-thiazolecarboxylate magnesium hydroxide | 3件: Hydroxide ion Hydroxide ion, Magnesium, Magnesium hydroxide | 1件: Magnesium hydroxide
Magnesium hydroxide
💬 | - | - | 1件: 284 284 💬 |
44 | (S)-5-(3-(1-((2-hydroxyethyl)amino)-2,3-dihydro-1H-inden-4-yl)-1,2,4-oxadiazol-5- yl)-2-isopropoxybenzonitrile hydrochloride | - | - | - | - | 1件: 97 97 💬 |
45 | (S)-5-(3-(1-((2-hydroxyethyl)amino)-2,3-dihydro-1H-inden-4-yl)-1,2,4-oxadiazol-5-yl)-2-isopropoxyben | - | - | - | - | 1件: 97 97 💬 |
46 | (S)-5-(3-(1-((2-hydroxyethyl)amino)-2,3-dihydro-1H-inden-4-yl)-1,2,4-oxadiazol-5-yl)-2-isopropoxybenzonitrile hydrochloride | - | - | - | - | 1件: 97 97 💬 |
47 | * D.3.4 Solution for infusion in pre-filled syringe | - | - | - | - | 1件: 97 97 💬 |
48 | * D.3.4 Solution for injection in pre-filled syringe | - | - | - | - | 1件: 97 97 💬 |
49 | * D.3.4 Solution for injection/infusion in pre-filled syringe | - | - | - | - | 1件: 97 97 💬 |
50 | * D.3.6.2.1 - valore : Every 4 weeks dosing of 200 mg | - | - | - | - | 1件: 41 41 💬 |
51 | * D.3.6.2.1 - valore :Every 4 weeks dosing of 400 mg | - | - | - | - | 1件: 41 41 💬 |
52 | .Nusinersen | 1件: Nusinersen Nusinersen | 1件: Nusinersen
Nusinersen
💬 | 1件: SMN2 SMN2 💬 | - | 1件: 3 3 💬 |
53 | 0.005% Lacripep | - | - | - | - | 1件: 53 53 💬 |
54 | 0.01% Lacripep | - | - | - | - | 1件: 53 53 💬 |
55 | 0.02% Fm, SH | - | - | - | - | 1件: 53 53 💬 |
56 | 0.02% Fm, SH, 0.05% CsA | - | - | - | - | 1件: 53 53 💬 |
57 | 0.02% Fm, SH, AS | - | - | - | - | 1件: 53 53 💬 |
58 | 0.04 mg Lu AE04621 | - | - | - | - | 1件: 6 6 💬 |
59 | 0.05%cyclosporin eye drop | 1件: Cyclosporine Cyclosporine | 1件: Cyclosporine
Cyclosporine
💬 | 5件: PPP3CA PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 💬 | 33件: Alzheimer disease Alzheimer disease, Amphetamine addiction, Amyotrophic lateral sclerosis, Axon guidance, B cell receptor signaling pathway, C-type lectin receptor signaling pathway, Calcium signaling pathway, Cellular senescence, Dopaminergic synapse, Glucagon signaling pathway, Glutamatergic synapse, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Lipid and atherosclerosis, Long-term potentiation, MAPK signaling pathway, Natural killer cell mediated cytotoxicity, Oocyte meiosis, Osteoclast differentiation, Oxytocin signaling pathway, PD-L1 expression and PD-1 checkpoint pathway in cancer, Pathways of neurodegeneration - multiple diseases, Prion disease, Renin secretion, T cell receptor signaling pathway, Th1 and Th2 cell differentiation, Th17 cell differentiation, Tuberculosis, VEGF signaling pathway, Wnt signaling pathway, cGMP-PKG signaling pathway 💬 | 1件: 38 38 💬 |
60 | 0.08 mg Lu AE04621 | - | - | - | - | 1件: 6 6 💬 |
61 | 0.15mg KPG-818 dose | - | - | - | - | 1件: 49 49 💬 |
62 | 0.4 mg Lu AE04621 | - | - | - | - | 1件: 6 6 💬 |
63 | 0.4mL prefilled syringes | - | - | - | - | 1件: 107 107 💬 |
64 | 0.6 mg Lu AE04621 | - | - | - | - | 1件: 6 6 💬 |
65 | 0.6mg KPG-818 dose | - | - | - | - | 1件: 49 49 💬 |
66 | 0.8 mg Lu AE04621 | - | - | - | - | 1件: 6 6 💬 |
67 | 0.9% Isotonic Saline (IS), 4mL | - | - | - | - | 1件: 299 299 💬 |
68 | 0.9% normal saline (control) | - | - | - | - | 1件: 299 299 💬 |
69 | 0.9% sodium chloride (normal saline) | 2件: Chloride ion Chloride ion, Sodium chloride | 1件: Sodium chloride
Sodium chloride
💬 | - | - | 1件: 6 6 💬 |
70 | 0002-8971 | - | - | - | - | 1件: 70 70 💬 |
71 | 009-0 | - | - | - | - | 1件: 6 6 💬 |
72 | 009-4 | - | - | - | - | 1件: 6 6 💬 |
73 | 0109-0012A 100 mg/ml | - | - | - | - | 1件: 46 46 💬 |
74 | 0109-0012A 25 mg/ml | - | - | - | - | 1件: 46 46 💬 |
75 | 0109-0012A 50 mg/ml | - | - | - | - | 1件: 46 46 💬 |
76 | 0114-0006B | - | - | - | - | 2件: 46 46, 96 💬 |
77 | 1 mg QD to 15 mg QD PF-06649751 | 1件: Tavapadon Tavapadon | 1件: Tavapadon
Tavapadon
💬 | 2件: DRD1 DRD1, DRD5 💬 | 10件: Alcoholism Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, cAMP signaling pathway 💬 | 1件: 6 6 💬 |
78 | 1 mg QD to 7 mg QD PF-06649751 (if de-escalated in parent study) | 1件: Tavapadon Tavapadon | 1件: Tavapadon
Tavapadon
💬 | 2件: DRD1 DRD1, DRD5 💬 | 10件: Alcoholism Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, cAMP signaling pathway 💬 | 1件: 6 6 💬 |
79 | 1 ml 0.9 % NaCl | - | - | - | - | 1件: 46 46 💬 |
80 | 1,5-anhydro-2,3-dideoxy-3-[[(1R,3S)-3-[[7,8-dihydro-3- (trifluoromethyl)-1,6-naphthyridin-6(5H)-yl]c | - | - | - | - | 1件: 46 46 💬 |
81 | 1-(2,3,4-Trimethoxybenzyl)piperazine dihydrochloride | 1件: Piperazine Piperazine | 1件: Piperazine
Piperazine
💬 | - | - | 1件: 58 58 💬 |
82 | 1-(2-Isopropoxyethyl)-2-thioxo-1,2,3,5-tetrahydro-pyrrolo[3,2-d] pyrimidin-4-one | - | - | - | - | 1件: 17 17 💬 |
83 | 1-(6-BENZOTHIAZOLYLSULFONYL)-5-CHLORO-1H-INDOLE-2-BUTANOIC ACID | 2件: Butyric Acid Butyric Acid, Indole | - | - | - | 1件: 51 51 💬 |
84 | 1-cyclopropyl-6-fluoro-1,4-dihydro-4-oxo-7-[1-piperazinyl]-3-quinoline carboxylic acid | - | - | - | - | 1件: 299 299 💬 |
85 | 1-{6-[(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)oxy]-3-pyridinyl}-2-pyrrolidinone | - | - | - | - | 1件: 13 13 💬 |
86 | 1. Tesofensine (NS 2330) | 1件: Tesofensine Tesofensine | - | - | - | 1件: 6 6 💬 |
87 | 1.0 mg Lu AE04621 | - | - | - | - | 1件: 6 6 💬 |
88 | 1.0 mg rasagiline mesylate | 1件: Rasagiline Rasagiline | 2件: Rasagiline
Rasagiline
,
Rasagiline tartrate
💬 | 1件: MAOB MAOB 💬 | 14件: Alcoholism Alcoholism, Amphetamine addiction, Arginine and proline metabolism, Cocaine addiction, Dopaminergic synapse, Drug metabolism - cytochrome P450, Glycine, serine and threonine metabolism, Histidine metabolism, Metabolic pathways, Parkinson disease, Phenylalanine metabolism, Serotonergic synapse, Tryptophan metabolism, Tyrosine metabolism 💬 | 1件: 6 6 💬 |
89 | 1.0 mg RPC103 | - | - | - | - | 1件: 97 97 💬 |
90 | 1.0 mg RPC1063 | - | - | - | - | 1件: 97 97 💬 |
91 | 1.0 MIU IL-2 per day | 1件: Human interleukin-2 Human interleukin-2 | - | - | - | 1件: 2 2 💬 |
92 | 1.0mg RPC1063 | - | - | - | - | 1件: 13 13 💬 |
93 | 1.2 mg ZGN-440 for injectable suspension | - | - | - | - | 1件: 193 193 💬 |
94 | 1.8 mg ZGN-440 for injectable suspension | - | - | - | - | 1件: 193 193 💬 |
95 | 10 mg Natura-alpha capsule | - | - | - | - | 1件: 97 97 💬 |
96 | 10 milligram (mg) fampridine-SR (4-aminopyridine, 4-AP) | 1件: Dalfampridine Dalfampridine | 1件: Dalfampridine
Dalfampridine
💬 | 4件: KCNA4 KCNA4, KCNC3, KCND2, KCND3 💬 | 4件: Cortisol synthesis and secretion Cortisol synthesis and secretion, Cushing syndrome, Serotonergic synapse, Spinocerebellar ataxia 💬 | 1件: 13 13 💬 |
97 | 10% nifedipine cream | 1件: Nifedipine Nifedipine | 1件: Nifedipine
Nifedipine
💬 | 4件: CACNA1C CACNA1C, CACNA1D, CACNA1F, CACNA1S 💬 | 37件: Adrenergic signaling in cardiomyocytes Adrenergic signaling in cardiomyocytes, Aldosterone synthesis and secretion, Alzheimer disease, Amphetamine addiction, Arrhythmogenic right ventricular cardiomyopathy, Calcium signaling pathway, Carbohydrate digestion and absorption, Cardiac muscle contraction, Cellular senescence, Chemical carcinogenesis - receptor activation, Cholinergic synapse, Circadian entrainment, Cortisol synthesis and secretion, Cushing syndrome, Dilated cardiomyopathy, Dopaminergic synapse, GABAergic synapse, Glutamatergic synapse, GnRH secretion, GnRH signaling pathway, Growth hormone synthesis, secretion and action, Hypertrophic cardiomyopathy, Insulin secretion, Long-term potentiation, MAPK signaling pathway, Oxytocin signaling pathway, Pathways of neurodegeneration - multiple diseases, Prion disease, Renin secretion, Retrograde endocannabinoid signaling, Serotonergic synapse, Taste transduction, Tight junction, Type II diabetes mellitus, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway 💬 | 1件: 50 50 💬 |
98 | 10% Nitroglycerine in Propylene Glycol, USP | 2件: Nitroglycerin Nitroglycerin, Propylene glycol | 2件: Propylene glycol
Propylene glycol
,
Nitroglycerin
💬 | - | - | 1件: 51 51 💬 |
99 | 10-nitro-9(E)-octadec-9-enoic acid | - | - | - | - | 1件: 86 86 💬 |
100 | 100 mg ELX (VX-445) / 50 mg TEZ / 75 mg IVA FDC | - | - | - | - | 1件: 299 299 💬 |
101 | 100 mg VX-445 /50 mg TEZ/75 mg IVA FDC | - | - | - | - | 1件: 299 299 💬 |
102 | 100 mg VX-445/50 mg TEZ /75 mg IVA FDC | - | - | - | - | 1件: 299 299 💬 |
103 | 100-mg ELX (VX-445) / 50-mg TEZ / 75-mg IVA FDC | - | - | - | - | 1件: 299 299 💬 |
104 | 100-mg ELX (VX-455) / 50-mg TEZ / 75-mg IVA FDC | - | - | - | - | 1件: 299 299 💬 |
105 | 100-mg VX-445 / 50-mg TEZ / 75- mg IVA FDC | - | - | - | - | 1件: 299 299 💬 |
106 | 100-mg VX-445 / 50-mg TEZ / 75-mg IVA FDC | - | - | - | - | 1件: 299 299 💬 |
107 | 100-mg VX-445 /50-mg TEZ/75-mg | - | - | - | - | 1件: 299 299 💬 |
108 | 100-mg VX-445/50-mg TEZ/75-mg IVA FDC | - | - | - | - | 1件: 299 299 💬 |
109 | 100mcg rhPTH(1-84) | 1件: Parathyroid hormone Parathyroid hormone | 1件: Parathyroid hormone
Parathyroid hormone
💬 | 2件: PTH1R PTH1R, PTH2R 💬 | 3件: Endocrine and other factor-regulated calcium reabsorption Endocrine and other factor-regulated calcium reabsorption, Neuroactive ligand-receptor interaction, Parathyroid hormone synthesis, secretion and action 💬 | 1件: 235 235 💬 |
110 | 100mg VX-445/50mg TEZ /75mg IVA FDC | - | - | - | - | 1件: 299 299 💬 |
111 | 118-42-3 | - | - | - | - | 1件: 46 46 💬 |
112 | 120 mg sodium nitrite inhalation solution | 1件: Nitrite Nitrite | - | - | - | 1件: 86 86 💬 |
113 | 14C]-RPC1063 Solution (0.1 mg/mL) for Oral Administration | - | - | - | - | 3件: 13 13, 96, 97 💬 |
114 | 15 mg fampridine-SR (4-aminopyridine, 4-AP) | 1件: Dalfampridine Dalfampridine | 1件: Dalfampridine
Dalfampridine
💬 | 4件: KCNA4 KCNA4, KCNC3, KCND2, KCND3 💬 | 4件: Cortisol synthesis and secretion Cortisol synthesis and secretion, Cushing syndrome, Serotonergic synapse, Spinocerebellar ataxia 💬 | 1件: 13 13 💬 |
115 | 15 mg QD de-escalated to 7 mg QD PF-06649751 in parent study remain at 7 mg QD | 1件: Tavapadon Tavapadon | 1件: Tavapadon
Tavapadon
💬 | 2件: DRD1 DRD1, DRD5 💬 | 10件: Alcoholism Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, cAMP signaling pathway 💬 | 1件: 6 6 💬 |
116 | 15 mg QD PF-06649751 | 1件: Tavapadon Tavapadon | 1件: Tavapadon
Tavapadon
💬 | 2件: DRD1 DRD1, DRD5 💬 | 10件: Alcoholism Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, cAMP signaling pathway 💬 | 1件: 6 6 💬 |
117 | 15 mg sodium nitrite inhalation solution | 1件: Nitrite Nitrite | - | - | - | 1件: 86 86 💬 |
118 | 15 or 45 mg | - | - | - | - | 1件: 67 67 💬 |
119 | 15-0 H20 | - | - | - | - | 2件: 6 6, 19 💬 |
120 | 1639325-43-1 | - | - | - | - | 1件: 254 254 💬 |
121 | 1643368-58-4 | - | - | - | - | 2件: 53 53, 160 💬 |
122 | 17,21-Dihydroxypregna-1,4-diene-3,11,20-trione | - | - | - | - | 1件: 41 41 💬 |
123 | 17beta-hydroxy-11beta-(4-dimethylaminophenyl)17a-(prop-1-ynyl)estra-4,9-dien-3-one | - | - | - | - | 1件: 75 75 💬 |
124 | 17ß-hydroxy-11ß-(4-dimethylaminophenyl)17a-(prop-1-ynyl)estra-4,9-dien-3-one | - | - | - | - | 1件: 75 75 💬 |
125 | 18F-AV-45 | - | - | - | - | 2件: 6 6, 127 💬 |
126 | 18F-OP-801 | - | - | - | - | 1件: 2 2 💬 |
127 | 18F]-(E)-N-(3-iodoprop-2-enyl)-2b-carbofluoroethoxy-3b-(4'-methylphenyl)nortropane | - | - | - | - | 1件: 6 6 💬 |
128 | 19 nor vitamin d | 1件: Vitamin D Vitamin D | - | - | - | 1件: 13 13 💬 |
129 | 1[(6- Allyl- 8beta- erg | - | - | - | - | 1件: 6 6 💬 |
130 | 1[(6- Allyl- 8beta- ergolinyl)carbonyl]- 1- [3- (dimethylamino)propyl]- | - | - | - | - | 1件: 6 6 💬 |
131 | 1[(6- Allyl- 8beta- ergolinyl)carbonyl]- 1- [3- (dimethylamino)propyl]- 3- ethylurea | - | - | - | - | 1件: 6 6 💬 |
132 | 1[(6- Allyl- 8ß- erg | - | - | - | - | 1件: 6 6 💬 |
133 | 1[(6- Allyl- 8ß- ergolinyl)carbonyl]- 1- [3- (dimethylamino)propyl]- | - | - | - | - | 1件: 6 6 💬 |
134 | 1[(6- Allyl- 8ß- ergolinyl)carbonyl]- 1- [3- (dimethylamino)propyl]- 3- ethylurea | - | - | - | - | 1件: 6 6 💬 |
135 | 2 x 10 mg Natura-alpha capsules | - | - | - | - | 1件: 97 97 💬 |
136 | 2',4'-difluoro-4-hydroxy-3-biphenylcarboxylic acid | 1件: Diflunisal Diflunisal | 1件: Diflunisal
Diflunisal
💬 | 1件: PTGS2 PTGS2 💬 | 22件: Alzheimer disease Alzheimer disease, Arachidonic acid metabolism, C-type lectin receptor signaling pathway, Chemical carcinogenesis - DNA adducts, Human cytomegalovirus infection, Human papillomavirus infection, IL-17 signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Metabolic pathways, MicroRNAs in cancer, NF-kappa B signaling pathway, Ovarian steroidogenesis, Oxytocin signaling pathway, Pathways in cancer, Pathways of neurodegeneration - multiple diseases, Regulation of lipolysis in adipocytes, Retrograde endocannabinoid signaling, Serotonergic synapse, Small cell lung cancer, TNF signaling pathway, VEGF signaling pathway 💬 | 1件: 28 28 💬 |
137 | 2(S)-(ACETYLAMINO)-4-METHYLPENTANOIC ACID | - | - | - | - | 2件: 19 19, 65 💬 |
138 | 2,5-Dichloro-3-(5-(3,4-dihydroxy-5-nitrophenyl)-1,2,4-oxadiazol-3-yl)-4,6-dimethylpyridine-1-oxide | - | - | - | - | 1件: 6 6 💬 |
139 | 2-(((2E)-3-(3-methoxy-4-(2-propyn-1-yloxy)phenyl)-1-oxo-2-propen-1-yl)amino)benzoic acid | 1件: Benzoic acid Benzoic acid | 1件: Benzoic acid
Benzoic acid
💬 | - | - | 1件: 51 51 💬 |
140 | 2-(3,5-dichloro-phenyl)-benzoxazole-6-carboxylat | - | - | - | - | 1件: 28 28 💬 |
141 | 2-(3,5-dichloro-phenyl)-benzoxazole-6-carboxylate | - | - | - | - | 1件: 28 28 💬 |
142 | 2-(4-[5,6-diphenylpyrazin-2-yl)(isopropyl)amino]butoxy)-N-(methylsulfonyl)actamide | - | - | - | - | 1件: 86 86 💬 |
143 | 2-[[[(2R)-1-[1-[(4-CHLORO-3-METHYLPHENYL)METHYL]-4- PIPERIDINYL]-5-OXO-2-PYRROLIDINYL]CARBONYL]AMINO]- N,N,6-TRIMETHYL-4-PYRIDINECARBOXAMIDE,DIHYDROCHLORIDE | - | - | - | - | 2件: 6 6, 162 💬 |
144 | 2-amino-4-(methyl[11C]sulfanyl)butanoic acid | 1件: Butyric Acid Butyric Acid | - | - | - | 1件: 34 34 💬 |
145 | 2-{4-[(5,6-diphenylpyrazin-2-yl)(isopropyl)amino]butoxy}-N-(methylsulfonyl) acetamide | 1件: Acetamide Acetamide | - | - | - | 1件: 86 86 💬 |
146 | 2-{7-[1,1-dimethyl-3-(4-sulfobutyl)-benz[e]indolin-2-ylidene]-1,3,5-heptatrienyl}-1,1-dimethyl-3-(sulfobutyl)-1H-benz[e]-indolium hydroxide,inner salt | 1件: Hydroxide ion Hydroxide ion | - | - | - | 1件: 46 46 💬 |
147 | 2.0 MIU IL-2 per day | 1件: Human interleukin-2 Human interleukin-2 | - | - | - | 1件: 2 2 💬 |
148 | 20 mg BID of PF-02545920 | - | - | - | - | 1件: 8 8 💬 |
149 | 20 mg fampridine-SR (4-aminopyridine, 4-AP) | 1件: Dalfampridine Dalfampridine | 1件: Dalfampridine
Dalfampridine
💬 | 4件: KCNA4 KCNA4, KCNC3, KCND2, KCND3 💬 | 4件: Cortisol synthesis and secretion Cortisol synthesis and secretion, Cushing syndrome, Serotonergic synapse, Spinocerebellar ataxia 💬 | 1件: 13 13 💬 |
150 | 200 mg BIA 6-512 | 1件: BIA BIA | - | - | - | 1件: 6 6 💬 |
151 | 2019171-69-6 | - | - | - | - | 1件: 61 61 💬 |
152 | 20mg/0.5ml GA | - | - | - | - | 1件: 13 13 💬 |
153 | 20mg/0.5ml glatiramer acetate | 2件: Acetate Acetate, Glatiramer | - | - | - | 1件: 13 13 💬 |
154 | 225mg SHP647 (PF-00547659) | - | - | - | - | 1件: 97 97 💬 |
155 | 25% MTD sodium nitrite inhalation solution | 1件: Nitrite Nitrite | - | - | - | 1件: 86 86 💬 |
156 | 25mcg rhPTH(1-84) | 1件: Parathyroid hormone Parathyroid hormone | 1件: Parathyroid hormone
Parathyroid hormone
💬 | 2件: PTH1R PTH1R, PTH2R 💬 | 3件: Endocrine and other factor-regulated calcium reabsorption Endocrine and other factor-regulated calcium reabsorption, Neuroactive ligand-receptor interaction, Parathyroid hormone synthesis, secretion and action 💬 | 1件: 235 235 💬 |
157 | 29180.00.00, 34681.00.00, 34681.01.00, 34681.02.00 | - | - | - | - | 1件: 113 113 💬 |
158 | 2mg KPG-818 dose | - | - | - | - | 1件: 49 49 💬 |
159 | 2S,4R-(-)-ketoconazole | 1件: Ketoconazole Ketoconazole | 1件: Ketoconazole
Ketoconazole
💬 | 1件: CYP17A1 CYP17A1 💬 | 6件: Cortisol synthesis and secretion Cortisol synthesis and secretion, Cushing syndrome, Metabolic pathways, Ovarian steroidogenesis, Prolactin signaling pathway, Steroid hormone biosynthesis 💬 | 1件: 75 75 💬 |
160 | 2S,4R-(-)-ketoconazole, levoketoconazole | 2件: Ketoconazole Ketoconazole, Levoketoconazole | 2件: Ketoconazole
Ketoconazole
,
Levoketoconazole
💬 | 3件: CYP11A1 CYP11A1, CYP11B1, CYP17A1 💬 | 7件: Aldosterone synthesis and secretion Aldosterone synthesis and secretion, Cortisol synthesis and secretion, Cushing syndrome, Metabolic pathways, Ovarian steroidogenesis, Prolactin signaling pathway, Steroid hormone biosynthesis 💬 | 1件: 75 75 💬 |
161 | 3 mg QD to 15 mg QD PF-06649751 | 1件: Tavapadon Tavapadon | 1件: Tavapadon
Tavapadon
💬 | 2件: DRD1 DRD1, DRD5 💬 | 10件: Alcoholism Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, cAMP signaling pathway 💬 | 1件: 6 6 💬 |
162 | 3 mg QD to 7 mg QD PF-06649751 (de-escalated in parent study) | 1件: Tavapadon Tavapadon | 1件: Tavapadon
Tavapadon
💬 | 2件: DRD1 DRD1, DRD5 💬 | 10件: Alcoholism Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, cAMP signaling pathway 💬 | 1件: 6 6 💬 |
163 | 3,4-DIAMINOPYRIDINE | - | - | - | - | 2件: 12 12, 13 💬 |
164 | 3,4-Diaminopyridine Phosphate | 2件: Amifampridine Amifampridine, Phosphate ion | 1件: Amifampridine
Amifampridine
💬 | 4件: KCNA4 KCNA4, KCNC3, KCND2, KCND3 💬 | 4件: Cortisol synthesis and secretion Cortisol synthesis and secretion, Cushing syndrome, Serotonergic synapse, Spinocerebellar ataxia 💬 | 1件: 3 3 💬 |
165 | 3- (9,10- Didehydro- 6- methyl- 8?- ergolinyl)-1,1- diethylurea hydrogenmaleate | - | - | - | - | 1件: 6 6 💬 |
166 | 3-(3,4-Dihydroxyphenyl)-L-alanine | 1件: Alanine Alanine | 1件: Alanine
Alanine
💬 | - | - | 1件: 6 6 💬 |
167 | 3-(3-(3,5-DIMETHYL-1H-PYRAZOL-4-YL)PROPOXY)-4-FLUOROBENZOIC ACID | 1件: Pyrazole Pyrazole | - | - | - | 1件: 28 28 💬 |
168 | 3-({[(3R,5R)-3-butyl-3-ethyl-7-(methyloxy)-1,1-dioxido-5-phenyl-2,3,4,5-tetrahydro- | - | - | - | - | 1件: 93 93 💬 |
169 | 3-({[(3R,5R)-3-butyl-3-ethyl-7-(methyloxy)-1,1-dioxido-5-phenyl-2,3,4,5-tetrahydro-1,4-benzothiazepin-8-yl]methyl}amino)pentanedioic acid | - | - | - | - | 1件: 93 93 💬 |
170 | 3-[4-(1H-imidazol-1-ylmethyl)phenyl]-5-(2-methylpropyl)thiophene-2-[(N-butyloxylcarbamate)-sulphonamide] sodium salt | - | - | - | - | 2件: 51 51, 85 💬 |
171 | 3-hydroxy-2-methyl-4H-pyrane-4-one iron (III) complex (3:1), Ferric (3-hydroxy-2-methyl-4-pyrone), Tris-maltol-iron (III), Tri=maltol-iron (III) | 1件: Tromethamine Tromethamine | 1件: Tromethamine
Tromethamine
💬 | - | - | 2件: 96 96, 97 💬 |
172 | 3-methyl-1-phenyl-4, 5-dihydro-1H-pyrazol-5-one. | 1件: Pyrazole Pyrazole | - | - | - | 1件: 2 2 💬 |
173 | 30 or 60 mg | - | - | - | - | 1件: 67 67 💬 |
174 | 36-482-Hyaluronoglucosaminidase PH20 (rHuPH20) | 1件: Hyaluronidase Hyaluronidase | 3件: Hyaluronidase
Hyaluronidase
,
Hyaluronidase
,
Hyaluronidase
💬 | - | - | 1件: 65 65 💬 |
175 | 3a,7a-dihydroxy-6a-ethyl-5betacholan-24-oic acid | - | - | - | - | 1件: 93 93 💬 |
176 | 3a,7a-dihydroxy-6a-ethyl-5ßcholan-24-oic acid | - | - | - | - | 1件: 93 93 💬 |
177 | 4'-chloro-2'-cyano-N-(trans-4-hydroxy-4-methylcyclohexyl)-biphenyl-4-sulphonamide | - | - | - | - | 1件: 46 46 💬 |
178 | 4'-iodo-4'-deoxydoxorubicin | 1件: Iodine Iodine | 1件: Iodine
Iodine
💬 | - | - | 1件: 28 28 💬 |
179 | 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-thiazolyl]amino]phenyl]-benzamide, methane sulphonic acid salt. AB1010base | 1件: Methane Methane | - | - | - | 1件: 2 2 💬 |
180 | 4-[5-(4-methylphenyl)-3-(trifluoromethyl)- 1H-pyrazol-1-yl] benzenesulfonamide | 1件: Pyrazole Pyrazole | - | - | - | 1件: 46 46 💬 |
181 | 4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl] benzenesulfonamide | 1件: Pyrazole Pyrazole | - | - | - | 1件: 46 46 💬 |
182 | 4-benzyl-2-naphtalen-1-yl-1,2,4-thiadiazolidine-3,5-dione | - | - | - | - | 1件: 5 5 💬 |
183 | 4-Benzyl-2-naphthalen-1-yl-1,2,4- thiadiazolidine-3,5-dione | - | - | - | - | 1件: 113 113 💬 |
184 | 4-benzyl-2-naphthalen-1-yl-1,2,4-thiadiazolidine-3,5-dione | - | - | - | - | 1件: 113 113 💬 |
185 | 4.2% NaCl/Inhalation solution | - | - | - | - | 1件: 299 299 💬 |
186 | 4.5 mg Naltrexone | 1件: Naltrexone Naltrexone | 1件: Naltrexone
Naltrexone
💬 | 3件: OPRD1 OPRD1, OPRK1, OPRM1 💬 | 5件: Estrogen signaling pathway Estrogen signaling pathway, Morphine addiction, Neuroactive ligand-receptor interaction, Sphingolipid signaling pathway, cGMP-PKG signaling pathway 💬 | 1件: 13 13 💬 |
187 | 40 MG- SOLUZIONE INIETTABILE IN SIRINGHE PRE-RIEMPITE- USO SOTTOCUTANEO- SIRINGA PRERIEMPITA (0,4ML)- 2 SIRINGHE PRE-RIEMPITE + 2 TAMPONI IMBEVUTI DI ALCOOL | - | - | - | - | 1件: 107 107 💬 |
188 | 44/154/85-C | - | - | - | - | 1件: 50 50 💬 |
189 | 44/196/81-C | - | - | - | - | 1件: 50 50 💬 |
190 | 45 mg sodium nitrite inhalation solution | 1件: Nitrite Nitrite | - | - | - | 1件: 86 86 💬 |
191 | 4cc of lidocaïne® | - | - | - | - | 1件: 149 149 💬 |
192 | 5% lidocaine/5 mg/ml 0.02% estradiol compound cream | 2件: Estradiol Estradiol, Lidocaine | 3件: Estradiol
Estradiol
,
Lidocaine
,
Lidocaine hydrochloride monohydrate
💬 | 7件: ESR1 ESR1, ESR2, SCN1A, SCN2A, SCN3A, SCN5A, SCN9A 💬 | 13件: Adrenergic signaling in cardiomyocytes Adrenergic signaling in cardiomyocytes, Breast cancer, Chemical carcinogenesis - receptor activation, Dopaminergic synapse, Endocrine and other factor-regulated calcium reabsorption, Endocrine resistance, Estrogen signaling pathway, GnRH secretion, Pathways in cancer, Prolactin signaling pathway, Proteoglycans in cancer, Taste transduction, Thyroid hormone signaling pathway 💬 | 1件: 226 226 💬 |
193 | 5,6,7,8-tetrahydrobiopterin | 1件: Sapropterin Sapropterin | 1件: Sapropterin
Sapropterin
💬 | - | - | 1件: 240 240 💬 |
194 | 5-(ethylsulfonyl)-2-(naphthalen-2-yl)benzo[d]oxazole | - | - | - | - | 1件: 113 113 💬 |
195 | 5-[4-[2-(5-(1-hydroxyethyl)-2- pyridinyl)ethoxy]benzyl]-2,4- thiazolidinedione hydrochloride | 1件: 2,4-thiazolidinedione 2,4-thiazolidinedione | - | - | - | 1件: 20 20 💬 |
196 | 5-[4-[2-(5-(1-hydroxyethyl)-2-pyridinyl)ethoxy]benzyl]-2,4-thiazolidinedione hydrochloride | 1件: 2,4-thiazolidinedione 2,4-thiazolidinedione | - | - | - | 1件: 20 20 💬 |
197 | 5-[[4-[2-[5-(1-HYDROXYETHYL)-2-PYRIDINYL]ETHOXY]PHENYL]METHYL]-2,4-THIAZOLIDINEDIONE HYDROCHLORIDE | 1件: 2,4-thiazolidinedione 2,4-thiazolidinedione | - | - | - | 1件: 20 20 💬 |
198 | 5-Chlor-6'-methyl- 3-[4-(methylsulfonyl)phenyl]- 2,3'-bipyridin | 1件: Chlorine Chlorine | - | - | - | 2件: 46 46, 271 💬 |
199 | 5-Chloro-1,2-dihydro-N-ethyl-4-hydroxy-1-methyl-2-oxo-N-phenyl-3-quinolinecarboxamide sodium | - | - | - | - | 1件: 8 8 💬 |
200 | 500 0500 0 | - | - | - | - | 1件: 19 19 💬 |
201 | 50mcg rhPTH(1-84) | 1件: Parathyroid hormone Parathyroid hormone | 1件: Parathyroid hormone
Parathyroid hormone
💬 | 2件: PTH1R PTH1R, PTH2R 💬 | 3件: Endocrine and other factor-regulated calcium reabsorption Endocrine and other factor-regulated calcium reabsorption, Neuroactive ligand-receptor interaction, Parathyroid hormone synthesis, secretion and action 💬 | 1件: 235 235 💬 |
202 | 52069.00.01 | - | - | - | - | 1件: 13 13 💬 |
203 | 549-0261/F02-01 | - | - | - | - | 2件: 96 96, 97 💬 |
204 | 552-02 | - | - | - | - | 2件: 53 53, 299 💬 |
205 | 6 alpha-ethylchenodeoxycholic acid (6-EDCA), OCA, INT-747 | - | - | - | - | 1件: 93 93 💬 |
206 | 6% Hypertonic Saline (HS), 4mL | - | - | - | - | 1件: 299 299 💬 |
207 | 6-(2,3-dichlorophenyl)-1,2,4-triazine-3,5-diamine | - | - | - | - | 1件: 38 38 💬 |
208 | 6-(nitrooxy)hexyl(2Z)-4-(acetyloxy)-3-[4-(methylsulfonyl)phenyl]-2-phenylbut-2-enoate | - | - | - | - | 1件: 46 46 💬 |
209 | 6-[(methyl-4-nitro-1H-imidazol-5-yl)thio]-1H-purine | - | - | - | - | 1件: 96 96 💬 |
210 | 6-[2-(3,4-diethoxyphenyl)thiazol-4-yl] pyridine-2-carboxylic acid | - | - | - | - | 1件: 97 97 💬 |
211 | 6-ethynyl-1-(pentan-3-yl)-1H-imidazo[4,5-b]pyrazin-2(3H)-one | - | - | - | - | 1件: 2 2 💬 |
212 | 6-Mercaptopurine (Puri-Nethol) | 1件: Mercaptopurine Mercaptopurine | 2件: Mercaptopurine
Mercaptopurine
,
Mercaptopurine
💬 | 1件: HPRT1 HPRT1 💬 | 4件: Drug metabolism - other enzymes Drug metabolism - other enzymes, Metabolic pathways, Nucleotide metabolism, Purine metabolism 💬 | 1件: 96 96 💬 |
213 | 6036937.00.01 | - | - | - | - | 1件: 6 6 💬 |
214 | 68Ga-NEB | - | - | - | - | 3件: 46 46, 89, 280 💬 |
215 | 6?-ethylchenodeoxycholic acid (6-ECDCA), OCA, INT-747 | 1件: Obeticholic acid Obeticholic acid | 1件: Obeticholic acid
Obeticholic acid
💬 | 1件: NR1H4 NR1H4 💬 | 1件: Bile secretion Bile secretion 💬 | 1件: 93 93 💬 |
216 | 6a-ethylchenodeoxycholic acid (6-ECDCA), OCA, INT-747 | 1件: Obeticholic acid Obeticholic acid | 1件: Obeticholic acid
Obeticholic acid
💬 | 1件: NR1H4 NR1H4 💬 | 1件: Bile secretion Bile secretion 💬 | 1件: 93 93 💬 |
217 | 6a-ethylchenodeoxycholic acid , 6-ethylchenodeoxycholic acid | 1件: Obeticholic acid Obeticholic acid | 1件: Obeticholic acid
Obeticholic acid
💬 | 1件: NR1H4 NR1H4 💬 | 1件: Bile secretion Bile secretion 💬 | 1件: 93 93 💬 |
218 | 6a-ethylchenodeoxycholic acid , 6-ethylchenodeoxycholic acid, 3a,7a-dihydroxy-6a-ethyl-5betacholan-24-o | 1件: Obeticholic acid Obeticholic acid | 1件: Obeticholic acid
Obeticholic acid
💬 | 1件: NR1H4 NR1H4 💬 | 1件: Bile secretion Bile secretion 💬 | 1件: 93 93 💬 |
219 | 6a-ethylchenodeoxycholic acid , 6-ethylchenodeoxycholic acid, 3a,7a-dihydroxy-6a-ethyl-5betacholan-24-o, obeticholic acid (OCA) | 1件: Obeticholic acid Obeticholic acid | 1件: Obeticholic acid
Obeticholic acid
💬 | 1件: NR1H4 NR1H4 💬 | 1件: Bile secretion Bile secretion 💬 | 1件: 93 93 💬 |
220 | 6a-ethylchenodeoxycholic acid , 6-ethylchenodeoxycholic acid, 3a,7a-dihydroxy-6a-ethyl-5ßcholan-24-o | 1件: Obeticholic acid Obeticholic acid | 1件: Obeticholic acid
Obeticholic acid
💬 | 1件: NR1H4 NR1H4 💬 | 1件: Bile secretion Bile secretion 💬 | 1件: 93 93 💬 |
221 | 6a-ethylchenodeoxycholic acid , 6-ethylchenodeoxycholic acid, 3a,7a-dihydroxy-6a-ethyl-5ßcholan-24-o, obeticholic acid (OCA) | 1件: Obeticholic acid Obeticholic acid | 1件: Obeticholic acid
Obeticholic acid
💬 | 1件: NR1H4 NR1H4 💬 | 1件: Bile secretion Bile secretion 💬 | 1件: 93 93 💬 |
222 | 6a-ethylchenodeoxycholic acid, 6-ethylchenodeoxycholic acid | 1件: Obeticholic acid Obeticholic acid | 1件: Obeticholic acid
Obeticholic acid
💬 | 1件: NR1H4 NR1H4 💬 | 1件: Bile secretion Bile secretion 💬 | 1件: 93 93 💬 |
223 | 6a-ethylchenodeoxycholic acid, 6-ethylchenodeoxycholic acid, 3a,7a-dihydroxy-6a-ethyl-5betacholan-24-o | 1件: Obeticholic acid Obeticholic acid | 1件: Obeticholic acid
Obeticholic acid
💬 | 1件: NR1H4 NR1H4 💬 | 1件: Bile secretion Bile secretion 💬 | 1件: 93 93 💬 |
224 | 6a-ethylchenodeoxycholic acid, 6-ethylchenodeoxycholic acid, 3a,7a-dihydroxy-6a-ethyl-5betacholan-24-o , obeticholic acid (OCA) | 1件: Obeticholic acid Obeticholic acid | 1件: Obeticholic acid
Obeticholic acid
💬 | 1件: NR1H4 NR1H4 💬 | 1件: Bile secretion Bile secretion 💬 | 1件: 93 93 💬 |
225 | 6a-ethylchenodeoxycholic acid, 6-ethylchenodeoxycholic acid, 3a,7a-dihydroxy-6a-ethyl-5ßcholan-24-o | 1件: Obeticholic acid Obeticholic acid | 1件: Obeticholic acid
Obeticholic acid
💬 | 1件: NR1H4 NR1H4 💬 | 1件: Bile secretion Bile secretion 💬 | 1件: 93 93 💬 |
226 | 6a-ethylchenodeoxycholic acid, 6-ethylchenodeoxycholic acid, 3a,7a-dihydroxy-6a-ethyl-5ßcholan-24-o , obeticholic acid (OCA) | 1件: Obeticholic acid Obeticholic acid | 1件: Obeticholic acid
Obeticholic acid
💬 | 1件: NR1H4 NR1H4 💬 | 1件: Bile secretion Bile secretion 💬 | 1件: 93 93 💬 |
227 | 7 mg QD to 15 mg QD PF-06649751 | 1件: Tavapadon Tavapadon | 1件: Tavapadon
Tavapadon
💬 | 2件: DRD1 DRD1, DRD5 💬 | 10件: Alcoholism Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, cAMP signaling pathway 💬 | 1件: 6 6 💬 |
228 | 7 mg QD to 7 mg QD PF-06649751 (de-escalated in parent study) | 1件: Tavapadon Tavapadon | 1件: Tavapadon
Tavapadon
💬 | 2件: DRD1 DRD1, DRD5 💬 | 10件: Alcoholism Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, cAMP signaling pathway 💬 | 1件: 6 6 💬 |
229 | 7% NaCl | - | - | - | - | 1件: 299 299 💬 |
230 | 70930.00.00 | - | - | - | - | 1件: 46 46 💬 |
231 | 75mg SHP647 (PF-00547659) | - | - | - | - | 1件: 97 97 💬 |
232 | 80 mg DR-6MP | - | - | - | - | 1件: 96 96 💬 |
233 | 800 mg ibuprofen/26.6 mg famotidine | 2件: Famotidine Famotidine, Ibuprofen | 2件: Ibuprofen
Ibuprofen
,
Famotidine
💬 | 3件: HRH2 HRH2, PTGS1, PTGS2 💬 | 26件: Alzheimer disease Alzheimer disease, Arachidonic acid metabolism, C-type lectin receptor signaling pathway, Calcium signaling pathway, Chemical carcinogenesis - DNA adducts, Gastric acid secretion, Human cytomegalovirus infection, Human papillomavirus infection, IL-17 signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Metabolic pathways, MicroRNAs in cancer, NF-kappa B signaling pathway, Neuroactive ligand-receptor interaction, Ovarian steroidogenesis, Oxytocin signaling pathway, Pathways in cancer, Pathways of neurodegeneration - multiple diseases, Platelet activation, Regulation of lipolysis in adipocytes, Retrograde endocannabinoid signaling, Serotonergic synapse, Small cell lung cancer, TNF signaling pathway, VEGF signaling pathway 💬 | 1件: 107 107 💬 |
234 | 80mg ELX / 40mg TEZ / 60mg IVA | - | - | - | - | 1件: 299 299 💬 |
235 | 89 Zirconium Recombinant Human Alpha-N-Acetylglucosaminidase (rhNAGLU) (radiolabeled) | - | - | - | - | 1件: 19 19 💬 |
236 | 9-Chloro-2,3-dimethyl-6-(N,N-dimethylaminoethylamino-2-oxoethyl)-6H-indolo[2,3-b] quinoxaline | - | - | - | - | 1件: 46 46 💬 |
237 | 90 mg sodium nitrite inhalation solution | 1件: Nitrite Nitrite | - | - | - | 1件: 86 86 💬 |
238 | 98-92-0 | - | - | - | - | 1件: 107 107 💬 |
239 | : 2-{4-[(5,6-difenilpirazin-2-yl)(isopropil)amino]butoxi}-N- | - | - | - | - | 1件: 86 86 💬 |
240 | : immunoglobulina umana normale 10% per somministrazione endovenosa | - | - | - | - | 1件: 14 14 💬 |
241 | [123I]MNI-420 | - | - | - | - | 2件: 6 6, 8 💬 |
242 | [124I]IB PF 06687234 | - | - | - | - | 2件: 96 96, 97 💬 |
243 | [18F]MNI-815 (MNI-815) | - | - | - | - | 1件: 5 5 💬 |
244 | [18F]P17-059 | - | - | - | - | 1件: 6 6 💬 |
245 | [68Ga]CBP8 | - | - | - | - | 1件: 85 85 💬 |
246 | [68Ga]Ga-PentixaFor PET/CT | - | - | - | - | 1件: 84 84 💬 |
247 | [F-18]SDM-8 | - | - | - | - | 1件: 13 13 💬 |
248 | [Zr-89]Oxine-labeled leukocytes PET/MRI | 1件: Oxyquinoline Oxyquinoline | 1件: Oxyquinoline
Oxyquinoline
💬 | - | - | 1件: 13 13 💬 |
249 | A fixed-dose combination of 95 mg clarithromycin, 45 mg rifabutin, and 10 mg clofazimine | 3件: Clarithromycin Clarithromycin, Clofazimine, Rifabutin | 3件: Clarithromycin
Clarithromycin
,
Clofazimine
,
Rifabutin
💬 | - | - | 1件: 96 96 💬 |
250 | A Natural Remedy for Rheumatoid Arthritis vs. Common Drugs | - | - | - | - | 1件: 46 46 💬 |
251 | A novel synthetic, orally-administered, non-peptide small molecule, which acts as | - | - | - | - | 1件: 254 254 💬 |
252 | A novel synthetic, orally-administered, non-peptide small molecule, which acts as an agonist of the melanocortin-1 receptor (MC1R) | - | - | - | - | 1件: 51 51 💬 |
253 | A-623 | - | - | - | - | 1件: 49 49 💬 |
254 | A-623 or AMG 623 | - | - | - | - | 1件: 66 66 💬 |
255 | A-F-A-F (NovoRapid-FIASP-NovoRapid-FIASP) | - | - | - | - | 1件: 299 299 💬 |
256 | A-glucosidasi acida umana ricombinante coniugata con multiple copie di bis-mannosio-6- fosfato-tetra-mannosio glicano sintetico (NEOGAA) | 1件: Avalglucosidase alfa Avalglucosidase alfa | 1件: Avalglucosidase alfa
Avalglucosidase alfa
💬 | 1件: GAA GAA 💬 | 4件: Galactose metabolism Galactose metabolism, Lysosome, Metabolic pathways, Starch and sucrose metabolism 💬 | 1件: 256 256 💬 |
257 | A4250 (400 µg) | - | - | - | - | 1件: 338 338 💬 |
258 | A4250 (600 µg) | - | - | - | - | 1件: 338 338 💬 |
259 | A4250-015 | - | - | - | - | 1件: 297 297 💬 |
260 | A: PTH (1-84) | - | - | - | - | 1件: 235 235 💬 |
261 | AAV BBP-631 | - | - | - | - | 1件: 81 81 💬 |
262 | AAV2/8.TBG.hARSB | - | - | - | - | 1件: 19 19 💬 |
263 | AAV5-RPGR 4e11 | - | - | - | - | 1件: 90 90 💬 |
264 | AAV9 BBP-812 | 1件: BBP-812 BBP-812 | - | - | - | 1件: 307 307 💬 |
265 | AAVrh.10CUhCLN2 vector 2.85x10^11 genome copies | - | - | - | - | 1件: 19 19 💬 |
266 | AAVrh.10CUhCLN2 vector 9.0x10^11 genome copies | - | - | - | - | 1件: 19 19 💬 |
267 | ABBV-006 | - | - | - | - | 1件: 97 97 💬 |
268 | ABBV-066 | - | - | - | - | 2件: 96 96, 97 💬 |
269 | ABBV-0805 | - | - | - | - | 1件: 6 6 💬 |
270 | ABBV-105, A-1519938.0 | - | - | - | - | 1件: 46 46 💬 |
271 | ABBV-668 | - | - | - | - | 1件: 97 97 💬 |
272 | ABBV-8E12 | - | - | - | - | 2件: 5 5, 7 💬 |
273 | ABT 494 | - | - | - | - | 1件: 46 46 💬 |
274 | ABT 494 12mg | - | - | - | - | 2件: 46 46, 96 💬 |
275 | ABT 494 3mg | - | - | - | - | 2件: 46 46, 96 💬 |
276 | ABT-494 | - | - | - | - | 7件: 41 41, 46, 49, 96, 97, 107, 271 💬 |
277 | ABT-494 15mg | - | - | - | - | 1件: 46 46 💬 |
278 | ABT-494 30mg | - | - | - | - | 1件: 46 46 💬 |
279 | ABT-874 | - | - | - | - | 1件: 96 96 💬 |
280 | ABT-874/Human monoclonal antibody against IL-12 | - | - | - | - | 1件: 13 13 💬 |
281 | ABY-035 | - | - | - | - | 1件: 271 271 💬 |
282 | Accordion Pill ¿ Carbidopa/Levodopa 50/400 mg | 2件: Carbidopa Carbidopa, Levodopa | 2件: Levodopa
Levodopa
,
Carbidopa
💬 | 6件: DDC DDC, DRD1, DRD2, DRD3, DRD4, DRD5 💬 | 16件: Alcoholism Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Metabolic pathways, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Phenylalanine metabolism, Rap1 signaling pathway, Serotonergic synapse, Tryptophan metabolism, Tyrosine metabolism, cAMP signaling pathway 💬 | 1件: 6 6 💬 |
283 | Accordion Pill? Carbidopa/Levodopa 50/400 mg | 2件: Carbidopa Carbidopa, Levodopa | 2件: Levodopa
Levodopa
,
Carbidopa
💬 | 6件: DDC DDC, DRD1, DRD2, DRD3, DRD4, DRD5 💬 | 16件: Alcoholism Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Metabolic pathways, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Phenylalanine metabolism, Rap1 signaling pathway, Serotonergic synapse, Tryptophan metabolism, Tyrosine metabolism, cAMP signaling pathway 💬 | 1件: 6 6 💬 |
284 | Accordion Pill™ Carbidopa/Levodopa 50/400 mg | 2件: Carbidopa Carbidopa, Levodopa | 2件: Levodopa
Levodopa
,
Carbidopa
💬 | 6件: DDC DDC, DRD1, DRD2, DRD3, DRD4, DRD5 💬 | 16件: Alcoholism Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Metabolic pathways, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Phenylalanine metabolism, Rap1 signaling pathway, Serotonergic synapse, Tryptophan metabolism, Tyrosine metabolism, cAMP signaling pathway 💬 | 1件: 6 6 💬 |
285 | ACE-011 | - | - | - | - | 1件: 86 86 💬 |
286 | ACE-011 / MK - 7962 | - | - | - | - | 1件: 86 86 💬 |
287 | ACE-011 / MK-7962 | - | - | - | - | 1件: 86 86 💬 |
288 | ACE-011/ MK-7962 | - | - | - | - | 1件: 86 86 💬 |
289 | ACE-031 (Extension of cohort 1 from core study, A031-03) | - | - | - | - | 1件: 113 113 💬 |
290 | ACE-031 (Extension of cohort 2 from core study, A031-03) | - | - | - | - | 1件: 113 113 💬 |
291 | ACE-031 (Extension of cohort 3 from core study, A031-03) | - | - | - | - | 1件: 113 113 💬 |
292 | ACE-031 0.5 mg/kg q4wk | - | - | - | - | 1件: 113 113 💬 |
293 | ACE-031 1.0 mg/kg q2wk | - | - | - | - | 1件: 113 113 💬 |
294 | ACE-083 | - | - | - | - | 2件: 10 10, 113 💬 |
295 | ACER-002 (celiprolol) 200 mg BID | 1件: Celiprolol Celiprolol | 1件: Celiprolol
Celiprolol
💬 | 1件: ADRB1 ADRB1 💬 | 11件: Adrenergic signaling in cardiomyocytes Adrenergic signaling in cardiomyocytes, Calcium signaling pathway, Chemical carcinogenesis - receptor activation, Dilated cardiomyopathy, Gap junction, Neuroactive ligand-receptor interaction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, cAMP signaling pathway, cGMP-PKG signaling pathway 💬 | 1件: 168 168 💬 |
296 | Acetaminophen Tablet 650mg | 1件: Acetaminophen Acetaminophen | 1件: Acetaminophen
Acetaminophen
💬 | 2件: PTGS1 PTGS1, PTGS2 💬 | 23件: Alzheimer disease Alzheimer disease, Arachidonic acid metabolism, C-type lectin receptor signaling pathway, Chemical carcinogenesis - DNA adducts, Human cytomegalovirus infection, Human papillomavirus infection, IL-17 signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Metabolic pathways, MicroRNAs in cancer, NF-kappa B signaling pathway, Ovarian steroidogenesis, Oxytocin signaling pathway, Pathways in cancer, Pathways of neurodegeneration - multiple diseases, Platelet activation, Regulation of lipolysis in adipocytes, Retrograde endocannabinoid signaling, Serotonergic synapse, Small cell lung cancer, TNF signaling pathway, VEGF signaling pathway 💬 | 1件: 13 13 💬 |
297 | ACH-0144471 | - | - | - | - | 2件: 62 62, 222 💬 |
298 | ACH-0144471 compresse | - | - | - | - | 1件: 222 222 💬 |
299 | ACH-0145228 | - | - | - | - | 1件: 62 62 💬 |
300 | ACIDE TRANEXAMIQUE MYLAN 0,5 g/ 5 mL, solution injectable | - | - | - | - | 1件: 299 299 💬 |
301 | ACP-001 | - | - | - | - | 1件: 78 78 💬 |
302 | ACP-001 (TransCon hGH) | - | - | - | - | 1件: 78 78 💬 |
303 | ACP-011 | - | - | - | - | 1件: 78 78 💬 |
304 | ACR16 45 mg | - | - | - | - | 1件: 8 8 💬 |
305 | ACT - 064992 | - | - | - | - | 1件: 86 86 💬 |
306 | ACT-050089 | - | - | - | - | 1件: 86 86 💬 |
307 | ACT-050089 (Ro 61-0612) | - | - | - | - | 1件: 86 86 💬 |
308 | ACT-064992 | - | - | - | - | 5件: 51 51, 85, 86, 88, 210 💬 |
309 | ACT-064992 (macitentan) | 1件: Macitentan Macitentan | 1件: Macitentan
Macitentan
💬 | 2件: EDNRA EDNRA, EDNRB 💬 | 9件: Calcium signaling pathway Calcium signaling pathway, Melanogenesis, Neuroactive ligand-receptor interaction, Pathways in cancer, Relaxin signaling pathway, Renin secretion, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway 💬 | 1件: 85 85 💬 |
310 | ACT-064992 / JNJ-67896062 | - | - | - | - | 1件: 86 86 💬 |
311 | ACT-064992/ JNJ-67896062 | - | - | - | - | 1件: 86 86 💬 |
312 | ACT-064992D | - | - | - | - | 1件: 86 86 💬 |
313 | ACT-293987 (NS-304) | - | - | - | - | 1件: 86 86 💬 |
314 | ACT-293987 / JNJ-67896049 | - | - | - | - | 1件: 84 84 💬 |
315 | ACT-434964 | - | - | - | - | 1件: 19 19 💬 |
316 | ACT-HIB Polvere e solvente per soluzione iniettabile in siringa preriempita 0,5 ml | 1件: Haemophilus influenzae type B strain 1482 capsular polysaccharide tetanus toxoid conjugate antigen Haemophilus influenzae type B strain 1482 capsular polysaccharide tetanus toxoid conjugate antigen | - | - | - | 2件: 61 61, 62 💬 |
317 | Acthar 80 unit injection | 1件: Corticotropin Corticotropin | 1件: Corticotropin
Corticotropin
💬 | 1件: MC2R MC2R 💬 | 5件: Aldosterone synthesis and secretion Aldosterone synthesis and secretion, Cortisol synthesis and secretion, Cushing syndrome, Neuroactive ligand-receptor interaction, cAMP signaling pathway 💬 | 1件: 66 66 💬 |
318 | ACTHAR Gel 40 units twice weekly | 1件: Corticotropin Corticotropin | 1件: Corticotropin
Corticotropin
💬 | 1件: MC2R MC2R 💬 | 5件: Aldosterone synthesis and secretion Aldosterone synthesis and secretion, Cortisol synthesis and secretion, Cushing syndrome, Neuroactive ligand-receptor interaction, cAMP signaling pathway 💬 | 1件: 84 84 💬 |
319 | ACTHAR Gel 80 units twice weekly. | 1件: Corticotropin Corticotropin | 1件: Corticotropin
Corticotropin
💬 | 1件: MC2R MC2R 💬 | 5件: Aldosterone synthesis and secretion Aldosterone synthesis and secretion, Cortisol synthesis and secretion, Cushing syndrome, Neuroactive ligand-receptor interaction, cAMP signaling pathway 💬 | 1件: 84 84 💬 |
320 | Acthar high dose (80 U) | 1件: Corticotropin Corticotropin | 1件: Corticotropin
Corticotropin
💬 | 1件: MC2R MC2R 💬 | 5件: Aldosterone synthesis and secretion Aldosterone synthesis and secretion, Cortisol synthesis and secretion, Cushing syndrome, Neuroactive ligand-receptor interaction, cAMP signaling pathway 💬 | 1件: 49 49 💬 |
321 | Acthar low dose (40 U) | 1件: Corticotropin Corticotropin | 1件: Corticotropin
Corticotropin
💬 | 1件: MC2R MC2R 💬 | 5件: Aldosterone synthesis and secretion Aldosterone synthesis and secretion, Cortisol synthesis and secretion, Cushing syndrome, Neuroactive ligand-receptor interaction, cAMP signaling pathway 💬 | 1件: 49 49 💬 |
322 | ACTHIB - POLVERE E SOLVENTE PER SOLUZIONE INIETTABILE 1 FLACONCINO POLVERE+1 SIRINGA PRERIEMPITA SOLVENTE 0.5 ML | 1件: Haemophilus influenzae type B strain 1482 capsular polysaccharide tetanus toxoid conjugate antigen Haemophilus influenzae type B strain 1482 capsular polysaccharide tetanus toxoid conjugate antigen | - | - | - | 2件: 62 62, 66 💬 |
323 | Active Investigational Treatment ENT-01 | - | - | - | - | 1件: 6 6 💬 |
324 | Active topical NS2 1% dermatologic cream | - | - | - | - | 1件: 160 160 💬 |
325 | Actos 45 mg | 1件: Pioglitazone Pioglitazone | 1件: Pioglitazone
Pioglitazone
💬 | 1件: PPARG PPARG 💬 | 11件: AMPK signaling pathway AMPK signaling pathway, Huntington disease, Lipid and atherosclerosis, Longevity regulating pathway, Non-alcoholic fatty liver disease, Osteoclast differentiation, PPAR signaling pathway, Pathways in cancer, Thermogenesis, Thyroid cancer, Transcriptional misregulation in cancer 💬 | 1件: 2 2 💬 |
326 | ACU-4429 | - | - | - | - | 1件: 301 301 💬 |
327 | ACZ885, 150mg/1.0ml | - | - | - | - | 2件: 266 266, 267 💬 |
328 | AD 452 | - | - | - | - | 1件: 46 46 💬 |
329 | AD 452 18 mg tablet | - | - | - | - | 1件: 46 46 💬 |
330 | AD 452 4.5 mg Tablet | - | - | - | - | 1件: 46 46 💬 |
331 | AD 452 9 mg tablet | - | - | - | - | 1件: 46 46 💬 |
332 | AD-810N (zonisamide) | 1件: Zonisamide Zonisamide | 1件: Zonisamide
Zonisamide
💬 | 8件: CACNA1G CACNA1G, CACNA1H, CACNA1I, SCN1A, SCN2A, SCN3A, SCN5A, SCN9A 💬 | 11件: Adrenergic signaling in cardiomyocytes Adrenergic signaling in cardiomyocytes, Aldosterone synthesis and secretion, Calcium signaling pathway, Circadian entrainment, Cortisol synthesis and secretion, Cushing syndrome, Dopaminergic synapse, GnRH secretion, MAPK signaling pathway, Taste transduction, Type II diabetes mellitus 💬 | 1件: 6 6 💬 |
333 | Ad26.COV2-S.02 | - | - | - | - | 1件: 299 299 💬 |
334 | Adalimumab (40mg) | 1件: Adalimumab Adalimumab | 1件: Adalimumab
Adalimumab
💬 | 1件: TNF TNF 💬 | 67件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Dilated cardiomyopathy, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease, Osteoclast differentiation, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway 💬 | 1件: 107 107 💬 |
335 | Adalimumab 40 mg | 1件: Adalimumab Adalimumab | 1件: Adalimumab
Adalimumab
💬 | 1件: TNF TNF 💬 | 67件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Dilated cardiomyopathy, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease, Osteoclast differentiation, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway 💬 | 1件: 46 46 💬 |
336 | Adalimumab 40 mg eow or ew | 1件: Adalimumab Adalimumab | 1件: Adalimumab
Adalimumab
💬 | 1件: TNF TNF 💬 | 67件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Dilated cardiomyopathy, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease, Osteoclast differentiation, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway 💬 | 1件: 96 96 💬 |
337 | Adalimumab 40 mg sc every other week | 1件: Adalimumab Adalimumab | 1件: Adalimumab
Adalimumab
💬 | 1件: TNF TNF 💬 | 67件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Dilated cardiomyopathy, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease, Osteoclast differentiation, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway 💬 | 1件: 271 271 💬 |
338 | Adalimumab 40 mg subcutaneous (SC) every other week (EOW) | 1件: Adalimumab Adalimumab | 1件: Adalimumab
Adalimumab
💬 | 1件: TNF TNF 💬 | 67件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Dilated cardiomyopathy, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease, Osteoclast differentiation, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway 💬 | 1件: 46 46 💬 |
339 | Adalimumab 40mg | 1件: Adalimumab Adalimumab | 1件: Adalimumab
Adalimumab
💬 | 1件: TNF TNF 💬 | 67件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Dilated cardiomyopathy, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease, Osteoclast differentiation, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway 💬 | 1件: 97 97 💬 |
340 | Adalimumab 40mg q2w | 1件: Adalimumab Adalimumab | 1件: Adalimumab
Adalimumab
💬 | 1件: TNF TNF 💬 | 67件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Dilated cardiomyopathy, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease, Osteoclast differentiation, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway 💬 | 1件: 46 46 💬 |
341 | Adalimumab 80 mg | 1件: Adalimumab Adalimumab | 1件: Adalimumab
Adalimumab
💬 | 1件: TNF TNF 💬 | 67件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Dilated cardiomyopathy, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease, Osteoclast differentiation, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway 💬 | 1件: 46 46 💬 |
342 | Adalimumab, new formulation | 1件: Adalimumab Adalimumab | 1件: Adalimumab
Adalimumab
💬 | 1件: TNF TNF 💬 | 67件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Dilated cardiomyopathy, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease, Osteoclast differentiation, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway 💬 | 1件: 46 46 💬 |
343 | Adalimumab, Solution for Injection 40 mg/ (0.8 ml) Pre-filled Syringe | 1件: Adalimumab Adalimumab | 1件: Adalimumab
Adalimumab
💬 | 1件: TNF TNF 💬 | 67件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Dilated cardiomyopathy, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease, Osteoclast differentiation, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway 💬 | 1件: 46 46 💬 |
344 | ADEMPAS - 0,5 MG - COMPRESSA RIVESTITA CON FILM - USO ORALE - BLISTER (PP/ALU) - 42 COMPRESSE | 1件: Riociguat Riociguat | 1件: Riociguat
Riociguat
💬 | 3件: GUCY1A1 GUCY1A1, GUCY1A2, GUCY1B1 💬 | 11件: Circadian entrainment Circadian entrainment, Gap junction, Long-term depression, Metabolic pathways, Oxytocin signaling pathway, Platelet activation, Purine metabolism, Renin secretion, Salivary secretion, Vascular smooth muscle contraction, cGMP-PKG signaling pathway 💬 | 1件: 86 86 💬 |
345 | ADEMPAS - 1 MG - COMPRESSA RIVESTITA CON FILM - USO ORALE - BLISTER (PP/ALU) - 42 COMPRESSE | 1件: Riociguat Riociguat | 1件: Riociguat
Riociguat
💬 | 3件: GUCY1A1 GUCY1A1, GUCY1A2, GUCY1B1 💬 | 11件: Circadian entrainment Circadian entrainment, Gap junction, Long-term depression, Metabolic pathways, Oxytocin signaling pathway, Platelet activation, Purine metabolism, Renin secretion, Salivary secretion, Vascular smooth muscle contraction, cGMP-PKG signaling pathway 💬 | 2件: 51 51, 86 💬 |
346 | ADEMPAS - 1,5 MG - COMPRESSA RIVESTITA CON FILM - USO ORALE - BLISTER (PP/ALU) - 42 COMPRESSE | 1件: Riociguat Riociguat | 1件: Riociguat
Riociguat
💬 | 3件: GUCY1A1 GUCY1A1, GUCY1A2, GUCY1B1 💬 | 11件: Circadian entrainment Circadian entrainment, Gap junction, Long-term depression, Metabolic pathways, Oxytocin signaling pathway, Platelet activation, Purine metabolism, Renin secretion, Salivary secretion, Vascular smooth muscle contraction, cGMP-PKG signaling pathway 💬 | 2件: 51 51, 86 💬 |
347 | ADEMPAS - 2 MG - COMPRESSA RIVESTITA CON FILM - USO ORALE - BLISTER (PP/ALU) - 42 COMPRESSE | 1件: Riociguat Riociguat | 1件: Riociguat
Riociguat
💬 | 3件: GUCY1A1 GUCY1A1, GUCY1A2, GUCY1B1 💬 | 11件: Circadian entrainment Circadian entrainment, Gap junction, Long-term depression, Metabolic pathways, Oxytocin signaling pathway, Platelet activation, Purine metabolism, Renin secretion, Salivary secretion, Vascular smooth muscle contraction, cGMP-PKG signaling pathway 💬 | 2件: 51 51, 86 💬 |
348 | ADEMPAS - 2,5 MG - COMPRESSA RIVESTITA CON FILM - USO ORALE - BLISTER (PP/ALU) - 42 COMPRESSE | 1件: Riociguat Riociguat | 1件: Riociguat
Riociguat
💬 | 3件: GUCY1A1 GUCY1A1, GUCY1A2, GUCY1B1 💬 | 11件: Circadian entrainment Circadian entrainment, Gap junction, Long-term depression, Metabolic pathways, Oxytocin signaling pathway, Platelet activation, Purine metabolism, Renin secretion, Salivary secretion, Vascular smooth muscle contraction, cGMP-PKG signaling pathway 💬 | 2件: 51 51, 86 💬 |
349 | Adempas 0.125 mg | 1件: Riociguat Riociguat | 1件: Riociguat
Riociguat
💬 | 3件: GUCY1A1 GUCY1A1, GUCY1A2, GUCY1B1 💬 | 11件: Circadian entrainment Circadian entrainment, Gap junction, Long-term depression, Metabolic pathways, Oxytocin signaling pathway, Platelet activation, Purine metabolism, Renin secretion, Salivary secretion, Vascular smooth muscle contraction, cGMP-PKG signaling pathway 💬 | 1件: 299 299 💬 |
350 | Adempas 0.5 mg | 1件: Riociguat Riociguat | 1件: Riociguat
Riociguat
💬 | 3件: GUCY1A1 GUCY1A1, GUCY1A2, GUCY1B1 💬 | 11件: Circadian entrainment Circadian entrainment, Gap junction, Long-term depression, Metabolic pathways, Oxytocin signaling pathway, Platelet activation, Purine metabolism, Renin secretion, Salivary secretion, Vascular smooth muscle contraction, cGMP-PKG signaling pathway 💬 | 2件: 86 86, 299 💬 |
351 | Adempas 0.5 mg Film Coated Tablet | 1件: Riociguat Riociguat | 1件: Riociguat
Riociguat
💬 | 3件: GUCY1A1 GUCY1A1, GUCY1A2, GUCY1B1 💬 | 11件: Circadian entrainment Circadian entrainment, Gap junction, Long-term depression, Metabolic pathways, Oxytocin signaling pathway, Platelet activation, Purine metabolism, Renin secretion, Salivary secretion, Vascular smooth muscle contraction, cGMP-PKG signaling pathway 💬 | 1件: 86 86 💬 |
352 | Adempas 1.0 mg | 1件: Riociguat Riociguat | 1件: Riociguat
Riociguat
💬 | 3件: GUCY1A1 GUCY1A1, GUCY1A2, GUCY1B1 💬 | 11件: Circadian entrainment Circadian entrainment, Gap junction, Long-term depression, Metabolic pathways, Oxytocin signaling pathway, Platelet activation, Purine metabolism, Renin secretion, Salivary secretion, Vascular smooth muscle contraction, cGMP-PKG signaling pathway 💬 | 2件: 86 86, 299 💬 |
353 | Adempas 2.0 mg | 1件: Riociguat Riociguat | 1件: Riociguat
Riociguat
💬 | 3件: GUCY1A1 GUCY1A1, GUCY1A2, GUCY1B1 💬 | 11件: Circadian entrainment Circadian entrainment, Gap junction, Long-term depression, Metabolic pathways, Oxytocin signaling pathway, Platelet activation, Purine metabolism, Renin secretion, Salivary secretion, Vascular smooth muscle contraction, cGMP-PKG signaling pathway 💬 | 2件: 86 86, 299 💬 |
354 | Adempas® 0.5 mg film-coated tablets | 1件: Riociguat Riociguat | 1件: Riociguat
Riociguat
💬 | 3件: GUCY1A1 GUCY1A1, GUCY1A2, GUCY1B1 💬 | 11件: Circadian entrainment Circadian entrainment, Gap junction, Long-term depression, Metabolic pathways, Oxytocin signaling pathway, Platelet activation, Purine metabolism, Renin secretion, Salivary secretion, Vascular smooth muscle contraction, cGMP-PKG signaling pathway 💬 | 1件: 86 86 💬 |
355 | Adempas® 1.0 mg film-coated tablets | 1件: Riociguat Riociguat | 1件: Riociguat
Riociguat
💬 | 3件: GUCY1A1 GUCY1A1, GUCY1A2, GUCY1B1 💬 | 11件: Circadian entrainment Circadian entrainment, Gap junction, Long-term depression, Metabolic pathways, Oxytocin signaling pathway, Platelet activation, Purine metabolism, Renin secretion, Salivary secretion, Vascular smooth muscle contraction, cGMP-PKG signaling pathway 💬 | 1件: 86 86 💬 |
356 | Adempas® 2.0 mg film-coated tablets | 1件: Riociguat Riociguat | 1件: Riociguat
Riociguat
💬 | 3件: GUCY1A1 GUCY1A1, GUCY1A2, GUCY1B1 💬 | 11件: Circadian entrainment Circadian entrainment, Gap junction, Long-term depression, Metabolic pathways, Oxytocin signaling pathway, Platelet activation, Purine metabolism, Renin secretion, Salivary secretion, Vascular smooth muscle contraction, cGMP-PKG signaling pathway 💬 | 1件: 86 86 💬 |
357 | Adempas¿ 0.5 mg compressa rivestita con film | 1件: Riociguat Riociguat | 1件: Riociguat
Riociguat
💬 | 3件: GUCY1A1 GUCY1A1, GUCY1A2, GUCY1B1 💬 | 11件: Circadian entrainment Circadian entrainment, Gap junction, Long-term depression, Metabolic pathways, Oxytocin signaling pathway, Platelet activation, Purine metabolism, Renin secretion, Salivary secretion, Vascular smooth muscle contraction, cGMP-PKG signaling pathway 💬 | 1件: 86 86 💬 |
358 | Adempas¿ 1.0 | 1件: Riociguat Riociguat | 1件: Riociguat
Riociguat
💬 | 3件: GUCY1A1 GUCY1A1, GUCY1A2, GUCY1B1 💬 | 11件: Circadian entrainment Circadian entrainment, Gap junction, Long-term depression, Metabolic pathways, Oxytocin signaling pathway, Platelet activation, Purine metabolism, Renin secretion, Salivary secretion, Vascular smooth muscle contraction, cGMP-PKG signaling pathway 💬 | 1件: 86 86 💬 |
359 | Adempas¿ 2.0 mg | 1件: Riociguat Riociguat | 1件: Riociguat
Riociguat
💬 | 3件: GUCY1A1 GUCY1A1, GUCY1A2, GUCY1B1 💬 | 11件: Circadian entrainment Circadian entrainment, Gap junction, Long-term depression, Metabolic pathways, Oxytocin signaling pathway, Platelet activation, Purine metabolism, Renin secretion, Salivary secretion, Vascular smooth muscle contraction, cGMP-PKG signaling pathway 💬 | 1件: 86 86 💬 |
360 | ADENO-ASSOCIATED VIRAL (AAV) SEROTYPE 8 (AAV2/8) VECTOR WITH LIVER-SPECIFIC THYROXINE-BINDING GLOBULIN (TBG) PROMOTER, DRIVING THE EXPRESSION OF THE HUMAN ARSB GENE | 1件: Levothyroxine Levothyroxine | 1件: Levothyroxine
Levothyroxine
💬 | 2件: THRA THRA, THRB 💬 | 2件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Thyroid hormone signaling pathway 💬 | 1件: 19 19 💬 |
361 | Adeno-associated viral vector serotype 8 containing the human MD1 gene | - | - | - | - | 1件: 113 113 💬 |
362 | Adeno-associated viral vector serotype 9 containing the human N-acetyl-alpha-glucosaminidase gene | - | - | - | - | 1件: 19 19 💬 |
363 | Adeno-associated virus serotype 2/6 encoding human alpha-galactosidase A cDNA | 1件: Agalsidase alfa Agalsidase alfa | 1件: Agalsidase alfa
Agalsidase alfa
💬 | 1件: GLA GLA 💬 | 6件: Galactose metabolism Galactose metabolism, Glycerolipid metabolism, Glycosphingolipid biosynthesis - globo and isoglobo series, Lysosome, Metabolic pathways, Sphingolipid metabolism 💬 | 1件: 19 19 💬 |
364 | Adeno-associated virus serotype 2/6 encoding Human Iduronate 2-sulfatase (hIDS) gene donor vector, SB-A6P-HNT Donor Vector | 1件: Idursulfase Idursulfase | 1件: Idursulfase
Idursulfase
💬 | 1件: IDS IDS 💬 | 3件: Glycosaminoglycan degradation Glycosaminoglycan degradation, Lysosome, Metabolic pathways 💬 | 1件: 19 19 💬 |
365 | Adeno-associated virus serotype 2/6 encoding human iduronidase (hIDUA) gene donor vector, SB-A6P-HRL Donor Vector | - | - | - | - | 1件: 19 19 💬 |
366 | Adeno-associated virus serotype 2/6 encoding Left side-zinc finger nuclease (ZFN1), SB-A6P-ZLEFT Vector | - | - | - | - | 1件: 19 19 💬 |
367 | Adeno-associated virus serotype 2/6 encoding Right side-zinc finger nuclease (ZFN2), SB-A6P-ZRIGHT Vector | - | - | - | - | 1件: 19 19 💬 |
368 | Administration of an ACE-inhibitor or not | - | - | - | - | 1件: 210 210 💬 |
369 | ADS-001 | - | - | - | - | 1件: 231 231 💬 |
370 | Advagraf 0,5mg | 1件: Tacrolimus Tacrolimus | 2件: Tacrolimus
Tacrolimus
,
Tacrolimus
💬 | 5件: PPP3CA PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 💬 | 33件: Alzheimer disease Alzheimer disease, Amphetamine addiction, Amyotrophic lateral sclerosis, Axon guidance, B cell receptor signaling pathway, C-type lectin receptor signaling pathway, Calcium signaling pathway, Cellular senescence, Dopaminergic synapse, Glucagon signaling pathway, Glutamatergic synapse, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Lipid and atherosclerosis, Long-term potentiation, MAPK signaling pathway, Natural killer cell mediated cytotoxicity, Oocyte meiosis, Osteoclast differentiation, Oxytocin signaling pathway, PD-L1 expression and PD-1 checkpoint pathway in cancer, Pathways of neurodegeneration - multiple diseases, Prion disease, Renin secretion, T cell receptor signaling pathway, Th1 and Th2 cell differentiation, Th17 cell differentiation, Tuberculosis, VEGF signaling pathway, Wnt signaling pathway, cGMP-PKG signaling pathway 💬 | 1件: 222 222 💬 |
371 | ADVM-043 | - | - | - | - | 1件: 231 231 💬 |
372 | ADX-629 | - | - | - | - | 1件: 160 160 💬 |
373 | AER-901 Solution for Nebulization | - | - | - | - | 1件: 86 86 💬 |
374 | AEZS-130 (formerly ARD-07) | - | - | - | - | 1件: 78 78 💬 |
375 | AGS-009 | - | - | - | - | 1件: 49 49 💬 |
376 | AIR001 (sodium nitrite inhalation solution) | 1件: Nitrite Nitrite | - | - | - | 1件: 86 86 💬 |
377 | AK106-001616 | 1件: AK106-001616 AK106-001616 | - | - | - | 1件: 46 46 💬 |
378 | AKR-501, YM-477 | - | - | - | - | 1件: 63 63 💬 |
379 | Albuterol nebulizer | 1件: Salbutamol Salbutamol | 1件: Albuterol
Albuterol
💬 | 1件: ADRB2 ADRB2 💬 | 9件: Adrenergic signaling in cardiomyocytes Adrenergic signaling in cardiomyocytes, Calcium signaling pathway, Chemical carcinogenesis - receptor activation, Neuroactive ligand-receptor interaction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, cAMP signaling pathway, cGMP-PKG signaling pathway 💬 | 1件: 89 89 💬 |
380 | ALD518 monoclonal antibody (anti IL-6 mAb) | - | - | - | - | 1件: 46 46 💬 |
381 | Alemtuzumab 0.2 mg | 1件: Alemtuzumab Alemtuzumab | 1件: Alemtuzumab
Alemtuzumab
💬 | 1件: CD52 CD52 💬 | - | 2件: 65 65, 164 💬 |
382 | Alemtuzumab 0.3 mg | 1件: Alemtuzumab Alemtuzumab | 1件: Alemtuzumab
Alemtuzumab
💬 | 1件: CD52 CD52 💬 | - | 2件: 65 65, 164 💬 |
383 | ALK-001 | - | - | - | - | 1件: 301 301 💬 |
384 | ALK-001 (No generic name) | - | - | - | - | 1件: 301 301 💬 |
385 | ALKS 8700 | - | - | - | - | 1件: 13 13 💬 |
386 | ALKS 8700 Delayed Release (DR) | 1件: Manganese citrate Manganese citrate | - | - | - | 1件: 13 13 💬 |
387 | ALKS 8700 Delayed Release (DR) Capsule | 1件: Manganese citrate Manganese citrate | - | - | - | 1件: 13 13 💬 |
388 | All subjects will receive maraviroc 300mg orally twice a day for 6 weeks | 1件: Maraviroc Maraviroc | 1件: Maraviroc
Maraviroc
💬 | 1件: CCR5 CCR5 💬 | 11件: Chemokine signaling pathway Chemokine signaling pathway, Cytokine-cytokine receptor interaction, Endocytosis, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Toxoplasmosis, Viral carcinogenesis, Viral life cycle - HIV-1, Viral protein interaction with cytokine and cytokine receptor, Virion - Human immunodeficiency virus 💬 | 1件: 84 84 💬 |
389 | Allogeneic bone marrow-derived MSCs (1 x 10 6 MSC/kg) | - | - | - | - | 1件: 6 6 💬 |
390 | Allogeneic bone marrow-derived MSCs (10 x 10 6 MSC/kg) | - | - | - | - | 1件: 6 6 💬 |
391 | Allogeneic bone marrow-derived MSCs (3 x 10 6 MSC/kg) | - | - | - | - | 1件: 6 6 💬 |
392 | Allogeneic bone marrow-derived MSCs (6 x 10 6 MSC/kg) | - | - | - | - | 1件: 6 6 💬 |
393 | ALLOGENEIC NEURAL RETINA-DERIVED HUMAN NEURAL RETINAL PROGENITOR CELLS EX VIVO EXPANDED | - | - | - | - | 1件: 90 90 💬 |
394 | ALN-60212 | - | - | - | - | 1件: 79 79 💬 |
395 | ALN-60519 | - | - | - | - | 1件: 254 254 💬 |
396 | ALN-61444 | - | - | - | - | 1件: 231 231 💬 |
397 | ALN-62643 | - | - | - | - | 2件: 62 62, 109 💬 |
398 | ALN-65585 | - | - | - | - | 1件: 234 234 💬 |
399 | ALRN-5281 0.015 mg/kg | - | - | - | - | 1件: 78 78 💬 |
400 | ALRN-5281 0.05 mg/kg | - | - | - | - | 1件: 78 78 💬 |
401 | ALRN-5281 0.15 mg/kg | - | - | - | - | 1件: 78 78 💬 |
402 | ALTH12-1:4 | - | - | - | - | 1件: 97 97 💬 |
403 | ALTH12-2:4 | - | - | - | - | 1件: 97 97 💬 |
404 | ALTRI FARMACI DEL SISTEMA NERVOSO | - | - | - | - | 1件: 13 13 💬 |
405 | ALX-0061 | - | - | - | - | 2件: 46 46, 49 💬 |
406 | ALX-0061 150 mg/mL | - | - | - | - | 1件: 49 49 💬 |
407 | ALX-0061 Nanobody | - | - | - | - | 1件: 46 46 💬 |
408 | ALX-0081 | - | - | - | - | 1件: 64 64 💬 |
409 | ALX-009 | - | - | - | - | 1件: 299 299 💬 |
410 | ALX-0600 | - | - | - | - | 1件: 96 96 💬 |
411 | ALXN2040 (ACH-0144471) | - | - | - | - | 1件: 62 62 💬 |
412 | AM-01 | - | - | - | - | 1件: 51 51 💬 |
413 | AMB-05X | - | - | - | - | 1件: 85 85 💬 |
414 | AMBROSAN 60mg Tablets | - | - | - | - | 1件: 6 6 💬 |
415 | AMG 407 | - | - | - | - | 2件: 56 56, 107 💬 |
416 | AMG 623 | - | - | - | - | 1件: 49 49 💬 |
417 | AMG 811 | - | - | - | - | 1件: 49 49 💬 |
418 | AMG 827 | - | - | - | - | 2件: 46 46, 96 💬 |
419 | AMG 827 140 mg | - | - | - | - | 1件: 46 46 💬 |
420 | AMG 827 210 mg | - | - | - | - | 2件: 46 46, 96 💬 |
421 | AMG 827 350 MG | - | - | - | - | 1件: 96 96 💬 |
422 | AMG 827 70 mg | - | - | - | - | 1件: 46 46 💬 |
423 | AMG 827 700 MG | - | - | - | - | 1件: 96 96 💬 |
424 | AMG-407 | - | - | - | - | 2件: 56 56, 107 💬 |
425 | Amgevita 40 mg Injektionslösung im Fertigpen | 1件: Adalimumab Adalimumab | 1件: Adalimumab
Adalimumab
💬 | 1件: TNF TNF 💬 | 67件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Dilated cardiomyopathy, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease, Osteoclast differentiation, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway 💬 | 2件: 96 96, 97 💬 |
426 | Amgevita 40 mg Injektionslösung in einer Fertigspritze | 1件: Adalimumab Adalimumab | 1件: Adalimumab
Adalimumab
💬 | 1件: TNF TNF 💬 | 67件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Dilated cardiomyopathy, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease, Osteoclast differentiation, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway 💬 | 2件: 96 96, 97 💬 |
427 | Amgevita 40Mg Solution for Injection | - | - | - | - | 2件: 96 96, 97 💬 |
428 | Amikacin nebulization | 1件: Amikacin Amikacin | 1件: Amikacin
Amikacin
💬 | - | - | 1件: 299 299 💬 |
429 | Amikacine nebulization | 1件: Amikacin Amikacin | 1件: Amikacin
Amikacin
💬 | - | - | 1件: 299 299 💬 |
430 | Amikin, amiklin, amicacin, BB-K8, Biklin, Fabianol, Kaminax, Mikavir, Novamin, Pierami | 1件: Amikacin Amikacin | 1件: Amikacin
Amikacin
💬 | - | - | 1件: 299 299 💬 |
431 | Amikin®, amiklin, amicacin, BB-K8, Biklin®, Fabianol®, Kaminax, Mikavir, Novamin®, Pierami | 1件: Amikacin Amikacin | 1件: Amikacin
Amikacin
💬 | - | - | 1件: 299 299 💬 |
432 | Amyl Nitrite | 2件: Amyl Nitrite Amyl Nitrite, Nitrite | 1件: Amyl nitrite
Amyl nitrite
💬 | 3件: GUCY1A1 GUCY1A1, GUCY1A2, GUCY1B1 💬 | 11件: Circadian entrainment Circadian entrainment, Gap junction, Long-term depression, Metabolic pathways, Oxytocin signaling pathway, Platelet activation, Purine metabolism, Renin secretion, Salivary secretion, Vascular smooth muscle contraction, cGMP-PKG signaling pathway 💬 | 1件: 58 58 💬 |
433 | Amyl nitrite inhalation | 2件: Amyl Nitrite Amyl Nitrite, Nitrite | 1件: Amyl nitrite
Amyl nitrite
💬 | 3件: GUCY1A1 GUCY1A1, GUCY1A2, GUCY1B1 💬 | 11件: Circadian entrainment Circadian entrainment, Gap junction, Long-term depression, Metabolic pathways, Oxytocin signaling pathway, Platelet activation, Purine metabolism, Renin secretion, Salivary secretion, Vascular smooth muscle contraction, cGMP-PKG signaling pathway 💬 | 1件: 58 58 💬 |
434 | ANA001XHCl (Syntagon) or VEXA-04 (Patheon) | - | - | - | - | 1件: 156 156 💬 |
435 | Analysis of selected single nucleotide polymorphisms (SNPs) | - | - | - | - | 1件: 46 46 💬 |
436 | Anatomical Landmark-guided Suprascapular Nerve Block | - | - | - | - | 1件: 149 149 💬 |
437 | Anti IL 6 mAb | - | - | - | - | 1件: 46 46 💬 |
438 | Anti-(human tumor necrosis factor) immunoglobulin G (human-mouse monoclonal cA2 heavy chain) | - | - | - | - | 1件: 271 271 💬 |
439 | Anti-Beta Interferon (PF-06823859) | - | - | - | - | 1件: 50 50 💬 |
440 | Anti-CD20 small modular immunopharmaceutical, WYE-400087 | - | - | - | - | 1件: 46 46 💬 |
441 | Anti-IL-20 (109-0012) | 1件: Fletikumab Fletikumab | 1件: Fletikumab
Fletikumab
💬 | 1件: IL20 IL20 💬 | 3件: Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, JAK-STAT signaling pathway, Viral protein interaction with cytokine and cytokine receptor 💬 | 1件: 46 46 💬 |
442 | Anti-IL-6 mAb | - | - | - | - | 2件: 46 46, 96 💬 |
443 | Anti-Interleukin-6 Monoclonal | - | - | - | - | 1件: 46 46 💬 |
444 | Anti-Interleukin-6 Monoclonal Antibody | - | - | - | - | 2件: 46 46, 96 💬 |
445 | Anti-Tumor Necrosing Factor (TNF) Therapy | - | - | - | - | 1件: 46 46 💬 |
446 | Anti-Tumor Necrosis Factor | - | - | - | - | 1件: 271 271 💬 |
447 | Anti-Tumor Necrosis Factor Alpha Drug (Product) | - | - | - | - | 1件: 46 46 💬 |
448 | Anti-tumor necrosis factor alpha monoclonal antibody | - | - | - | - | 1件: 107 107 💬 |
449 | Anti-von Willebrand Factor Nanobody | 1件: Von Willebrand factor human Von Willebrand factor human | - | - | - | 1件: 64 64 💬 |
450 | Anti-von Willebrand Factor Nanobody, Caplacizumab | 2件: Caplacizumab Caplacizumab, Von Willebrand factor human | 1件: Caplacizumab
Caplacizumab
💬 | 1件: VWF VWF 💬 | 8件: Complement and coagulation cascades Complement and coagulation cascades, Coronavirus disease - COVID-19, ECM-receptor interaction, Focal adhesion, Human papillomavirus infection, Neutrophil extracellular trap formation, PI3K-Akt signaling pathway, Platelet activation 💬 | 1件: 64 64 💬 |
451 | Anti-von Willebrand Factor Nanobody, INN = Caplacizumab | 2件: Caplacizumab Caplacizumab, Von Willebrand factor human | 1件: Caplacizumab
Caplacizumab
💬 | 1件: VWF VWF 💬 | 8件: Complement and coagulation cascades Complement and coagulation cascades, Coronavirus disease - COVID-19, ECM-receptor interaction, Focal adhesion, Human papillomavirus infection, Neutrophil extracellular trap formation, PI3K-Akt signaling pathway, Platelet activation 💬 | 1件: 64 64 💬 |
452 | Anticuerpo monoclonal anti-humano recombinante humanizado, receptor de IL-6R. | - | - | - | - | 1件: 46 46 💬 |
453 | AP1189, 60 mg | - | - | - | - | 1件: 46 46 💬 |
454 | AP1189, 80 mg | - | - | - | - | 1件: 46 46 💬 |
455 | Apomorphine 0.25% (2.5mg/ml) | 1件: Apomorphine Apomorphine | 1件: Apomorphine
Apomorphine
💬 | 2件: DRD1 DRD1, DRD2 💬 | 11件: Alcoholism Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway 💬 | 1件: 6 6 💬 |
456 | Apomorphine hydrochloride 1.8mg inhalation powder, pre-dispensed | 1件: Apomorphine Apomorphine | 1件: Apomorphine
Apomorphine
💬 | 2件: DRD1 DRD1, DRD2 💬 | 11件: Alcoholism Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway 💬 | 1件: 6 6 💬 |
457 | Apomorphine hydrochloride 2.8mg inhalation powder, pre-dispensed | 1件: Apomorphine Apomorphine | 1件: Apomorphine
Apomorphine
💬 | 2件: DRD1 DRD1, DRD2 💬 | 11件: Alcoholism Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway 💬 | 1件: 6 6 💬 |
458 | Apomorphine hydrochloride 4.0 mg inhalation powder, pre-dispensed | 1件: Apomorphine Apomorphine | 1件: Apomorphine
Apomorphine
💬 | 2件: DRD1 DRD1, DRD2 💬 | 11件: Alcoholism Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway 💬 | 1件: 6 6 💬 |
459 | Apomorphine hydrochloride 5.8 mg inhalation powder, pre-dispensed | 1件: Apomorphine Apomorphine | 1件: Apomorphine
Apomorphine
💬 | 2件: DRD1 DRD1, DRD2 💬 | 11件: Alcoholism Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway 💬 | 1件: 6 6 💬 |
460 | Apomorphine Nasal Powder | 1件: Apomorphine Apomorphine | 1件: Apomorphine
Apomorphine
💬 | 2件: DRD1 DRD1, DRD2 💬 | 11件: Alcoholism Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway 💬 | 1件: 6 6 💬 |
461 | Apraclonidine Hcl 0.5% Oph Soln | 1件: Apraclonidine Apraclonidine | 1件: Apraclonidine
Apraclonidine
💬 | 3件: ADRA2A ADRA2A, ADRA2B, ADRA2C 💬 | 2件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, cGMP-PKG signaling pathway 💬 | 1件: 11 11 💬 |
462 | Apriso 0.375G ER CAP | - | - | - | - | 1件: 97 97 💬 |
463 | AR-42 | 1件: AR-42 AR-42 | - | - | - | 1件: 34 34 💬 |
464 | Arbaclofen placarbil 45 mg BID | 2件: Arbaclofen Arbaclofen, Arbaclofen Placarbil | 2件: Arbaclofen placarbil
Arbaclofen placarbil
,
Arbaclofen
💬 | 2件: GABBR1 GABBR1, GABBR2 💬 | 7件: Estrogen signaling pathway Estrogen signaling pathway, GABAergic synapse, GnRH secretion, Morphine addiction, Neuroactive ligand-receptor interaction, Taste transduction, cAMP signaling pathway 💬 | 1件: 13 13 💬 |
465 | ARCT-032 | - | - | - | - | 1件: 299 299 💬 |
466 | ARCT-810 | - | - | - | - | 1件: 251 251 💬 |
467 | ARN-6039 | - | - | - | - | 1件: 13 13 💬 |
468 | ARRY-438162 | - | - | - | - | 1件: 46 46 💬 |
469 | ARRY-438162, MEK inhibitor | - | - | - | - | 1件: 46 46 💬 |
470 | Asacol 400 mg | - | - | - | - | 1件: 97 97 💬 |
471 | Asacol 400 mg (mesalamine) | 1件: Mesalazine Mesalazine | 1件: Mesalamine
Mesalamine
💬 | - | - | 1件: 97 97 💬 |
472 | Asacol 400 mg tablet | 1件: Mesalazine Mesalazine | 1件: Mesalamine
Mesalamine
💬 | - | - | 1件: 97 97 💬 |
473 | Asacol 400mg tablet | 1件: Mesalazine Mesalazine | 1件: Mesalamine
Mesalamine
💬 | - | - | 1件: 97 97 💬 |
474 | Asacol 800 mg (mesalamine) | 1件: Mesalazine Mesalazine | 1件: Mesalamine
Mesalamine
💬 | - | - | 1件: 97 97 💬 |
475 | Asacol 800 mg tablet | 1件: Mesalazine Mesalazine | 1件: Mesalamine
Mesalamine
💬 | - | - | 1件: 97 97 💬 |
476 | Asacol 800mg tablet | 1件: Mesalazine Mesalazine | 1件: Mesalamine
Mesalamine
💬 | - | - | 1件: 97 97 💬 |
477 | Asacol® 400 mg | - | - | - | - | 1件: 97 97 💬 |
478 | ASB-683699 | - | - | - | - | 1件: 13 13 💬 |
479 | ASF-1096 Cream 0.25% | - | - | - | - | 1件: 49 49 💬 |
480 | ASF-1096 Cream 0.5% | - | - | - | - | 1件: 49 49 💬 |
481 | ASF-1096 Cream 1.0% | - | - | - | - | 1件: 49 49 💬 |
482 | ASK Nr. 21972 | - | - | - | - | 1件: 5 5 💬 |
483 | ASP015K hydrobromide, AS1940150-BR, JKT-201A, 4-{[(1R,2s,3S,5s,7s)-5-Hydroxy-2-adamantyl]amino}-1H-pyrrolo[2,3-b]pyridine-5-carboxamide monohydrobromide | - | - | - | - | 1件: 46 46 💬 |
484 | Aspirin 650mg Oral Capsule | 1件: Acetylsalicylic acid Acetylsalicylic acid | 1件: Aspirin
Aspirin
💬 | 2件: PTGS1 PTGS1, PTGS2 💬 | 23件: Alzheimer disease Alzheimer disease, Arachidonic acid metabolism, C-type lectin receptor signaling pathway, Chemical carcinogenesis - DNA adducts, Human cytomegalovirus infection, Human papillomavirus infection, IL-17 signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Metabolic pathways, MicroRNAs in cancer, NF-kappa B signaling pathway, Ovarian steroidogenesis, Oxytocin signaling pathway, Pathways in cancer, Pathways of neurodegeneration - multiple diseases, Platelet activation, Regulation of lipolysis in adipocytes, Retrograde endocannabinoid signaling, Serotonergic synapse, Small cell lung cancer, TNF signaling pathway, VEGF signaling pathway 💬 | 1件: 13 13 💬 |
485 | Aspirin 81mg tablet | 1件: Acetylsalicylic acid Acetylsalicylic acid | 1件: Aspirin
Aspirin
💬 | 2件: PTGS1 PTGS1, PTGS2 💬 | 23件: Alzheimer disease Alzheimer disease, Arachidonic acid metabolism, C-type lectin receptor signaling pathway, Chemical carcinogenesis - DNA adducts, Human cytomegalovirus infection, Human papillomavirus infection, IL-17 signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Metabolic pathways, MicroRNAs in cancer, NF-kappa B signaling pathway, Ovarian steroidogenesis, Oxytocin signaling pathway, Pathways in cancer, Pathways of neurodegeneration - multiple diseases, Platelet activation, Regulation of lipolysis in adipocytes, Retrograde endocannabinoid signaling, Serotonergic synapse, Small cell lung cancer, TNF signaling pathway, VEGF signaling pathway 💬 | 1件: 46 46 💬 |
486 | AT2221 65 mg Formulated Capsules | - | - | - | - | 1件: 256 256 💬 |
487 | Atazanavir (ATV) + ritonavir (RTV), continuation of backbone 2 nucleoside reverse transcriptase inhibitor (NRTIs) | 2件: Atazanavir Atazanavir, Ritonavir | 2件: Ritonavir
Ritonavir
,
Atazanavir
💬 | - | - | 1件: 265 265 💬 |
488 | ATI-450 | - | - | - | - | 2件: 46 46, 106 💬 |
489 | ATI-450 20mg oral tablet BID | - | - | - | - | 1件: 46 46 💬 |
490 | ATI-450 50mg oral tablet BID | - | - | - | - | 1件: 46 46 💬 |
491 | ATN-103 80 mg q4wks | - | - | - | - | 1件: 46 46 💬 |
492 | ATN-103 80 mg q8wks | - | - | - | - | 1件: 46 46 💬 |
493 | Atorvastatin 40 Mg Oral Tablet + N-acetylcysteine 400 mg Oral tablet | 2件: Acetylcysteine Acetylcysteine, Atorvastatin | 2件: Acetylcysteine
Acetylcysteine
,
Atorvastatin
💬 | 1件: HMGCR HMGCR 💬 | 4件: AMPK signaling pathway AMPK signaling pathway, Bile secretion, Metabolic pathways, Terpenoid backbone biosynthesis 💬 | 1件: 63 63 💬 |
494 | Atorvastatin 80mg | 1件: Atorvastatin Atorvastatin | 1件: Atorvastatin
Atorvastatin
💬 | 1件: HMGCR HMGCR 💬 | 4件: AMPK signaling pathway AMPK signaling pathway, Bile secretion, Metabolic pathways, Terpenoid backbone biosynthesis 💬 | 1件: 97 97 💬 |
495 | ATYR1923 1.0 mg/kg | 1件: ATYR1923 ATYR1923 | - | - | - | 1件: 84 84 💬 |
496 | ATYR1923 3.0 mg/kg | 1件: ATYR1923 ATYR1923 | - | - | - | 1件: 84 84 💬 |
497 | ATYR1923 5.0 mg/kg | 1件: ATYR1923 ATYR1923 | - | - | - | 1件: 84 84 💬 |
498 | Autologous cardiac stem cells (JRM-001) | - | - | - | - | 2件: 210 210, 211 💬 |
499 | AUTOLOGOUS CD34+CELLS TRANSDUCED WITH THE W1.6_HWASP_WPRE (VSVG) LENTIVIRAL VECTOR | - | - | - | - | 1件: 65 65 💬 |
500 | Autologous MSC-NTF cells | - | - | - | - | 1件: 2 2 💬 |
501 | Avalglucosidase Alfa (NeoGAA) | 1件: Avalglucosidase alfa Avalglucosidase alfa | 1件: Avalglucosidase alfa
Avalglucosidase alfa
💬 | 1件: GAA GAA 💬 | 4件: Galactose metabolism Galactose metabolism, Lysosome, Metabolic pathways, Starch and sucrose metabolism 💬 | 1件: 256 256 💬 |
502 | Avalglucosidase alfa-NGPT (GZ402666) | 1件: Avalglucosidase alfa Avalglucosidase alfa | 1件: Avalglucosidase alfa
Avalglucosidase alfa
💬 | 1件: GAA GAA 💬 | 4件: Galactose metabolism Galactose metabolism, Lysosome, Metabolic pathways, Starch and sucrose metabolism 💬 | 1件: 256 256 💬 |
503 | Avalglucosidase alfa-NGPT (GZ402666) IV | 1件: Avalglucosidase alfa Avalglucosidase alfa | 1件: Avalglucosidase alfa
Avalglucosidase alfa
💬 | 1件: GAA GAA 💬 | 4件: Galactose metabolism Galactose metabolism, Lysosome, Metabolic pathways, Starch and sucrose metabolism 💬 | 1件: 256 256 💬 |
504 | AVALOX - 400 | - | - | - | - | 1件: 6 6 💬 |
505 | Avandia administration for 6-12 weeks | - | - | - | - | 1件: 265 265 💬 |
506 | AVI-4658 | - | - | - | - | 1件: 113 113 💬 |
507 | AVI-4658 (Eteplirsen) | 1件: Eteplirsen Eteplirsen | 1件: Eteplirsen
Eteplirsen
💬 | 1件: DMD DMD 💬 | 4件: Arrhythmogenic right ventricular cardiomyopathy Arrhythmogenic right ventricular cardiomyopathy, Dilated cardiomyopathy, Hypertrophic cardiomyopathy, Viral myocarditis 💬 | 1件: 113 113 💬 |
508 | AVI-4658 (PMO) | - | - | - | - | 1件: 113 113 💬 |
509 | AVI-4658 for Injection | - | - | - | - | 1件: 113 113 💬 |
510 | Aviptadil, 66 microgram/mL | 1件: Aviptadil Aviptadil | 1件: Aviptadil
Aviptadil
💬 | - | - | 1件: 85 85 💬 |
511 | AVONEX - 30 MCG (6 MILIONI UI) POLVERE E SOLVENTE PER SOLUZIONE INIETTABILE 4 FLACONI CON DISPOSITIVO BIOSET + 4 SIRINGHE PRERIEMPITE USO INTRAMUSCOLARE | 1件: Interferon beta-1a Interferon beta-1a | 1件: Interferon beta-1a
Interferon beta-1a
💬 | 2件: IFNAR1 IFNAR1, IFNAR2 💬 | 18件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Measles, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Osteoclast differentiation, PI3K-Akt signaling pathway, Pathways in cancer, Toll-like receptor signaling pathway 💬 | 1件: 13 13 💬 |
512 | Avonex 30 microgram/0.5 ml Solution for Injection | 1件: Interferon beta-1a Interferon beta-1a | 1件: Interferon beta-1a
Interferon beta-1a
💬 | 2件: IFNAR1 IFNAR1, IFNAR2 💬 | 18件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Measles, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Osteoclast differentiation, PI3K-Akt signaling pathway, Pathways in cancer, Toll-like receptor signaling pathway 💬 | 1件: 13 13 💬 |
513 | AVONEX 30 microgramos/0,5 ml (Interferón Beta - 1a) Solución inyectable | 1件: Interferon beta-1a Interferon beta-1a | 1件: Interferon beta-1a
Interferon beta-1a
💬 | 2件: IFNAR1 IFNAR1, IFNAR2 💬 | 18件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Measles, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Osteoclast differentiation, PI3K-Akt signaling pathway, Pathways in cancer, Toll-like receptor signaling pathway 💬 | 1件: 13 13 💬 |
514 | Avonex 30 microgramos/0.5 ml Solución para inyección | 1件: Interferon beta-1a Interferon beta-1a | 1件: Interferon beta-1a
Interferon beta-1a
💬 | 2件: IFNAR1 IFNAR1, IFNAR2 💬 | 18件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Measles, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Osteoclast differentiation, PI3K-Akt signaling pathway, Pathways in cancer, Toll-like receptor signaling pathway 💬 | 1件: 13 13 💬 |
515 | AVONEX 30 µg/0,5 ml solution for injection | 1件: Interferon beta-1a Interferon beta-1a | 1件: Interferon beta-1a
Interferon beta-1a
💬 | 2件: IFNAR1 IFNAR1, IFNAR2 💬 | 18件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Measles, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Osteoclast differentiation, PI3K-Akt signaling pathway, Pathways in cancer, Toll-like receptor signaling pathway 💬 | 1件: 13 13 💬 |
516 | AVONEX IM 4SIR 30MCG/0,5ML 4AG | 1件: Interferon beta-1a Interferon beta-1a | 1件: Interferon beta-1a
Interferon beta-1a
💬 | 2件: IFNAR1 IFNAR1, IFNAR2 💬 | 18件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Measles, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Osteoclast differentiation, PI3K-Akt signaling pathway, Pathways in cancer, Toll-like receptor signaling pathway 💬 | 1件: 13 13 💬 |
517 | AVONEX*IM 4SIR 30MCG/0,5ML+4AG | 1件: Interferon beta-1a Interferon beta-1a | 1件: Interferon beta-1a
Interferon beta-1a
💬 | 2件: IFNAR1 IFNAR1, IFNAR2 💬 | 18件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Measles, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Osteoclast differentiation, PI3K-Akt signaling pathway, Pathways in cancer, Toll-like receptor signaling pathway 💬 | 1件: 13 13 💬 |
518 | Avonex® monotherapy (6.0 MIU administered i.m. each week) | 1件: Interferon beta-1a Interferon beta-1a | 1件: Interferon beta-1a
Interferon beta-1a
💬 | 2件: IFNAR1 IFNAR1, IFNAR2 💬 | 18件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Measles, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Osteoclast differentiation, PI3K-Akt signaling pathway, Pathways in cancer, Toll-like receptor signaling pathway 💬 | 1件: 13 13 💬 |
519 | AVP-923-45 | - | - | - | - | 1件: 6 6 💬 |
520 | AVR-RD-01 | - | - | - | - | 1件: 19 19 💬 |
521 | AVR-RD-02 | - | - | - | - | 1件: 19 19 💬 |
522 | AVTX-803 | - | - | - | - | 1件: 65 65 💬 |
523 | AVTX-803 (L-Fucose) | 1件: Fucose Fucose | - | - | - | 1件: 65 65 💬 |
524 | AVX 470 | - | - | - | - | 1件: 97 97 💬 |
525 | Azathioprine (AZA) or 6-mercaptopurine (6-MP) | 2件: Azathioprine Azathioprine, Mercaptopurine | 3件: Mercaptopurine
Mercaptopurine
,
Azathioprine
,
Mercaptopurine
💬 | 1件: HPRT1 HPRT1 💬 | 4件: Drug metabolism - other enzymes Drug metabolism - other enzymes, Metabolic pathways, Nucleotide metabolism, Purine metabolism 💬 | 2件: 96 96, 97 💬 |
526 | Azathioprine / 6 Mercaptopurine | 2件: Azathioprine Azathioprine, Mercaptopurine | 3件: Mercaptopurine
Mercaptopurine
,
Azathioprine
,
Mercaptopurine
💬 | 1件: HPRT1 HPRT1 💬 | 4件: Drug metabolism - other enzymes Drug metabolism - other enzymes, Metabolic pathways, Nucleotide metabolism, Purine metabolism 💬 | 1件: 96 96 💬 |
527 | Azathioprine or 6-mercaptopurine | 2件: Azathioprine Azathioprine, Mercaptopurine | 3件: Mercaptopurine
Mercaptopurine
,
Azathioprine
,
Mercaptopurine
💬 | 1件: HPRT1 HPRT1 💬 | 4件: Drug metabolism - other enzymes Drug metabolism - other enzymes, Metabolic pathways, Nucleotide metabolism, Purine metabolism 💬 | 2件: 96 96, 97 💬 |
528 | Azathioprine+enteral nutrition | 1件: Azathioprine Azathioprine | 1件: Azathioprine
Azathioprine
💬 | - | - | 1件: 96 96 💬 |
529 | AZD3241 600 mg BID | - | - | - | - | 1件: 6 6 💬 |
530 | AZD9567 40 mg | - | - | - | - | 1件: 46 46 💬 |
531 | AZD9567 80 mg | - | - | - | - | 1件: 46 46 💬 |
532 | Azithromycin + N-acetylcystein + inhaled corticosteroid | 1件: Azithromycin Azithromycin | 2件: Azithromycin
Azithromycin
,
Azithromycin
💬 | - | - | 1件: 228 228 💬 |
533 | Aztreonam solución para inhalación | 1件: Aztreonam Aztreonam | 1件: Aztreonam
Aztreonam
💬 | - | - | 1件: 299 299 💬 |
534 | Aún no establecido | - | - | - | - | 1件: 53 53 💬 |
535 | Baclofen ER Capsules (GRS) 40mg | 1件: Baclofen Baclofen | 1件: Baclofen
Baclofen
💬 | 2件: GABBR1 GABBR1, GABBR2 💬 | 7件: Estrogen signaling pathway Estrogen signaling pathway, GABAergic synapse, GnRH secretion, Morphine addiction, Neuroactive ligand-receptor interaction, Taste transduction, cAMP signaling pathway 💬 | 1件: 13 13 💬 |
536 | BAF312 0,25 mg tablet | - | - | - | - | 1件: 13 13 💬 |
537 | BAF312 0,5 mg tablet | - | - | - | - | 1件: 50 50 💬 |
538 | BAF312 0.25 mg | - | - | - | - | 1件: 50 50 💬 |
539 | BAF312 0.25 mg tablet | - | - | - | - | 1件: 50 50 💬 |
540 | BAF312 0.25mg tablet | - | - | - | - | 1件: 50 50 💬 |
541 | BAF312 0.5 mg | - | - | - | - | 1件: 50 50 💬 |
542 | BAF312 0.50 mg | - | - | - | - | 1件: 50 50 💬 |
543 | BAF312 4 mg tablet | - | - | - | - | 1件: 13 13 💬 |
544 | BAF312 4mg tablet | - | - | - | - | 1件: 50 50 💬 |
545 | BARDOXOLONE METHYL, CDDO-Me, CDDO-Methyl Ester, NSC 713200, Chemical Name: Oleana-1,9(11)-dien-28-oic acid, 2-cyano-3,12-dioxo-, methyl ester | 2件: Bardoxolone Bardoxolone, Bardoxolone methyl | 2件: Bardoxolone
Bardoxolone
,
Bardoxolone methyl
💬 | - | - | 1件: 86 86 💬 |
546 | Baricitinib 4 MG | 1件: Baricitinib Baricitinib | 1件: Baricitinib
Baricitinib
💬 | 2件: JAK1 JAK1, JAK2 💬 | 35件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, Chemical carcinogenesis - receptor activation, Chemokine signaling pathway, Cholinergic synapse, Coronavirus disease - COVID-19, EGFR tyrosine kinase inhibitor resistance, Epstein-Barr virus infection, Growth hormone synthesis, secretion and action, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Lipid and atherosclerosis, Measles, NOD-like receptor signaling pathway, Necroptosis, Osteoclast differentiation, PD-L1 expression and PD-1 checkpoint pathway in cancer, PI3K-Akt signaling pathway, Pancreatic cancer, Pathways in cancer, Prolactin signaling pathway, Signaling pathways regulating pluripotency of stem cells, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toxoplasmosis, Tuberculosis, Viral carcinogenesis 💬 | 1件: 46 46 💬 |
547 | Batoclimab 680 mg SC weekly | 1件: Batoclimab Batoclimab | 1件: Batoclimab
Batoclimab
💬 | 1件: FCGRT FCGRT 💬 | - | 1件: 11 11 💬 |
548 | Batoclimab 680 milligrams (mg) subcutaneous (SC) weekly | 1件: Batoclimab Batoclimab | 1件: Batoclimab
Batoclimab
💬 | 1件: FCGRT FCGRT 💬 | - | 1件: 14 14 💬 |
549 | BAY 63-2521 | - | - | - | - | 2件: 86 86, 88 💬 |
550 | BAY 63-2521 0.06 % | - | - | - | - | 1件: 86 86 💬 |
551 | BAY 63-2521 0.3 % | - | - | - | - | 1件: 86 86 💬 |
552 | BAY 63-2521 coated tablets 0.5 mg | - | - | - | - | 2件: 86 86, 88 💬 |
553 | BAY 63-2521 coated tablets 1 mg | - | - | - | - | 2件: 86 86, 88 💬 |
554 | BAY 63-2521 coated tablets 1.5 mg | - | - | - | - | 2件: 86 86, 88 💬 |
555 | BAY 63-2521 coated tablets 2 mg | - | - | - | - | 2件: 86 86, 88 💬 |
556 | BAY 63-2521 coated tablets 2.5 mg | - | - | - | - | 2件: 86 86, 88 💬 |
557 | BAY 63-2521 IR coated tablet 1.0 mg | - | - | - | - | 1件: 88 88 💬 |
558 | BAY 63-2521 IR coated tablet 1.5 mg | - | - | - | - | 1件: 88 88 💬 |
559 | BAY 63-2521 IR coated tablet 2.0 mg | - | - | - | - | 1件: 88 88 💬 |
560 | BAY 63-2521 IR coated tablet 2.5 mg | - | - | - | - | 1件: 88 88 💬 |
561 | BAY 63-2521 IR tablet 0.5 mg | - | - | - | - | 1件: 88 88 💬 |
562 | BAY 63-2521 IR tablet 1.0 mg | - | - | - | - | 1件: 88 88 💬 |
563 | BAY 63-2521 IR tablet 1.5 mg | - | - | - | - | 1件: 88 88 💬 |
564 | BAY 63-2521 IR tablet 2.0 mg | - | - | - | - | 1件: 88 88 💬 |
565 | BAY 63-2521 IR tablet 2.5 mg | - | - | - | - | 1件: 88 88 💬 |
566 | BAY 63-2521 IR tablets 0.5 mg | - | - | - | - | 1件: 86 86 💬 |
567 | BAY 63-2521 IR tablets 1 mg | - | - | - | - | 1件: 86 86 💬 |
568 | BAY 63-2521 IR tablets 1.0 mg | - | - | - | - | 1件: 86 86 💬 |
569 | BAY 63-2521 IR tablets 1.5 mg | - | - | - | - | 1件: 86 86 💬 |
570 | BAY 63-2521 IR tablets 2.0 mg | - | - | - | - | 1件: 86 86 💬 |
571 | BAY 63-2521 IR tablets 2.5 mg | - | - | - | - | 1件: 86 86 💬 |
572 | BAY 63-2521 Tablet | - | - | - | - | 1件: 86 86 💬 |
573 | BAY 63-2521 tablets 0.5 mg | - | - | - | - | 2件: 86 86, 88 💬 |
574 | BAY 63-2521 tablets 1 mg | - | - | - | - | 2件: 86 86, 88 💬 |
575 | BAY 63-2521 tablets 1.5 mg | - | - | - | - | 2件: 86 86, 88 💬 |
576 | BAY 63-2521 tablets 2 mg | - | - | - | - | 2件: 86 86, 88 💬 |
577 | BAY 63-2521 tablets 2.5 mg | - | - | - | - | 2件: 86 86, 88 💬 |
578 | BAY 79-4998 | - | - | - | - | 1件: 13 13 💬 |
579 | BAY 85-8501 | - | - | - | - | 1件: 299 299 💬 |
580 | Bay Q 6256 | - | - | - | - | 1件: 86 86 💬 |
581 | BAY85-8501 | - | - | - | - | 1件: 299 299 💬 |
582 | BBP-418 | - | - | - | - | 1件: 113 113 💬 |
583 | BBP-671 | - | - | - | - | 2件: 245 245, 246 💬 |
584 | BBP-812 | 1件: BBP-812 BBP-812 | - | - | - | 1件: 307 307 💬 |
585 | BBT-401-1S | - | - | - | - | 1件: 97 97 💬 |
586 | BBT-401-1S, Multiple doses | - | - | - | - | 1件: 97 97 💬 |
587 | BBT-401-1S, Single dose | - | - | - | - | 1件: 97 97 💬 |
588 | BBT-877 | - | - | - | - | 1件: 85 85 💬 |
589 | BBT-877, Multiple doses | - | - | - | - | 1件: 85 85 💬 |
590 | BBT-877, Single dose | - | - | - | - | 1件: 85 85 💬 |
591 | BCD-033 (interferon beta 1a) | 2件: Human interferon beta Human interferon beta, Interferon beta-1a | 1件: Interferon beta-1a
Interferon beta-1a
💬 | 2件: IFNAR1 IFNAR1, IFNAR2 💬 | 18件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Measles, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Osteoclast differentiation, PI3K-Akt signaling pathway, Pathways in cancer, Toll-like receptor signaling pathway 💬 | 1件: 13 13 💬 |
592 | BCD-054 180 mcg | - | - | - | - | 1件: 13 13 💬 |
593 | BCD-054 240 mcg | - | - | - | - | 1件: 13 13 💬 |
594 | BCD-055 | - | - | - | - | 2件: 46 46, 271 💬 |
595 | BCD-063 | - | - | - | - | 1件: 13 13 💬 |
596 | BCD-085 | - | - | - | - | 2件: 93 93, 271 💬 |
597 | BCD-089 | - | - | - | - | 1件: 46 46 💬 |
598 | BCD-089, 162 mg, s/c, q2w | - | - | - | - | 1件: 46 46 💬 |
599 | BCD-089, 162 mg, s/c, qw | - | - | - | - | 1件: 46 46 💬 |
600 | BCG20-0134 | - | - | - | - | 1件: 13 13 💬 |
601 | BEFIZAL L.P. 400 mg, comprimé enrobé à libération prolongée | - | - | - | - | 1件: 94 94 💬 |
602 | Belantamab mafodotin 1.9 mg/kg (8 weeks) | 1件: Belantamab mafodotin Belantamab mafodotin | 1件: Belantamab mafodotin
Belantamab mafodotin
💬 | 10件: TNFRSF17 TNFRSF17, TUBB, TUBB1, TUBB2A, TUBB2B, TUBB3, TUBB4A, TUBB4B, TUBB6, TUBB8 💬 | 12件: Alzheimer disease Alzheimer disease, Amyotrophic lateral sclerosis, Cytokine-cytokine receptor interaction, Gap junction, Huntington disease, Intestinal immune network for IgA production, Parkinson disease, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Phagosome, Prion disease, Salmonella infection 💬 | 1件: 28 28 💬 |
603 | Belantamab mafodotin 1.9mg/kg or 2.5mg/kg every 4 weeks, 6 weeks or 8 weeks as determined by Part 1 recommended dosages | 1件: Belantamab mafodotin Belantamab mafodotin | 1件: Belantamab mafodotin
Belantamab mafodotin
💬 | 10件: TNFRSF17 TNFRSF17, TUBB, TUBB1, TUBB2A, TUBB2B, TUBB3, TUBB4A, TUBB4B, TUBB6, TUBB8 💬 | 12件: Alzheimer disease Alzheimer disease, Amyotrophic lateral sclerosis, Cytokine-cytokine receptor interaction, Gap junction, Huntington disease, Intestinal immune network for IgA production, Parkinson disease, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Phagosome, Prion disease, Salmonella infection 💬 | 1件: 28 28 💬 |
604 | Belantamab mafodotin 2.5 mg/kg (4 weeks) | 1件: Belantamab mafodotin Belantamab mafodotin | 1件: Belantamab mafodotin
Belantamab mafodotin
💬 | 10件: TNFRSF17 TNFRSF17, TUBB, TUBB1, TUBB2A, TUBB2B, TUBB3, TUBB4A, TUBB4B, TUBB6, TUBB8 💬 | 12件: Alzheimer disease Alzheimer disease, Amyotrophic lateral sclerosis, Cytokine-cytokine receptor interaction, Gap junction, Huntington disease, Intestinal immune network for IgA production, Parkinson disease, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Phagosome, Prion disease, Salmonella infection 💬 | 1件: 28 28 💬 |
605 | Belantamab mafodotin 2.5 mg/kg (6 weeks) | 1件: Belantamab mafodotin Belantamab mafodotin | 1件: Belantamab mafodotin
Belantamab mafodotin
💬 | 10件: TNFRSF17 TNFRSF17, TUBB, TUBB1, TUBB2A, TUBB2B, TUBB3, TUBB4A, TUBB4B, TUBB6, TUBB8 💬 | 12件: Alzheimer disease Alzheimer disease, Amyotrophic lateral sclerosis, Cytokine-cytokine receptor interaction, Gap junction, Huntington disease, Intestinal immune network for IgA production, Parkinson disease, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Phagosome, Prion disease, Salmonella infection 💬 | 1件: 28 28 💬 |
606 | Belantamab mafodotin 2.5 mg/kg (8 weeks) | 1件: Belantamab mafodotin Belantamab mafodotin | 1件: Belantamab mafodotin
Belantamab mafodotin
💬 | 10件: TNFRSF17 TNFRSF17, TUBB, TUBB1, TUBB2A, TUBB2B, TUBB3, TUBB4A, TUBB4B, TUBB6, TUBB8 💬 | 12件: Alzheimer disease Alzheimer disease, Amyotrophic lateral sclerosis, Cytokine-cytokine receptor interaction, Gap junction, Huntington disease, Intestinal immune network for IgA production, Parkinson disease, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Phagosome, Prion disease, Salmonella infection 💬 | 1件: 28 28 💬 |
607 | Belimumab 4 mg/kg | 1件: Belimumab Belimumab | 1件: Belimumab
Belimumab
💬 | 1件: TNFSF13B TNFSF13B 💬 | 4件: Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, Intestinal immune network for IgA production, NF-kappa B signaling pathway, Rheumatoid arthritis 💬 | 2件: 46 46, 49 💬 |
608 | Benlysta 400 mg powder for concentrate for solution for infusion | 1件: Belimumab Belimumab | 1件: Belimumab
Belimumab
💬 | 1件: TNFSF13B TNFSF13B 💬 | 4件: Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, Intestinal immune network for IgA production, NF-kappa B signaling pathway, Rheumatoid arthritis 💬 | 2件: 43 43, 49 💬 |
609 | Benlysta 400 mg powder for concentrate for solution for infusions | 1件: Belimumab Belimumab | 1件: Belimumab
Belimumab
💬 | 1件: TNFSF13B TNFSF13B 💬 | 4件: Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, Intestinal immune network for IgA production, NF-kappa B signaling pathway, Rheumatoid arthritis 💬 | 1件: 49 49 💬 |
610 | Benlysta 400mg polvere per concentrato per soluzione per infusione | 1件: Belimumab Belimumab | 1件: Belimumab
Belimumab
💬 | 1件: TNFSF13B TNFSF13B 💬 | 4件: Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, Intestinal immune network for IgA production, NF-kappa B signaling pathway, Rheumatoid arthritis 💬 | 1件: 43 43 💬 |
611 | Benzimidazole,5-methoxy-2-[[(4-methoxy- 3,5-dimethyl-2-pyridinyl)methyl]sulfinyl]-1 H-benzimidazole | 1件: Benzimidazole Benzimidazole | - | - | - | 1件: 46 46 💬 |
612 | Benzimidazole,5-methoxy-2-[[(4-methoxy-3,5-dimethyl-2-pyridinyl)methyl]sulfinyl]-1 H-benzimidazole | 1件: Benzimidazole Benzimidazole | - | - | - | 1件: 46 46 💬 |
613 | Beta-1,3/1,6-D-Glucan | - | - | - | - | 1件: 97 97 💬 |
614 | BETAFERON - 15 FLACONCINI 0.25 MG + 15 FLACONCINI 2 ML | 1件: Interferon beta-1b Interferon beta-1b | 1件: Interferon beta-1b
Interferon beta-1b
💬 | 2件: IFNAR1 IFNAR1, IFNAR2 💬 | 18件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Measles, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Osteoclast differentiation, PI3K-Akt signaling pathway, Pathways in cancer, Toll-like receptor signaling pathway 💬 | 1件: 13 13 💬 |
615 | BETAFERON SC 15F 0,25MG 15SIR | 1件: Interferon beta-1b Interferon beta-1b | 1件: Interferon beta-1b
Interferon beta-1b
💬 | 2件: IFNAR1 IFNAR1, IFNAR2 💬 | 18件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Measles, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Osteoclast differentiation, PI3K-Akt signaling pathway, Pathways in cancer, Toll-like receptor signaling pathway 💬 | 1件: 13 13 💬 |
616 | BETAFERON*15CONFEZ 0,25MG/ML+ | 1件: Interferon beta-1b Interferon beta-1b | 1件: Interferon beta-1b
Interferon beta-1b
💬 | 2件: IFNAR1 IFNAR1, IFNAR2 💬 | 18件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Measles, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Osteoclast differentiation, PI3K-Akt signaling pathway, Pathways in cancer, Toll-like receptor signaling pathway 💬 | 1件: 13 13 💬 |
617 | BEVACIZUMAB ZIRCONIUM ZR-89 | 2件: Bevacizumab Bevacizumab, Bevacizumab zirconium Zr-89 | 1件: Bevacizumab
Bevacizumab
💬 | 1件: VEGFA VEGFA 💬 | 24件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Bladder cancer, Calcium signaling pathway, Chemical carcinogenesis - reactive oxygen species, Chemical carcinogenesis - receptor activation, EGFR tyrosine kinase inhibitor resistance, Fluid shear stress and atherosclerosis, Focal adhesion, HIF-1 signaling pathway, Human cytomegalovirus infection, Human papillomavirus infection, Kaposi sarcoma-associated herpesvirus infection, MAPK signaling pathway, MicroRNAs in cancer, PI3K-Akt signaling pathway, Pancreatic cancer, Pathways in cancer, Proteoglycans in cancer, Rap1 signaling pathway, Ras signaling pathway, Relaxin signaling pathway, Renal cell carcinoma, Rheumatoid arthritis, VEGF signaling pathway 💬 | 1件: 34 34 💬 |
618 | BEXSERO - SOSPENSIONE INIETTABILE - USO INTRAMUSCOLARE - SIRINGA PRERIEMPITA (VETRO) - 0.5ML - 1 SIRINGA PRERIEMPITA CON AGO | 4件: Neisseria meningitidis serogroup B strain NZ98/254 outer membrane vesicle Neisseria meningitidis serogroup B strain NZ98/254 outer membrane vesicle, Neisseria meningitidis serogroup b fhbp fusion protein antigen, Neisseria meningitidis serogroup b nada protein antigen, Neisseria meningitidis serogroup b nhba fusion protein antigen | - | - | - | 1件: 66 66 💬 |
619 | Bezafibrat Genericon retard 400 mg | - | - | - | - | 1件: 93 93 💬 |
620 | Bezafibrate (400mg) in addition to standard 15-20 mg/kg/jour UDCA therapy | 2件: Bezafibrate Bezafibrate, Ursodeoxycholic acid | 2件: Ursodiol
Ursodiol
,
Bezafibrate
💬 | 2件: NR1H4 NR1H4, PPARA 💬 | 11件: Adipocytokine signaling pathway Adipocytokine signaling pathway, Alcoholic liver disease, Bile secretion, Chemical carcinogenesis - receptor activation, Diabetic cardiomyopathy, Glucagon signaling pathway, Hepatitis C, Insulin resistance, Non-alcoholic fatty liver disease, PPAR signaling pathway, cAMP signaling pathway 💬 | 1件: 94 94 💬 |
621 | Bezafibrate 400 MG | 1件: Bezafibrate Bezafibrate | 1件: Bezafibrate
Bezafibrate
💬 | 1件: PPARA PPARA 💬 | 10件: Adipocytokine signaling pathway Adipocytokine signaling pathway, Alcoholic liver disease, Chemical carcinogenesis - receptor activation, Diabetic cardiomyopathy, Glucagon signaling pathway, Hepatitis C, Insulin resistance, Non-alcoholic fatty liver disease, PPAR signaling pathway, cAMP signaling pathway 💬 | 1件: 93 93 💬 |
622 | BF 2.649 | - | - | - | - | 1件: 6 6 💬 |
623 | BF 2.649 10 mg | - | - | - | - | 1件: 6 6 💬 |
624 | BF 2.649 20 mg | - | - | - | - | 1件: 6 6 💬 |
625 | BF 2.649 40 mg | - | - | - | - | 1件: 6 6 💬 |
626 | BF 2.649 5 mg | - | - | - | - | 1件: 6 6 💬 |
627 | BF2.649 | - | - | - | - | 1件: 6 6 💬 |
628 | BF2.649 (Pitolisant) | 1件: Pitolisant Pitolisant | 1件: Pitolisant
Pitolisant
💬 | 1件: HRH3 HRH3 💬 | 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 1件: 6 6 💬 |
629 | BG00002 (natalizumab) | 1件: Natalizumab Natalizumab | 1件: Natalizumab
Natalizumab
💬 | 1件: ITGA4 ITGA4 💬 | 14件: Arrhythmogenic right ventricular cardiomyopathy Arrhythmogenic right ventricular cardiomyopathy, Cell adhesion molecules, Dilated cardiomyopathy, ECM-receptor interaction, Focal adhesion, Hematopoietic cell lineage, Human papillomavirus infection, Hypertrophic cardiomyopathy, Intestinal immune network for IgA production, Leishmaniasis, Leukocyte transendothelial migration, PI3K-Akt signaling pathway, Regulation of actin cytoskeleton, Yersinia infection 💬 | 1件: 13 13 💬 |
630 | BG00002-E (natalizumab high titer) | 1件: Natalizumab Natalizumab | 1件: Natalizumab
Natalizumab
💬 | 1件: ITGA4 ITGA4 💬 | 14件: Arrhythmogenic right ventricular cardiomyopathy Arrhythmogenic right ventricular cardiomyopathy, Cell adhesion molecules, Dilated cardiomyopathy, ECM-receptor interaction, Focal adhesion, Hematopoietic cell lineage, Human papillomavirus infection, Hypertrophic cardiomyopathy, Intestinal immune network for IgA production, Leishmaniasis, Leukocyte transendothelial migration, PI3K-Akt signaling pathway, Regulation of actin cytoskeleton, Yersinia infection 💬 | 1件: 13 13 💬 |
631 | BG0002 (natalizumab) | 1件: Natalizumab Natalizumab | 1件: Natalizumab
Natalizumab
💬 | 1件: ITGA4 ITGA4 💬 | 14件: Arrhythmogenic right ventricular cardiomyopathy Arrhythmogenic right ventricular cardiomyopathy, Cell adhesion molecules, Dilated cardiomyopathy, ECM-receptor interaction, Focal adhesion, Hematopoietic cell lineage, Human papillomavirus infection, Hypertrophic cardiomyopathy, Intestinal immune network for IgA production, Leishmaniasis, Leukocyte transendothelial migration, PI3K-Akt signaling pathway, Regulation of actin cytoskeleton, Yersinia infection 💬 | 1件: 13 13 💬 |
632 | BGC20-0134 | - | - | - | - | 1件: 13 13 💬 |
633 | BGJ398 (also known as BBP-831) | - | - | - | - | 1件: 276 276 💬 |
634 | BGP-014 | - | - | - | - | 1件: 97 97 💬 |
635 | BGP-014 Capsules | - | - | - | - | 1件: 97 97 💬 |
636 | BGX-0214 | - | - | - | - | 1件: 46 46 💬 |
637 | BHT-3009 0.5 mg | - | - | - | - | 1件: 13 13 💬 |
638 | BHT-3009-01 | - | - | - | - | 1件: 13 13 💬 |
639 | BHV-0223 | - | - | - | - | 1件: 2 2 💬 |
640 | BHV-4157 | - | - | - | - | 1件: 17 17 💬 |
641 | BI 443651 | - | - | - | - | 1件: 299 299 💬 |
642 | BI 655064 | - | - | - | - | 1件: 46 46 💬 |
643 | BI 655064 high dose | - | - | - | - | 1件: 46 46 💬 |
644 | BI 655064 low dose | - | - | - | - | 1件: 46 46 💬 |
645 | BI 655064 medium dose | - | - | - | - | 1件: 46 46 💬 |
646 | BI 655066 | - | - | - | - | 2件: 96 96, 271 💬 |
647 | BI 655066 10 mg/ml | - | - | - | - | 1件: 96 96 💬 |
648 | BI 655066 90 mg/ml | - | - | - | - | 2件: 96 96, 271 💬 |
649 | BI 655130 | - | - | - | - | 3件: 37 37, 96, 97 💬 |
650 | BI 685509 | - | - | - | - | 1件: 51 51 💬 |
651 | BI 695500 | - | - | - | - | 1件: 46 46 💬 |
652 | BI 695501 | - | - | - | - | 2件: 46 46, 96 💬 |
653 | BI 695501 Autoinjector | - | - | - | - | 1件: 46 46 💬 |
654 | BI 695501 Prefilled syringe | - | - | - | - | 1件: 46 46 💬 |
655 | BIA 6-512 | 1件: BIA BIA | - | - | - | 1件: 6 6 💬 |
656 | BIA 6-512 100 mg | 1件: BIA BIA | - | - | - | 1件: 6 6 💬 |
657 | BIA 6-512 100 mg dose | 1件: BIA BIA | - | - | - | 1件: 6 6 💬 |
658 | BIA 6-512 200 mg dose | 1件: BIA BIA | - | - | - | 1件: 6 6 💬 |
659 | BIA 6-512 25 mg | 1件: BIA BIA | - | - | - | 1件: 6 6 💬 |
660 | BIA 6-512 25 mg dose | 1件: BIA BIA | - | - | - | 1件: 6 6 💬 |
661 | BIA 6-512 400 mg | 1件: BIA BIA | - | - | - | 1件: 6 6 💬 |
662 | BIA 6-512 50 mg dose | 1件: BIA BIA | - | - | - | 1件: 6 6 💬 |
663 | BIA 9-1067 non-micronized | 1件: BIA BIA | - | - | - | 1件: 6 6 💬 |
664 | BIIB 017 | - | - | - | - | 1件: 13 13 💬 |
665 | Bilateral surgical infusion of AAV-GAD into the subthalamic nucleus | - | - | - | - | 1件: 6 6 💬 |
666 | BINOCRIT*1SIR 40000UI/1ML | 1件: Erythropoietin Erythropoietin | - | - | - | 1件: 18 18 💬 |
667 | Biological : I10E (Human normal Immunoglobulin for intravenous administration 100mg/mL) | 1件: Human immunoglobulin G Human immunoglobulin G | - | - | - | 1件: 14 14 💬 |
668 | BL-8040 | - | - | - | - | 1件: 60 60 💬 |
669 | Bladder tissue of Interstitial Cystitis and normal bladder tissue | - | - | - | - | 1件: 226 226 💬 |
670 | BMN 044 | - | - | - | - | 1件: 113 113 💬 |
671 | BMN 044 IV 6 mg/kg | - | - | - | - | 1件: 113 113 💬 |
672 | BMN 044 IV 9 mg/kg | - | - | - | - | 1件: 113 113 💬 |
673 | BMN 044 SC 6 mg/kg | - | - | - | - | 1件: 113 113 💬 |
674 | BMN 045 | 1件: BMN-045 BMN-045 | - | - | - | 1件: 113 113 💬 |
675 | BMN 053 | - | - | - | - | 1件: 113 113 💬 |
676 | BMN165 40mg/day | - | - | - | - | 1件: 240 240 💬 |
677 | BMS-817399 | 1件: BMS-817399 BMS-817399 | - | - | - | 1件: 46 46 💬 |
678 | BMS-986004 675 mg IV | - | - | - | - | 1件: 63 63 💬 |
679 | BMS-986089-01 (RO7239361) , anti-myostatin | - | - | - | - | 1件: 113 113 💬 |
680 | BMS-986089-01 (RO7239361) Injections, 15 mg/Syringe (21.4 mg/mL) | - | - | - | - | 1件: 113 113 💬 |
681 | BMS-986089-01 (RO7239361) Injections, 35 mg/Syringe (50 mg/mL) | - | - | - | - | 1件: 113 113 💬 |
682 | BMS-986089-01 (RO7239361) Injections, 50 mg/Syringe (71.4 mg/mL) | - | - | - | - | 1件: 113 113 💬 |
683 | BMS-986089-01 (RO7239361) Injections, 7.5 mg/Syringe (10.7 mg/mL) | - | - | - | - | 1件: 113 113 💬 |
684 | BMS-986089-01 (RO7239361), anti-myostatin | - | - | - | - | 1件: 113 113 💬 |
685 | BMS-986089-01 Injections, 15 mg/Syringe (21.4 mg/mL) | - | - | - | - | 1件: 113 113 💬 |
686 | BMS-986089-01 Injections, 35 mg/Syringe (50 mg/mL) | - | - | - | - | 1件: 113 113 💬 |
687 | BMS-986089-01 Injections, 50 mg/Syringe (71.4 mg/mL) | - | - | - | - | 1件: 113 113 💬 |
688 | BMS-986089-01 Injections, 7.5 mg/Syringe (10.7 mg/mL) | - | - | - | - | 1件: 113 113 💬 |
689 | BMS-986089-01, Anti-myostatin | - | - | - | - | 1件: 113 113 💬 |
690 | BMS-986256-06, TLR7/8 Antagonist | 1件: Afimetoran Afimetoran | 1件: Afimetoran
Afimetoran
💬 | - | - | 1件: 49 49 💬 |
691 | Bosentan 62.5 mg | 1件: Bosentan Bosentan | 2件: Bosentan
Bosentan
,
Bosentan
💬 | 2件: EDNRA EDNRA, EDNRB 💬 | 9件: Calcium signaling pathway Calcium signaling pathway, Melanogenesis, Neuroactive ligand-receptor interaction, Pathways in cancer, Relaxin signaling pathway, Renin secretion, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway 💬 | 1件: 51 51 💬 |
692 | BOTOX 100U in normal saline | 1件: Botulinum toxin type A Botulinum toxin type A | 1件: Botulinum toxin type A
Botulinum toxin type A
💬 | 1件: SNAP25 SNAP25 💬 | 2件: Insulin secretion Insulin secretion, Synaptic vesicle cycle 💬 | 1件: 226 226 💬 |
693 | BOTOX 200U in normal saline | 1件: Botulinum toxin type A Botulinum toxin type A | 1件: Botulinum toxin type A
Botulinum toxin type A
💬 | 1件: SNAP25 SNAP25 💬 | 2件: Insulin secretion Insulin secretion, Synaptic vesicle cycle 💬 | 1件: 226 226 💬 |
694 | Botulinum Neurotoxin | - | - | - | - | 1件: 226 226 💬 |
695 | Botulinum toxin type A (Nabota®) injection into the gastrocnemius muscle | 1件: Botulinum toxin type A Botulinum toxin type A | 1件: Botulinum toxin type A
Botulinum toxin type A
💬 | 1件: SNAP25 SNAP25 💬 | 2件: Insulin secretion Insulin secretion, Synaptic vesicle cycle 💬 | 1件: 70 70 💬 |
696 | BPLG-003 | - | - | - | - | 1件: 78 78 💬 |
697 | BRAMITOB - 300 MG/4 ML SOLUZIONE DA NEBULIZZARE 56 CONTENITORI MONODOSE 4 ML | - | - | - | - | 1件: 299 299 💬 |
698 | Bramitob 300mg/4ml Nebuliser Solution | - | - | - | - | 1件: 299 299 💬 |
699 | BRAMITOB*NEBUL 28F 300MG/4ML | - | - | - | - | 1件: 299 299 💬 |
700 | BRAMITOB*NEBUL 56F 300MG/4ML | - | - | - | - | 1件: 299 299 💬 |
701 | Bramitob® administered by PARI eFlow® rapid electronic nebulizer | - | - | - | - | 1件: 299 299 💬 |
702 | Bramitob® administered by PARI LC® PLUS nebulizer | - | - | - | - | 1件: 299 299 💬 |
703 | BRL-049653 | - | - | - | - | 1件: 46 46 💬 |
704 | BT-11 1,000 mg | - | - | - | - | 1件: 96 96 💬 |
705 | BT051 800 mg | - | - | - | - | 1件: 97 97 💬 |
706 | Budesonide (6 mg) | 1件: Budesonide Budesonide | 1件: Budesonide
Budesonide
💬 | 1件: NR3C1 NR3C1 💬 | 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 1件: 97 97 💬 |
707 | Budesonide 0.5 mg compresse orodispersibili | 1件: Budesonide Budesonide | 1件: Budesonide
Budesonide
💬 | 1件: NR3C1 NR3C1 💬 | 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 1件: 98 98 💬 |
708 | Budesonide 0.5 mg orodispersible tablets | 1件: Budesonide Budesonide | 1件: Budesonide
Budesonide
💬 | 1件: NR3C1 NR3C1 💬 | 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 1件: 98 98 💬 |
709 | Budesonide 0.5mg orodispersible tablet twice daily | 1件: Budesonide Budesonide | 1件: Budesonide
Budesonide
💬 | 1件: NR3C1 NR3C1 💬 | 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 1件: 98 98 💬 |
710 | Budesonide 6 mg prolonged-release capsule, hard (BUX-PVII prototype) | 1件: Budesonide Budesonide | 1件: Budesonide
Budesonide
💬 | 1件: NR3C1 NR3C1 💬 | 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 1件: 97 97 💬 |
711 | Budesonide 6 mg prolonged-release capsules, hard (BUX-PVII prototype) | 1件: Budesonide Budesonide | 1件: Budesonide
Budesonide
💬 | 1件: NR3C1 NR3C1 💬 | 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 1件: 97 97 💬 |
712 | Budesonide [0.4mg/ml] viscous suspension | 1件: Budesonide Budesonide | 1件: Budesonide
Budesonide
💬 | 1件: NR3C1 NR3C1 💬 | 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 1件: 98 98 💬 |
713 | Budesonide MMX 6 mg Tablet | 1件: Budesonide Budesonide | 1件: Budesonide
Budesonide
💬 | 1件: NR3C1 NR3C1 💬 | 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 1件: 97 97 💬 |
714 | Budesonide MMX® 6 mg | 1件: Budesonide Budesonide | 1件: Budesonide
Budesonide
💬 | 1件: NR3C1 NR3C1 💬 | 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 1件: 97 97 💬 |
715 | Budesonide oral suspension [0.2 mg/ml] | 1件: Budesonide Budesonide | 1件: Budesonide
Budesonide
💬 | 1件: NR3C1 NR3C1 💬 | 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 1件: 98 98 💬 |
716 | Budesonide-MMX® 6 mg | 1件: Budesonide Budesonide | 1件: Budesonide
Budesonide
💬 | 1件: NR3C1 NR3C1 💬 | 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 1件: 97 97 💬 |
717 | BUET 0.5 mg | - | - | - | - | 1件: 98 98 💬 |
718 | BUL 0.5 mg | - | - | - | - | 1件: 98 98 💬 |
719 | Bupivacaine hydrochloride 0.5% (Marcaine, Pfizer) | 1件: Bupivacaine Bupivacaine | 1件: Bupivacaine
Bupivacaine
💬 | 5件: SCN1A SCN1A, SCN2A, SCN3A, SCN5A, SCN9A 💬 | 3件: Adrenergic signaling in cardiomyocytes Adrenergic signaling in cardiomyocytes, Dopaminergic synapse, Taste transduction 💬 | 1件: 46 46 💬 |
720 | Bupivacaine Injection 0.5% | 1件: Bupivacaine Bupivacaine | 1件: Bupivacaine
Bupivacaine
💬 | 5件: SCN1A SCN1A, SCN2A, SCN3A, SCN5A, SCN9A 💬 | 3件: Adrenergic signaling in cardiomyocytes Adrenergic signaling in cardiomyocytes, Dopaminergic synapse, Taste transduction 💬 | 1件: 168 168 💬 |
721 | Bupivacaine-Epinephrine 0.25%-1:200,000 Injectable Solution plus clonidine | 3件: Bupivacaine Bupivacaine, Clonidine, Epinephrine | 3件: Epinephrine
Epinephrine
,
Clonidine
,
Bupivacaine
💬 | 14件: ADRA1A ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C, ADRB1, ADRB2, ADRB3, SCN1A, SCN2A, SCN3A, SCN5A, SCN9A 💬 | 16件: AMPK signaling pathway AMPK signaling pathway, Adrenergic signaling in cardiomyocytes, Calcium signaling pathway, Chemical carcinogenesis - receptor activation, Dilated cardiomyopathy, Dopaminergic synapse, Gap junction, Neuroactive ligand-receptor interaction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Taste transduction, Thermogenesis, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway 💬 | 1件: 70 70 💬 |
722 | Bupivacaïne HCl 0,125% / Sufentanil 50 µg flacon à 50 ml | 1件: Sufentanil Sufentanil | 1件: Sufentanil
Sufentanil
💬 | 1件: OPRM1 OPRM1 💬 | 3件: Estrogen signaling pathway Estrogen signaling pathway, Morphine addiction, Neuroactive ligand-receptor interaction 💬 | 1件: 70 70 💬 |
723 | BUSILVEX - 6 MG/ML - CONCENTRATO PER SOLUZIONE PER INFUSIONE - USO ENDOVENOSO - FLACONCINO - 10 ML 8 FLACONCINI | 1件: Busulfan Busulfan | 1件: Busulfan
Busulfan
💬 | - | - | 2件: 19 19, 65 💬 |
724 | BUU 0.4mg/ml | - | - | - | - | 1件: 98 98 💬 |
725 | C-028380 | - | - | - | - | 1件: 106 106 💬 |
726 | C-82 Topical Gel, 1% | - | - | - | - | 1件: 51 51 💬 |
727 | C-type natriuretic peptide conjugated to a multi-arm polyethylene glycol carrier molecule through a cleavable linker | 1件: Polyethylene glycol Polyethylene glycol | 1件: Polyethylene glycol 3350
Polyethylene glycol 3350
💬 | - | - | 1件: 276 276 💬 |
728 | C-TYPE NATRIURETIC PEPTIDE CONJUGATED TO MULTI-ARM POLYETHYLENE GLYCOL CARRIER THROUGH A CLEAVABLE LINKER | 1件: Polyethylene glycol Polyethylene glycol | 1件: Polyethylene glycol 3350
Polyethylene glycol 3350
💬 | - | - | 1件: 276 276 💬 |
729 | C326, IL-6 Inhibitory Avimer protein | - | - | - | - | 1件: 96 96 💬 |
730 | Cabaseril, 1,0 mg Tablette | - | - | - | - | 1件: 6 6 💬 |
731 | Cabaseril, 2,0 mg Tablette | - | - | - | - | 1件: 6 6 💬 |
732 | Calcitonin nasal spray (salmon) | 1件: Salmon, unspecified Salmon, unspecified | - | - | - | 2件: 96 96, 97 💬 |
733 | CALCIUM D3 SANDOZ - 1000 MG + 880 U.I. COMPRESSE EFFERVESCENTI 30 COMPRESSE DIVISIBILI | 2件: Calcium Calcium, Calcium carbonate | 2件: Calcium carbonate
Calcium carbonate
,
Calcium carbonate
💬 | - | - | 1件: 274 274 💬 |
734 | CALY-002 | - | - | - | - | 1件: 98 98 💬 |
735 | Camoteskimab (CERC-007, AVTX-007, AEVI-007) | - | - | - | - | 1件: 107 107 💬 |
736 | Candesartan plus non-CCB agents | 1件: Candesartan Candesartan | 1件: Candesartan
Candesartan
💬 | 1件: AGTR1 AGTR1 💬 | 16件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adrenergic signaling in cardiomyocytes, Aldosterone synthesis and secretion, Apelin signaling pathway, Calcium signaling pathway, Coronavirus disease - COVID-19, Cortisol synthesis and secretion, Cushing syndrome, Diabetic cardiomyopathy, Neuroactive ligand-receptor interaction, Pathways in cancer, Phospholipase D signaling pathway, Renin secretion, Renin-angiotensin system, Vascular smooth muscle contraction, cGMP-PKG signaling pathway 💬 | 1件: 67 67 💬 |
737 | Cannabidiol Oral Solution, is known as Epidyolex 100 mg/mL oral solution and is the approved name in the EU. Epidiolex (cannabidiol) oral solution is the approved name in the US. | 1件: Cannabidiol Cannabidiol | 1件: Cannabidiol
Cannabidiol
💬 | 2件: CNR1 CNR1, CNR2 💬 | 4件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Rap1 signaling pathway, Retrograde endocannabinoid signaling, Thermogenesis 💬 | 1件: 158 158 💬 |
738 | Caplacizumab (ALX-0081) | 1件: Caplacizumab Caplacizumab | 1件: Caplacizumab
Caplacizumab
💬 | 1件: VWF VWF 💬 | 8件: Complement and coagulation cascades Complement and coagulation cascades, Coronavirus disease - COVID-19, ECM-receptor interaction, Focal adhesion, Human papillomavirus infection, Neutrophil extracellular trap formation, PI3K-Akt signaling pathway, Platelet activation 💬 | 1件: 64 64 💬 |
739 | Caplacizumab (an anti-von Willebrand Factor Nanobody ALX-0081) | 2件: Caplacizumab Caplacizumab, Von Willebrand factor human | 1件: Caplacizumab
Caplacizumab
💬 | 1件: VWF VWF 💬 | 8件: Complement and coagulation cascades Complement and coagulation cascades, Coronavirus disease - COVID-19, ECM-receptor interaction, Focal adhesion, Human papillomavirus infection, Neutrophil extracellular trap formation, PI3K-Akt signaling pathway, Platelet activation 💬 | 1件: 64 64 💬 |
740 | Caplacizumab (an anti-von Willebrand Factor Nanobody) | 2件: Caplacizumab Caplacizumab, Von Willebrand factor human | 1件: Caplacizumab
Caplacizumab
💬 | 1件: VWF VWF 💬 | 8件: Complement and coagulation cascades Complement and coagulation cascades, Coronavirus disease - COVID-19, ECM-receptor interaction, Focal adhesion, Human papillomavirus infection, Neutrophil extracellular trap formation, PI3K-Akt signaling pathway, Platelet activation 💬 | 1件: 64 64 💬 |
741 | Carbidopa 65 mg capsule | 1件: Carbidopa Carbidopa | 1件: Carbidopa
Carbidopa
💬 | 1件: DDC DDC 💬 | 9件: Alcoholism Alcoholism, Amphetamine addiction, Cocaine addiction, Dopaminergic synapse, Metabolic pathways, Phenylalanine metabolism, Serotonergic synapse, Tryptophan metabolism, Tyrosine metabolism 💬 | 1件: 6 6 💬 |
742 | Carbidopa-4'-Monophosphate | 1件: Carbidopa Carbidopa | 1件: Carbidopa
Carbidopa
💬 | 1件: DDC DDC 💬 | 9件: Alcoholism Alcoholism, Amphetamine addiction, Cocaine addiction, Dopaminergic synapse, Metabolic pathways, Phenylalanine metabolism, Serotonergic synapse, Tryptophan metabolism, Tyrosine metabolism 💬 | 1件: 6 6 💬 |
743 | Carbon-14 BIA 28-6156 | 2件: Activated charcoal Activated charcoal, BIA | - | - | - | 1件: 6 6 💬 |
744 | Carnosine, capsulle, 2 g/day, 8 weeks | 1件: Carnosine Carnosine | - | - | - | 1件: 13 13 💬 |
745 | CAS # in D.3.9.1 for Sodium Salt. CAS number 1639325-43-1 (Parent Acid) | - | - | - | - | 1件: 254 254 💬 |
746 | CAS Name: 1,4-Benzoxazepin-5(2H)-one, 3,4-dihydro-4-(2-pyrimidinylmethyl)-7-[4- (trifluoromethoxy)phenyl] IUPAC Name: 4-(Pyrimidin-2-ylmethyl)-7-[4- (trifluoromethoxy)phenyl]-3,4-dihydro-1,4-benzoxazepin-5(2H)-one | - | - | - | - | 1件: 58 58 💬 |
747 | CAS Name: 1,4-Benzoxazepin-5(2H)-one, 3,4-dihydro-4-(2-pyrimidinylmethyl)-7-[4-(trifluoromethoxy)phenyl] IUPAC Name: 4-(Pyrimidin-2-ylmethyl)-7-[4-(trifluoromethoxy)phenyl]-3,4-dihydro-1,4-benzoxazepin-5(2H)-one | - | - | - | - | 1件: 58 58 💬 |
748 | CAS No.: 7758-16-9 | - | - | - | - | 1件: 166 166 💬 |
749 | CAS# in D.3.9.1 for Sodium Salt. CAS number 1639325-43-1 (Parent Acid) | - | - | - | - | 1件: 254 254 💬 |
750 | Caveolin-1-Scaffolding-Protein-Derived Peptide (LTI-03) | - | - | - | - | 1件: 85 85 💬 |
751 | CAYSTON aztreonam 75 mg powder and solvent for nebuliser solution | 1件: Aztreonam Aztreonam | 1件: Aztreonam
Aztreonam
💬 | - | - | 1件: 299 299 💬 |
752 | CB-01-02 | - | - | - | - | 1件: 97 97 💬 |
753 | CB-01-05-MMX | - | - | - | - | 1件: 97 97 💬 |
754 | CBD - Oral Solution, is known as Epidiolex, and is the approved name in the USA. | 1件: Cannabidiol Cannabidiol | 1件: Cannabidiol
Cannabidiol
💬 | 2件: CNR1 CNR1, CNR2 💬 | 4件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Rap1 signaling pathway, Retrograde endocannabinoid signaling, Thermogenesis 💬 | 2件: 140 140, 144 💬 |
755 | CBD - Oral Solution, is known as Epidyolex, and is the approved name | 1件: Cannabidiol Cannabidiol | 1件: Cannabidiol
Cannabidiol
💬 | 2件: CNR1 CNR1, CNR2 💬 | 4件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Rap1 signaling pathway, Retrograde endocannabinoid signaling, Thermogenesis 💬 | 1件: 156 156 💬 |
756 | CBD - Solution Orale, conosciuto come Epidiolex, questo è il nome approvato negli Stati Uniti | 1件: Cannabidiol Cannabidiol | 1件: Cannabidiol
Cannabidiol
💬 | 2件: CNR1 CNR1, CNR2 💬 | 4件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Rap1 signaling pathway, Retrograde endocannabinoid signaling, Thermogenesis 💬 | 1件: 156 156 💬 |
757 | CBD Oral solution, is known as Epidyolex and is the approved name in the EU | 1件: Cannabidiol Cannabidiol | 1件: Cannabidiol
Cannabidiol
💬 | 2件: CNR1 CNR1, CNR2 💬 | 4件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Rap1 signaling pathway, Retrograde endocannabinoid signaling, Thermogenesis 💬 | 1件: 156 156 💬 |
758 | CBD soluzione orale nota come Epidyolex e con tale nome è stato approvato in UE | 1件: Cannabidiol Cannabidiol | 1件: Cannabidiol
Cannabidiol
💬 | 2件: CNR1 CNR1, CNR2 💬 | 4件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Rap1 signaling pathway, Retrograde endocannabinoid signaling, Thermogenesis 💬 | 1件: 156 156 💬 |
759 | CBD-Oral Solution, is known as Epidiolex, and is the approved name in the USA. | 1件: Cannabidiol Cannabidiol | 1件: Cannabidiol
Cannabidiol
💬 | 2件: CNR1 CNR1, CNR2 💬 | 4件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Rap1 signaling pathway, Retrograde endocannabinoid signaling, Thermogenesis 💬 | 1件: 158 158 💬 |
760 | CC-220 0.3 mg Daily | - | - | - | - | 1件: 84 84 💬 |
761 | CC-220 0.6mg Daily | - | - | - | - | 1件: 84 84 💬 |
762 | CC-4047 | - | - | - | - | 2件: 28 28, 51 💬 |
763 | CC-99677 60mg Capsule | - | - | - | - | 1件: 271 271 💬 |
764 | CCP-020 | - | - | - | - | 1件: 36 36 💬 |
765 | CCP-690-550-10 | - | - | - | - | 1件: 107 107 💬 |
766 | CD-4 guided therapy interruption | - | - | - | - | 1件: 265 265 💬 |
767 | CD3/CD19 neg allogeneic BMT | - | - | - | - | 1件: 65 65 💬 |
768 | CD3/CD19 negative allogeneic hematopoietic stem cells | - | - | - | - | 1件: 65 65 💬 |
769 | CD3/CD19 negative hematopoietic stem cells | - | - | - | - | 1件: 85 85 💬 |
770 | CD34+ HSCs transduced with the lentivirus vector, VSV-G pseudotyped CL20-4i-EF1a-h?c-OPT | - | - | - | - | 1件: 65 65 💬 |
771 | CDP870 400mg | - | - | - | - | 1件: 46 46 💬 |
772 | CDX 6114 | - | - | - | - | 1件: 240 240 💬 |
773 | Celecoxib 400 milligrams | 1件: Celecoxib Celecoxib | 1件: Celecoxib
Celecoxib
💬 | 1件: PTGS2 PTGS2 💬 | 22件: Alzheimer disease Alzheimer disease, Arachidonic acid metabolism, C-type lectin receptor signaling pathway, Chemical carcinogenesis - DNA adducts, Human cytomegalovirus infection, Human papillomavirus infection, IL-17 signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Metabolic pathways, MicroRNAs in cancer, NF-kappa B signaling pathway, Ovarian steroidogenesis, Oxytocin signaling pathway, Pathways in cancer, Pathways of neurodegeneration - multiple diseases, Regulation of lipolysis in adipocytes, Retrograde endocannabinoid signaling, Serotonergic synapse, Small cell lung cancer, TNF signaling pathway, VEGF signaling pathway 💬 | 1件: 271 271 💬 |
774 | Celulas madre mesenquimales troncales adultas alogenicas de médula ósea no expandida | - | - | - | - | 1件: 274 274 💬 |
775 | Cenerimod 0.5 mg | 1件: Cenerimod Cenerimod | 1件: Cenerimod
Cenerimod
💬 | 1件: S1PR1 S1PR1 💬 | 3件: FoxO signaling pathway FoxO signaling pathway, Neuroactive ligand-receptor interaction, Sphingolipid signaling pathway 💬 | 1件: 49 49 💬 |
776 | Cenerimod 4 mg | 1件: Cenerimod Cenerimod | 1件: Cenerimod
Cenerimod
💬 | 1件: S1PR1 S1PR1 💬 | 3件: FoxO signaling pathway FoxO signaling pathway, Neuroactive ligand-receptor interaction, Sphingolipid signaling pathway 💬 | 1件: 49 49 💬 |
777 | CER-001 | - | - | - | - | 1件: 79 79 💬 |
778 | CERC-006 | - | - | - | - | 1件: 278 278 💬 |
779 | CERE-120 (Adeno-Associated Virus Serotype 2 [AAV2]-Neurturin [NTN]) | - | - | - | - | 1件: 6 6 💬 |
780 | CERE-120: AAV2-NTN | - | - | - | - | 1件: 6 6 💬 |
781 | CERE-120: Adeno-Associated Virus Delivery of Neurturin | - | - | - | - | 1件: 6 6 💬 |
782 | Cerebral Dopamine Neurotrophic Factor | 1件: Dopamine Dopamine | 1件: Dopamine
Dopamine
💬 | 5件: DRD1 DRD1, DRD2, DRD3, DRD4, DRD5 💬 | 11件: Alcoholism Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway 💬 | 1件: 6 6 💬 |
783 | Cerezyme 400 Units Powder for concentrate for solution for infusion | 1件: Imiglucerase Imiglucerase | 1件: Imiglucerase
Imiglucerase
💬 | 1件: GBA1 GBA1 💬 | 4件: Lysosome Lysosome, Metabolic pathways, Other glycan degradation, Sphingolipid metabolism 💬 | 1件: 19 19 💬 |
784 | Certican 0,5 | 1件: Everolimus Everolimus | 1件: Everolimus
Everolimus
💬 | 1件: MTOR MTOR 💬 | 51件: AMPK signaling pathway AMPK signaling pathway, Acute myeloid leukemia, Adipocytokine signaling pathway, Alzheimer disease, Amyotrophic lateral sclerosis, Apelin signaling pathway, Autophagy - animal, Autophagy - other, Breast cancer, Cellular senescence, Central carbon metabolism in cancer, Chemical carcinogenesis - receptor activation, Choline metabolism in cancer, Colorectal cancer, Diabetic cardiomyopathy, EGFR tyrosine kinase inhibitor resistance, Endocrine resistance, ErbB signaling pathway, Gastric cancer, Glioma, Growth hormone synthesis, secretion and action, HIF-1 signaling pathway, Hepatocellular carcinoma, Herpes simplex virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Huntington disease, Insulin resistance, Insulin signaling pathway, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Longevity regulating pathway, Longevity regulating pathway - multiple species, MicroRNAs in cancer, Neutrophil extracellular trap formation, PD-L1 expression and PD-1 checkpoint pathway in cancer, PI3K-Akt signaling pathway, Pancreatic cancer, Pathways in cancer, Pathways of neurodegeneration - multiple diseases, Phospholipase D signaling pathway, Prostate cancer, Proteoglycans in cancer, Shigellosis, Spinocerebellar ataxia, Th17 cell differentiation, Thermogenesis, Thyroid hormone signaling pathway, Type II diabetes mellitus, mTOR signaling pathway 💬 | 1件: 228 228 💬 |
785 | Certican 0,5 mg Tabletten | 1件: Everolimus Everolimus | 1件: Everolimus
Everolimus
💬 | 1件: MTOR MTOR 💬 | 51件: AMPK signaling pathway AMPK signaling pathway, Acute myeloid leukemia, Adipocytokine signaling pathway, Alzheimer disease, Amyotrophic lateral sclerosis, Apelin signaling pathway, Autophagy - animal, Autophagy - other, Breast cancer, Cellular senescence, Central carbon metabolism in cancer, Chemical carcinogenesis - receptor activation, Choline metabolism in cancer, Colorectal cancer, Diabetic cardiomyopathy, EGFR tyrosine kinase inhibitor resistance, Endocrine resistance, ErbB signaling pathway, Gastric cancer, Glioma, Growth hormone synthesis, secretion and action, HIF-1 signaling pathway, Hepatocellular carcinoma, Herpes simplex virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Huntington disease, Insulin resistance, Insulin signaling pathway, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Longevity regulating pathway, Longevity regulating pathway - multiple species, MicroRNAs in cancer, Neutrophil extracellular trap formation, PD-L1 expression and PD-1 checkpoint pathway in cancer, PI3K-Akt signaling pathway, Pancreatic cancer, Pathways in cancer, Pathways of neurodegeneration - multiple diseases, Phospholipase D signaling pathway, Prostate cancer, Proteoglycans in cancer, Shigellosis, Spinocerebellar ataxia, Th17 cell differentiation, Thermogenesis, Thyroid hormone signaling pathway, Type II diabetes mellitus, mTOR signaling pathway 💬 | 1件: 228 228 💬 |
786 | Certican 0,75mg | 1件: Everolimus Everolimus | 1件: Everolimus
Everolimus
💬 | 1件: MTOR MTOR 💬 | 51件: AMPK signaling pathway AMPK signaling pathway, Acute myeloid leukemia, Adipocytokine signaling pathway, Alzheimer disease, Amyotrophic lateral sclerosis, Apelin signaling pathway, Autophagy - animal, Autophagy - other, Breast cancer, Cellular senescence, Central carbon metabolism in cancer, Chemical carcinogenesis - receptor activation, Choline metabolism in cancer, Colorectal cancer, Diabetic cardiomyopathy, EGFR tyrosine kinase inhibitor resistance, Endocrine resistance, ErbB signaling pathway, Gastric cancer, Glioma, Growth hormone synthesis, secretion and action, HIF-1 signaling pathway, Hepatocellular carcinoma, Herpes simplex virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Huntington disease, Insulin resistance, Insulin signaling pathway, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Longevity regulating pathway, Longevity regulating pathway - multiple species, MicroRNAs in cancer, Neutrophil extracellular trap formation, PD-L1 expression and PD-1 checkpoint pathway in cancer, PI3K-Akt signaling pathway, Pancreatic cancer, Pathways in cancer, Pathways of neurodegeneration - multiple diseases, Phospholipase D signaling pathway, Prostate cancer, Proteoglycans in cancer, Shigellosis, Spinocerebellar ataxia, Th17 cell differentiation, Thermogenesis, Thyroid hormone signaling pathway, Type II diabetes mellitus, mTOR signaling pathway 💬 | 1件: 228 228 💬 |
787 | Certican 0,75mg Tabletten | 1件: Everolimus Everolimus | 1件: Everolimus
Everolimus
💬 | 1件: MTOR MTOR 💬 | 51件: AMPK signaling pathway AMPK signaling pathway, Acute myeloid leukemia, Adipocytokine signaling pathway, Alzheimer disease, Amyotrophic lateral sclerosis, Apelin signaling pathway, Autophagy - animal, Autophagy - other, Breast cancer, Cellular senescence, Central carbon metabolism in cancer, Chemical carcinogenesis - receptor activation, Choline metabolism in cancer, Colorectal cancer, Diabetic cardiomyopathy, EGFR tyrosine kinase inhibitor resistance, Endocrine resistance, ErbB signaling pathway, Gastric cancer, Glioma, Growth hormone synthesis, secretion and action, HIF-1 signaling pathway, Hepatocellular carcinoma, Herpes simplex virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Huntington disease, Insulin resistance, Insulin signaling pathway, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Longevity regulating pathway, Longevity regulating pathway - multiple species, MicroRNAs in cancer, Neutrophil extracellular trap formation, PD-L1 expression and PD-1 checkpoint pathway in cancer, PI3K-Akt signaling pathway, Pancreatic cancer, Pathways in cancer, Pathways of neurodegeneration - multiple diseases, Phospholipase D signaling pathway, Prostate cancer, Proteoglycans in cancer, Shigellosis, Spinocerebellar ataxia, Th17 cell differentiation, Thermogenesis, Thyroid hormone signaling pathway, Type II diabetes mellitus, mTOR signaling pathway 💬 | 1件: 228 228 💬 |
788 | Certolizumab Pegol (CZP) 400 mg | 1件: Certolizumab pegol Certolizumab pegol | 1件: Certolizumab pegol
Certolizumab pegol
💬 | 1件: TNF TNF 💬 | 67件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Dilated cardiomyopathy, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease, Osteoclast differentiation, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway 💬 | 1件: 46 46 💬 |
789 | Certolizumab pegol 400 mg | 1件: Certolizumab pegol Certolizumab pegol | 1件: Certolizumab pegol
Certolizumab pegol
💬 | 1件: TNF TNF 💬 | 67件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Dilated cardiomyopathy, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease, Osteoclast differentiation, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway 💬 | 1件: 96 96 💬 |
790 | Cesamet™ (nabilone) | 1件: Nabilone Nabilone | 1件: Nabilone
Nabilone
💬 | 2件: CNR1 CNR1, CNR2 💬 | 4件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Rap1 signaling pathway, Retrograde endocannabinoid signaling, Thermogenesis 💬 | 1件: 13 13 💬 |
791 | CH-4051 | - | - | - | - | 1件: 46 46 💬 |
792 | Ch11-1F4 (NSC-711516) | - | - | - | - | 1件: 28 28 💬 |
793 | ChAdOx1 nCoV-19 | 1件: AstraZeneca COVID-19 Vaccine AstraZeneca COVID-19 Vaccine | - | - | - | 3件: 46 46, 51, 299 💬 |
794 | CHF 6333 | - | - | - | - | 1件: 299 299 💬 |
795 | Chimeric murine human anti-IL-6 monoclonal antibody | - | - | - | - | 1件: 331 331 💬 |
796 | Chinese herbal concoction twice a day for 6 months | - | - | - | - | 1件: 60 60 💬 |
797 | Cholecalciferol 10,000 IU | 1件: Cholecalciferol Cholecalciferol | 1件: Cholecalciferol
Cholecalciferol
💬 | 1件: VDR VDR 💬 | 5件: Chemical carcinogenesis - receptor activation Chemical carcinogenesis - receptor activation, Endocrine and other factor-regulated calcium reabsorption, Mineral absorption, Parathyroid hormone synthesis, secretion and action, Tuberculosis 💬 | 1件: 96 96 💬 |
798 | Cholecalciferol 400 IU | 1件: Cholecalciferol Cholecalciferol | 1件: Cholecalciferol
Cholecalciferol
💬 | 1件: VDR VDR 💬 | 5件: Chemical carcinogenesis - receptor activation Chemical carcinogenesis - receptor activation, Endocrine and other factor-regulated calcium reabsorption, Mineral absorption, Parathyroid hormone synthesis, secretion and action, Tuberculosis 💬 | 1件: 96 96 💬 |
799 | CHS-0214 | - | - | - | - | 1件: 46 46 💬 |
800 | Ciliary neurotrophic factor | 1件: Ciliary neurotrophic factor Ciliary neurotrophic factor | - | - | - | 1件: 90 90 💬 |
801 | Ciliary Neurotrophic Factor Implant NT-501 | 1件: Ciliary neurotrophic factor Ciliary neurotrophic factor | - | - | - | 1件: 90 90 💬 |
802 | CIMZIA - 200MG-SOLUZIONE INIETTABILE-USO SOTTOCUTANEO-SIRINGA PRERIEMPITA(VETRO) 1ML 6(3X2) SIRINGHE PRERIEMPITE+6(3X2) SALVIETTINE IMBEVUTE DI | 1件: Certolizumab pegol Certolizumab pegol | 1件: Certolizumab pegol
Certolizumab pegol
💬 | 1件: TNF TNF 💬 | 67件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Dilated cardiomyopathy, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease, Osteoclast differentiation, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway 💬 | 1件: 46 46 💬 |
803 | CIMZIA - 200MG-SOLUZIONE INIETTABILE-USO SOTTOCUTANEO-SIRINGA PRERIEMPITA(VETRO) 1ML 6(3X2) SIRINGHE PRERIEMPITE+6(3X2) SALVIETTINE IMBEVUTE DI ALCOOL | 1件: Certolizumab pegol Certolizumab pegol | 1件: Certolizumab pegol
Certolizumab pegol
💬 | 1件: TNF TNF 💬 | 67件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Dilated cardiomyopathy, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease, Osteoclast differentiation, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway 💬 | 1件: 46 46 💬 |
804 | CIPROXIN*6CPR RIV 500MG | - | - | - | - | 1件: 299 299 💬 |
805 | CIRCADIN 2 mg comprimidos de liberación prolongada | 1件: Melatonin Melatonin | 1件: Melatonin
Melatonin
💬 | 2件: MTNR1A MTNR1A, MTNR1B 💬 | 2件: Circadian entrainment Circadian entrainment, Neuroactive ligand-receptor interaction 💬 | 1件: 90 90 💬 |
806 | Cis-4-Hydroxy-L-Proline | 1件: Proline Proline | 1件: Proline
Proline
💬 | - | - | 1件: 94 94 💬 |
807 | CITICOLIN*1G/4ML IM IV 5 F | - | - | - | - | 1件: 6 6 💬 |
808 | CJNJ-68150420-ZZZ-G001 (ACT- 064992D) | - | - | - | - | 1件: 86 86 💬 |
809 | CJNJ-68150420-ZZZ-G001 (ACT-064992D) | - | - | - | - | 1件: 86 86 💬 |
810 | CJNJ-68150420-ZZZ-G001(ACT-064992D) | - | - | - | - | 1件: 86 86 💬 |
811 | Clarithromycin (Not used as of 4/2020) | 1件: Clarithromycin Clarithromycin | 1件: Clarithromycin
Clarithromycin
💬 | - | - | 1件: 6 6 💬 |
812 | Clobetasol 0.05% ointment | 1件: Clobetasol Clobetasol | 1件: Clobetasol
Clobetasol
💬 | 1件: NR3C1 NR3C1 💬 | 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 1件: 39 39 💬 |
813 | Clobetasol 0.05% Topical Ointment | 1件: Clobetasol Clobetasol | 1件: Clobetasol
Clobetasol
💬 | 1件: NR3C1 NR3C1 💬 | 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 1件: 162 162 💬 |
814 | Clonidine HCl CF 0,150 mg, tabletten | 1件: Clonidine Clonidine | 1件: Clonidine
Clonidine
💬 | 3件: ADRA2A ADRA2A, ADRA2B, ADRA2C 💬 | 2件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, cGMP-PKG signaling pathway 💬 | 1件: 78 78 💬 |
815 | Cnp-MS-0601 | - | - | - | - | 1件: 13 13 💬 |
816 | CNS10-NPC implantation | - | - | - | - | 1件: 90 90 💬 |
817 | CNS10-NPC-GDNF | - | - | - | - | 1件: 2 2 💬 |
818 | CNSA-001 | - | - | - | - | 1件: 240 240 💬 |
819 | CNT-02 | - | - | - | - | 1件: 160 160 💬 |
820 | CNTO 1959 + MTX (Group 4) | - | - | - | - | 1件: 46 46 💬 |
821 | CNTO 6785 100 mg | - | - | - | - | 1件: 46 46 💬 |
822 | CNTO 6785 15 mg | - | - | - | - | 1件: 46 46 💬 |
823 | CNTO 6785 200 mg | - | - | - | - | 1件: 46 46 💬 |
824 | CNTO 6785 50 mg | - | - | - | - | 1件: 46 46 💬 |
825 | CNTO 888 1 mg/kg | - | - | - | - | 1件: 85 85 💬 |
826 | CNTO 888 15 mg/kg | - | - | - | - | 1件: 85 85 💬 |
827 | CNTO 888 5 mg/kg | - | - | - | - | 1件: 85 85 💬 |
828 | Coagulación factor VIII | 1件: Beroctocog alfa Beroctocog alfa | - | - | - | 1件: 288 288 💬 |
829 | Coenzym Q10 Nanodispersion | - | - | - | - | 1件: 5 5 💬 |
830 | Coenzyme Q-10 in Normal Control subjects | 1件: Ubidecarenone Ubidecarenone | 1件: Ubidecarenone
Ubidecarenone
💬 | - | - | 1件: 86 86 💬 |
831 | Coenzyme Q10 Nanodispersion (Nanoquinone) | 1件: Ubidecarenone Ubidecarenone | 1件: Ubidecarenone
Ubidecarenone
💬 | - | - | 1件: 6 6 💬 |
832 | Cohort 1 0.225g | - | - | - | - | 1件: 240 240 💬 |
833 | Cohort 1: 1.0 x 10^8 PolyTregs | - | - | - | - | 1件: 35 35 💬 |
834 | Cohort 1: hATG, CsA, EPAG Day 14 to Month 6 | 1件: Antilymphocyte immunoglobulin (horse) Antilymphocyte immunoglobulin (horse) | - | - | - | 1件: 60 60 💬 |
835 | Cohort 1:Nilotinib Oral Capsules (150mg or 300mg) | 1件: Nilotinib Nilotinib | 1件: Nilotinib
Nilotinib
💬 | 4件: ABL1 ABL1, KIT, PDGFRA, PDGFRB 💬 | 33件: Acute myeloid leukemia Acute myeloid leukemia, Axon guidance, Breast cancer, Calcium signaling pathway, Cell cycle, Central carbon metabolism in cancer, Chemical carcinogenesis - reactive oxygen species, Choline metabolism in cancer, Chronic myeloid leukemia, EGFR tyrosine kinase inhibitor resistance, Endocytosis, ErbB signaling pathway, Focal adhesion, Gap junction, Glioma, Hematopoietic cell lineage, Human cytomegalovirus infection, Human papillomavirus infection, JAK-STAT signaling pathway, MAPK signaling pathway, Melanogenesis, Melanoma, MicroRNAs in cancer, Neurotrophin signaling pathway, PI3K-Akt signaling pathway, Pathogenic Escherichia coli infection, Pathways in cancer, Phospholipase D signaling pathway, Prostate cancer, Rap1 signaling pathway, Ras signaling pathway, Regulation of actin cytoskeleton, Viral myocarditis 💬 | 1件: 6 6 💬 |
836 | Cohort 2 0.75g | - | - | - | - | 1件: 240 240 💬 |
837 | Cohort 2: 2.5x10^8 PolyTregs | - | - | - | - | 1件: 35 35 💬 |
838 | Cohort 2: Nilotinib Oral Capsules (dose to be determined from Cohort 1) | 1件: Nilotinib Nilotinib | 1件: Nilotinib
Nilotinib
💬 | 4件: ABL1 ABL1, KIT, PDGFRA, PDGFRB 💬 | 33件: Acute myeloid leukemia Acute myeloid leukemia, Axon guidance, Breast cancer, Calcium signaling pathway, Cell cycle, Central carbon metabolism in cancer, Chemical carcinogenesis - reactive oxygen species, Choline metabolism in cancer, Chronic myeloid leukemia, EGFR tyrosine kinase inhibitor resistance, Endocytosis, ErbB signaling pathway, Focal adhesion, Gap junction, Glioma, Hematopoietic cell lineage, Human cytomegalovirus infection, Human papillomavirus infection, JAK-STAT signaling pathway, MAPK signaling pathway, Melanogenesis, Melanoma, MicroRNAs in cancer, Neurotrophin signaling pathway, PI3K-Akt signaling pathway, Pathogenic Escherichia coli infection, Pathways in cancer, Phospholipase D signaling pathway, Prostate cancer, Rap1 signaling pathway, Ras signaling pathway, Regulation of actin cytoskeleton, Viral myocarditis 💬 | 1件: 6 6 💬 |
839 | Cohort 3: hATG, CsA (dose reduced), EPAG day 1 to month 6 | 1件: Antilymphocyte immunoglobulin (horse) Antilymphocyte immunoglobulin (horse) | - | - | - | 1件: 60 60 💬 |
840 | COLCHICINA LIRCA - 1 MG COMPRESSE 60 COMPRESSE | 1件: Colchicine Colchicine | 1件: Colchicine
Colchicine
💬 | 9件: TUBB TUBB, TUBB1, TUBB2A, TUBB2B, TUBB3, TUBB4A, TUBB4B, TUBB6, TUBB8 💬 | 10件: Alzheimer disease Alzheimer disease, Amyotrophic lateral sclerosis, Gap junction, Huntington disease, Parkinson disease, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Phagosome, Prion disease, Salmonella infection 💬 | 1件: 2 2 💬 |
841 | Colfinair 2 MIU Powder for Nebuliser Solution | - | - | - | - | 1件: 299 299 💬 |
842 | COLIMICINA - 1000000 U/4 ML POLVERE E SOLVENTE PER SOLUZIONE INIETTABILE PER USO INTRAMUSCOLARE1 FLACONCINO POLVERE + 1 FIALA SOLVENTE 4 ML | - | - | - | - | 1件: 299 299 💬 |
843 | Colistimethat-Natrium | - | - | - | - | 1件: 299 299 💬 |
844 | Colistimethate sodium (BAN, USAN), Colistimethatum natricum, Colistin sodium methanesulfonate | 2件: Colistimethate Colistimethate, Colistin | 1件: Colistin
Colistin
💬 | - | - | 1件: 299 299 💬 |
845 | Combination Product: EGCG 300 mg + Nintedanib | 2件: Epigallocatechin gallate Epigallocatechin gallate, Nintedanib | 1件: Nintedanib
Nintedanib
💬 | 8件: FGFR1 FGFR1, FGFR2, FGFR3, FLT1, FLT4, KDR, PDGFRA, PDGFRB 💬 | 34件: Adherens junction Adherens junction, Bladder cancer, Breast cancer, Calcium signaling pathway, Central carbon metabolism in cancer, Choline metabolism in cancer, EGFR tyrosine kinase inhibitor resistance, Endocytosis, Fluid shear stress and atherosclerosis, Focal adhesion, Gap junction, Gastric cancer, Glioma, HIF-1 signaling pathway, Human cytomegalovirus infection, Human papillomavirus infection, JAK-STAT signaling pathway, MAPK signaling pathway, Melanoma, MicroRNAs in cancer, PI3K-Akt signaling pathway, Parathyroid hormone synthesis, secretion and action, Pathways in cancer, Phospholipase D signaling pathway, Prostate cancer, Proteoglycans in cancer, Rap1 signaling pathway, Ras signaling pathway, Regulation of actin cytoskeleton, Rheumatoid arthritis, Signaling pathways regulating pluripotency of stem cells, Thermogenesis, Transcriptional misregulation in cancer, VEGF signaling pathway 💬 | 1件: 85 85 💬 |
846 | Combination Product: EGCG 600 mg + Nintedanib | 2件: Epigallocatechin gallate Epigallocatechin gallate, Nintedanib | 1件: Nintedanib
Nintedanib
💬 | 8件: FGFR1 FGFR1, FGFR2, FGFR3, FLT1, FLT4, KDR, PDGFRA, PDGFRB 💬 | 34件: Adherens junction Adherens junction, Bladder cancer, Breast cancer, Calcium signaling pathway, Central carbon metabolism in cancer, Choline metabolism in cancer, EGFR tyrosine kinase inhibitor resistance, Endocytosis, Fluid shear stress and atherosclerosis, Focal adhesion, Gap junction, Gastric cancer, Glioma, HIF-1 signaling pathway, Human cytomegalovirus infection, Human papillomavirus infection, JAK-STAT signaling pathway, MAPK signaling pathway, Melanoma, MicroRNAs in cancer, PI3K-Akt signaling pathway, Parathyroid hormone synthesis, secretion and action, Pathways in cancer, Phospholipase D signaling pathway, Prostate cancer, Proteoglycans in cancer, Rap1 signaling pathway, Ras signaling pathway, Regulation of actin cytoskeleton, Rheumatoid arthritis, Signaling pathways regulating pluripotency of stem cells, Thermogenesis, Transcriptional misregulation in cancer, VEGF signaling pathway 💬 | 1件: 85 85 💬 |
847 | Combination Product: EGCG 600 mg + Pirfenidone | 2件: Epigallocatechin gallate Epigallocatechin gallate, Pirfenidone | 1件: Pirfenidone
Pirfenidone
💬 | 6件: CCL2 CCL2, IL10, IL1A, IL1B, IL6, TNF 💬 | 84件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, Autoimmune thyroid disease, C-type lectin receptor signaling pathway, Cellular senescence, Chagas disease, Chemokine signaling pathway, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Cytosolic DNA-sensing pathway, Dilated cardiomyopathy, EGFR tyrosine kinase inhibitor resistance, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, FoxO signaling pathway, Graft-versus-host disease, HIF-1 signaling pathway, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Inflammatory mediator regulation of TRP channels, Influenza A, Insulin resistance, Intestinal immune network for IgA production, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, MAPK signaling pathway, Malaria, Measles, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease, Osteoclast differentiation, PI3K-Akt signaling pathway, Pathogenic Escherichia coli infection, Pathways in cancer, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Staphylococcus aureus infection, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Th17 cell differentiation, Toll-like receptor signaling pathway, Toxoplasmosis, Transcriptional misregulation in cancer, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway 💬 | 1件: 85 85 💬 |
848 | Combination Product: ND0612 Solution for SC infusion | - | - | - | - | 1件: 6 6 💬 |
849 | Common Name: Sialic Acid | - | - | - | - | 1件: 30 30 💬 |
850 | Comparator: naproxen tablet 500 mg | 1件: Naproxen Naproxen | 1件: Naproxen
Naproxen
💬 | 2件: PTGS1 PTGS1, PTGS2 💬 | 23件: Alzheimer disease Alzheimer disease, Arachidonic acid metabolism, C-type lectin receptor signaling pathway, Chemical carcinogenesis - DNA adducts, Human cytomegalovirus infection, Human papillomavirus infection, IL-17 signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Metabolic pathways, MicroRNAs in cancer, NF-kappa B signaling pathway, Ovarian steroidogenesis, Oxytocin signaling pathway, Pathways in cancer, Pathways of neurodegeneration - multiple diseases, Platelet activation, Regulation of lipolysis in adipocytes, Retrograde endocannabinoid signaling, Serotonergic synapse, Small cell lung cancer, TNF signaling pathway, VEGF signaling pathway 💬 | 1件: 46 46 💬 |
851 | Compressa effervescente 0,5 mg di budesonide per uso orodispersibile | 1件: Budesonide Budesonide | 1件: Budesonide
Budesonide
💬 | 1件: NR3C1 NR3C1 💬 | 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 1件: 98 98 💬 |
852 | COMTAN 200* 60 CPR 200 MG | 1件: Entacapone Entacapone | 1件: Entacapone
Entacapone
💬 | 1件: COMT COMT 💬 | 4件: Dopaminergic synapse Dopaminergic synapse, Metabolic pathways, Steroid hormone biosynthesis, Tyrosine metabolism 💬 | 1件: 6 6 💬 |
853 | Conjugated equine estrogens 0.625 mg/d + MPA 5 mg/d/10d | 1件: Conjugated estrogens Conjugated estrogens | 1件: Estrogens, conjugated
Estrogens, conjugated
💬 | - | - | 1件: 49 49 💬 |
854 | Continuation of current HAART (boosted protease inhibitor [PI] combination + 2 NRTIs) | - | - | - | - | 1件: 265 265 💬 |
855 | Control Group 0.9% Isotonic Saline | - | - | - | - | 1件: 299 299 💬 |
856 | Control intervention (no dexamethasone) | 1件: Dexamethasone Dexamethasone | 1件: Dexamethasone
Dexamethasone
💬 | 1件: NR3C1 NR3C1 💬 | 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 1件: 46 46 💬 |
857 | COPAXONE - 40 MG/ML SOLUZIONE INIETTABILE IN | 1件: Glatiramer Glatiramer | - | - | - | 1件: 13 13 💬 |
858 | COPAXONE - 40 MG/ML SOLUZIONE INIETTABILE IN SIRINGA PRERIEMPITA 12 SIRINGHE PRERIEMPITE DA 1 ML CON AGO | 1件: Glatiramer Glatiramer | - | - | - | 1件: 13 13 💬 |
859 | COPAXONE 20 mg/ml solución inyectable en jeringa precargada | 1件: Glatiramer Glatiramer | - | - | - | 1件: 13 13 💬 |
860 | Copaxone 20 mg/ml solución para inyección en jeringa precargada | 1件: Glatiramer Glatiramer | - | - | - | 1件: 13 13 💬 |
861 | Copaxone 40 mg/ml | 1件: Glatiramer Glatiramer | - | - | - | 1件: 13 13 💬 |
862 | Copaxone 40 mg/ml solution for injection, pre-filled syringe | 1件: Glatiramer Glatiramer | - | - | - | 1件: 13 13 💬 |
863 | COPPER (64CU) CHLORIDE | 2件: Chloride ion Chloride ion, Copper | - | - | - | 1件: 171 171 💬 |
864 | COR-003 | - | - | - | - | 1件: 75 75 💬 |
865 | Corticoids+ tocilizumab 8mg/Kg/4 weeks | 1件: Tocilizumab Tocilizumab | 1件: Tocilizumab
Tocilizumab
💬 | 1件: IL6R IL6R 💬 | 12件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, EGFR tyrosine kinase inhibitor resistance, HIF-1 signaling pathway, Hematopoietic cell lineage, Human cytomegalovirus infection, JAK-STAT signaling pathway, Non-alcoholic fatty liver disease, PI3K-Akt signaling pathway, Pathways in cancer, Th17 cell differentiation, Viral protein interaction with cytokine and cytokine receptor 💬 | 1件: 41 41 💬 |
866 | Corticosteroid and non-biological agents. | - | - | - | - | 1件: 46 46 💬 |
867 | Corticosteroid or NSAID | - | - | - | - | 1件: 46 46 💬 |
868 | Corticotrophin 80 units | 1件: Corticotropin Corticotropin | 1件: Corticotropin
Corticotropin
💬 | 1件: MC2R MC2R 💬 | 5件: Aldosterone synthesis and secretion Aldosterone synthesis and secretion, Cortisol synthesis and secretion, Cushing syndrome, Neuroactive ligand-receptor interaction, cAMP signaling pathway 💬 | 1件: 46 46 💬 |
869 | COVID-19 mRNA Vaccine (nucleoside modified) | - | - | - | - | 3件: 13 13, 46, 51 💬 |
870 | COVID-19 mRNA vaccine (nucleoside-modified) | - | - | - | - | 4件: 13 13, 46, 51, 299 💬 |
871 | COVID-19 mRNA vaccine Moderna (CX-024414) | - | - | - | - | 4件: 13 13, 46, 51, 299 💬 |
872 | COVID-19 vaccine AstraZeneca (ChAdOx1 nCoV-19) | 1件: AstraZeneca COVID-19 Vaccine AstraZeneca COVID-19 Vaccine | - | - | - | 3件: 46 46, 51, 299 💬 |
873 | CP 690,550 | - | - | - | - | 1件: 46 46 💬 |
874 | CP 690550 MR | - | - | - | - | 1件: 46 46 💬 |
875 | CP- 690 550 | - | - | - | - | 1件: 97 97 💬 |
876 | CP-461 | - | - | - | - | 1件: 96 96 💬 |
877 | CP-690, 550 - 10 | - | - | - | - | 1件: 46 46 💬 |
878 | CP-690, 550-10 | - | - | - | - | 2件: 97 97, 107 💬 |
879 | CP-690,500 5 mg | - | - | - | - | 1件: 97 97 💬 |
880 | CP-690,55-10 | - | - | - | - | 1件: 46 46 💬 |
881 | CP-690,550 | - | - | - | - | 5件: 46 46, 96, 97, 107, 271 💬 |
882 | CP-690,550 (tasocitinib) | 1件: Tofacitinib Tofacitinib | 1件: Tofacitinib
Tofacitinib
💬 | 4件: JAK1 JAK1, JAK2, JAK3, TYK2 💬 | 37件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, Chemical carcinogenesis - receptor activation, Chemokine signaling pathway, Cholinergic synapse, Coronavirus disease - COVID-19, EGFR tyrosine kinase inhibitor resistance, Epstein-Barr virus infection, Growth hormone synthesis, secretion and action, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Lipid and atherosclerosis, Measles, NOD-like receptor signaling pathway, Necroptosis, Non-small cell lung cancer, Osteoclast differentiation, PD-L1 expression and PD-1 checkpoint pathway in cancer, PI3K-Akt signaling pathway, Pancreatic cancer, Pathways in cancer, Primary immunodeficiency, Prolactin signaling pathway, Signaling pathways regulating pluripotency of stem cells, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toxoplasmosis, Tuberculosis, Viral carcinogenesis 💬 | 1件: 46 46 💬 |
883 | CP-690,550 (tofacitinib) | 1件: Tofacitinib Tofacitinib | 1件: Tofacitinib
Tofacitinib
💬 | 4件: JAK1 JAK1, JAK2, JAK3, TYK2 💬 | 37件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, Chemical carcinogenesis - receptor activation, Chemokine signaling pathway, Cholinergic synapse, Coronavirus disease - COVID-19, EGFR tyrosine kinase inhibitor resistance, Epstein-Barr virus infection, Growth hormone synthesis, secretion and action, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Lipid and atherosclerosis, Measles, NOD-like receptor signaling pathway, Necroptosis, Non-small cell lung cancer, Osteoclast differentiation, PD-L1 expression and PD-1 checkpoint pathway in cancer, PI3K-Akt signaling pathway, Pancreatic cancer, Pathways in cancer, Primary immunodeficiency, Prolactin signaling pathway, Signaling pathways regulating pluripotency of stem cells, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toxoplasmosis, Tuberculosis, Viral carcinogenesis 💬 | 2件: 46 46, 107 💬 |
884 | CP-690,550 + methotrexate | 1件: Methotrexate Methotrexate | 1件: Methotrexate
Methotrexate
💬 | 2件: DHFR DHFR, DHFR2 💬 | 5件: Antifolate resistance Antifolate resistance, Biosynthesis of cofactors, Folate biosynthesis, Metabolic pathways, One carbon pool by folate 💬 | 1件: 46 46 💬 |
885 | CP-690,550 10 mg | - | - | - | - | 1件: 97 97 💬 |
886 | CP-690,550 – 10 | - | - | - | - | 1件: 46 46 💬 |
887 | CP-690,550-10 | - | - | - | - | 5件: 46 46, 96, 97, 107, 271 💬 |
888 | CP-690-550 | - | - | - | - | 1件: 46 46 💬 |
889 | CP-690-550-10 | - | - | - | - | 1件: 107 107 💬 |
890 | CP-690-550-10 (DMID D1600180) | - | - | - | - | 1件: 107 107 💬 |
891 | CR845 1.0 mg | - | - | - | - | 1件: 93 93 💬 |
892 | CRD-TMH-001 | - | - | - | - | 1件: 113 113 💬 |
893 | Creon 10.000, hårde enterokapsler | - | - | - | - | 1件: 299 299 💬 |
894 | Creon 25.000, hårde enterokapsler | - | - | - | - | 1件: 299 299 💬 |
895 | Creon 40.000, hårde enterokapsler | - | - | - | - | 1件: 299 299 💬 |
896 | Creon N | - | - | - | - | 1件: 299 299 💬 |
897 | CREON N 25000 | - | - | - | - | 1件: 299 299 💬 |
898 | Creon® 25,000 | - | - | - | - | 1件: 299 299 💬 |
899 | Crinecerfont is a novel non-peptide selective corticotropin releasing factor 1 (CRF1 ) receptor antagonist. | 1件: Corticotropin Corticotropin | 1件: Corticotropin
Corticotropin
💬 | 1件: MC2R MC2R 💬 | 5件: Aldosterone synthesis and secretion Aldosterone synthesis and secretion, Cortisol synthesis and secretion, Cushing syndrome, Neuroactive ligand-receptor interaction, cAMP signaling pathway 💬 | 1件: 81 81 💬 |
900 | CS-0777 tablets | - | - | - | - | 1件: 13 13 💬 |
901 | CSM allogéniques issues de cordons ombilicaux ( MTI-PP) | - | - | - | - | 1件: 49 49 💬 |
902 | CTNS-RD-04 or CTNS-RD-04-LB (where the suffix -LB stands for LentiBOOST) | - | - | - | - | 1件: 19 19 💬 |
903 | CTX-4430 | - | - | - | - | 1件: 299 299 💬 |
904 | Cu-64 DOTATATE | 1件: Dotatate Dotatate | - | - | - | 1件: 84 84 💬 |
905 | Cudetaxestat (BLD-0409) | - | - | - | - | 1件: 85 85 💬 |
906 | Curcuma Longa Extract cpl formaat 00 23,2 x 8,5 mm 723 mg | 1件: Turmeric Turmeric | - | - | - | 1件: 299 299 💬 |
907 | CVXL-0107 | - | - | - | - | 1件: 6 6 💬 |
908 | CX-016492 | - | - | - | - | 1件: 245 245 💬 |
909 | CX-017950 | - | - | - | - | 1件: 245 245 💬 |
910 | CX-4945 oral formulation | - | - | - | - | 1件: 331 331 💬 |
911 | CX-8998 | - | - | - | - | 1件: 6 6 💬 |
912 | Cyclophosphamide 40 | 1件: Cyclophosphamide Cyclophosphamide | 2件: Cyclophosphamide
Cyclophosphamide
,
Cyclophosphamide
💬 | - | - | 3件: 65 65, 285, 326 💬 |
913 | Cyclophosphamide Dose Level 4 | 1件: Cyclophosphamide Cyclophosphamide | 2件: Cyclophosphamide
Cyclophosphamide
,
Cyclophosphamide
💬 | - | - | 2件: 65 65, 284 💬 |
914 | Cyclosporine 0.09% Ophthalmic Solution | 1件: Cyclosporine Cyclosporine | 1件: Cyclosporine
Cyclosporine
💬 | 5件: PPP3CA PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 💬 | 33件: Alzheimer disease Alzheimer disease, Amphetamine addiction, Amyotrophic lateral sclerosis, Axon guidance, B cell receptor signaling pathway, C-type lectin receptor signaling pathway, Calcium signaling pathway, Cellular senescence, Dopaminergic synapse, Glucagon signaling pathway, Glutamatergic synapse, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Lipid and atherosclerosis, Long-term potentiation, MAPK signaling pathway, Natural killer cell mediated cytotoxicity, Oocyte meiosis, Osteoclast differentiation, Oxytocin signaling pathway, PD-L1 expression and PD-1 checkpoint pathway in cancer, Pathways of neurodegeneration - multiple diseases, Prion disease, Renin secretion, T cell receptor signaling pathway, Th1 and Th2 cell differentiation, Th17 cell differentiation, Tuberculosis, VEGF signaling pathway, Wnt signaling pathway, cGMP-PKG signaling pathway 💬 | 1件: 53 53 💬 |
915 | Cyclosporine 5 mg/kg bid days 0-14 | 1件: Cyclosporine Cyclosporine | 1件: Cyclosporine
Cyclosporine
💬 | 5件: PPP3CA PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 💬 | 33件: Alzheimer disease Alzheimer disease, Amphetamine addiction, Amyotrophic lateral sclerosis, Axon guidance, B cell receptor signaling pathway, C-type lectin receptor signaling pathway, Calcium signaling pathway, Cellular senescence, Dopaminergic synapse, Glucagon signaling pathway, Glutamatergic synapse, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Lipid and atherosclerosis, Long-term potentiation, MAPK signaling pathway, Natural killer cell mediated cytotoxicity, Oocyte meiosis, Osteoclast differentiation, Oxytocin signaling pathway, PD-L1 expression and PD-1 checkpoint pathway in cancer, Pathways of neurodegeneration - multiple diseases, Prion disease, Renin secretion, T cell receptor signaling pathway, Th1 and Th2 cell differentiation, Th17 cell differentiation, Tuberculosis, VEGF signaling pathway, Wnt signaling pathway, cGMP-PKG signaling pathway 💬 | 2件: 38 38, 39 💬 |
916 | CYSTADROPS 0.55% eye drops, solution | 1件: Cysteamine Cysteamine | 1件: Cysteamine
Cysteamine
💬 | - | - | 1件: 19 19 💬 |
917 | Cápsulas de Laquinimod 0.6 mg | 1件: Laquinimod Laquinimod | - | - | - | 1件: 13 13 💬 |
918 | Células madre mesenquimales haploidénticas derivadas de médula ósea | - | - | - | - | 1件: 36 36 💬 |
919 | Células mesenquimales troncales adultas alogénicas de médula ósea no expandidas | - | - | - | - | 1件: 274 274 💬 |
920 | Células mesenquimales troncales adultas alogénicas de médula ósea no expandidas(ref cruzada PEI nº 12-088) | - | - | - | - | 1件: 274 274 💬 |
921 | D-glucitol, 1-deoxy-1-(methylamino)-, 2-(3,5-dichlorophenyl)-6-benzoxazolecarboxylate (1:1) | 1件: Sorbitol Sorbitol | 1件: Sorbitol solution
Sorbitol solution
💬 | - | - | 1件: 28 28 💬 |
922 | D-glucitol, 1-deoxy-1-(methylamino)-,2-(3,5-dichlorophenyl)-6-benzoxazolecarboxylate (1:1) | 1件: Sorbitol Sorbitol | 1件: Sorbitol solution
Sorbitol solution
💬 | - | - | 1件: 28 28 💬 |
923 | D.3.6.2 - dose massima specificare: giornaliera | - | - | - | - | 1件: 86 86 💬 |
924 | D.3.6.2.1 - valore: 45 / 0.45 mg/ml | - | - | - | - | 1件: 97 97 💬 |
925 | D.3.6.2.1 - valore: 5 o 10 mg/kg | - | - | - | - | 1件: 97 97 💬 |
926 | DA-9805 45mg | - | - | - | - | 1件: 6 6 💬 |
927 | Dacortín 2,5mg | - | - | - | - | 1件: 222 222 💬 |
928 | Dacortín 30mg | - | - | - | - | 1件: 222 222 💬 |
929 | Dacortín 5mg | - | - | - | - | 1件: 222 222 💬 |
930 | Darifenacin (BAY79-4998) | 1件: Darifenacin Darifenacin | 1件: Darifenacin
Darifenacin
💬 | 1件: CHRM3 CHRM3 💬 | 11件: Alzheimer disease Alzheimer disease, Calcium signaling pathway, Cholinergic synapse, Gastric acid secretion, Insulin secretion, Neuroactive ligand-receptor interaction, Pancreatic secretion, Pathways of neurodegeneration - multiple diseases, Regulation of actin cytoskeleton, Salivary secretion, Taste transduction 💬 | 1件: 13 13 💬 |
931 | Dark chocolate (85% cocoa) | 1件: Cocoa Cocoa | - | - | - | 1件: 6 6 💬 |
932 | DAS-001 | - | - | - | - | 1件: 11 11 💬 |
933 | Davunetide (AL-108, NAP) | 1件: Davunetide Davunetide | 1件: Davunetide
Davunetide
💬 | - | - | 3件: 5 5, 7, 127 💬 |
934 | DB adalimumab 40 mg eow | 1件: Adalimumab Adalimumab | 1件: Adalimumab
Adalimumab
💬 | 1件: TNF TNF 💬 | 67件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Dilated cardiomyopathy, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease, Osteoclast differentiation, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway 💬 | 1件: 96 96 💬 |
935 | DB adalimumab 40 mg ew | 1件: Adalimumab Adalimumab | 1件: Adalimumab
Adalimumab
💬 | 1件: TNF TNF 💬 | 67件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Dilated cardiomyopathy, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease, Osteoclast differentiation, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway 💬 | 1件: 96 96 💬 |
936 | Deferiprone 600 mg delayed release tablet | 1件: Deferiprone Deferiprone | 1件: Deferiprone
Deferiprone
💬 | - | - | 1件: 6 6 💬 |
937 | Deferiprone 80 mg/mL oral solution | 1件: Deferiprone Deferiprone | 1件: Deferiprone
Deferiprone
💬 | - | - | 1件: 120 120 💬 |
938 | Deferiprone 80 mg/mL oral solution (Ferriprox) | 1件: Deferiprone Deferiprone | 1件: Deferiprone
Deferiprone
💬 | - | - | 1件: 120 120 💬 |
939 | DEFLAN*10CPR 6MG | - | - | - | - | 1件: 113 113 💬 |
940 | Deflazacort 6 mg Tablets | 1件: Deflazacort Deflazacort | 1件: Deflazacort
Deflazacort
💬 | 1件: NR3C1 NR3C1 💬 | 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 1件: 113 113 💬 |
941 | Dehydroepiandrosterone 100 and 400 mg | 1件: Prasterone Prasterone | 1件: Prasterone
Prasterone
💬 | 3件: AR AR, ESR1, ESR2 💬 | 12件: Breast cancer Breast cancer, Chemical carcinogenesis - receptor activation, Endocrine and other factor-regulated calcium reabsorption, Endocrine resistance, Estrogen signaling pathway, GnRH secretion, Oocyte meiosis, Pathways in cancer, Prolactin signaling pathway, Prostate cancer, Proteoglycans in cancer, Thyroid hormone signaling pathway 💬 | 1件: 113 113 💬 |
942 | Dekristol 20.000 ie | - | - | - | - | 1件: 96 96 💬 |
943 | Dekristol® 400-Tabletten | - | - | - | - | 1件: 13 13 💬 |
944 | Dekristol®-Tablette 1 (400 IE) | - | - | - | - | 1件: 13 13 💬 |
945 | Delayed Release 6 mercaptopurine | 1件: Mercaptopurine Mercaptopurine | 2件: Mercaptopurine
Mercaptopurine
,
Mercaptopurine
💬 | 1件: HPRT1 HPRT1 💬 | 4件: Drug metabolism - other enzymes Drug metabolism - other enzymes, Metabolic pathways, Nucleotide metabolism, Purine metabolism 💬 | 1件: 96 96 💬 |
946 | Delayed Release 6MP or Calcitriol vs. Purinethol | 1件: Calcitriol Calcitriol | 1件: Calcitriol
Calcitriol
💬 | 1件: VDR VDR 💬 | 5件: Chemical carcinogenesis - receptor activation Chemical carcinogenesis - receptor activation, Endocrine and other factor-regulated calcium reabsorption, Mineral absorption, Parathyroid hormone synthesis, secretion and action, Tuberculosis 💬 | 1件: 96 96 💬 |
947 | Depo-Medrol 40Mg/Ml Suspension for Injection | - | - | - | - | 1件: 70 70 💬 |
948 | Descartes-08 | - | - | - | - | 1件: 11 11 💬 |
949 | Desmopressine nasal spray 10 mg/ml, flacon 60 doses | 1件: Desmopressin Desmopressin | 1件: Desmopressin
Desmopressin
💬 | 2件: AVPR2 AVPR2, F8 💬 | 4件: Complement and coagulation cascades Complement and coagulation cascades, Neuroactive ligand-receptor interaction, Phospholipase D signaling pathway, Vasopressin-regulated water reabsorption 💬 | 1件: 225 225 💬 |
950 | Desmotabs® 0,2 mg Tabletten | - | - | - | - | 1件: 6 6 💬 |
951 | Desmotabs® 0,2mg Tabletten | - | - | - | - | 1件: 6 6 💬 |
952 | Dexamethasone (4 cycles) | 1件: Dexamethasone Dexamethasone | 1件: Dexamethasone
Dexamethasone
💬 | 1件: NR3C1 NR3C1 💬 | 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 1件: 63 63 💬 |
953 | Dexamethasone 0,1 mg Tablets | 1件: Dexamethasone Dexamethasone | 1件: Dexamethasone
Dexamethasone
💬 | 1件: NR3C1 NR3C1 💬 | 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 1件: 81 81 💬 |
954 | Dexamethasone 0,5mg | 1件: Dexamethasone Dexamethasone | 1件: Dexamethasone
Dexamethasone
💬 | 1件: NR3C1 NR3C1 💬 | 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 1件: 84 84 💬 |
955 | Dexamethasone 0.5mg Tablet | 1件: Dexamethasone Dexamethasone | 1件: Dexamethasone
Dexamethasone
💬 | 1件: NR3C1 NR3C1 💬 | 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 1件: 81 81 💬 |
956 | Dexamethasone 0.5mg/5ml solution | 1件: Dexamethasone Dexamethasone | 1件: Dexamethasone
Dexamethasone
💬 | 1件: NR3C1 NR3C1 💬 | 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 2件: 35 35, 162 💬 |
957 | Dexamethasone 0.5mg/5ml solution in Mucolox™ | 1件: Dexamethasone Dexamethasone | 1件: Dexamethasone
Dexamethasone
💬 | 1件: NR3C1 NR3C1 💬 | 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 2件: 35 35, 162 💬 |
958 | Dexamethasone 4 mg JENAPHARM | 1件: Dexamethasone Dexamethasone | 1件: Dexamethasone
Dexamethasone
💬 | 1件: NR3C1 NR3C1 💬 | 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 1件: 28 28 💬 |
959 | Dexamethasone oral tablet 8mg (Dexamethasone Krka tablets(8mg), Warsaw, Poland). | 1件: Dexamethasone Dexamethasone | 1件: Dexamethasone
Dexamethasone
💬 | 1件: NR3C1 NR3C1 💬 | 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 1件: 235 235 💬 |
960 | Dexamethasone, 40 mg | 1件: Dexamethasone Dexamethasone | 1件: Dexamethasone
Dexamethasone
💬 | 1件: NR3C1 NR3C1 💬 | 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 1件: 28 28 💬 |
961 | Diethyl-[6-(4-hydroxycarbamoyl- phenyl carbamoyloxymethyl)-naphthalen-2-yl methyl]-ammonium chloride | 2件: Ammonium chloride Ammonium chloride, Chloride ion | 1件: Ammonium chloride
Ammonium chloride
💬 | - | - | 1件: 107 107 💬 |
962 | Diethyl-[6-(4-hydroxycarbamoyl-phenylcarbamoyloxymethyl)-naphtalen-2-ylmethyl]-ammonium chloride mon | 2件: Ammonium chloride Ammonium chloride, Chloride ion | 1件: Ammonium chloride
Ammonium chloride
💬 | - | - | 1件: 96 96 💬 |
963 | Digoxin 0.25 mg | 1件: Digoxin Digoxin | 1件: Digoxin
Digoxin
💬 | 4件: ATP1A1 ATP1A1, ATP1A2, ATP1A3, ATP1A4 💬 | 18件: Adrenergic signaling in cardiomyocytes Adrenergic signaling in cardiomyocytes, Aldosterone synthesis and secretion, Aldosterone-regulated sodium reabsorption, Bile secretion, Carbohydrate digestion and absorption, Cardiac muscle contraction, Endocrine and other factor-regulated calcium reabsorption, Gastric acid secretion, Insulin secretion, Mineral absorption, Pancreatic secretion, Protein digestion and absorption, Proximal tubule bicarbonate reclamation, Salivary secretion, Thyroid hormone signaling pathway, Thyroid hormone synthesis, cAMP signaling pathway, cGMP-PKG signaling pathway 💬 | 1件: 46 46 💬 |
964 | Diovan 40 mg | 1件: Valsartan Valsartan | 1件: Valsartan
Valsartan
💬 | 1件: AGTR1 AGTR1 💬 | 16件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adrenergic signaling in cardiomyocytes, Aldosterone synthesis and secretion, Apelin signaling pathway, Calcium signaling pathway, Coronavirus disease - COVID-19, Cortisol synthesis and secretion, Cushing syndrome, Diabetic cardiomyopathy, Neuroactive ligand-receptor interaction, Pathways in cancer, Phospholipase D signaling pathway, Renin secretion, Renin-angiotensin system, Vascular smooth muscle contraction, cGMP-PKG signaling pathway 💬 | 1件: 58 58 💬 |
965 | Diovan 80 mg | 1件: Valsartan Valsartan | 1件: Valsartan
Valsartan
💬 | 1件: AGTR1 AGTR1 💬 | 16件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adrenergic signaling in cardiomyocytes, Aldosterone synthesis and secretion, Apelin signaling pathway, Calcium signaling pathway, Coronavirus disease - COVID-19, Cortisol synthesis and secretion, Cushing syndrome, Diabetic cardiomyopathy, Neuroactive ligand-receptor interaction, Pathways in cancer, Phospholipase D signaling pathway, Renin secretion, Renin-angiotensin system, Vascular smooth muscle contraction, cGMP-PKG signaling pathway 💬 | 1件: 58 58 💬 |
966 | DIURF-006 | - | - | - | - | 1件: 81 81 💬 |
967 | Dl-3-n-butylphthalide (NBP) | 1件: Butylphthalide Butylphthalide | - | - | - | 1件: 22 22 💬 |
968 | Dose level 4 | - | - | - | - | 1件: 46 46 💬 |
969 | Dose of 60 mg/kg alpha1-proteinase inhibitor | 1件: Alpha-1-proteinase inhibitor Alpha-1-proteinase inhibitor | - | - | - | 1件: 231 231 💬 |
970 | Dose of 60 mg/kg Fraction IV-1 Alpha1-Proteinase Inhibitor | 1件: Alpha-1-proteinase inhibitor Alpha-1-proteinase inhibitor | - | - | - | 1件: 231 231 💬 |
971 | Dose-Establishing Study 1 Niacin 250mg | 1件: Niacin Niacin | 1件: Niacin
Niacin
💬 | - | - | 1件: 78 78 💬 |
972 | Dose-Establishing Study 1 Niacin 500mg | 1件: Niacin Niacin | 1件: Niacin
Niacin
💬 | - | - | 1件: 78 78 💬 |
973 | Dose-Establishing Study 2 Niacin 500mg | 1件: Niacin Niacin | 1件: Niacin
Niacin
💬 | - | - | 1件: 78 78 💬 |
974 | Dosing Interruption of Natalizumab | 1件: Natalizumab Natalizumab | 1件: Natalizumab
Natalizumab
💬 | 1件: ITGA4 ITGA4 💬 | 14件: Arrhythmogenic right ventricular cardiomyopathy Arrhythmogenic right ventricular cardiomyopathy, Cell adhesion molecules, Dilated cardiomyopathy, ECM-receptor interaction, Focal adhesion, Hematopoietic cell lineage, Human papillomavirus infection, Hypertrophic cardiomyopathy, Intestinal immune network for IgA production, Leishmaniasis, Leukocyte transendothelial migration, PI3K-Akt signaling pathway, Regulation of actin cytoskeleton, Yersinia infection 💬 | 1件: 13 13 💬 |
975 | Dotarem 0,5mmol/ml, | 1件: Gadoteric acid Gadoteric acid | 1件: Gadoteric acid
Gadoteric acid
💬 | - | - | 1件: 13 13 💬 |
976 | Doxycycline 100-200mg capsules daily for 6 months | 1件: Doxycycline Doxycycline | 2件: Doxycycline
Doxycycline
,
Doxycycline
💬 | - | - | 1件: 167 167 💬 |
977 | Droxidopa 100 MG [Northera] | 1件: Droxidopa Droxidopa | 1件: Droxidopa
Droxidopa
💬 | 9件: ADRA1A ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C, ADRB1, ADRB2, ADRB3 💬 | 14件: AMPK signaling pathway AMPK signaling pathway, Adrenergic signaling in cardiomyocytes, Calcium signaling pathway, Chemical carcinogenesis - receptor activation, Dilated cardiomyopathy, Gap junction, Neuroactive ligand-receptor interaction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Thermogenesis, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway 💬 | 1件: 6 6 💬 |
978 | DTR Melatonin (NIH CC PDS) | 1件: Melatonin Melatonin | 1件: Melatonin
Melatonin
💬 | 2件: MTNR1A MTNR1A, MTNR1B 💬 | 2件: Circadian entrainment Circadian entrainment, Neuroactive ligand-receptor interaction 💬 | 1件: 202 202 💬 |
979 | Dulaglutide 0.75Mg/0.5Ml Inj Pen | 1件: Dulaglutide Dulaglutide | 1件: Dulaglutide
Dulaglutide
💬 | 1件: GLP1R GLP1R 💬 | 3件: Insulin secretion Insulin secretion, Neuroactive ligand-receptor interaction, cAMP signaling pathway 💬 | 1件: 299 299 💬 |
980 | DUOC-01 | - | - | - | - | 3件: 13 13, 19, 20 💬 |
981 | DX-890 | - | - | - | - | 1件: 299 299 💬 |
982 | E. coli Nissle | - | - | - | - | 1件: 97 97 💬 |
983 | E. coli Nissle 1917 (Mutaflor®) | - | - | - | - | 1件: 97 97 💬 |
984 | E5501 40 mg 2 x 20-mg tablets, orally, fasted | - | - | - | - | 1件: 63 63 💬 |
985 | E5501 40 mg 2 x 20-mg tablets, orally, with food | - | - | - | - | 1件: 63 63 💬 |
986 | E5501 40mg 2 x 20-mg tablets, orally, fasted | - | - | - | - | 1件: 63 63 💬 |
987 | Ebetrex 15 mg = 0,75 ml, oplossing voor injectie in voorgevulde injectiespuit 20 mg/ml | - | - | - | - | 1件: 96 96 💬 |
988 | Ecologic 825 | - | - | - | - | 1件: 97 97 💬 |
989 | EDG-5506 Dose 4 | - | - | - | - | 1件: 113 113 💬 |
990 | EEN (Nestle Modulen®) | - | - | - | - | 1件: 96 96 💬 |
991 | Eflornithine plus Nifurtimox combination therapy | 2件: Eflornithine Eflornithine, Nifurtimox | 2件: Nifurtimox
Nifurtimox
,
Eflornithine
💬 | 1件: ODC1 ODC1 💬 | 3件: Arginine and proline metabolism Arginine and proline metabolism, Glutathione metabolism, Metabolic pathways 💬 | 1件: 65 65 💬 |
992 | EGCG as putative neuroprotective agent | 1件: Epigallocatechin gallate Epigallocatechin gallate | - | - | - | 1件: 17 17 💬 |
993 | EH301 (Nicotinamide Riboside/Pterostilbene) | 2件: Nicotinamide Nicotinamide, Nicotinamide riboside | 1件: Niacinamide
Niacinamide
💬 | - | - | 1件: 2 2 💬 |
994 | Elafibranor 80 mg | 1件: Elafibranor Elafibranor | 1件: Elafibranor
Elafibranor
💬 | 1件: PPARA PPARA 💬 | 10件: Adipocytokine signaling pathway Adipocytokine signaling pathway, Alcoholic liver disease, Chemical carcinogenesis - receptor activation, Diabetic cardiomyopathy, Glucagon signaling pathway, Hepatitis C, Insulin resistance, Non-alcoholic fatty liver disease, PPAR signaling pathway, cAMP signaling pathway 💬 | 2件: 93 93, 94 💬 |
995 | Elafibranor 80mg | 1件: Elafibranor Elafibranor | 1件: Elafibranor
Elafibranor
💬 | 1件: PPARA PPARA 💬 | 10件: Adipocytokine signaling pathway Adipocytokine signaling pathway, Alcoholic liver disease, Chemical carcinogenesis - receptor activation, Diabetic cardiomyopathy, Glucagon signaling pathway, Hepatitis C, Insulin resistance, Non-alcoholic fatty liver disease, PPAR signaling pathway, cAMP signaling pathway 💬 | 1件: 93 93 💬 |
996 | Elelyso 60 units/kg | 1件: Taliglucerase alfa Taliglucerase alfa | 1件: Taliglucerase alfa
Taliglucerase alfa
💬 | 1件: GBA1 GBA1 💬 | 4件: Lysosome Lysosome, Metabolic pathways, Other glycan degradation, Sphingolipid metabolism 💬 | 1件: 19 19 💬 |
997 | Else nutrition formula | - | - | - | - | 1件: 98 98 💬 |
998 | Eltrombopag olamine (SB-497115-GR) | 1件: Eltrombopag Eltrombopag | - | - | - | 1件: 63 63 💬 |
999 | ELX (VX-445)/TEZ (VX-661)/IVA (VX-770) | - | - | - | - | 1件: 299 299 💬 |
1000 | ELX-02 | 1件: ELX-02 ELX-02 | - | - | - | 3件: 19 19, 218, 299 💬 |
1001 | EMD 87580 | - | - | - | - | 1件: 113 113 💬 |
1002 | EMEA/H/C/000109 | - | - | - | - | 1件: 203 203 💬 |
1003 | EMEA/H/C/000125 | - | - | - | - | 1件: 299 299 💬 |
1004 | EMEA/H/C/000240 | - | - | - | - | 2件: 96 96, 97 💬 |
1005 | EMEA/H/C/000481 | - | - | - | - | 1件: 97 97 💬 |
1006 | EMEA/H/C/000638 | - | - | - | - | 1件: 113 113 💬 |
1007 | EMEA/H/C/000701 | - | - | - | - | 1件: 50 50 💬 |
1008 | EMEA/H/C/000712 | - | - | - | - | 1件: 227 227 💬 |
1009 | EMEA/H/C/002576 | - | - | - | - | 1件: 96 96 💬 |
1010 | EMEA/H/C/002778 | - | - | - | - | 1件: 96 96 💬 |
1011 | EMEA/H/C/004214 | - | - | - | - | 1件: 46 46 💬 |
1012 | EMIXUSTAT HYDROCHLORIDE (ACU-4429) | 1件: Emixustat Emixustat | 1件: Emixustat
Emixustat
💬 | - | - | 1件: 301 301 💬 |
1013 | ENB-0040 | - | - | - | - | 1件: 172 172 💬 |
1014 | ENBREL 25 mg/ml polvo y disolvente para solución inyectable para uso pediátrico | 1件: Etanercept Etanercept | 1件: Etanercept
Etanercept
💬 | 2件: LTA LTA, TNF 💬 | 67件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Dilated cardiomyopathy, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease, Osteoclast differentiation, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway 💬 | 1件: 107 107 💬 |
1015 | ENBREL 50 mg solución inyectable en jeringas precargadas | 1件: Etanercept Etanercept | 1件: Etanercept
Etanercept
💬 | 2件: LTA LTA, TNF 💬 | 67件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Dilated cardiomyopathy, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease, Osteoclast differentiation, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway 💬 | 1件: 107 107 💬 |
1016 | ENBREL*BB SC 4FL 25MG 1ML+4SIR | 1件: Etanercept Etanercept | 1件: Etanercept
Etanercept
💬 | 2件: LTA LTA, TNF 💬 | 67件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Dilated cardiomyopathy, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease, Osteoclast differentiation, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway 💬 | 1件: 107 107 💬 |
1017 | ENBREL*SC 4FL 25MG+4SIR 1ML | 1件: Etanercept Etanercept | 1件: Etanercept
Etanercept
💬 | 2件: LTA LTA, TNF 💬 | 67件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Dilated cardiomyopathy, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease, Osteoclast differentiation, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway 💬 | 3件: 46 46, 60, 285 💬 |
1018 | ENBREL*SC 4FL 50MG+4SIR+4AGHI+ | 1件: Etanercept Etanercept | 1件: Etanercept
Etanercept
💬 | 2件: LTA LTA, TNF 💬 | 67件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Dilated cardiomyopathy, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease, Osteoclast differentiation, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway 💬 | 1件: 46 46 💬 |
1019 | ENBREL*SC 4SIR 25MG 0,5ML+8TAM | 1件: Etanercept Etanercept | 1件: Etanercept
Etanercept
💬 | 2件: LTA LTA, TNF 💬 | 67件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Dilated cardiomyopathy, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease, Osteoclast differentiation, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway 💬 | 1件: 46 46 💬 |
1020 | ENBREL*SC 4SIR 50MG 1ML+8TAMP | 1件: Etanercept Etanercept | 1件: Etanercept
Etanercept
💬 | 2件: LTA LTA, TNF 💬 | 67件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Dilated cardiomyopathy, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease, Osteoclast differentiation, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway 💬 | 1件: 46 46 💬 |
1021 | End-of-life nursing education consortium-pediatric palliative care as web based-training plus usual care | - | - | - | - | 2件: 113 113, 299 💬 |
1022 | ENDOPROST - 0.05 MG/0.5 ML CONCENTRATO PER SOLUZIONE PER INFUSIONE 1 FIALA | - | - | - | - | 1件: 51 51 💬 |
1023 | ENDOPROST 0,05MG/0,5ML 1F | - | - | - | - | 1件: 51 51 💬 |
1024 | ENDOPROST 50*INFUS 1F 0,050MG/ | - | - | - | - | 1件: 51 51 💬 |
1025 | Engineerd Protein Inhibitor of human Neutrophil Elastase | - | - | - | - | 1件: 299 299 💬 |
1026 | Engineered humanized monoclonal anti-human CD19 antibody. Lot Numbers: 1-FIN-1588 (9.6mg/ml) | - | - | - | - | 1件: 46 46 💬 |
1027 | Engineered Protein Inhibitor of human Neutrophil Elastase | - | - | - | - | 1件: 299 299 💬 |
1028 | ENT-01 | - | - | - | - | 1件: 6 6 💬 |
1029 | Entacapone 400mg oral dose | 1件: Entacapone Entacapone | 1件: Entacapone
Entacapone
💬 | 1件: COMT COMT 💬 | 4件: Dopaminergic synapse Dopaminergic synapse, Metabolic pathways, Steroid hormone biosynthesis, Tyrosine metabolism 💬 | 2件: 6 6, 17 💬 |
1030 | Enteral nutrition | - | - | - | - | 1件: 96 96 💬 |
1031 | Enteral nutrition. | - | - | - | - | 1件: 96 96 💬 |
1032 | EPARMEFOLIN 30 CPR 0,1/0,5MG | - | - | - | - | 1件: 13 13 💬 |
1033 | EPAX 6000 EE 1000mg (0.6 gr DHA+EPA) | - | - | - | - | 1件: 46 46 💬 |
1034 | EPI-743 400mg | - | - | - | - | 1件: 6 6 💬 |
1035 | EPI-hNE4 DX-890 | - | - | - | - | 1件: 299 299 💬 |
1036 | Epidyolex and is the approved name in the EU | 1件: Cannabidiol Cannabidiol | 1件: Cannabidiol
Cannabidiol
💬 | 2件: CNR1 CNR1, CNR2 💬 | 4件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Rap1 signaling pathway, Retrograde endocannabinoid signaling, Thermogenesis 💬 | 1件: 156 156 💬 |
1037 | Epratuzumab 400 mg | 1件: Epratuzumab Epratuzumab | 1件: Epratuzumab
Epratuzumab
💬 | 1件: CD22 CD22 💬 | 3件: B cell receptor signaling pathway B cell receptor signaling pathway, Cell adhesion molecules, Hematopoietic cell lineage 💬 | 1件: 49 49 💬 |
1038 | Epratuzumab 600 mg | 1件: Epratuzumab Epratuzumab | 1件: Epratuzumab
Epratuzumab
💬 | 1件: CD22 CD22 💬 | 3件: B cell receptor signaling pathway B cell receptor signaling pathway, Cell adhesion molecules, Hematopoietic cell lineage 💬 | 1件: 49 49 💬 |
1039 | EPREX IV SC 1FL 1ML 40000 UI | - | - | - | - | 1件: 2 2 💬 |
1040 | EPREX*1FL 40000UI/ML 1ML | - | - | - | - | 1件: 18 18 💬 |
1041 | EPREX*1SIR 40000UI/ML 1ML | - | - | - | - | 2件: 2 2, 18 💬 |
1042 | ERB-041 | - | - | - | - | 3件: 46 46, 96, 226 💬 |
1043 | Etanercept (50mg per week, for 4 weeks) | 1件: Etanercept Etanercept | 1件: Etanercept
Etanercept
💬 | 2件: LTA LTA, TNF 💬 | 67件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Dilated cardiomyopathy, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease, Osteoclast differentiation, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway 💬 | 1件: 271 271 💬 |
1044 | Etanercept 50 mg sc day 0 and day 3 | 1件: Etanercept Etanercept | 1件: Etanercept
Etanercept
💬 | 2件: LTA LTA, TNF 💬 | 67件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Dilated cardiomyopathy, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease, Osteoclast differentiation, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway 💬 | 2件: 38 38, 39 💬 |
1045 | Ethylmethylcarbamic acid 3-[(1S)-1-(dimethylamino)ethyl]phenyl ester (**See other 2 names below) | - | - | - | - | 1件: 6 6 💬 |
1046 | Etoricoxib 60 mg | 1件: Etoricoxib Etoricoxib | 1件: Etoricoxib
Etoricoxib
💬 | 1件: PTGS2 PTGS2 💬 | 22件: Alzheimer disease Alzheimer disease, Arachidonic acid metabolism, C-type lectin receptor signaling pathway, Chemical carcinogenesis - DNA adducts, Human cytomegalovirus infection, Human papillomavirus infection, IL-17 signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Metabolic pathways, MicroRNAs in cancer, NF-kappa B signaling pathway, Ovarian steroidogenesis, Oxytocin signaling pathway, Pathways in cancer, Pathways of neurodegeneration - multiple diseases, Regulation of lipolysis in adipocytes, Retrograde endocannabinoid signaling, Serotonergic synapse, Small cell lung cancer, TNF signaling pathway, VEGF signaling pathway 💬 | 1件: 46 46 💬 |
1047 | EU Orphan Designation Number EU/3/02/120 | - | - | - | - | 1件: 299 299 💬 |
1048 | EU/1/03/256/001 | - | - | - | - | 1件: 107 107 💬 |
1049 | EU/1/03/268/002 | - | - | - | - | 1件: 96 96 💬 |
1050 | EU/1/06/362/003: 5µg (1 pen) | - | - | - | - | 1件: 193 193 💬 |
1051 | EU/1/07/389/001 | - | - | - | - | 1件: 107 107 💬 |
1052 | EU/1/08/454/001-002, EU/1/08/454/005-007 | - | - | - | - | 1件: 13 13 💬 |
1053 | EU/1/14/980/002 | - | - | - | - | 1件: 269 269 💬 |
1054 | EU/1/14/980/003 | - | - | - | - | 1件: 269 269 💬 |
1055 | EU/1/95/003/005-010 | - | - | - | - | 1件: 13 13 💬 |
1056 | EU/1/97/033/002 | - | - | - | - | 1件: 13 13 💬 |
1057 | EU/1/98/063/001-003 | - | - | - | - | 1件: 13 13 💬 |
1058 | EU/1/98/063/004-006 | - | - | - | - | 1件: 13 13 💬 |
1059 | EU/1/99/116/003 | - | - | - | - | 1件: 96 96 💬 |
1060 | EU/1/99/126/001 | - | - | - | - | 1件: 107 107 💬 |
1061 | EU/1/99/126/017 | - | - | - | - | 1件: 46 46 💬 |
1062 | EU/1/99/126/020 | - | - | - | - | 1件: 46 46 💬 |
1063 | EU1/97/031-032 | - | - | - | - | 1件: 18 18 💬 |
1064 | EU1/97/031/031-032 | - | - | - | - | 1件: 18 18 💬 |
1065 | EUR-1008 25,000 Units | - | - | - | - | 1件: 299 299 💬 |
1066 | EVP-0334 | - | - | - | - | 1件: 127 127 💬 |
1067 | Ex vivo culture and transduction of the patient's autologous CD34+ HSC with lentivirus vector VSV-G pseudotyped CL20- 4i-EF1alpha-hgammac-OPT vector | - | - | - | - | 1件: 65 65 💬 |
1068 | EXCL-100, 600 MG Oral Tablet | - | - | - | - | 1件: 85 85 💬 |
1069 | Exclusive Enteral Nutrition | - | - | - | - | 1件: 96 96 💬 |
1070 | Exclusive Enteral Nutrition Therapy | - | - | - | - | 1件: 96 96 💬 |
1071 | Exelon 3,0 mg Hartkapseln | 1件: Rivastigmine Rivastigmine | 1件: Rivastigmine
Rivastigmine
💬 | 1件: ACHE ACHE 💬 | 2件: Cholinergic synapse Cholinergic synapse, Glycerophospholipid metabolism 💬 | 1件: 5 5 💬 |
1072 | Exelon 4.6 mg/24 h transdermal patch | 1件: Rivastigmine Rivastigmine | 1件: Rivastigmine
Rivastigmine
💬 | 1件: ACHE ACHE 💬 | 2件: Cholinergic synapse Cholinergic synapse, Glycerophospholipid metabolism 💬 | 1件: 6 6 💬 |
1073 | Exelon 6,0 mg Hartkapseln | 1件: Rivastigmine Rivastigmine | 1件: Rivastigmine
Rivastigmine
💬 | 1件: ACHE ACHE 💬 | 2件: Cholinergic synapse Cholinergic synapse, Glycerophospholipid metabolism 💬 | 1件: 5 5 💬 |
1074 | EXN-44 | - | - | - | - | 1件: 6 6 💬 |
1075 | EXN-44(LEVODOPA) | 1件: Levodopa Levodopa | 1件: Levodopa
Levodopa
💬 | 5件: DRD1 DRD1, DRD2, DRD3, DRD4, DRD5 💬 | 11件: Alcoholism Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway 💬 | 1件: 6 6 💬 |
1076 | Experimental (Non Immunosuppressive Symptomatic Treatment (NIST) and Rituximab) | 1件: Rituximab Rituximab | 1件: Rituximab
Rituximab
💬 | 1件: MS4A1 MS4A1 💬 | 1件: Hematopoietic cell lineage Hematopoietic cell lineage 💬 | 1件: 222 222 💬 |
1077 | Experimental: Seladelpar / MBX-8025 200 mg | 1件: Seladelpar Seladelpar | 1件: Seladelpar
Seladelpar
💬 | 1件: PPARG PPARG 💬 | 11件: AMPK signaling pathway AMPK signaling pathway, Huntington disease, Lipid and atherosclerosis, Longevity regulating pathway, Non-alcoholic fatty liver disease, Osteoclast differentiation, PPAR signaling pathway, Pathways in cancer, Thermogenesis, Thyroid cancer, Transcriptional misregulation in cancer 💬 | 1件: 93 93 💬 |
1078 | Experimental: Seladelpar / MBX-8025 50 mg | 1件: Seladelpar Seladelpar | 1件: Seladelpar
Seladelpar
💬 | 1件: PPARG PPARG 💬 | 11件: AMPK signaling pathway AMPK signaling pathway, Huntington disease, Lipid and atherosclerosis, Longevity regulating pathway, Non-alcoholic fatty liver disease, Osteoclast differentiation, PPAR signaling pathway, Pathways in cancer, Thermogenesis, Thyroid cancer, Transcriptional misregulation in cancer 💬 | 1件: 93 93 💬 |
1079 | Extavia (interferon beta-1b), Novartis Pharma AG | 2件: Human interferon beta Human interferon beta, Interferon beta-1b | 1件: Interferon beta-1b
Interferon beta-1b
💬 | 2件: IFNAR1 IFNAR1, IFNAR2 💬 | 18件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Measles, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Osteoclast differentiation, PI3K-Akt signaling pathway, Pathways in cancer, Toll-like receptor signaling pathway 💬 | 1件: 13 13 💬 |
1080 | F-18 FEDAA1106 (BAY85-8101) | - | - | - | - | 1件: 13 13 💬 |
1081 | F-A-F-A (FIASP-NovoRapid-FIASP-NovoRapid) | - | - | - | - | 1件: 299 299 💬 |
1082 | FAMPYRA - 10 MG - COMPRESSA A RILASCIO PROLUNGATO - USO ORALE - FLACONE (HDPE) 56 COMPRESSE (4 FLACONI DA 14) | 1件: Dalfampridine Dalfampridine | 1件: Dalfampridine
Dalfampridine
💬 | 4件: KCNA4 KCNA4, KCNC3, KCND2, KCND3 💬 | 4件: Cortisol synthesis and secretion Cortisol synthesis and secretion, Cushing syndrome, Serotonergic synapse, Spinocerebellar ataxia 💬 | 1件: 13 13 💬 |
1083 | Fanhdi 50 UI FVIII-60 UI FVW | - | - | - | - | 1件: 288 288 💬 |
1084 | Fasudil (WP-0512) | 1件: Fasudil Fasudil | 1件: Fasudil
Fasudil
💬 | 2件: ROCK1 ROCK1, ROCK2 💬 | 23件: Axon guidance Axon guidance, Chemokine signaling pathway, Focal adhesion, Human cytomegalovirus infection, Leukocyte transendothelial migration, Lipid and atherosclerosis, MicroRNAs in cancer, Oxytocin signaling pathway, Pathogenic Escherichia coli infection, Pathways in cancer, Platelet activation, Proteoglycans in cancer, Regulation of actin cytoskeleton, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, TGF-beta signaling pathway, Tight junction, Vascular smooth muscle contraction, Wnt signaling pathway, Yersinia infection, cAMP signaling pathway, cGMP-PKG signaling pathway 💬 | 1件: 2 2 💬 |
1085 | FCX-007 | - | - | - | - | 1件: 36 36 💬 |
1086 | FCX-013 | - | - | - | - | 1件: 51 51 💬 |
1087 | Fetal porcine cells, Neurocell-PD | - | - | - | - | 1件: 6 6 💬 |
1088 | Fingolimod 0.5 mg | 1件: Fingolimod Fingolimod | 1件: Fingolimod
Fingolimod
💬 | 1件: S1PR1 S1PR1 💬 | 3件: FoxO signaling pathway FoxO signaling pathway, Neuroactive ligand-receptor interaction, Sphingolipid signaling pathway 💬 | 1件: 13 13 💬 |
1089 | Fingolimod 0.5mg | 1件: Fingolimod Fingolimod | 1件: Fingolimod
Fingolimod
💬 | 1件: S1PR1 S1PR1 💬 | 3件: FoxO signaling pathway FoxO signaling pathway, Neuroactive ligand-receptor interaction, Sphingolipid signaling pathway 💬 | 1件: 13 13 💬 |
1090 | Fipamezole hydrochloride 60 mg oral disintegrating tablets | 1件: Fipamezole Fipamezole | - | - | - | 2件: 6 6, 17 💬 |
1091 | Firategrast (USAN approved name) | 1件: Firategrast Firategrast | 1件: Firategrast
Firategrast
💬 | 1件: ITGA4 ITGA4 💬 | 14件: Arrhythmogenic right ventricular cardiomyopathy Arrhythmogenic right ventricular cardiomyopathy, Cell adhesion molecules, Dilated cardiomyopathy, ECM-receptor interaction, Focal adhesion, Hematopoietic cell lineage, Human papillomavirus infection, Hypertrophic cardiomyopathy, Intestinal immune network for IgA production, Leishmaniasis, Leukocyte transendothelial migration, PI3K-Akt signaling pathway, Regulation of actin cytoskeleton, Yersinia infection 💬 | 1件: 13 13 💬 |
1092 | FK506 level 2-3 ng/ml | - | - | - | - | 1件: 86 86 💬 |
1093 | FK506 level 3-5 ng/ml | - | - | - | - | 1件: 86 86 💬 |
1094 | FK506 level < 2 ng/ml | - | - | - | - | 1件: 86 86 💬 |
1095 | Florence 60 µg/mL | - | - | - | - | 1件: 98 98 💬 |
1096 | Fludarabine phosphate 40 mg | 2件: Fludarabine Fludarabine, Phosphate ion | 1件: Fludarabine
Fludarabine
💬 | 1件: RRM1 RRM1 💬 | 6件: Drug metabolism - other enzymes Drug metabolism - other enzymes, Glutathione metabolism, Metabolic pathways, Nucleotide metabolism, Purine metabolism, Pyrimidine metabolism 💬 | 2件: 65 65, 164 💬 |
1097 | FLUIMUCIL*20CPR EFF 600MG | - | - | - | - | 2件: 94 94, 298 💬 |
1098 | Fluimucil® 600 mg effervescent tablets | - | - | - | - | 1件: 85 85 💬 |
1099 | Folic acid (non-investigational product) | 1件: Folic acid Folic acid | 1件: Folic acid
Folic acid
💬 | - | - | 1件: 46 46 💬 |
1100 | FORLAX 4 g, poudre pour solution buvable en sachet | - | - | - | - | 1件: 299 299 💬 |
1101 | Fortecortin Inject 40 mg Amp. | - | - | - | - | 1件: 65 65 💬 |
1102 | Fosmetpantotenate (RE-024) | - | - | - | - | 1件: 120 120 💬 |
1103 | Fospropofol (Lusedra®) 6.5 | 1件: Fospropofol Fospropofol | - | - | - | 1件: 226 226 💬 |
1104 | FP-CYA-050 | - | - | - | - | 1件: 97 97 💬 |
1105 | FP-CYA-053 | - | - | - | - | 1件: 97 97 💬 |
1106 | Freeze-Dried Sulfonated Human Normal Immunoglobulin (GGS) | 1件: Human immunoglobulin G Human immunoglobulin G | - | - | - | 3件: 14 14, 43, 45 💬 |
1107 | FRM-0334 | - | - | - | - | 1件: 127 127 💬 |
1108 | From August 2020 'no additional treatment' | - | - | - | - | 1件: 51 51 💬 |
1109 | Fully humanized anti-human IL-6 receptor (IL-6R) neutralizing monoclonal antibody | - | - | - | - | 1件: 13 13 💬 |
1110 | Fultium-D3 800IU capsules | - | - | - | - | 1件: 274 274 💬 |
1111 | G2-SFM (IFN-beta-1a from clone 484-39,FBS-free process) | - | - | - | - | 1件: 13 13 💬 |
1112 | GA 40 mg/mL | - | - | - | - | 1件: 13 13 💬 |
1113 | GA Depot 40 mg | - | - | - | - | 1件: 13 13 💬 |
1114 | GA Depot 40mg once monthly | - | - | - | - | 1件: 13 13 💬 |
1115 | GA Depot 80 mg | - | - | - | - | 1件: 13 13 💬 |
1116 | Ga-68-DOTA-NOC | - | - | - | - | 1件: 84 84 💬 |
1117 | Gabapentin (neurontin® capsule 300mg) treatment | 1件: Gabapentin Gabapentin | 1件: Gabapentin
Gabapentin
💬 | 5件: CACNA2D1 CACNA2D1, CACNA2D2, CACNA2D3, CACNA2D4, SLC6A1 💬 | 9件: Adrenergic signaling in cardiomyocytes Adrenergic signaling in cardiomyocytes, Arrhythmogenic right ventricular cardiomyopathy, Cardiac muscle contraction, Dilated cardiomyopathy, GABAergic synapse, Hypertrophic cardiomyopathy, MAPK signaling pathway, Oxytocin signaling pathway, Synaptic vesicle cycle 💬 | 1件: 70 70 💬 |
1118 | Gaboxadol (HLX-0206) | 1件: Gaboxadol Gaboxadol | 1件: Gaboxadol
Gaboxadol
💬 | 16件: GABRA1 GABRA1, GABRA2, GABRA3, GABRA4, GABRA5, GABRA6, GABRB1, GABRB2, GABRB3, GABRD, GABRE, GABRG1, GABRG2, GABRG3, GABRP, GABRQ 💬 | 7件: GABAergic synapse GABAergic synapse, Morphine addiction, Neuroactive ligand-receptor interaction, Nicotine addiction, Retrograde endocannabinoid signaling, Serotonergic synapse, Taste transduction 💬 | 1件: 206 206 💬 |
1119 | Gaboxadol monohydrate 0.5 mg | 1件: Gaboxadol Gaboxadol | 1件: Gaboxadol
Gaboxadol
💬 | 16件: GABRA1 GABRA1, GABRA2, GABRA3, GABRA4, GABRA5, GABRA6, GABRB1, GABRB2, GABRB3, GABRD, GABRE, GABRG1, GABRG2, GABRG3, GABRP, GABRQ 💬 | 7件: GABAergic synapse GABAergic synapse, Morphine addiction, Neuroactive ligand-receptor interaction, Nicotine addiction, Retrograde endocannabinoid signaling, Serotonergic synapse, Taste transduction 💬 | 1件: 201 201 💬 |
1120 | Gaboxadol monohydrate 0.5 mg (intended commercial formulation) | 1件: Gaboxadol Gaboxadol | 1件: Gaboxadol
Gaboxadol
💬 | 16件: GABRA1 GABRA1, GABRA2, GABRA3, GABRA4, GABRA5, GABRA6, GABRB1, GABRB2, GABRB3, GABRD, GABRE, GABRG1, GABRG2, GABRG3, GABRP, GABRQ 💬 | 7件: GABAergic synapse GABAergic synapse, Morphine addiction, Neuroactive ligand-receptor interaction, Nicotine addiction, Retrograde endocannabinoid signaling, Serotonergic synapse, Taste transduction 💬 | 1件: 201 201 💬 |
1121 | Gaboxadol monohydrate 0.5 mg capsule | 1件: Gaboxadol Gaboxadol | 1件: Gaboxadol
Gaboxadol
💬 | 16件: GABRA1 GABRA1, GABRA2, GABRA3, GABRA4, GABRA5, GABRA6, GABRB1, GABRB2, GABRB3, GABRD, GABRE, GABRG1, GABRG2, GABRG3, GABRP, GABRQ 💬 | 7件: GABAergic synapse GABAergic synapse, Morphine addiction, Neuroactive ligand-receptor interaction, Nicotine addiction, Retrograde endocannabinoid signaling, Serotonergic synapse, Taste transduction 💬 | 1件: 201 201 💬 |
1122 | GADOVIST 1 mmol/ml solución inyectable en jeringa precargada/ cartucho precargado | - | - | - | - | 1件: 13 13 💬 |
1123 | Gadovist 1.0 mmol/ml Injektionslösung | 1件: Gadobutrol Gadobutrol | 1件: Gadobutrol
Gadobutrol
💬 | - | - | 1件: 13 13 💬 |
1124 | Gallium nitrate | 2件: Gallium nitrate Gallium nitrate, Nitrate | 2件: Gallium nitrate
Gallium nitrate
,
Nitric acid
💬 | - | - | 1件: 299 299 💬 |
1125 | Gallium-68 DOTATATE | 1件: Dotatate Dotatate | - | - | - | 1件: 84 84 💬 |
1126 | Gallium-68-DOTA-N-Octreotide | 1件: Octreotide Octreotide | 1件: Octreotide
Octreotide
💬 | 1件: SSTR2 SSTR2 💬 | 4件: Gastric acid secretion Gastric acid secretion, Growth hormone synthesis, secretion and action, Neuroactive ligand-receptor interaction, cAMP signaling pathway 💬 | 1件: 84 84 💬 |
1127 | Gallium68-Dota-Noc | - | - | - | - | 1件: 85 85 💬 |
1128 | Gamma-secretase/Notch signalling pathway inhibitor RO4929097 | - | - | - | - | 1件: 74 74 💬 |
1129 | GAZYVARO - 1000 MG - CONCENTRATO PER SOLUZIONE PER INFUSIONE - USO ENDOVENOSO - FLACONCINO - 1000MG/40ML - 1 FLACONCINO | 1件: Obinutuzumab Obinutuzumab | 1件: Obinutuzumab
Obinutuzumab
💬 | 1件: MS4A1 MS4A1 💬 | 1件: Hematopoietic cell lineage Hematopoietic cell lineage 💬 | 1件: 222 222 💬 |
1130 | GB-0998 | - | - | - | - | 1件: 50 50 💬 |
1131 | GB-0998 (Intravenous immunoglobulin) | - | - | - | - | 1件: 11 11 💬 |
1132 | GC1111_1.0mg/kg | - | - | - | - | 1件: 19 19 💬 |
1133 | GDC-0134 | 1件: GDC-0134 GDC-0134 | - | - | - | 1件: 2 2 💬 |
1134 | GDC-0853 | - | - | - | - | 3件: 13 13, 46, 49 💬 |
1135 | GDC-0853 RO7010939 | - | - | - | - | 3件: 13 13, 46, 49 💬 |
1136 | GED-0301 | - | - | - | - | 2件: 96 96, 97 💬 |
1137 | GED-0507-34-LEVO | 1件: GED-0507-34-Levo GED-0507-34-Levo | - | - | - | 1件: 97 97 💬 |
1138 | GED-0507-34-Levo 160 mg | 1件: GED-0507-34-Levo GED-0507-34-Levo | - | - | - | 1件: 97 97 💬 |
1139 | GED-0507-34-Levo 80 mg | 1件: GED-0507-34-Levo GED-0507-34-Levo | - | - | - | 1件: 97 97 💬 |
1140 | Gene Therapy-vMCO-010 | - | - | - | - | 1件: 301 301 💬 |
1141 | Gene-Activated Human Glucocerebrosidase 400U/vial | - | - | - | - | 1件: 19 19 💬 |
1142 | Genetic analysis by SANGER and WHOLE EXOME NEXT GENERATION SEQUENCING | - | - | - | - | 1件: 84 84 💬 |
1143 | Genicular nerve block | - | - | - | - | 1件: 107 107 💬 |
1144 | Genisteine Plus 150 mg cpl formaat 1 18,7 x 6,4 mm 438 mg | - | - | - | - | 1件: 299 299 💬 |
1145 | Genotonorm Kabipen 5.3 mg polvo y disolvente para solución inyectable (Marca internacional Genotropin) | 1件: Somatotropin Somatotropin | - | - | - | 1件: 78 78 💬 |
1146 | Genotonorm Miniquick 0,2 mg | - | - | - | - | 1件: 193 193 💬 |
1147 | GENOTROPIN (Somatropin) is a growth hormone treatment. It is an exact copy of the natural growth hormone that our bodies make. The main difference is that GENOTROPIN is man-made. | 1件: Somatotropin Somatotropin | - | - | - | 1件: 193 193 💬 |
1148 | Genotropin Miniquick 0.2mg | 1件: Somatotropin Somatotropin | - | - | - | 3件: 74 74, 75, 78 💬 |
1149 | Genotropin Miniquick 0.4mg | 1件: Somatotropin Somatotropin | - | - | - | 3件: 74 74, 75, 78 💬 |
1150 | Genotropin miniquick 0.5 mg, injection | - | - | - | - | 1件: 78 78 💬 |
1151 | Genotropin Miniquick 0.6mg | 1件: Somatotropin Somatotropin | - | - | - | 3件: 74 74, 75, 78 💬 |
1152 | Genotropin Miniquick 0.8mg | 1件: Somatotropin Somatotropin | - | - | - | 3件: 74 74, 75, 78 💬 |
1153 | Genotropin Miniquick 1.0mg | 1件: Somatotropin Somatotropin | - | - | - | 3件: 74 74, 75, 78 💬 |
1154 | Gentamicin sulfate 0.1% ointment | 2件: Gentamicin Gentamicin, Sulfate ion | 1件: Gentamicin
Gentamicin
💬 | - | - | 1件: 36 36 💬 |
1155 | GENZ-682452 | 1件: Venglustat Venglustat | 1件: Venglustat
Venglustat
💬 | 1件: UGCG UGCG 💬 | 2件: Metabolic pathways Metabolic pathways, Sphingolipid metabolism 💬 | 3件: 6 6, 19, 67 💬 |
1156 | Genz-682452-AA | 1件: Venglustat Venglustat | 1件: Venglustat
Venglustat
💬 | 1件: UGCG UGCG 💬 | 2件: Metabolic pathways Metabolic pathways, Sphingolipid metabolism 💬 | 1件: 19 19 💬 |
1157 | Genz-682452-AU | 1件: Venglustat Venglustat | 1件: Venglustat
Venglustat
💬 | 1件: UGCG UGCG 💬 | 2件: Metabolic pathways Metabolic pathways, Sphingolipid metabolism 💬 | 3件: 6 6, 19, 67 💬 |
1158 | Gernebcin 80 mg | - | - | - | - | 1件: 299 299 💬 |
1159 | GFB-887 | - | - | - | - | 1件: 222 222 💬 |
1160 | GFI 38518168-AEK-B-007 | - | - | - | - | 1件: 46 46 💬 |
1161 | GILENYA - 0.25 MG - CAPSULE RIGIDE - USO ORALE | 1件: Fingolimod Fingolimod | 1件: Fingolimod
Fingolimod
💬 | 1件: S1PR1 S1PR1 💬 | 3件: FoxO signaling pathway FoxO signaling pathway, Neuroactive ligand-receptor interaction, Sphingolipid signaling pathway 💬 | 1件: 13 13 💬 |
1162 | GILENYA - 0.5 MG - CAPSULE RIGIDE - USO ORALE | 1件: Fingolimod Fingolimod | 1件: Fingolimod
Fingolimod
💬 | 1件: S1PR1 S1PR1 💬 | 3件: FoxO signaling pathway FoxO signaling pathway, Neuroactive ligand-receptor interaction, Sphingolipid signaling pathway 💬 | 1件: 13 13 💬 |
1163 | GILENYA - 0.5 MG - CAPSULE RIGIDE - USO ORALE - BLISTER DIVISIBILE PER DOSE UNITARIA(PVC/PVDC/ALU) SCATOLA DA 7X1 CAPSULE | 1件: Fingolimod Fingolimod | 1件: Fingolimod
Fingolimod
💬 | 1件: S1PR1 S1PR1 💬 | 3件: FoxO signaling pathway FoxO signaling pathway, Neuroactive ligand-receptor interaction, Sphingolipid signaling pathway 💬 | 1件: 13 13 💬 |
1164 | GILENYA - 0.5 MG - CAPSULE RIGIDE - USO ORALE - BLISTER(PVC/PVDC/ALU) SCATOLA DA 28 CAPSULE | 1件: Fingolimod Fingolimod | 1件: Fingolimod
Fingolimod
💬 | 1件: S1PR1 S1PR1 💬 | 3件: FoxO signaling pathway FoxO signaling pathway, Neuroactive ligand-receptor interaction, Sphingolipid signaling pathway 💬 | 1件: 13 13 💬 |
1165 | GILENYA 0,5 mg cápsulas duras | 1件: Fingolimod Fingolimod | 1件: Fingolimod
Fingolimod
💬 | 1件: S1PR1 S1PR1 💬 | 3件: FoxO signaling pathway FoxO signaling pathway, Neuroactive ligand-receptor interaction, Sphingolipid signaling pathway 💬 | 1件: 14 14 💬 |
1166 | Gilenya 0,5 mg Hartkapseln | 1件: Fingolimod Fingolimod | 1件: Fingolimod
Fingolimod
💬 | 1件: S1PR1 S1PR1 💬 | 3件: FoxO signaling pathway FoxO signaling pathway, Neuroactive ligand-receptor interaction, Sphingolipid signaling pathway 💬 | 1件: 13 13 💬 |
1167 | Glatiramer Acetate (GA) 40 mg | 2件: Acetate Acetate, Glatiramer | - | - | - | 1件: 13 13 💬 |
1168 | Glatiramer Acetate 20 mg/0.5 mL | 2件: Acetate Acetate, Glatiramer | - | - | - | 1件: 13 13 💬 |
1169 | Glatiramer acetate 40 mg | 2件: Acetate Acetate, Glatiramer | - | - | - | 1件: 13 13 💬 |
1170 | Glatiramer Acetate, N-Acetylcysteine | 3件: Acetate Acetate, Acetylcysteine, Glatiramer | 1件: Acetylcysteine
Acetylcysteine
💬 | - | - | 1件: 13 13 💬 |
1171 | Glial cell line-derived neurotrophic factor | - | - | - | - | 1件: 6 6 💬 |
1172 | Glial Cell Line-Derived Neurotrophic Factor (GDNF) | - | - | - | - | 1件: 6 6 💬 |
1173 | Glicerol-1,3-didecanoato-2-octadeca-(6Z,9Z,12Z)-trienoato | - | - | - | - | 1件: 13 13 💬 |
1174 | GLIVEC 400 mg comprimidos recubiertos con película | 1件: Imatinib Imatinib | 1件: Imatinib
Imatinib
💬 | 3件: ABL1 ABL1, KIT, PDGFRA 💬 | 32件: Acute myeloid leukemia Acute myeloid leukemia, Axon guidance, Breast cancer, Calcium signaling pathway, Cell cycle, Central carbon metabolism in cancer, Chemical carcinogenesis - reactive oxygen species, Choline metabolism in cancer, Chronic myeloid leukemia, EGFR tyrosine kinase inhibitor resistance, Endocytosis, ErbB signaling pathway, Focal adhesion, Gap junction, Glioma, Hematopoietic cell lineage, Human cytomegalovirus infection, JAK-STAT signaling pathway, MAPK signaling pathway, Melanogenesis, Melanoma, MicroRNAs in cancer, Neurotrophin signaling pathway, PI3K-Akt signaling pathway, Pathogenic Escherichia coli infection, Pathways in cancer, Phospholipase D signaling pathway, Prostate cancer, Rap1 signaling pathway, Ras signaling pathway, Regulation of actin cytoskeleton, Viral myocarditis 💬 | 1件: 34 34 💬 |
1175 | GLPG1690 600 mg QD | - | - | - | - | 1件: 85 85 💬 |
1176 | GLPG2222 400 mg | - | - | - | - | 1件: 299 299 💬 |
1177 | Glucocorticoids (permitted,not necessary) | - | - | - | - | 1件: 46 46 💬 |
1178 | GLWL-01 | - | - | - | - | 1件: 193 193 💬 |
1179 | Glycerol-1,3-didecanoate-2-octadeca-(6Z,9Z,12Z)-trienoate | 1件: Glycerin Glycerin | 1件: Glycerin
Glycerin
💬 | - | - | 1件: 13 13 💬 |
1180 | Glyceryl tri-(4-phenylbutyrate) | 1件: Phenylbutyric acid Phenylbutyric acid | - | - | - | 1件: 251 251 💬 |
1181 | Glyceryl tri-(4-phenylbutyrate)(GT4P) | 2件: Glycerol phenylbutyrate Glycerol phenylbutyrate, Phenylbutyric acid | 1件: Glycerol phenylbutyrate
Glycerol phenylbutyrate
💬 | - | - | 1件: 251 251 💬 |
1182 | GlycosBio Nutritional Supplement | - | - | - | - | 1件: 299 299 💬 |
1183 | GNR-055 | - | - | - | - | 1件: 19 19 💬 |
1184 | GNR-055 1.0-2.0-3.0 mg/kg | - | - | - | - | 1件: 19 19 💬 |
1185 | GNR-055 2.0 mg/kg | - | - | - | - | 1件: 19 19 💬 |
1186 | GNR-055 3.0 mg/kg | - | - | - | - | 1件: 19 19 💬 |
1187 | GNR-069 | - | - | - | - | 1件: 63 63 💬 |
1188 | Gold Nanocrystals | 1件: Gold Gold | - | - | - | 3件: 2 2, 6, 13 💬 |
1189 | Golimumab 4 mg per kg | 1件: Golimumab Golimumab | 1件: Golimumab
Golimumab
💬 | 1件: TNF TNF 💬 | 67件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Dilated cardiomyopathy, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease, Osteoclast differentiation, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway 💬 | 1件: 97 97 💬 |
1190 | Golimumab 400 mg | 1件: Golimumab Golimumab | 1件: Golimumab
Golimumab
💬 | 1件: TNF TNF 💬 | 67件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Dilated cardiomyopathy, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease, Osteoclast differentiation, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway 💬 | 1件: 97 97 💬 |
1191 | Golimumab 50 mg in patients <80 kg and Golimumab 100 mg in patients >80 kg | 1件: Golimumab Golimumab | 1件: Golimumab
Golimumab
💬 | 1件: TNF TNF 💬 | 67件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Dilated cardiomyopathy, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease, Osteoclast differentiation, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway 💬 | 1件: 97 97 💬 |
1192 | Graft intracerebral of foetal neurons | - | - | - | - | 1件: 8 8 💬 |
1193 | GRC 4039 | - | - | - | - | 1件: 46 46 💬 |
1194 | Group 3: ustekinumab approximately 6 mg/kg | 1件: Ustekinumab Ustekinumab | 1件: Ustekinumab
Ustekinumab
💬 | 3件: IL12A IL12A, IL12B, IL23A 💬 | 28件: African trypanosomiasis African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Amoebiasis, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Herpes simplex virus 1 infection, Inflammatory bowel disease, Influenza A, JAK-STAT signaling pathway, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, Malaria, Measles, Pathways in cancer, Pertussis, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus 💬 | 1件: 96 96 💬 |
1195 | Growth hormone (Nutropin) | 1件: Somatotropin Somatotropin | - | - | - | 1件: 78 78 💬 |
1196 | Growth hormone administration for 6 months | 1件: Somatotropin Somatotropin | - | - | - | 1件: 78 78 💬 |
1197 | Growth hormone releasing hormone (GHRH) 1-44 | 2件: Somatorelin Somatorelin, Somatotropin | 1件: Somatorelin
Somatorelin
💬 | 1件: GHRHR GHRHR 💬 | 2件: Growth hormone synthesis, secretion and action Growth hormone synthesis, secretion and action, Neuroactive ligand-receptor interaction 💬 | 1件: 78 78 💬 |
1198 | GS-4059 | - | - | - | - | 1件: 53 53 💬 |
1199 | GS-4875 | - | - | - | - | 1件: 97 97 💬 |
1200 | GS-4997 18 mg | - | - | - | - | 1件: 86 86 💬 |
1201 | GS-4997 2 mg | - | - | - | - | 1件: 86 86 💬 |
1202 | GS-4997 6 mg | - | - | - | - | 1件: 86 86 💬 |
1203 | GS-6034 | - | - | - | - | 4件: 46 46, 53, 96, 97 💬 |
1204 | GS-6615 3 mg | - | - | - | - | 1件: 58 58 💬 |
1205 | GS-6615 3 mg Pink | - | - | - | - | 1件: 58 58 💬 |
1206 | GS-6615 3 mg White | - | - | - | - | 1件: 58 58 💬 |
1207 | GS-6615 6 mg | - | - | - | - | 1件: 58 58 💬 |
1208 | GS-6615 6 mg White | - | - | - | - | 1件: 58 58 💬 |
1209 | GS-6624 | 1件: Simtuzumab Simtuzumab | - | - | - | 2件: 85 85, 94 💬 |
1210 | GSK2018682 CD3 non-micronised Tablet | - | - | - | - | 1件: 13 13 💬 |
1211 | GSK2018682 CD3 non-micronised Tablet in fed state | - | - | - | - | 1件: 13 13 💬 |
1212 | GSK2330672/linerixibat 40 mg | - | - | - | - | 1件: 93 93 💬 |
1213 | GSK2402968 6 mg/kg/week | - | - | - | - | 1件: 113 113 💬 |
1214 | GSK2402968 6mg/kg/week | - | - | - | - | 1件: 113 113 💬 |
1215 | GSK2586184 400 mg | - | - | - | - | 1件: 49 49 💬 |
1216 | GSK2586184 400mg | - | - | - | - | 1件: 97 97 💬 |
1217 | GSK2586184 800mg single and repeat dose | - | - | - | - | 1件: 49 49 💬 |
1218 | GSK2586184 new formulation | - | - | - | - | 1件: 49 49 💬 |
1219 | GSK2982772 60 mg | - | - | - | - | 1件: 46 46 💬 |
1220 | GSK3008348 Nebuliser solution | - | - | - | - | 1件: 85 85 💬 |
1221 | GTG003.08 | - | - | - | - | 1件: 65 65 💬 |
1222 | Guna-Interleukin 4 | - | - | - | - | 1件: 46 46 💬 |
1223 | Guselkumab Dose 4 | 1件: Guselkumab Guselkumab | 1件: Guselkumab
Guselkumab
💬 | 1件: IL23A IL23A 💬 | 9件: C-type lectin receptor signaling pathway C-type lectin receptor signaling pathway, Cytokine-cytokine receptor interaction, Inflammatory bowel disease, JAK-STAT signaling pathway, Pathways in cancer, Pertussis, Rheumatoid arthritis, Th17 cell differentiation, Tuberculosis 💬 | 1件: 96 96 💬 |
1224 | GW-1000-02 | - | - | - | - | 1件: 13 13 💬 |
1225 | GX 623 | - | - | - | - | 1件: 135 135 💬 |
1226 | GYLENIA 0,5 mg | - | - | - | - | 1件: 13 13 💬 |
1227 | GYPP-06 (GKT137831 free base), C10071301-D | - | - | - | - | 1件: 93 93 💬 |
1228 | H5.001CBCFTR | - | - | - | - | 1件: 299 299 💬 |
1229 | HBM9161 Injection (680mg and 340 mg) | - | - | - | - | 1件: 11 11 💬 |
1230 | HBM9161 Injection (680mg) | - | - | - | - | 1件: 11 11 💬 |
1231 | HBVAXPRO 5 micrograms/0.5 ml | 1件: Hepatitis B Vaccine (Recombinant) Hepatitis B Vaccine (Recombinant) | - | - | - | 1件: 46 46 💬 |
1232 | HBVAXPRO 5 micrograms/0.5 ml Suspension for injection Hepatitis B vaccine (rDNA) | 1件: Hepatitis B Vaccine (Recombinant) Hepatitis B Vaccine (Recombinant) | - | - | - | 1件: 46 46 💬 |
1233 | HBVAXPRO® 40 micrograms | 1件: Hepatitis B Vaccine (Recombinant) Hepatitis B Vaccine (Recombinant) | - | - | - | 1件: 46 46 💬 |
1234 | HEC 68498 | - | - | - | - | 1件: 85 85 💬 |
1235 | Hemay007 600 mg QD group | - | - | - | - | 1件: 46 46 💬 |
1236 | Hemay007 800 mg QD group | - | - | - | - | 1件: 46 46 💬 |
1237 | Heparán N sulfatasa humana recombinante | - | - | - | - | 1件: 19 19 💬 |
1238 | Heparán N sulfatasa humana recombinante (rhHNS) | - | - | - | - | 1件: 19 19 💬 |
1239 | HIBERIX - POLVERE E SOLVENTE PER SOLUZIONE INIETTABILE PER USO INTRAMUSCOLARE 1 FLACONCINO DI POLVERE + 1 SIRINGA PRERIEMPITA DI SOLVENTE DA 0.5 ML | 1件: Haemophilus influenzae type B strain 20752 capsular polysaccharide tetanus toxoid conjugate antigen Haemophilus influenzae type B strain 20752 capsular polysaccharide tetanus toxoid conjugate antigen | - | - | - | 3件: 61 61, 62, 66 💬 |
1240 | Hiomega-3 supplement of Naturalis® company - | - | - | - | - | 1件: 49 49 💬 |
1241 | HK-001 | - | - | - | - | 1件: 2 2 💬 |
1242 | HL-085 | - | - | - | - | 1件: 34 34 💬 |
1243 | HLADQA1*05A>G screening | - | - | - | - | 2件: 96 96, 97 💬 |
1244 | HLB-001 | - | - | - | - | 1件: 246 246 💬 |
1245 | HLL2 (trivial name or chemical description) | - | - | - | - | 1件: 49 49 💬 |
1246 | HMPL-004 | - | - | - | - | 2件: 96 96, 97 💬 |
1247 | HMPL-004 1800 mg/day | - | - | - | - | 1件: 97 97 💬 |
1248 | HMPL-004 2400 mg/day | - | - | - | - | 1件: 97 97 💬 |
1249 | HMPL-004 high dose | - | - | - | - | 1件: 97 97 💬 |
1250 | HMPL-004 low dose | - | - | - | - | 1件: 97 97 💬 |
1251 | HMPL004-6599 | - | - | - | - | 2件: 96 96, 97 💬 |
1252 | Hourly dosing of the nychtemeral secretion of melatonin | 1件: Melatonin Melatonin | 1件: Melatonin
Melatonin
💬 | 2件: MTNR1A MTNR1A, MTNR1B 💬 | 2件: Circadian entrainment Circadian entrainment, Neuroactive ligand-receptor interaction 💬 | 1件: 202 202 💬 |
1253 | Human fetal-derived Neural Stem Cells (hNSCs) | - | - | - | - | 1件: 13 13 💬 |
1254 | Human Monoclonal Antibody (CNTO 1275) to Interleukin 12p-40 | - | - | - | - | 1件: 96 96 💬 |
1255 | Human neural stem cell | - | - | - | - | 1件: 6 6 💬 |
1256 | Human Neural Stem Cells | - | - | - | - | 2件: 2 2, 13 💬 |
1257 | Human normal 10% immunoglobulin for intravenous administration | - | - | - | - | 1件: 14 14 💬 |
1258 | Human normal 10% immunoglobulin for intravenous administrationn | - | - | - | - | 1件: 14 14 💬 |
1259 | Human normal immunoglobulin | 1件: Human immunoglobulin G Human immunoglobulin G | - | - | - | 9件: 11 11, 13, 14, 43, 45, 50, 51, 63, 65 💬 |
1260 | HUMAN NORMAL IMMUNOGLOBULIN (IV) | 1件: Human immunoglobulin G Human immunoglobulin G | - | - | - | 4件: 11 11, 14, 63, 65 💬 |
1261 | Human normal immunoglobulin (IVIg) | 1件: Human immunoglobulin G Human immunoglobulin G | - | - | - | 3件: 14 14, 50, 65 💬 |
1262 | Human normal immunoglobulin (SCIg) | 1件: Human immunoglobulin G Human immunoglobulin G | - | - | - | 1件: 14 14 💬 |
1263 | Human Normal Immunoglobulin (Subcutaneous - Intramuscular Immunoglobulin) | 1件: Human immunoglobulin G Human immunoglobulin G | - | - | - | 1件: 65 65 💬 |
1264 | Human normal immunoglobulin (subcutaneous) | 1件: Human immunoglobulin G Human immunoglobulin G | - | - | - | 1件: 65 65 💬 |
1265 | HUMAN NORMAL IMMUNOGLOBULIN FOR | 1件: Human immunoglobulin G Human immunoglobulin G | - | - | - | 1件: 65 65 💬 |
1266 | Human normal immunoglobulin for intravenous (IV) administration | 1件: Human immunoglobulin G Human immunoglobulin G | - | - | - | 1件: 51 51 💬 |
1267 | Human normal immunoglobulin for intravenous administration | 1件: Human immunoglobulin G Human immunoglobulin G | - | - | - | 3件: 14 14, 51, 65 💬 |
1268 | HUMAN NORMAL IMMUNOGLOBULIN FOR INTRAVENOUS USE | 1件: Human immunoglobulin G Human immunoglobulin G | - | - | - | 2件: 63 63, 65 💬 |
1269 | Human normal immunoglobulin for intravenous use (IVIG) | 1件: Human immunoglobulin G Human immunoglobulin G | - | - | - | 1件: 65 65 💬 |
1270 | HUMAN NORMAL IMMUNOGLOBULIN FOR INTRVENOUS USE | 1件: Human immunoglobulin G Human immunoglobulin G | - | - | - | 1件: 63 63 💬 |
1271 | Human normal immunoglobulin for subcutaneous administration | 1件: Human immunoglobulin G Human immunoglobulin G | - | - | - | 2件: 51 51, 65 💬 |
1272 | Human Normal Immunoglobulin for Subcutaneous Administration (IGSC) | 1件: Human immunoglobulin G Human immunoglobulin G | - | - | - | 1件: 65 65 💬 |
1273 | Human normal immunoglobulin G (IgG > 98% purity) | 1件: Human immunoglobulin G Human immunoglobulin G | - | - | - | 3件: 14 14, 63, 65 💬 |
1274 | Human normal immunoglobulin G (IgG) | 1件: Human immunoglobulin G Human immunoglobulin G | - | - | - | 1件: 11 11 💬 |
1275 | Human normal immunoglogulin (IVIg) | 1件: Human immunoglobulin G Human immunoglobulin G | - | - | - | 1件: 50 50 💬 |
1276 | Human Recombinant Tissue Non-Specific Alkaline Phosphatase Fusion Protein | 1件: Alkaline Phosphatase Alkaline Phosphatase | - | - | - | 1件: 172 172 💬 |
1277 | Humanized anti-alpha v beta 6 mAb | - | - | - | - | 1件: 85 85 💬 |
1278 | Humatrope 6 mg/12 mg/24 mg injektiokuiva-aine ja liuotin, liuosta varten | 1件: Somatotropin Somatotropin | - | - | - | 1件: 193 193 💬 |
1279 | Humatrope® 6 mg, powder and solvent for solution for injection | 1件: Somatotropin Somatotropin | - | - | - | 1件: 78 78 💬 |
1280 | HuMax-CD38, 3003-005 | - | - | - | - | 1件: 28 28 💬 |
1281 | Humira (adalimumab) 40 mg in 0.4 ml s.c. injection | 1件: Adalimumab Adalimumab | 1件: Adalimumab
Adalimumab
💬 | 1件: TNF TNF 💬 | 67件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Dilated cardiomyopathy, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease, Osteoclast differentiation, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway 💬 | 1件: 46 46 💬 |
1282 | Humira (adalimumab) 40 mg s.c. injection | 1件: Adalimumab Adalimumab | 1件: Adalimumab
Adalimumab
💬 | 1件: TNF TNF 💬 | 67件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Dilated cardiomyopathy, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease, Osteoclast differentiation, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway 💬 | 1件: 46 46 💬 |
1283 | Humira (adalimumab) 40mg in 0.4 ml s.c. injection | 1件: Adalimumab Adalimumab | 1件: Adalimumab
Adalimumab
💬 | 1件: TNF TNF 💬 | 67件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Dilated cardiomyopathy, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease, Osteoclast differentiation, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway 💬 | 1件: 46 46 💬 |
1284 | Humira (adalimumab) 40mg in 0.4ml s.c.injection | 1件: Adalimumab Adalimumab | 1件: Adalimumab
Adalimumab
💬 | 1件: TNF TNF 💬 | 67件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Dilated cardiomyopathy, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease, Osteoclast differentiation, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway 💬 | 1件: 46 46 💬 |
1285 | HUMIRA - 40 MG SOLUZIONE INIETTABILE USO SOTTOCUTANEO 1 SIRINGA PRERIEMPITA 0.8 ML + 1 TAMPONE IMBEVUTO DI ALCOL IN UN BLISTER | 1件: Adalimumab Adalimumab | 1件: Adalimumab
Adalimumab
💬 | 1件: TNF TNF 💬 | 67件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Dilated cardiomyopathy, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease, Osteoclast differentiation, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway 💬 | 2件: 56 56, 97 💬 |
1286 | HUMIRA - 40 MG SOLUZIONE INIETTABILE USO SOTTOCUTANEO 2 SIRINGHE PRERIEMPITE 0.8 ML + 2 TAMPONI IMBEVUTI DI ALCOL IN 1 BLISTER | 1件: Adalimumab Adalimumab | 1件: Adalimumab
Adalimumab
💬 | 1件: TNF TNF 💬 | 67件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Dilated cardiomyopathy, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease, Osteoclast differentiation, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway 💬 | 1件: 46 46 💬 |
1287 | HUMIRA - 40MG/0.8ML SOLUZ. INIETTABILE- USO SOTTOCUTANEO-FLACONCINO(VETRO) 0.8ML 2 ASTUCCI:1 FLACONCINO+1SIRINGA+1AGO+1ADATT.STERILE-2TAMPONI IMBEVUTI ALCOOL | 1件: Adalimumab Adalimumab | 1件: Adalimumab
Adalimumab
💬 | 1件: TNF TNF 💬 | 67件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Dilated cardiomyopathy, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease, Osteoclast differentiation, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway 💬 | 2件: 46 46, 96 💬 |
1288 | Humira 20 mg solution for injection in pre-filled syringe (20 mg/0.2mL) | 1件: Adalimumab Adalimumab | 1件: Adalimumab
Adalimumab
💬 | 1件: TNF TNF 💬 | 67件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Dilated cardiomyopathy, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease, Osteoclast differentiation, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway 💬 | 1件: 97 97 💬 |
1289 | Humira 40 mg injekcní roztok v predplnené injekcní stríkacce | 1件: Adalimumab Adalimumab | 1件: Adalimumab
Adalimumab
💬 | 1件: TNF TNF 💬 | 67件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Dilated cardiomyopathy, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease, Osteoclast differentiation, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway 💬 | 1件: 96 96 💬 |
1290 | Humira 40 mg injeksjonsvæske, oppløsning, i ferdigfylt sprøyte | - | - | - | - | 1件: 46 46 💬 |
1291 | HUMIRA 40 mg solución inyectable en jeringa precargada | 1件: Adalimumab Adalimumab | 1件: Adalimumab
Adalimumab
💬 | 1件: TNF TNF 💬 | 67件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Dilated cardiomyopathy, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease, Osteoclast differentiation, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway 💬 | 2件: 46 46, 96 💬 |
1292 | Humira 40 mg solution for injection in pre-filled pen | 1件: Adalimumab Adalimumab | 1件: Adalimumab
Adalimumab
💬 | 1件: TNF TNF 💬 | 67件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Dilated cardiomyopathy, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease, Osteoclast differentiation, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway 💬 | 1件: 96 96 💬 |
1293 | Humira 40 mg solution for injection in pre-filled syringe | 1件: Adalimumab Adalimumab | 1件: Adalimumab
Adalimumab
💬 | 1件: TNF TNF 💬 | 67件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Dilated cardiomyopathy, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease, Osteoclast differentiation, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway 💬 | 3件: 46 46, 96, 97 💬 |
1294 | Humira 40 mg solution for injection in pre-filled syringe (40 mg/0.4 mL) | 1件: Adalimumab Adalimumab | 1件: Adalimumab
Adalimumab
💬 | 1件: TNF TNF 💬 | 67件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Dilated cardiomyopathy, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease, Osteoclast differentiation, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway 💬 | 1件: 97 97 💬 |
1295 | Humira 40 mg solution for injection in pre-filled syringes | - | - | - | - | 1件: 97 97 💬 |
1296 | Humira 40 mg/0.8 ml solution for injection | 1件: Adalimumab Adalimumab | 1件: Adalimumab
Adalimumab
💬 | 1件: TNF TNF 💬 | 67件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Dilated cardiomyopathy, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease, Osteoclast differentiation, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway 💬 | 4件: 46 46, 96, 97, 271 💬 |
1297 | Humira 40 mg/0.8 ml solution for injection for paediatric use | 1件: Adalimumab Adalimumab | 1件: Adalimumab
Adalimumab
💬 | 1件: TNF TNF 💬 | 67件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Dilated cardiomyopathy, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease, Osteoclast differentiation, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway 💬 | 1件: 97 97 💬 |
1298 | Humira 40mg Injektionslösung | - | - | - | - | 1件: 46 46 💬 |
1299 | HUMIRA 40Mg Solution for Injection | - | - | - | - | 2件: 96 96, 97 💬 |
1300 | Humira 40mg solution for injection in pre-filled syringe | 1件: Adalimumab Adalimumab | 1件: Adalimumab
Adalimumab
💬 | 1件: TNF TNF 💬 | 67件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Dilated cardiomyopathy, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease, Osteoclast differentiation, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway 💬 | 1件: 46 46 💬 |
1301 | Humira 40mg solution for injection in pre-filled syringe (adalimumab) | 1件: Adalimumab Adalimumab | 1件: Adalimumab
Adalimumab
💬 | 1件: TNF TNF 💬 | 67件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Dilated cardiomyopathy, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease, Osteoclast differentiation, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway 💬 | 1件: 46 46 💬 |
1302 | Humira 40mg/0.4ml pre-filled syringe | 1件: Adalimumab Adalimumab | 1件: Adalimumab
Adalimumab
💬 | 1件: TNF TNF 💬 | 67件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Dilated cardiomyopathy, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease, Osteoclast differentiation, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway 💬 | 1件: 96 96 💬 |
1303 | Humira 40mg/0.8 ml solution for injection for paediatric use | 1件: Adalimumab Adalimumab | 1件: Adalimumab
Adalimumab
💬 | 1件: TNF TNF 💬 | 67件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Dilated cardiomyopathy, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease, Osteoclast differentiation, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway 💬 | 1件: 46 46 💬 |
1304 | Humira 40mg/0.8ml solution for injection for paediatric use | 1件: Adalimumab Adalimumab | 1件: Adalimumab
Adalimumab
💬 | 1件: TNF TNF 💬 | 67件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Dilated cardiomyopathy, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease, Osteoclast differentiation, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway 💬 | 1件: 96 96 💬 |
1305 | Humira 40mg/0.8ml solution for injection in pre-filled syringe | 1件: Adalimumab Adalimumab | 1件: Adalimumab
Adalimumab
💬 | 1件: TNF TNF 💬 | 67件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Dilated cardiomyopathy, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease, Osteoclast differentiation, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway 💬 | 1件: 46 46 💬 |
1306 | Humira 80 mg solution for injection in pre-filled syringe (80 mg/0.8 mL) | 1件: Adalimumab Adalimumab | 1件: Adalimumab
Adalimumab
💬 | 1件: TNF TNF 💬 | 67件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Dilated cardiomyopathy, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease, Osteoclast differentiation, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway 💬 | 1件: 97 97 💬 |
1307 | Humira ® (Adalimumab) 40mg/0.8mL Pre-filled Syringe | 1件: Adalimumab Adalimumab | 1件: Adalimumab
Adalimumab
💬 | 1件: TNF TNF 💬 | 67件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Dilated cardiomyopathy, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease, Osteoclast differentiation, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway 💬 | 1件: 46 46 💬 |
1308 | HUMIRA*SC 2SIR+F 40MG 0,8ML+2T | 1件: Adalimumab Adalimumab | 1件: Adalimumab
Adalimumab
💬 | 1件: TNF TNF 💬 | 67件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Dilated cardiomyopathy, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease, Osteoclast differentiation, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway 💬 | 2件: 46 46, 96 💬 |
1309 | Humira, 40 mg solution for injection in pre-filled syringe | 1件: Adalimumab Adalimumab | 1件: Adalimumab
Adalimumab
💬 | 1件: TNF TNF 💬 | 67件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Dilated cardiomyopathy, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease, Osteoclast differentiation, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway 💬 | 1件: 46 46 💬 |
1310 | Humira® 40 mg Injektionslösung in Fertigspritze | 1件: Adalimumab Adalimumab | 1件: Adalimumab
Adalimumab
💬 | 1件: TNF TNF 💬 | 67件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Dilated cardiomyopathy, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease, Osteoclast differentiation, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway 💬 | 1件: 46 46 💬 |
1311 | Humira® 40 mg solution for injection in pre-filled syringe | 1件: Adalimumab Adalimumab | 1件: Adalimumab
Adalimumab
💬 | 1件: TNF TNF 💬 | 67件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Dilated cardiomyopathy, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease, Osteoclast differentiation, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway 💬 | 1件: 46 46 💬 |
1312 | Humira® 40 mg/ 0.8 ml solution for injection in pre-filled syringe | 1件: Adalimumab Adalimumab | 1件: Adalimumab
Adalimumab
💬 | 1件: TNF TNF 💬 | 67件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Dilated cardiomyopathy, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease, Osteoclast differentiation, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway 💬 | 1件: 46 46 💬 |
1313 | Hydroxychloroquine 400mg/d | 1件: Hydroxychloroquine Hydroxychloroquine | 1件: Hydroxychloroquine
Hydroxychloroquine
💬 | - | - | 1件: 53 53 💬 |
1314 | Hypertonic saline (7 %) and isotonic saline (0.9%) | - | - | - | - | 1件: 299 299 💬 |
1315 | Hypertonic saline 6% - | - | - | - | - | 1件: 299 299 💬 |
1316 | HZN-825 | - | - | - | - | 2件: 51 51, 85 💬 |
1317 | HZN-825 BID | - | - | - | - | 1件: 51 51 💬 |
1318 | HZN-825 QD | - | - | - | - | 1件: 51 51 💬 |
1319 | Iberogast N | - | - | - | - | 1件: 97 97 💬 |
1320 | Ibuprofen Sandoz 400 mg Filmtabletten | 1件: Ibuprofen Ibuprofen | 1件: Ibuprofen
Ibuprofen
💬 | 2件: PTGS1 PTGS1, PTGS2 💬 | 23件: Alzheimer disease Alzheimer disease, Arachidonic acid metabolism, C-type lectin receptor signaling pathway, Chemical carcinogenesis - DNA adducts, Human cytomegalovirus infection, Human papillomavirus infection, IL-17 signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Metabolic pathways, MicroRNAs in cancer, NF-kappa B signaling pathway, Ovarian steroidogenesis, Oxytocin signaling pathway, Pathways in cancer, Pathways of neurodegeneration - multiple diseases, Platelet activation, Regulation of lipolysis in adipocytes, Retrograde endocannabinoid signaling, Serotonergic synapse, Small cell lung cancer, TNF signaling pathway, VEGF signaling pathway 💬 | 1件: 13 13 💬 |
1321 | ICP-022 | - | - | - | - | 2件: 46 46, 49 💬 |
1322 | ICX-RHY-013 | - | - | - | - | 1件: 36 36 💬 |
1323 | IDEC-C2B8, Ro 45-2294 | - | - | - | - | 1件: 64 64 💬 |
1324 | IdeS (0.25 mg/kg) | 1件: Imlifidase Imlifidase | 1件: Imlifidase
Imlifidase
💬 | - | - | 1件: 64 64 💬 |
1325 | IdeS (0.50 mg/kg) | 1件: Imlifidase Imlifidase | 1件: Imlifidase
Imlifidase
💬 | - | - | 1件: 64 64 💬 |
1326 | IFB-088 | - | - | - | - | 1件: 2 2 💬 |
1327 | IFB-088 50mg/day | - | - | - | - | 1件: 2 2 💬 |
1328 | IFN beta 1a 44 mcg TIW | - | - | - | - | 1件: 13 13 💬 |
1329 | IgG Next Generation | - | - | - | - | 2件: 63 63, 65 💬 |
1330 | IgG Next Generation (BT595) | - | - | - | - | 1件: 65 65 💬 |
1331 | IgG2/4? | - | - | - | - | 1件: 109 109 💬 |
1332 | IL-6 receptor inhibitor, humanized monoclonal antibody | - | - | - | - | 1件: 46 46 💬 |
1333 | IL-6 receptor inhibitor, recombinant humanized monoclonal antibody | - | - | - | - | 2件: 46 46, 107 💬 |
1334 | IL-6R Monoclonal Antibody Injection 4mg/kg | - | - | - | - | 1件: 46 46 💬 |
1335 | IL-6R Monoclonal Antibody Injection 6mg/kg | - | - | - | - | 1件: 46 46 💬 |
1336 | IL-6R Monoclonal Antibody Injection 8mg/kg | - | - | - | - | 1件: 46 46 💬 |
1337 | IL-6R nanobody | - | - | - | - | 1件: 49 49 💬 |
1338 | Iloprost (Ventavis, BAYQ 6256) | 1件: Iloprost Iloprost | 1件: Iloprost
Iloprost
💬 | 1件: PTGIR PTGIR 💬 | 3件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Platelet activation, Vascular smooth muscle contraction 💬 | 1件: 86 86 💬 |
1339 | Iloprost PD-6 | 1件: Iloprost Iloprost | 1件: Iloprost
Iloprost
💬 | 1件: PTGIR PTGIR 💬 | 3件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Platelet activation, Vascular smooth muscle contraction 💬 | 1件: 86 86 💬 |
1340 | Iloprost therapy up to 2 ng/kg x min | 1件: Iloprost Iloprost | 1件: Iloprost
Iloprost
💬 | 1件: PTGIR PTGIR 💬 | 3件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Platelet activation, Vascular smooth muscle contraction 💬 | 1件: 51 51 💬 |
1341 | ILV-094 | - | - | - | - | 1件: 46 46 💬 |
1342 | Imatinib Mesylate 400Mg Capsule | 1件: Imatinib Imatinib | 1件: Imatinib
Imatinib
💬 | 3件: ABL1 ABL1, KIT, PDGFRA 💬 | 32件: Acute myeloid leukemia Acute myeloid leukemia, Axon guidance, Breast cancer, Calcium signaling pathway, Cell cycle, Central carbon metabolism in cancer, Chemical carcinogenesis - reactive oxygen species, Choline metabolism in cancer, Chronic myeloid leukemia, EGFR tyrosine kinase inhibitor resistance, Endocytosis, ErbB signaling pathway, Focal adhesion, Gap junction, Glioma, Hematopoietic cell lineage, Human cytomegalovirus infection, JAK-STAT signaling pathway, MAPK signaling pathway, Melanogenesis, Melanoma, MicroRNAs in cancer, Neurotrophin signaling pathway, PI3K-Akt signaling pathway, Pathogenic Escherichia coli infection, Pathways in cancer, Phospholipase D signaling pathway, Prostate cancer, Rap1 signaling pathway, Ras signaling pathway, Regulation of actin cytoskeleton, Viral myocarditis 💬 | 1件: 89 89 💬 |
1343 | IMCY-0141 | 1件: IMCY-0141 IMCY-0141 | - | - | - | 1件: 13 13 💬 |
1344 | Immunoglobulin G (Ig NextGen 16%) | - | - | - | - | 1件: 65 65 💬 |
1345 | Immunoglobulin G1, anti (protein Nogo A) (human Mus musculus monoclonal heavy | - | - | - | - | 1件: 2 2 💬 |
1346 | Immunoglobulin G1, anti (protein Nogo A) (human Mus musculus monoclonal heavy chain), disulfide with human Mus musculus monoclonal light chain, dimer | - | - | - | - | 1件: 2 2 💬 |
1347 | Immunoglobulina normale umana | - | - | - | - | 1件: 51 51 💬 |
1348 | Immunoglobulina Normale Umana per somministrazione endovenosa | - | - | - | - | 1件: 51 51 💬 |
1349 | Immunoglobulina Normale Umana per somministrazione sottocutanea | - | - | - | - | 1件: 51 51 💬 |
1350 | IMMUNOGLOBULINA UMANA NORMALE | - | - | - | - | 2件: 51 51, 65 💬 |
1351 | IMMUNOGLOBULINA UMANA NORMALE per somministrazione endovenosa | - | - | - | - | 1件: 14 14 💬 |
1352 | Immunoglobulins, normal human | - | - | - | - | 1件: 65 65 💬 |
1353 | Immunoglobulins, normal human, for extravascular adm. | - | - | - | - | 1件: 14 14 💬 |
1354 | Immunoglobulins, normal human, for intravascular adm. | - | - | - | - | 2件: 14 14, 15 💬 |
1355 | IMO-8400 | - | - | - | - | 1件: 50 50 💬 |
1356 | IMO-8400 Dose Group 1 | - | - | - | - | 1件: 50 50 💬 |
1357 | IMO-8400 Dose Group 2 | - | - | - | - | 1件: 50 50 💬 |
1358 | IMod.Fc, H-Fcv3-N4 | - | - | - | - | 1件: 84 84 💬 |
1359 | IMP will be labeled as ''PF-04236921 106mg/vial, Clonal SC lyophilized form''. | - | - | - | - | 1件: 96 96 💬 |
1360 | IMP will be labeled as PF-04236921 106mg/vial, Clonal SC lyophilized form | - | - | - | - | 1件: 96 96 💬 |
1361 | Impact-Nutridrink | - | - | - | - | 1件: 299 299 💬 |
1362 | IMU-838 | - | - | - | - | 3件: 13 13, 96, 97 💬 |
1363 | IMU-838 (30 mg/day) | - | - | - | - | 1件: 13 13 💬 |
1364 | IMU-838 (45 mg/day) | - | - | - | - | 1件: 13 13 💬 |
1365 | IMU-838 tablets | - | - | - | - | 1件: 13 13 💬 |
1366 | IMU-838-RC | - | - | - | - | 1件: 13 13 💬 |
1367 | IMUKIN - 6 FLACONI 0.5 ML 100 MCG | - | - | - | - | 2件: 18 18, 58 💬 |
1368 | IMUKIN*SC 6F 0,5ML 100MCG | - | - | - | - | 1件: 18 18 💬 |
1369 | Inactivated and fragmented influenza vaccine (A / Michigan / 45/2015 (H1N1) pdm09-like virus, A / Singapore / INFIMH-16-0019 / 2016 (H3N2) -like virus | - | - | - | - | 1件: 53 53 💬 |
1370 | INALOSSIN - 800 PPM MOL/MOL GAS MEDICINALE COMPRESSO BOMBOLA IN ALLUMINIO CON VALVOLA VI DA 20 LITRI | - | - | - | - | 1件: 294 294 💬 |
1371 | INALOSSIN 800 PPM MOL/MOL GAS MEDICINALE COMPRESSO | - | - | - | - | 1件: 294 294 💬 |
1372 | INCB050465 0.3 mg | 1件: Parsaclisib Parsaclisib | 1件: Parsaclisib
Parsaclisib
💬 | 1件: PIK3CD PIK3CD 💬 | 106件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, AMPK signaling pathway, Acute myeloid leukemia, Aldosterone-regulated sodium reabsorption, Alzheimer disease, Amoebiasis, Apoptosis, Autophagy - animal, Axon guidance, B cell receptor signaling pathway, Bacterial invasion of epithelial cells, Breast cancer, C-type lectin receptor signaling pathway, Carbohydrate digestion and absorption, Cellular senescence, Central carbon metabolism in cancer, Chagas disease, Chemical carcinogenesis - reactive oxygen species, Chemical carcinogenesis - receptor activation, Chemokine signaling pathway, Choline metabolism in cancer, Cholinergic synapse, Chronic myeloid leukemia, Colorectal cancer, Coronavirus disease - COVID-19, Diabetic cardiomyopathy, EGFR tyrosine kinase inhibitor resistance, Endocrine resistance, Endometrial cancer, Epstein-Barr virus infection, ErbB signaling pathway, Estrogen signaling pathway, Fc epsilon RI signaling pathway, Fc gamma R-mediated phagocytosis, Fluid shear stress and atherosclerosis, Focal adhesion, FoxO signaling pathway, Gastric cancer, Glioma, GnRH secretion, Growth hormone synthesis, secretion and action, HIF-1 signaling pathway, Hepatitis B, Hepatitis C, Hepatocellular carcinoma, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Inflammatory mediator regulation of TRP channels, Influenza A, Inositol phosphate metabolism, Insulin resistance, Insulin signaling pathway, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Leukocyte transendothelial migration, Lipid and atherosclerosis, Longevity regulating pathway, Longevity regulating pathway - multiple species, Measles, Melanoma, Metabolic pathways, MicroRNAs in cancer, Natural killer cell mediated cytotoxicity, Neurotrophin signaling pathway, Neutrophil extracellular trap formation, Non-alcoholic fatty liver disease, Non-small cell lung cancer, Osteoclast differentiation, PD-L1 expression and PD-1 checkpoint pathway in cancer, PI3K-Akt signaling pathway, Pancreatic cancer, Pathways in cancer, Phosphatidylinositol signaling system, Phospholipase D signaling pathway, Platelet activation, Platinum drug resistance, Prion disease, Progesterone-mediated oocyte maturation, Prolactin signaling pathway, Prostate cancer, Proteoglycans in cancer, Rap1 signaling pathway, Ras signaling pathway, Regulation of actin cytoskeleton, Regulation of lipolysis in adipocytes, Relaxin signaling pathway, Renal cell carcinoma, Salmonella infection, Shigellosis, Signaling pathways regulating pluripotency of stem cells, Small cell lung cancer, Sphingolipid signaling pathway, Spinocerebellar ataxia, T cell receptor signaling pathway, TNF signaling pathway, Thyroid hormone signaling pathway, Toll-like receptor signaling pathway, Type II diabetes mellitus, VEGF signaling pathway, Viral carcinogenesis, Yersinia infection, cAMP signaling pathway, mTOR signaling pathway 💬 | 1件: 35 35 💬 |
1373 | INCB050465 0.3mg | 1件: Parsaclisib Parsaclisib | 1件: Parsaclisib
Parsaclisib
💬 | 1件: PIK3CD PIK3CD 💬 | 106件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, AMPK signaling pathway, Acute myeloid leukemia, Aldosterone-regulated sodium reabsorption, Alzheimer disease, Amoebiasis, Apoptosis, Autophagy - animal, Axon guidance, B cell receptor signaling pathway, Bacterial invasion of epithelial cells, Breast cancer, C-type lectin receptor signaling pathway, Carbohydrate digestion and absorption, Cellular senescence, Central carbon metabolism in cancer, Chagas disease, Chemical carcinogenesis - reactive oxygen species, Chemical carcinogenesis - receptor activation, Chemokine signaling pathway, Choline metabolism in cancer, Cholinergic synapse, Chronic myeloid leukemia, Colorectal cancer, Coronavirus disease - COVID-19, Diabetic cardiomyopathy, EGFR tyrosine kinase inhibitor resistance, Endocrine resistance, Endometrial cancer, Epstein-Barr virus infection, ErbB signaling pathway, Estrogen signaling pathway, Fc epsilon RI signaling pathway, Fc gamma R-mediated phagocytosis, Fluid shear stress and atherosclerosis, Focal adhesion, FoxO signaling pathway, Gastric cancer, Glioma, GnRH secretion, Growth hormone synthesis, secretion and action, HIF-1 signaling pathway, Hepatitis B, Hepatitis C, Hepatocellular carcinoma, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Inflammatory mediator regulation of TRP channels, Influenza A, Inositol phosphate metabolism, Insulin resistance, Insulin signaling pathway, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Leukocyte transendothelial migration, Lipid and atherosclerosis, Longevity regulating pathway, Longevity regulating pathway - multiple species, Measles, Melanoma, Metabolic pathways, MicroRNAs in cancer, Natural killer cell mediated cytotoxicity, Neurotrophin signaling pathway, Neutrophil extracellular trap formation, Non-alcoholic fatty liver disease, Non-small cell lung cancer, Osteoclast differentiation, PD-L1 expression and PD-1 checkpoint pathway in cancer, PI3K-Akt signaling pathway, Pancreatic cancer, Pathways in cancer, Phosphatidylinositol signaling system, Phospholipase D signaling pathway, Platelet activation, Platinum drug resistance, Prion disease, Progesterone-mediated oocyte maturation, Prolactin signaling pathway, Prostate cancer, Proteoglycans in cancer, Rap1 signaling pathway, Ras signaling pathway, Regulation of actin cytoskeleton, Regulation of lipolysis in adipocytes, Relaxin signaling pathway, Renal cell carcinoma, Salmonella infection, Shigellosis, Signaling pathways regulating pluripotency of stem cells, Small cell lung cancer, Sphingolipid signaling pathway, Spinocerebellar ataxia, T cell receptor signaling pathway, TNF signaling pathway, Thyroid hormone signaling pathway, Toll-like receptor signaling pathway, Type II diabetes mellitus, VEGF signaling pathway, Viral carcinogenesis, Yersinia infection, cAMP signaling pathway, mTOR signaling pathway 💬 | 1件: 35 35 💬 |
1374 | INCB050465 1.0 mg | 1件: Parsaclisib Parsaclisib | 1件: Parsaclisib
Parsaclisib
💬 | 1件: PIK3CD PIK3CD 💬 | 106件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, AMPK signaling pathway, Acute myeloid leukemia, Aldosterone-regulated sodium reabsorption, Alzheimer disease, Amoebiasis, Apoptosis, Autophagy - animal, Axon guidance, B cell receptor signaling pathway, Bacterial invasion of epithelial cells, Breast cancer, C-type lectin receptor signaling pathway, Carbohydrate digestion and absorption, Cellular senescence, Central carbon metabolism in cancer, Chagas disease, Chemical carcinogenesis - reactive oxygen species, Chemical carcinogenesis - receptor activation, Chemokine signaling pathway, Choline metabolism in cancer, Cholinergic synapse, Chronic myeloid leukemia, Colorectal cancer, Coronavirus disease - COVID-19, Diabetic cardiomyopathy, EGFR tyrosine kinase inhibitor resistance, Endocrine resistance, Endometrial cancer, Epstein-Barr virus infection, ErbB signaling pathway, Estrogen signaling pathway, Fc epsilon RI signaling pathway, Fc gamma R-mediated phagocytosis, Fluid shear stress and atherosclerosis, Focal adhesion, FoxO signaling pathway, Gastric cancer, Glioma, GnRH secretion, Growth hormone synthesis, secretion and action, HIF-1 signaling pathway, Hepatitis B, Hepatitis C, Hepatocellular carcinoma, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Inflammatory mediator regulation of TRP channels, Influenza A, Inositol phosphate metabolism, Insulin resistance, Insulin signaling pathway, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Leukocyte transendothelial migration, Lipid and atherosclerosis, Longevity regulating pathway, Longevity regulating pathway - multiple species, Measles, Melanoma, Metabolic pathways, MicroRNAs in cancer, Natural killer cell mediated cytotoxicity, Neurotrophin signaling pathway, Neutrophil extracellular trap formation, Non-alcoholic fatty liver disease, Non-small cell lung cancer, Osteoclast differentiation, PD-L1 expression and PD-1 checkpoint pathway in cancer, PI3K-Akt signaling pathway, Pancreatic cancer, Pathways in cancer, Phosphatidylinositol signaling system, Phospholipase D signaling pathway, Platelet activation, Platinum drug resistance, Prion disease, Progesterone-mediated oocyte maturation, Prolactin signaling pathway, Prostate cancer, Proteoglycans in cancer, Rap1 signaling pathway, Ras signaling pathway, Regulation of actin cytoskeleton, Regulation of lipolysis in adipocytes, Relaxin signaling pathway, Renal cell carcinoma, Salmonella infection, Shigellosis, Signaling pathways regulating pluripotency of stem cells, Small cell lung cancer, Sphingolipid signaling pathway, Spinocerebellar ataxia, T cell receptor signaling pathway, TNF signaling pathway, Thyroid hormone signaling pathway, Toll-like receptor signaling pathway, Type II diabetes mellitus, VEGF signaling pathway, Viral carcinogenesis, Yersinia infection, cAMP signaling pathway, mTOR signaling pathway 💬 | 1件: 35 35 💬 |
1375 | INCB050465 1.0mg | 1件: Parsaclisib Parsaclisib | 1件: Parsaclisib
Parsaclisib
💬 | 1件: PIK3CD PIK3CD 💬 | 106件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, AMPK signaling pathway, Acute myeloid leukemia, Aldosterone-regulated sodium reabsorption, Alzheimer disease, Amoebiasis, Apoptosis, Autophagy - animal, Axon guidance, B cell receptor signaling pathway, Bacterial invasion of epithelial cells, Breast cancer, C-type lectin receptor signaling pathway, Carbohydrate digestion and absorption, Cellular senescence, Central carbon metabolism in cancer, Chagas disease, Chemical carcinogenesis - reactive oxygen species, Chemical carcinogenesis - receptor activation, Chemokine signaling pathway, Choline metabolism in cancer, Cholinergic synapse, Chronic myeloid leukemia, Colorectal cancer, Coronavirus disease - COVID-19, Diabetic cardiomyopathy, EGFR tyrosine kinase inhibitor resistance, Endocrine resistance, Endometrial cancer, Epstein-Barr virus infection, ErbB signaling pathway, Estrogen signaling pathway, Fc epsilon RI signaling pathway, Fc gamma R-mediated phagocytosis, Fluid shear stress and atherosclerosis, Focal adhesion, FoxO signaling pathway, Gastric cancer, Glioma, GnRH secretion, Growth hormone synthesis, secretion and action, HIF-1 signaling pathway, Hepatitis B, Hepatitis C, Hepatocellular carcinoma, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Inflammatory mediator regulation of TRP channels, Influenza A, Inositol phosphate metabolism, Insulin resistance, Insulin signaling pathway, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Leukocyte transendothelial migration, Lipid and atherosclerosis, Longevity regulating pathway, Longevity regulating pathway - multiple species, Measles, Melanoma, Metabolic pathways, MicroRNAs in cancer, Natural killer cell mediated cytotoxicity, Neurotrophin signaling pathway, Neutrophil extracellular trap formation, Non-alcoholic fatty liver disease, Non-small cell lung cancer, Osteoclast differentiation, PD-L1 expression and PD-1 checkpoint pathway in cancer, PI3K-Akt signaling pathway, Pancreatic cancer, Pathways in cancer, Phosphatidylinositol signaling system, Phospholipase D signaling pathway, Platelet activation, Platinum drug resistance, Prion disease, Progesterone-mediated oocyte maturation, Prolactin signaling pathway, Prostate cancer, Proteoglycans in cancer, Rap1 signaling pathway, Ras signaling pathway, Regulation of actin cytoskeleton, Regulation of lipolysis in adipocytes, Relaxin signaling pathway, Renal cell carcinoma, Salmonella infection, Shigellosis, Signaling pathways regulating pluripotency of stem cells, Small cell lung cancer, Sphingolipid signaling pathway, Spinocerebellar ataxia, T cell receptor signaling pathway, TNF signaling pathway, Thyroid hormone signaling pathway, Toll-like receptor signaling pathway, Type II diabetes mellitus, VEGF signaling pathway, Viral carcinogenesis, Yersinia infection, cAMP signaling pathway, mTOR signaling pathway 💬 | 1件: 35 35 💬 |
1376 | INCRELEX 10 mg/ml, solución inyectable | 1件: Mecasermin Mecasermin | 1件: Mecasermin
Mecasermin
💬 | 2件: GHR GHR, IGF1R 💬 | 33件: AMPK signaling pathway AMPK signaling pathway, Adherens junction, Autophagy - animal, Breast cancer, Cytokine-cytokine receptor interaction, EGFR tyrosine kinase inhibitor resistance, Endocrine resistance, Endocytosis, Focal adhesion, FoxO signaling pathway, Glioma, Growth hormone synthesis, secretion and action, HIF-1 signaling pathway, Hepatocellular carcinoma, JAK-STAT signaling pathway, Long-term depression, Longevity regulating pathway, Longevity regulating pathway - multiple species, MAPK signaling pathway, Melanoma, Neuroactive ligand-receptor interaction, Oocyte meiosis, Ovarian steroidogenesis, PI3K-Akt signaling pathway, Pathways in cancer, Progesterone-mediated oocyte maturation, Prostate cancer, Proteoglycans in cancer, Rap1 signaling pathway, Ras signaling pathway, Signaling pathways regulating pluripotency of stem cells, Transcriptional misregulation in cancer, mTOR signaling pathway 💬 | 1件: 78 78 💬 |
1377 | INCRELEX*SC 1FL 4ML 10MG/ML | 1件: Mecasermin Mecasermin | 1件: Mecasermin
Mecasermin
💬 | 2件: GHR GHR, IGF1R 💬 | 33件: AMPK signaling pathway AMPK signaling pathway, Adherens junction, Autophagy - animal, Breast cancer, Cytokine-cytokine receptor interaction, EGFR tyrosine kinase inhibitor resistance, Endocrine resistance, Endocytosis, Focal adhesion, FoxO signaling pathway, Glioma, Growth hormone synthesis, secretion and action, HIF-1 signaling pathway, Hepatocellular carcinoma, JAK-STAT signaling pathway, Long-term depression, Longevity regulating pathway, Longevity regulating pathway - multiple species, MAPK signaling pathway, Melanoma, Neuroactive ligand-receptor interaction, Oocyte meiosis, Ovarian steroidogenesis, PI3K-Akt signaling pathway, Pathways in cancer, Progesterone-mediated oocyte maturation, Prostate cancer, Proteoglycans in cancer, Rap1 signaling pathway, Ras signaling pathway, Signaling pathways regulating pluripotency of stem cells, Transcriptional misregulation in cancer, mTOR signaling pathway 💬 | 1件: 299 299 💬 |
1378 | Infigratinib 0.016 mg/kg | 1件: Infigratinib Infigratinib | 1件: Infigratinib
Infigratinib
💬 | 3件: FGFR1 FGFR1, FGFR2, FGFR3 💬 | 21件: Adherens junction Adherens junction, Bladder cancer, Breast cancer, Calcium signaling pathway, Central carbon metabolism in cancer, EGFR tyrosine kinase inhibitor resistance, Endocytosis, Gastric cancer, MAPK signaling pathway, Melanoma, MicroRNAs in cancer, PI3K-Akt signaling pathway, Parathyroid hormone synthesis, secretion and action, Pathways in cancer, Prostate cancer, Proteoglycans in cancer, Rap1 signaling pathway, Ras signaling pathway, Regulation of actin cytoskeleton, Signaling pathways regulating pluripotency of stem cells, Thermogenesis 💬 | 1件: 276 276 💬 |
1379 | Infigratinib 0.032 mg/kg | 1件: Infigratinib Infigratinib | 1件: Infigratinib
Infigratinib
💬 | 3件: FGFR1 FGFR1, FGFR2, FGFR3 💬 | 21件: Adherens junction Adherens junction, Bladder cancer, Breast cancer, Calcium signaling pathway, Central carbon metabolism in cancer, EGFR tyrosine kinase inhibitor resistance, Endocytosis, Gastric cancer, MAPK signaling pathway, Melanoma, MicroRNAs in cancer, PI3K-Akt signaling pathway, Parathyroid hormone synthesis, secretion and action, Pathways in cancer, Prostate cancer, Proteoglycans in cancer, Rap1 signaling pathway, Ras signaling pathway, Regulation of actin cytoskeleton, Signaling pathways regulating pluripotency of stem cells, Thermogenesis 💬 | 1件: 276 276 💬 |
1380 | Infigratinib 0.064 mg/kg | 1件: Infigratinib Infigratinib | 1件: Infigratinib
Infigratinib
💬 | 3件: FGFR1 FGFR1, FGFR2, FGFR3 💬 | 21件: Adherens junction Adherens junction, Bladder cancer, Breast cancer, Calcium signaling pathway, Central carbon metabolism in cancer, EGFR tyrosine kinase inhibitor resistance, Endocytosis, Gastric cancer, MAPK signaling pathway, Melanoma, MicroRNAs in cancer, PI3K-Akt signaling pathway, Parathyroid hormone synthesis, secretion and action, Pathways in cancer, Prostate cancer, Proteoglycans in cancer, Rap1 signaling pathway, Ras signaling pathway, Regulation of actin cytoskeleton, Signaling pathways regulating pluripotency of stem cells, Thermogenesis 💬 | 1件: 276 276 💬 |
1381 | Infigratinib 0.128 mg/kg | 1件: Infigratinib Infigratinib | 1件: Infigratinib
Infigratinib
💬 | 3件: FGFR1 FGFR1, FGFR2, FGFR3 💬 | 21件: Adherens junction Adherens junction, Bladder cancer, Breast cancer, Calcium signaling pathway, Central carbon metabolism in cancer, EGFR tyrosine kinase inhibitor resistance, Endocytosis, Gastric cancer, MAPK signaling pathway, Melanoma, MicroRNAs in cancer, PI3K-Akt signaling pathway, Parathyroid hormone synthesis, secretion and action, Pathways in cancer, Prostate cancer, Proteoglycans in cancer, Rap1 signaling pathway, Ras signaling pathway, Regulation of actin cytoskeleton, Signaling pathways regulating pluripotency of stem cells, Thermogenesis 💬 | 1件: 276 276 💬 |
1382 | Infigratinib 0.25 mg/kg | 1件: Infigratinib Infigratinib | 1件: Infigratinib
Infigratinib
💬 | 3件: FGFR1 FGFR1, FGFR2, FGFR3 💬 | 21件: Adherens junction Adherens junction, Bladder cancer, Breast cancer, Calcium signaling pathway, Central carbon metabolism in cancer, EGFR tyrosine kinase inhibitor resistance, Endocytosis, Gastric cancer, MAPK signaling pathway, Melanoma, MicroRNAs in cancer, PI3K-Akt signaling pathway, Parathyroid hormone synthesis, secretion and action, Pathways in cancer, Prostate cancer, Proteoglycans in cancer, Rap1 signaling pathway, Ras signaling pathway, Regulation of actin cytoskeleton, Signaling pathways regulating pluripotency of stem cells, Thermogenesis 💬 | 1件: 276 276 💬 |
1383 | Infliximab (BCD-055) | 1件: Infliximab Infliximab | 1件: Infliximab
Infliximab
💬 | 1件: TNF TNF 💬 | 67件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Dilated cardiomyopathy, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease, Osteoclast differentiation, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway 💬 | 1件: 271 271 💬 |
1384 | Infliximab 5 mg/kg every 6 weeks | 1件: Infliximab Infliximab | 1件: Infliximab
Infliximab
💬 | 1件: TNF TNF 💬 | 67件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Dilated cardiomyopathy, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease, Osteoclast differentiation, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway 💬 | 1件: 96 96 💬 |
1385 | Infliximab 7 mg/kg every 8 weeks | 1件: Infliximab Infliximab | 1件: Infliximab
Infliximab
💬 | 1件: TNF TNF 💬 | 67件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Dilated cardiomyopathy, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease, Osteoclast differentiation, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway 💬 | 1件: 96 96 💬 |
1386 | Infliximab and azathioprine combination at week 0 | 2件: Azathioprine Azathioprine, Infliximab | 2件: Azathioprine
Azathioprine
,
Infliximab
💬 | 1件: TNF TNF 💬 | 67件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Dilated cardiomyopathy, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease, Osteoclast differentiation, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway 💬 | 1件: 96 96 💬 |
1387 | Infusion of ADR-001 (Mesenchymal stem cell) | - | - | - | - | 1件: 66 66 💬 |
1388 | Inhaled Nitric Oxide | 1件: Nitric Oxide Nitric Oxide | 1件: Nitric oxide
Nitric oxide
💬 | - | - | 2件: 85 85, 86 💬 |
1389 | Inhaled nitric oxide & INOpulse delivery | 1件: Nitric Oxide Nitric Oxide | 1件: Nitric oxide
Nitric oxide
💬 | - | - | 1件: 86 86 💬 |
1390 | Inhaled Nitric Oxide (iNO) use | 1件: Nitric Oxide Nitric Oxide | 1件: Nitric oxide
Nitric oxide
💬 | - | - | 1件: 294 294 💬 |
1391 | Inhaled Nitric Oxide - 30 mcg/kg IBW/hr | 1件: Nitric Oxide Nitric Oxide | 1件: Nitric oxide
Nitric oxide
💬 | - | - | 1件: 85 85 💬 |
1392 | Inhaled Nitric Oxide 5,10,15 mcg/Kg IBW/hr | 1件: Nitric Oxide Nitric Oxide | 1件: Nitric oxide
Nitric oxide
💬 | - | - | 1件: 85 85 💬 |
1393 | Inhaled nitric oxide 75 mcg/kg IBW/hr | 1件: Nitric Oxide Nitric Oxide | 1件: Nitric oxide
Nitric oxide
💬 | - | - | 2件: 85 85, 86 💬 |
1394 | Inhaled NO with pulsed delivery | - | - | - | - | 1件: 86 86 💬 |
1395 | Injection of normal saline | - | - | - | - | 1件: 6 6 💬 |
1396 | INN Not available | - | - | - | - | 2件: 19 19, 46 💬 |
1397 | INN not available yet | - | - | - | - | 1件: 222 222 💬 |
1398 | INN Not yet proposed | - | - | - | - | 1件: 193 193 💬 |
1399 | INN Parathyroid Hormone (1-84) human | 1件: Parathyroid hormone Parathyroid hormone | 1件: Parathyroid hormone
Parathyroid hormone
💬 | 2件: PTH1R PTH1R, PTH2R 💬 | 3件: Endocrine and other factor-regulated calcium reabsorption Endocrine and other factor-regulated calcium reabsorption, Neuroactive ligand-receptor interaction, Parathyroid hormone synthesis, secretion and action 💬 | 1件: 235 235 💬 |
1400 | INOmax 400ppm mol/mol inhalation gas | 1件: Nitric Oxide Nitric Oxide | 1件: Nitric oxide
Nitric oxide
💬 | - | - | 2件: 85 85, 299 💬 |
1401 | INOmax 800ppm mol/mol inhalatiegas | 1件: Nitric Oxide Nitric Oxide | 1件: Nitric oxide
Nitric oxide
💬 | - | - | 1件: 294 294 💬 |
1402 | INTELENCE - 200 MG - COMPRESSA -USO ORALE - FLACONE (HDPE) 60 COMPRESSE | 1件: Etravirine Etravirine | 1件: Etravirine
Etravirine
💬 | - | - | 1件: 18 18 💬 |
1403 | Interferon beta-1a (new process, manufactured without FBS) | 2件: Human interferon beta Human interferon beta, Interferon beta-1a | 1件: Interferon beta-1a
Interferon beta-1a
💬 | 2件: IFNAR1 IFNAR1, IFNAR2 💬 | 18件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Measles, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Osteoclast differentiation, PI3K-Akt signaling pathway, Pathways in cancer, Toll-like receptor signaling pathway 💬 | 1件: 13 13 💬 |
1404 | Interferon beta-1a, 30 µg/0.5 ml | 2件: Human interferon beta Human interferon beta, Interferon beta-1a | 1件: Interferon beta-1a
Interferon beta-1a
💬 | 2件: IFNAR1 IFNAR1, IFNAR2 💬 | 18件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Measles, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Osteoclast differentiation, PI3K-Akt signaling pathway, Pathways in cancer, Toll-like receptor signaling pathway 💬 | 1件: 13 13 💬 |
1405 | Interferon beta-1b (Betaferon, BAY 86-5046) | 2件: Human interferon beta Human interferon beta, Interferon beta-1b | 1件: Interferon beta-1b
Interferon beta-1b
💬 | 2件: IFNAR1 IFNAR1, IFNAR2 💬 | 18件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Measles, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Osteoclast differentiation, PI3K-Akt signaling pathway, Pathways in cancer, Toll-like receptor signaling pathway 💬 | 1件: 13 13 💬 |
1406 | Interferon beta-1b (Betaferon®, BAY 86-5046) | 2件: Human interferon beta Human interferon beta, Interferon beta-1b | 1件: Interferon beta-1b
Interferon beta-1b
💬 | 2件: IFNAR1 IFNAR1, IFNAR2 💬 | 18件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Measles, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Osteoclast differentiation, PI3K-Akt signaling pathway, Pathways in cancer, Toll-like receptor signaling pathway 💬 | 1件: 13 13 💬 |
1407 | Interferon beta-1b, FRP about 6 weeks after randomization | 2件: Human interferon beta Human interferon beta, Interferon beta-1b | 1件: Interferon beta-1b
Interferon beta-1b
💬 | 2件: IFNAR1 IFNAR1, IFNAR2 💬 | 18件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Measles, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Osteoclast differentiation, PI3K-Akt signaling pathway, Pathways in cancer, Toll-like receptor signaling pathway 💬 | 1件: 13 13 💬 |
1408 | Interferon-beta-1a, 44 microgram | 2件: Human interferon beta Human interferon beta, Interferon beta-1a | 1件: Interferon beta-1a
Interferon beta-1a
💬 | 2件: IFNAR1 IFNAR1, IFNAR2 💬 | 18件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Measles, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Osteoclast differentiation, PI3K-Akt signaling pathway, Pathways in cancer, Toll-like receptor signaling pathway 💬 | 1件: 97 97 💬 |
1409 | Interferon-beta-1a, 66 microgram | 2件: Human interferon beta Human interferon beta, Interferon beta-1a | 1件: Interferon beta-1a
Interferon beta-1a
💬 | 2件: IFNAR1 IFNAR1, IFNAR2 💬 | 18件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Measles, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Osteoclast differentiation, PI3K-Akt signaling pathway, Pathways in cancer, Toll-like receptor signaling pathway 💬 | 1件: 97 97 💬 |
1410 | Interferon-beta-1b (BETASERON, BAY 86-5046) | 2件: Human interferon beta Human interferon beta, Interferon beta-1b | 1件: Interferon beta-1b
Interferon beta-1b
💬 | 2件: IFNAR1 IFNAR1, IFNAR2 💬 | 18件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Measles, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Osteoclast differentiation, PI3K-Akt signaling pathway, Pathways in cancer, Toll-like receptor signaling pathway 💬 | 1件: 13 13 💬 |
1411 | Interferons, glatiramer acetate, teriflunomide, dimethyl fumarate, alemtuzumab, cladribine, fingolimod, ponesimod, rituximab, ocrelizumab, ofatumumab, natalizumab | 12件: Acetate Acetate, Alemtuzumab, Cladribine, Dimethyl fumarate, Fingolimod, Glatiramer, Natalizumab, Ocrelizumab, Ofatumumab, Ponesimod, Rituximab, Teriflunomide | 10件: Cladribine
Cladribine
,
Alemtuzumab
,
Rituximab
,
Dimethyl fumarate
,
Ocrelizumab
,
Natalizumab
,
Ofatumumab
,
Fingolimod
,
Teriflunomide
,
Ponesimod
💬 | 7件: CD52 CD52, DHODH, ITGA4, KEAP1, MS4A1, RRM1, S1PR1 💬 | 30件: Arrhythmogenic right ventricular cardiomyopathy Arrhythmogenic right ventricular cardiomyopathy, Biosynthesis of cofactors, Cell adhesion molecules, Chemical carcinogenesis - reactive oxygen species, Dilated cardiomyopathy, Drug metabolism - other enzymes, ECM-receptor interaction, Fluid shear stress and atherosclerosis, Focal adhesion, FoxO signaling pathway, Glutathione metabolism, Hematopoietic cell lineage, Hepatocellular carcinoma, Human papillomavirus infection, Hypertrophic cardiomyopathy, Intestinal immune network for IgA production, Leishmaniasis, Leukocyte transendothelial migration, Metabolic pathways, Neuroactive ligand-receptor interaction, Nucleotide metabolism, PI3K-Akt signaling pathway, Parkinson disease, Pathways in cancer, Purine metabolism, Pyrimidine metabolism, Regulation of actin cytoskeleton, Sphingolipid signaling pathway, Ubiquitin mediated proteolysis, Yersinia infection 💬 | 1件: 13 13 💬 |
1412 | Interferón beta 1a | - | - | - | - | 1件: 13 13 💬 |
1413 | Interferón beta 1a pegilado | - | - | - | - | 1件: 13 13 💬 |
1414 | Interferón Beta-1a pegilado | - | - | - | - | 1件: 13 13 💬 |
1415 | Interleukin 4 | - | - | - | - | 1件: 46 46 💬 |
1416 | Intrathecal administration of autologous MSC-NP | - | - | - | - | 1件: 13 13 💬 |
1417 | Intrathecal MSC-NP injection | - | - | - | - | 1件: 13 13 💬 |
1418 | Intravenous administration of 4 million of MSC | - | - | - | - | 1件: 2 2 💬 |
1419 | ION-682884 | - | - | - | - | 1件: 28 28 💬 |
1420 | Ips-nsc cells | - | - | - | - | 1件: 6 6 💬 |
1421 | IPX056 40 mg | - | - | - | - | 1件: 13 13 💬 |
1422 | IPX056-40 mg | - | - | - | - | 1件: 13 13 💬 |
1423 | IRAK 4 | - | - | - | - | 1件: 46 46 💬 |
1424 | Irbesartan 150-300mg capsules daily for 6 months | 1件: Irbesartan Irbesartan | 1件: Irbesartan
Irbesartan
💬 | 1件: AGTR1 AGTR1 💬 | 16件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adrenergic signaling in cardiomyocytes, Aldosterone synthesis and secretion, Apelin signaling pathway, Calcium signaling pathway, Coronavirus disease - COVID-19, Cortisol synthesis and secretion, Cushing syndrome, Diabetic cardiomyopathy, Neuroactive ligand-receptor interaction, Pathways in cancer, Phospholipase D signaling pathway, Renin secretion, Renin-angiotensin system, Vascular smooth muscle contraction, cGMP-PKG signaling pathway 💬 | 1件: 167 167 💬 |
1425 | Irbesartan tablets (Approved in the USA. Reference listed drug Avapro) NDC # 43547-0374-03 | 1件: Irbesartan Irbesartan | 1件: Irbesartan
Irbesartan
💬 | 1件: AGTR1 AGTR1 💬 | 16件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adrenergic signaling in cardiomyocytes, Aldosterone synthesis and secretion, Apelin signaling pathway, Calcium signaling pathway, Coronavirus disease - COVID-19, Cortisol synthesis and secretion, Cushing syndrome, Diabetic cardiomyopathy, Neuroactive ligand-receptor interaction, Pathways in cancer, Phospholipase D signaling pathway, Renin secretion, Renin-angiotensin system, Vascular smooth muscle contraction, cGMP-PKG signaling pathway 💬 | 2件: 66 66, 222 💬 |
1426 | Irbesartan tablets (NDA 020 757) | 1件: Irbesartan Irbesartan | 1件: Irbesartan
Irbesartan
💬 | 1件: AGTR1 AGTR1 💬 | 16件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adrenergic signaling in cardiomyocytes, Aldosterone synthesis and secretion, Apelin signaling pathway, Calcium signaling pathway, Coronavirus disease - COVID-19, Cortisol synthesis and secretion, Cushing syndrome, Diabetic cardiomyopathy, Neuroactive ligand-receptor interaction, Pathways in cancer, Phospholipase D signaling pathway, Renin secretion, Renin-angiotensin system, Vascular smooth muscle contraction, cGMP-PKG signaling pathway 💬 | 1件: 66 66 💬 |
1427 | Irbesartan tablets (NDC# 31722-729-30 approved in the United states) | 1件: Irbesartan Irbesartan | 1件: Irbesartan
Irbesartan
💬 | 1件: AGTR1 AGTR1 💬 | 16件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adrenergic signaling in cardiomyocytes, Aldosterone synthesis and secretion, Apelin signaling pathway, Calcium signaling pathway, Coronavirus disease - COVID-19, Cortisol synthesis and secretion, Cushing syndrome, Diabetic cardiomyopathy, Neuroactive ligand-receptor interaction, Pathways in cancer, Phospholipase D signaling pathway, Renin secretion, Renin-angiotensin system, Vascular smooth muscle contraction, cGMP-PKG signaling pathway 💬 | 1件: 222 222 💬 |
1428 | Irbesartan tablets (NDC# 43547-0374-03 and NDC 43547-374-09, approved in the USA) Generic tablets distributed by Solco Healthcare US, LLC | 1件: Irbesartan Irbesartan | 1件: Irbesartan
Irbesartan
💬 | 1件: AGTR1 AGTR1 💬 | 16件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adrenergic signaling in cardiomyocytes, Aldosterone synthesis and secretion, Apelin signaling pathway, Calcium signaling pathway, Coronavirus disease - COVID-19, Cortisol synthesis and secretion, Cushing syndrome, Diabetic cardiomyopathy, Neuroactive ligand-receptor interaction, Pathways in cancer, Phospholipase D signaling pathway, Renin secretion, Renin-angiotensin system, Vascular smooth muscle contraction, cGMP-PKG signaling pathway 💬 | 1件: 222 222 💬 |
1429 | Iron supplement 300-600 mg/day | 1件: Iron Iron | - | - | - | 2件: 96 96, 97 💬 |
1430 | ISIS 420915 | - | - | - | - | 1件: 28 28 💬 |
1431 | Isis 420915/GSK 299872 | - | - | - | - | 1件: 28 28 💬 |
1432 | ISIS 443139 10 mg | - | - | - | - | 1件: 8 8 💬 |
1433 | ISIS 443139 120 mg | - | - | - | - | 1件: 8 8 💬 |
1434 | ISIS 443139 30 mg | - | - | - | - | 1件: 8 8 💬 |
1435 | ISIS 443139 60 mg | - | - | - | - | 1件: 8 8 💬 |
1436 | ISIS 443139 90 mg | - | - | - | - | 1件: 8 8 💬 |
1437 | Isosorbide Dinitrate 40 mg | 2件: Isosorbide Isosorbide, Isosorbide dinitrate | 2件: Isosorbide
Isosorbide
,
Isosorbide dinitrate
💬 | - | - | 1件: 113 113 💬 |
1438 | Isosorbide Dinitrate 60 mg | 2件: Isosorbide Isosorbide, Isosorbide dinitrate | 2件: Isosorbide
Isosorbide
,
Isosorbide dinitrate
💬 | - | - | 1件: 113 113 💬 |
1439 | Isosorbide Dinitrate 80 mg | 2件: Isosorbide Isosorbide, Isosorbide dinitrate | 2件: Isosorbide
Isosorbide
,
Isosorbide dinitrate
💬 | - | - | 1件: 113 113 💬 |
1440 | Isotone Kochsalz-Lösung 0,9 % Braun Infusionslösung | - | - | - | - | 1件: 50 50 💬 |
1441 | Isotonic saline 0.9% | 1件: Sodium chloride Sodium chloride | 1件: Sodium chloride
Sodium chloride
💬 | - | - | 1件: 299 299 💬 |
1442 | Istradefylline ( KW-6002) | 1件: Istradefylline Istradefylline | 1件: Istradefylline
Istradefylline
💬 | 1件: ADORA2A ADORA2A 💬 | 7件: Alcoholism Alcoholism, Calcium signaling pathway, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, Vascular smooth muscle contraction, cAMP signaling pathway 💬 | 1件: 6 6 💬 |
1443 | Istradefylline (KW-6002) | 1件: Istradefylline Istradefylline | 1件: Istradefylline
Istradefylline
💬 | 1件: ADORA2A ADORA2A 💬 | 7件: Alcoholism Alcoholism, Calcium signaling pathway, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, Vascular smooth muscle contraction, cAMP signaling pathway 💬 | 1件: 6 6 💬 |
1444 | Istradefylline 20 mg or 40 mg | 1件: Istradefylline Istradefylline | 1件: Istradefylline
Istradefylline
💬 | 1件: ADORA2A ADORA2A 💬 | 7件: Alcoholism Alcoholism, Calcium signaling pathway, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, Vascular smooth muscle contraction, cAMP signaling pathway 💬 | 1件: 6 6 💬 |
1445 | Istradefylline 40 mg | 1件: Istradefylline Istradefylline | 1件: Istradefylline
Istradefylline
💬 | 1件: ADORA2A ADORA2A 💬 | 7件: Alcoholism Alcoholism, Calcium signaling pathway, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, Vascular smooth muscle contraction, cAMP signaling pathway 💬 | 1件: 6 6 💬 |
1446 | Itolizumab [Bmab 600] | 1件: Itolizumab Itolizumab | 1件: Itolizumab
Itolizumab
💬 | 1件: CD6 CD6 💬 | 1件: Cell adhesion molecules Cell adhesion molecules 💬 | 1件: 49 49 💬 |
1447 | Itraconazole 400 mg/day and terbinafine 500 mg/day administered orally. | 2件: Itraconazole Itraconazole, Terbinafine | 2件: Itraconazole
Itraconazole
,
Terbinafine
💬 | - | - | 1件: 96 96 💬 |
1448 | IUPAC name: 1-(2-Isopropoxyethyl)-2-thioxo-1,2,3,5-tetrahydro-pyrrolo[3,2-d] pyrimidin-4-one | - | - | - | - | 1件: 17 17 💬 |
1449 | IUPAC name: 2-[4-[(2-amino-5-methyl-4-oxo-1,6,7,8-tetrahydropteridin-6-yl)methylam ino]benzoyl]amino | - | - | - | - | 1件: 337 337 💬 |
1450 | Ixazomib (NINLARO®) capsules | 1件: Ixazomib Ixazomib | 1件: Ixazomib
Ixazomib
💬 | 1件: PSMB5 PSMB5 💬 | 8件: Alzheimer disease Alzheimer disease, Amyotrophic lateral sclerosis, Huntington disease, Parkinson disease, Pathways of neurodegeneration - multiple diseases, Prion disease, Proteasome, Spinocerebellar ataxia 💬 | 1件: 13 13 💬 |
1451 | J695, BSF 415977 (formerly LU415977), WAY-165772, A-796874.0 | - | - | - | - | 1件: 96 96 💬 |
1452 | Jevity 1.0 | - | - | - | - | 1件: 2 2 💬 |
1453 | JINARC - 15 MG +45 MG - COMPRESSA - USO ORALE - BLISTER(ALU/PVC) IN CONFEZIONE A PORTAFOGLIO - 56 COMPRESSE (28X15 MG + 28 X 45 MG) | 1件: Tolvaptan Tolvaptan | 1件: Tolvaptan
Tolvaptan
💬 | 1件: AVPR2 AVPR2 💬 | 3件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Phospholipase D signaling pathway, Vasopressin-regulated water reabsorption 💬 | 1件: 67 67 💬 |
1454 | JINARC - 30 MG + 60 MG - COMPRESSA - USO ORALE - BLISTER(ALU/PVC) IN CONFEZIONE A PORTAFOGLIO - 56 COMPRESSE (28 X 30 MG + 28 X 60 MG) | 1件: Tolvaptan Tolvaptan | 1件: Tolvaptan
Tolvaptan
💬 | 1件: AVPR2 AVPR2 💬 | 3件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Phospholipase D signaling pathway, Vasopressin-regulated water reabsorption 💬 | 1件: 67 67 💬 |
1455 | Jinarc 15 mg tablets, Jinarc 45 mg tablets | 1件: Tolvaptan Tolvaptan | 1件: Tolvaptan
Tolvaptan
💬 | 1件: AVPR2 AVPR2 💬 | 3件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Phospholipase D signaling pathway, Vasopressin-regulated water reabsorption 💬 | 1件: 67 67 💬 |
1456 | Jinarc 30 mg tablets, Jinarc 60 mg tablets | 1件: Tolvaptan Tolvaptan | 1件: Tolvaptan
Tolvaptan
💬 | 1件: AVPR2 AVPR2 💬 | 3件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Phospholipase D signaling pathway, Vasopressin-regulated water reabsorption 💬 | 1件: 67 67 💬 |
1457 | JM-010 | - | - | - | - | 1件: 6 6 💬 |
1458 | JM-4 | - | - | - | - | 1件: 13 13 💬 |
1459 | JNJ-40346527 | 1件: JNJ-40346527 JNJ-40346527 | - | - | - | 2件: 46 46, 96 💬 |
1460 | JNJ-40346527-AAC | 1件: JNJ-40346527 JNJ-40346527 | - | - | - | 1件: 96 96 💬 |
1461 | JNJ-40346527-AAC - capsule - 50 mg | 1件: JNJ-40346527 JNJ-40346527 | - | - | - | 1件: 46 46 💬 |
1462 | JNJ-42160443 | - | - | - | - | 1件: 226 226 💬 |
1463 | JNJ-64304500 | - | - | - | - | 1件: 96 96 💬 |
1464 | JNJ-64304500-AAA | - | - | - | - | 1件: 96 96 💬 |
1465 | JNJ-64841829 | - | - | - | - | 1件: 97 97 💬 |
1466 | JNJ-64841842 | - | - | - | - | 1件: 97 97 💬 |
1467 | JNJ-64841855 | - | - | - | - | 1件: 97 97 💬 |
1468 | JNJ-64841894 | - | - | - | - | 1件: 97 97 💬 |
1469 | JNJ-64841907 | - | - | - | - | 1件: 97 97 💬 |
1470 | JNJ-64841920 | - | - | - | - | 1件: 97 97 💬 |
1471 | JNJ-64841933 | - | - | - | - | 1件: 97 97 💬 |
1472 | JNJ-64841946 | - | - | - | - | 1件: 97 97 💬 |
1473 | JNJ-66525433 | - | - | - | - | 1件: 97 97 💬 |
1474 | JNJ-67484703 | - | - | - | - | 1件: 46 46 💬 |
1475 | JNJ-67864238 | - | - | - | - | 1件: 96 96 💬 |
1476 | JNJ-67896049 | - | - | - | - | 1件: 86 86 💬 |
1477 | JNJ-67896049 (ACT-293987) | - | - | - | - | 1件: 86 86 💬 |
1478 | JNJ-67896062 / ACT-064992 | - | - | - | - | 2件: 86 86, 88 💬 |
1479 | JNJ-67896062/ ACT-064992 | - | - | - | - | 2件: 86 86, 88 💬 |
1480 | JNJ-67896062/ACT-064922 | - | - | - | - | 1件: 86 86 💬 |
1481 | JNJ-67896153/ACT-128800 | - | - | - | - | 1件: 13 13 💬 |
1482 | JNJ-80202135 | - | - | - | - | 4件: 11 11, 46, 49, 53 💬 |
1483 | Jorveza 0.5 mg compresse orodispersibili | 1件: Budesonide Budesonide | 1件: Budesonide
Budesonide
💬 | 1件: NR3C1 NR3C1 💬 | 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 1件: 98 98 💬 |
1484 | Jorveza 0.5 mg orodispersible tablets | 1件: Budesonide Budesonide | 1件: Budesonide
Budesonide
💬 | 1件: NR3C1 NR3C1 💬 | 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 1件: 98 98 💬 |
1485 | JTE-051 | - | - | - | - | 1件: 46 46 💬 |
1486 | K-832 | - | - | - | - | 1件: 46 46 💬 |
1487 | Kamada-AAT for Inhalation, 80mg | - | - | - | - | 1件: 231 231 💬 |
1488 | KB407 (Nebulization) | - | - | - | - | 1件: 299 299 💬 |
1489 | KCT-0809 ophthalmic solution | - | - | - | - | 1件: 53 53 💬 |
1490 | Ketocal 4:1 liquid Nutricia (intervention) | - | - | - | - | 1件: 256 256 💬 |
1491 | Ketone Ester Elite endurance Nutrition Drink | - | - | - | - | 1件: 6 6 💬 |
1492 | Keyhole limpet hemocyanin (KLH) neo-antigen | 1件: Keyhole limpet hemocyanin Keyhole limpet hemocyanin | - | - | - | 1件: 13 13 💬 |
1493 | KINERET*SC 7SIR 100MG 0,67ML | 1件: Anakinra Anakinra | 1件: Anakinra
Anakinra
💬 | 2件: IL1R1 IL1R1, IL1R2 💬 | 15件: Amoebiasis Amoebiasis, Cytokine-cytokine receptor interaction, Fluid shear stress and atherosclerosis, Hematopoietic cell lineage, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Inflammatory mediator regulation of TRP channels, MAPK signaling pathway, NF-kappa B signaling pathway, Osteoclast differentiation, Pathogenic Escherichia coli infection, Prostate cancer, Shigellosis, Th17 cell differentiation, Transcriptional misregulation in cancer 💬 | 3件: 28 28, 46, 107 💬 |
1494 | Kiovig® (Human normal Immunoglobulin for intravenous administration 100mg/mL) | 1件: Human immunoglobulin G Human immunoglobulin G | - | - | - | 1件: 14 14 💬 |
1495 | KM-819 | - | - | - | - | 2件: 6 6, 17 💬 |
1496 | KPG-818 | - | - | - | - | 1件: 49 49 💬 |
1497 | KPL-404 | - | - | - | - | 1件: 46 46 💬 |
1498 | KPS-0373 | - | - | - | - | 1件: 18 18 💬 |
1499 | KPS-0373, High dose | - | - | - | - | 1件: 18 18 💬 |
1500 | KPS-0373, Low dose | - | - | - | - | 1件: 18 18 💬 |
1501 | Kreon 25 000 | - | - | - | - | 1件: 299 299 💬 |
1502 | Kreon 25,000 Units | - | - | - | - | 1件: 299 299 💬 |
1503 | KREON de Liberación Inmediata | - | - | - | - | 1件: 299 299 💬 |
1504 | KREON N 25000 | - | - | - | - | 1件: 299 299 💬 |
1505 | Kreon® 25,000 | - | - | - | - | 1件: 299 299 💬 |
1506 | KVD900 600 mg | - | - | - | - | 1件: 65 65 💬 |
1507 | KW-0761 | - | - | - | - | 1件: 26 26 💬 |
1508 | KW-0761 0.3 mg/kg IV | - | - | - | - | 1件: 26 26 💬 |
1509 | KW-6002 | - | - | - | - | 1件: 6 6 💬 |
1510 | KW-6002 (istradefylline) | 1件: Istradefylline Istradefylline | 1件: Istradefylline
Istradefylline
💬 | 1件: ADORA2A ADORA2A 💬 | 7件: Alcoholism Alcoholism, Calcium signaling pathway, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, Vascular smooth muscle contraction, cAMP signaling pathway 💬 | 1件: 6 6 💬 |
1511 | KW-6356 | 1件: KW-6356 KW-6356 | - | - | - | 1件: 6 6 💬 |
1512 | KW-6356 High Dose | 1件: KW-6356 KW-6356 | - | - | - | 1件: 6 6 💬 |
1513 | KW-6356 Low Dose | 1件: KW-6356 KW-6356 | - | - | - | 1件: 6 6 💬 |
1514 | KW-6356 Middle Dose | 1件: KW-6356 KW-6356 | - | - | - | 1件: 6 6 💬 |
1515 | KW-6356 X Dose | 1件: KW-6356 KW-6356 | - | - | - | 1件: 6 6 💬 |
1516 | KW-6356 Y Dose | 1件: KW-6356 KW-6356 | - | - | - | 1件: 6 6 💬 |
1517 | KW-6500 | - | - | - | - | 1件: 6 6 💬 |
1518 | KZR-616 | 1件: KZR-616 KZR-616 | - | - | - | 3件: 49 49, 50, 61 💬 |
1519 | KZR-616 maleate | 1件: KZR-616 KZR-616 | - | - | - | 1件: 50 50 💬 |
1520 | L 44 | - | - | - | - | 1件: 96 96 💬 |
1521 | L-000124467 | - | - | - | - | 2件: 13 13, 46 💬 |
1522 | L-000124467 (freebase) | - | - | - | - | 1件: 46 46 💬 |
1523 | L-000124467-009J (succinat | - | - | - | - | 1件: 46 46 💬 |
1524 | L-000883191 | - | - | - | - | 1件: 46 46 💬 |
1525 | L-001069957 | - | - | - | - | 1件: 46 46 💬 |
1526 | L-3-(3,4-Dihydroxyphenyl)alanine | 1件: Alanine Alanine | 1件: Alanine
Alanine
💬 | - | - | 1件: 6 6 💬 |
1527 | L-883191 | - | - | - | - | 1件: 46 46 💬 |
1528 | L-Lysine N acetylcysteinate | 1件: Lysine Lysine | 1件: Lysine
Lysine
💬 | - | - | 1件: 299 299 💬 |
1529 | L-Lysine N-acetylcysteinate | 1件: Lysine Lysine | 1件: Lysine
Lysine
💬 | - | - | 1件: 299 299 💬 |
1530 | L-Lysine- N-acetylcysteinate | 1件: Lysine Lysine | 1件: Lysine
Lysine
💬 | - | - | 1件: 299 299 💬 |
1531 | L-Lysine-N-acetyl-L-cysteinate | 1件: Lysine Lysine | 1件: Lysine
Lysine
💬 | - | - | 1件: 299 299 💬 |
1532 | L-Lysine-N-acetylcysteinate | 1件: Lysine Lysine | 1件: Lysine
Lysine
💬 | - | - | 1件: 299 299 💬 |
1533 | L01XE31 - Nintedanib | 1件: Nintedanib Nintedanib | 1件: Nintedanib
Nintedanib
💬 | 8件: FGFR1 FGFR1, FGFR2, FGFR3, FLT1, FLT4, KDR, PDGFRA, PDGFRB 💬 | 34件: Adherens junction Adherens junction, Bladder cancer, Breast cancer, Calcium signaling pathway, Central carbon metabolism in cancer, Choline metabolism in cancer, EGFR tyrosine kinase inhibitor resistance, Endocytosis, Fluid shear stress and atherosclerosis, Focal adhesion, Gap junction, Gastric cancer, Glioma, HIF-1 signaling pathway, Human cytomegalovirus infection, Human papillomavirus infection, JAK-STAT signaling pathway, MAPK signaling pathway, Melanoma, MicroRNAs in cancer, PI3K-Akt signaling pathway, Parathyroid hormone synthesis, secretion and action, Pathways in cancer, Phospholipase D signaling pathway, Prostate cancer, Proteoglycans in cancer, Rap1 signaling pathway, Ras signaling pathway, Regulation of actin cytoskeleton, Rheumatoid arthritis, Signaling pathways regulating pluripotency of stem cells, Thermogenesis, Transcriptional misregulation in cancer, VEGF signaling pathway 💬 | 1件: 85 85 💬 |
1534 | L03 AB 08 | - | - | - | - | 1件: 13 13 💬 |
1535 | Lactizole nebulization | - | - | - | - | 1件: 299 299 💬 |
1536 | Lamotrigin ”Nordic Prime 100 mg | - | - | - | - | 1件: 114 114 💬 |
1537 | Lamotrigin ”Nordic Prime 25 mg | - | - | - | - | 1件: 114 114 💬 |
1538 | Lamotrigin ”Nordic Prime 50 mg | - | - | - | - | 1件: 114 114 💬 |
1539 | Laquinimod 0.3 | 1件: Laquinimod Laquinimod | - | - | - | 1件: 13 13 💬 |
1540 | Laquinimod 0.6 | 1件: Laquinimod Laquinimod | - | - | - | 1件: 13 13 💬 |
1541 | Laquinimod Capsulas 0.6 mg | 1件: Laquinimod Laquinimod | - | - | - | 1件: 13 13 💬 |
1542 | Laquinimod Capsules 0.3 mg | 1件: Laquinimod Laquinimod | - | - | - | 1件: 13 13 💬 |
1543 | Laquinimod capsules 0.5 mg | 1件: Laquinimod Laquinimod | - | - | - | 2件: 8 8, 96 💬 |
1544 | Laquinimod Capsules 0.6 mg | 1件: Laquinimod Laquinimod | - | - | - | 1件: 13 13 💬 |
1545 | Laquinimod Cápsulas 0.5 mg | 1件: Laquinimod Laquinimod | - | - | - | 1件: 96 96 💬 |
1546 | Laquinimod Tablets 0.3 mg | 1件: Laquinimod Laquinimod | - | - | - | 1件: 13 13 💬 |
1547 | Large Neutral Amino Acid Therapy | - | - | - | - | 1件: 240 240 💬 |
1548 | LC51-0255 | - | - | - | - | 1件: 97 97 💬 |
1549 | LDP-02 | - | - | - | - | 2件: 96 96, 97 💬 |
1550 | Leflunomide (permitted, not necessary) | 1件: Leflunomide Leflunomide | 1件: Leflunomide
Leflunomide
💬 | 1件: DHODH DHODH 💬 | 3件: Biosynthesis of cofactors Biosynthesis of cofactors, Metabolic pathways, Pyrimidine metabolism 💬 | 1件: 46 46 💬 |
1551 | Leflunomide 20 mg+prednisone 0.5mg/kg/d | 2件: Leflunomide Leflunomide, Prednisone | 2件: Prednisone
Prednisone
,
Leflunomide
💬 | 2件: DHODH DHODH, NR3C1 💬 | 4件: Biosynthesis of cofactors Biosynthesis of cofactors, Metabolic pathways, Neuroactive ligand-receptor interaction, Pyrimidine metabolism 💬 | 1件: 66 66 💬 |
1552 | Lenadogene nolparvovec | 1件: Lenadogene nolparvovec Lenadogene nolparvovec | - | - | - | 1件: 302 302 💬 |
1553 | Leuprolide Acetate 45 mg | 2件: Acetate Acetate, Leuprolide | - | - | - | 1件: 76 76 💬 |
1554 | Levodopa-4'-Monophosphate | 2件: Foslevodopa Foslevodopa, Levodopa | 2件: Levodopa
Levodopa
,
Foslevodopa
💬 | 5件: DRD1 DRD1, DRD2, DRD3, DRD4, DRD5 💬 | 11件: Alcoholism Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway 💬 | 1件: 6 6 💬 |
1555 | Levodopa/Carbidopa (4:1) | 2件: Carbidopa Carbidopa, Levodopa | 2件: Levodopa
Levodopa
,
Carbidopa
💬 | 6件: DDC DDC, DRD1, DRD2, DRD3, DRD4, DRD5 💬 | 16件: Alcoholism Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Metabolic pathways, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Phenylalanine metabolism, Rap1 signaling pathway, Serotonergic synapse, Tryptophan metabolism, Tyrosine metabolism, cAMP signaling pathway 💬 | 1件: 201 201 💬 |
1556 | LEVOFOLENE 4 MG 30 CPR | 1件: Levoleucovorin Levoleucovorin | - | - | - | 1件: 13 13 💬 |
1557 | Linerixibat (GSK2330672) 40 mg | - | - | - | - | 1件: 93 93 💬 |
1558 | Linerixibat (GSK2330672) 45 mg | - | - | - | - | 1件: 93 93 💬 |
1559 | Linerixibat (GSK2330672) 45mg | - | - | - | - | 1件: 93 93 💬 |
1560 | Liposomal amikacin for inhalation (Arikayce™) using the PARI Investigational eFlow® Nebulizer. | 1件: Amikacin Amikacin | 1件: Amikacin
Amikacin
💬 | - | - | 1件: 299 299 💬 |
1561 | LiRIS 400 mg | - | - | - | - | 1件: 226 226 💬 |
1562 | LiRIS® 400 mg | - | - | - | - | 1件: 226 226 💬 |
1563 | Lithiumcarbonaat 400 PCH tabletten | - | - | - | - | 1件: 2 2 💬 |
1564 | Live Necator americanus larvae | - | - | - | - | 1件: 13 13 💬 |
1565 | LJN452, 0,01 mg | - | - | - | - | 1件: 93 93 💬 |
1566 | LJN452, 0,03 mg | - | - | - | - | 1件: 93 93 💬 |
1567 | LJN452, 0,1 mg | - | - | - | - | 1件: 93 93 💬 |
1568 | LMX 4 Topical Cream | - | - | - | - | 1件: 256 256 💬 |
1569 | Local Trade Name, 2mg | - | - | - | - | 1件: 6 6 💬 |
1570 | Local Trade Name, 4mg | - | - | - | - | 1件: 6 6 💬 |
1571 | Local Trade Name, 8mg | - | - | - | - | 1件: 6 6 💬 |
1572 | Loestrin (norethindrone acetate and ethinyl estradiol) | 4件: Acetate Acetate, Estradiol, Ethinylestradiol, Norethisterone | 3件: Estradiol
Estradiol
,
Norethindrone
,
Ethinyl estradiol
💬 | 3件: ESR1 ESR1, ESR2, PGR 💬 | 12件: Breast cancer Breast cancer, Chemical carcinogenesis - receptor activation, Endocrine and other factor-regulated calcium reabsorption, Endocrine resistance, Estrogen signaling pathway, GnRH secretion, Oocyte meiosis, Pathways in cancer, Progesterone-mediated oocyte maturation, Prolactin signaling pathway, Proteoglycans in cancer, Thyroid hormone signaling pathway 💬 | 1件: 299 299 💬 |
1573 | Loestrin 1.5/30 (1.5 mg norethindrone acetate/30 µg ethinyl estradiol) | 4件: Acetate Acetate, Estradiol, Ethinylestradiol, Norethisterone | 3件: Estradiol
Estradiol
,
Norethindrone
,
Ethinyl estradiol
💬 | 3件: ESR1 ESR1, ESR2, PGR 💬 | 12件: Breast cancer Breast cancer, Chemical carcinogenesis - receptor activation, Endocrine and other factor-regulated calcium reabsorption, Endocrine resistance, Estrogen signaling pathway, GnRH secretion, Oocyte meiosis, Pathways in cancer, Progesterone-mediated oocyte maturation, Prolactin signaling pathway, Proteoglycans in cancer, Thyroid hormone signaling pathway 💬 | 2件: 46 46, 49 💬 |
1574 | Long-chain n-3 PUFA | - | - | - | - | 1件: 46 46 💬 |
1575 | Lopinavir/ritonavir + nevirapine | 3件: Lopinavir Lopinavir, Nevirapine, Ritonavir | 3件: Ritonavir
Ritonavir
,
Nevirapine
,
Lopinavir
💬 | - | - | 1件: 265 265 💬 |
1576 | Losartan and nebivolol | 2件: Losartan Losartan, Nebivolol | 2件: Nebivolol
Nebivolol
,
Losartan
💬 | 2件: ADRB1 ADRB1, AGTR1 💬 | 22件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adrenergic signaling in cardiomyocytes, Aldosterone synthesis and secretion, Apelin signaling pathway, Calcium signaling pathway, Chemical carcinogenesis - receptor activation, Coronavirus disease - COVID-19, Cortisol synthesis and secretion, Cushing syndrome, Diabetic cardiomyopathy, Dilated cardiomyopathy, Gap junction, Neuroactive ligand-receptor interaction, Pathways in cancer, Phospholipase D signaling pathway, Regulation of lipolysis in adipocytes, Renin secretion, Renin-angiotensin system, Salivary secretion, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway 💬 | 1件: 167 167 💬 |
1577 | Lovastatin 60 MG | 1件: Lovastatin Lovastatin | 1件: Lovastatin
Lovastatin
💬 | 1件: HMGCR HMGCR 💬 | 4件: AMPK signaling pathway AMPK signaling pathway, Bile secretion, Metabolic pathways, Terpenoid backbone biosynthesis 💬 | 1件: 34 34 💬 |
1578 | Low dose arm receiving neutral oil and 400 IU/g of Vitamin D every second day | 1件: Vitamin D Vitamin D | - | - | - | 1件: 13 13 💬 |
1579 | Low dose naltrexone | 1件: Naltrexone Naltrexone | 1件: Naltrexone
Naltrexone
💬 | 3件: OPRD1 OPRD1, OPRK1, OPRM1 💬 | 5件: Estrogen signaling pathway Estrogen signaling pathway, Morphine addiction, Neuroactive ligand-receptor interaction, Sphingolipid signaling pathway, cGMP-PKG signaling pathway 💬 | 2件: 96 96, 97 💬 |
1580 | Low-dose naltrexone | 1件: Naltrexone Naltrexone | 1件: Naltrexone
Naltrexone
💬 | 3件: OPRD1 OPRD1, OPRK1, OPRM1 💬 | 5件: Estrogen signaling pathway Estrogen signaling pathway, Morphine addiction, Neuroactive ligand-receptor interaction, Sphingolipid signaling pathway, cGMP-PKG signaling pathway 💬 | 1件: 226 226 💬 |
1581 | LP-08 20mg | - | - | - | - | 1件: 226 226 💬 |
1582 | LP-08 80mg | - | - | - | - | 1件: 226 226 💬 |
1583 | LT-02 | - | - | - | - | 1件: 97 97 💬 |
1584 | LT-02 (modified-release PC pellets) | 1件: Manganese citrate Manganese citrate | - | - | - | 1件: 97 97 💬 |
1585 | LTS 0.25mg | - | - | - | - | 1件: 46 46 💬 |
1586 | LTS 0.5mg | - | - | - | - | 1件: 46 46 💬 |
1587 | LTS 1.0mg | - | - | - | - | 1件: 46 46 💬 |
1588 | Lu 00-800 | - | - | - | - | 1件: 6 6 💬 |
1589 | Lumacaftor/ivacaftor 200mg/83mg tablet | 2件: Ivacaftor Ivacaftor, Lumacaftor | 2件: Ivacaftor
Ivacaftor
,
Lumacaftor
💬 | 1件: CFTR CFTR 💬 | 8件: ABC transporters ABC transporters, AMPK signaling pathway, Bile secretion, Gastric acid secretion, Pancreatic secretion, Tight junction, Vibrio cholerae infection, cAMP signaling pathway 💬 | 1件: 299 299 💬 |
1590 | Lumbar Interbody Fusion with NeoFuse | 2件: Iron polymaltose Iron polymaltose, Lactobacillus casei | 1件: Lactobacillus casei
Lactobacillus casei
💬 | - | - | 1件: 70 70 💬 |
1591 | Lumentin 44 | - | - | - | - | 1件: 96 96 💬 |
1592 | LY03003( the name of rotigotine) | 1件: Rotigotine Rotigotine | 1件: Rotigotine
Rotigotine
💬 | 1件: DRD2 DRD2 💬 | 8件: Alcoholism Alcoholism, Cocaine addiction, Dopaminergic synapse, Gap junction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway 💬 | 1件: 6 6 💬 |
1593 | M2951 (Other Name: Evobrutinib) | 1件: Evobrutinib Evobrutinib | 1件: Evobrutinib
Evobrutinib
💬 | 1件: BTK BTK 💬 | 7件: B cell receptor signaling pathway B cell receptor signaling pathway, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, NF-kappa B signaling pathway, Osteoclast differentiation, Platelet activation, Primary immunodeficiency 💬 | 1件: 49 49 💬 |
1594 | MABCAMPATH 10 mg/ml concentrado para solución para perfusión | 1件: Alemtuzumab Alemtuzumab | 1件: Alemtuzumab
Alemtuzumab
💬 | 1件: CD52 CD52 💬 | - | 1件: 13 13 💬 |
1595 | MABTHERA 500 mg concentrado para solución para perfusión | 1件: Rituximab Rituximab | 1件: Rituximab
Rituximab
💬 | 1件: MS4A1 MS4A1 💬 | 1件: Hematopoietic cell lineage Hematopoietic cell lineage 💬 | 1件: 46 46 💬 |
1596 | MabThera®, 100 mg Concentrado para solución para perfusión | 1件: Rituximab Rituximab | 1件: Rituximab
Rituximab
💬 | 1件: MS4A1 MS4A1 💬 | 1件: Hematopoietic cell lineage Hematopoietic cell lineage 💬 | 1件: 46 46 💬 |
1597 | Macitentan (ACT-064992) | 1件: Macitentan Macitentan | 1件: Macitentan
Macitentan
💬 | 2件: EDNRA EDNRA, EDNRB 💬 | 9件: Calcium signaling pathway Calcium signaling pathway, Melanogenesis, Neuroactive ligand-receptor interaction, Pathways in cancer, Relaxin signaling pathway, Renin secretion, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway 💬 | 1件: 86 86 💬 |
1598 | Macrogol 4000 | 1件: Polyethylene glycol Polyethylene glycol | 1件: Polyethylene glycol 3350
Polyethylene glycol 3350
💬 | - | - | 1件: 299 299 💬 |
1599 | Masitinib (3.0) | 1件: Masitinib Masitinib | 1件: Masitinib
Masitinib
💬 | 1件: KIT KIT 💬 | 11件: Acute myeloid leukemia Acute myeloid leukemia, Breast cancer, Central carbon metabolism in cancer, Hematopoietic cell lineage, MAPK signaling pathway, Melanogenesis, PI3K-Akt signaling pathway, Pathways in cancer, Phospholipase D signaling pathway, Rap1 signaling pathway, Ras signaling pathway 💬 | 1件: 2 2 💬 |
1600 | Masitinib (4.5) | 1件: Masitinib Masitinib | 1件: Masitinib
Masitinib
💬 | 1件: KIT KIT 💬 | 11件: Acute myeloid leukemia Acute myeloid leukemia, Breast cancer, Central carbon metabolism in cancer, Hematopoietic cell lineage, MAPK signaling pathway, Melanogenesis, PI3K-Akt signaling pathway, Pathways in cancer, Phospholipase D signaling pathway, Rap1 signaling pathway, Ras signaling pathway 💬 | 2件: 2 2, 13 💬 |
1601 | Masitinib (6.0) | 1件: Masitinib Masitinib | 1件: Masitinib
Masitinib
💬 | 1件: KIT KIT 💬 | 11件: Acute myeloid leukemia Acute myeloid leukemia, Breast cancer, Central carbon metabolism in cancer, Hematopoietic cell lineage, MAPK signaling pathway, Melanogenesis, PI3K-Akt signaling pathway, Pathways in cancer, Phospholipase D signaling pathway, Rap1 signaling pathway, Ras signaling pathway 💬 | 1件: 2 2 💬 |
1602 | Masitinib 6.0 mg | 1件: Masitinib Masitinib | 1件: Masitinib
Masitinib
💬 | 1件: KIT KIT 💬 | 11件: Acute myeloid leukemia Acute myeloid leukemia, Breast cancer, Central carbon metabolism in cancer, Hematopoietic cell lineage, MAPK signaling pathway, Melanogenesis, PI3K-Akt signaling pathway, Pathways in cancer, Phospholipase D signaling pathway, Rap1 signaling pathway, Ras signaling pathway 💬 | 1件: 46 46 💬 |
1603 | MAVENCLAD - 10 MG - COMPRESSA - USO ORALE - BLISTER (AL/AL) - 6 COMPRESSE | 1件: Cladribine Cladribine | 1件: Cladribine
Cladribine
💬 | 1件: RRM1 RRM1 💬 | 6件: Drug metabolism - other enzymes Drug metabolism - other enzymes, Glutathione metabolism, Metabolic pathways, Nucleotide metabolism, Purine metabolism, Pyrimidine metabolism 💬 | 1件: 13 13 💬 |
1604 | Mayzent 0,25 mg Filmtabletten | 1件: Siponimod Siponimod | 1件: Siponimod
Siponimod
💬 | 2件: S1PR1 S1PR1, S1PR5 💬 | 3件: FoxO signaling pathway FoxO signaling pathway, Neuroactive ligand-receptor interaction, Sphingolipid signaling pathway 💬 | 1件: 13 13 💬 |
1605 | Mayzent 0.25 mg fi | 1件: Siponimod Siponimod | 1件: Siponimod
Siponimod
💬 | 2件: S1PR1 S1PR1, S1PR5 💬 | 3件: FoxO signaling pathway FoxO signaling pathway, Neuroactive ligand-receptor interaction, Sphingolipid signaling pathway 💬 | 1件: 13 13 💬 |
1606 | MBM-01 | - | - | - | - | 1件: 65 65 💬 |
1607 | MBS2320 40 mg | - | - | - | - | 1件: 46 46 💬 |
1608 | MBX 8025 | - | - | - | - | 1件: 93 93 💬 |
1609 | MBX-8025 | - | - | - | - | 3件: 79 79, 93, 94 💬 |
1610 | MBX-8025 50 mg (Dose Escalation Period 1) | - | - | - | - | 1件: 79 79 💬 |
1611 | MBX-8025 50 mg or 100 mg (Dose Escalation Period 2) | - | - | - | - | 1件: 79 79 💬 |
1612 | MBX-8025 50 mg, 100 mg or 200 mg (Dose Escalation Period 3) | - | - | - | - | 1件: 79 79 💬 |
1613 | MBX-8025, DSIC | - | - | - | - | 1件: 93 93 💬 |
1614 | MBX-8025, Formulation 2 | - | - | - | - | 1件: 93 93 💬 |
1615 | MD-0901 | - | - | - | - | 1件: 97 97 💬 |
1616 | MDGN-002 | - | - | - | - | 1件: 96 96 💬 |
1617 | MEDI-545 600 | - | - | - | - | 1件: 49 49 💬 |
1618 | MEDI-551 60 MG-SC | - | - | - | - | 1件: 13 13 💬 |
1619 | MEDI-551 600 MG-IV | - | - | - | - | 1件: 13 13 💬 |
1620 | MEDI-570 0.03 MG | - | - | - | - | 1件: 49 49 💬 |
1621 | MEDI-570 0.1 MG | - | - | - | - | 1件: 49 49 💬 |
1622 | MEDI-570 0.3 MG | - | - | - | - | 1件: 49 49 💬 |
1623 | MEDROL - 4 MG COMPRESSE 30 COMPRESSE | - | - | - | - | 1件: 56 56 💬 |
1624 | Medrol 4 mg tablets | 1件: Methylprednisolone Methylprednisolone | 1件: Methylprednisolone
Methylprednisolone
💬 | 1件: NR3C1 NR3C1 💬 | 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 1件: 46 46 💬 |
1625 | MEDROL*10CPR DIV 4MG | 1件: Methylprednisolone Methylprednisolone | 1件: Methylprednisolone
Methylprednisolone
💬 | 1件: NR3C1 NR3C1 💬 | 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 1件: 222 222 💬 |
1626 | Melarsoprol 1.8 mg/kg/d, 10d + eflornithine 400 mg/kg/d, 7d | 2件: Eflornithine Eflornithine, Melarsoprol | 2件: Melarsoprol
Melarsoprol
,
Eflornithine
💬 | 1件: ODC1 ODC1 💬 | 3件: Arginine and proline metabolism Arginine and proline metabolism, Glutathione metabolism, Metabolic pathways 💬 | 1件: 65 65 💬 |
1627 | Melarsoprol 1.8 mg/kg/d, 10d + nifurtimox 15/20 mg/kg/d, 10d | 2件: Melarsoprol Melarsoprol, Nifurtimox | 2件: Melarsoprol
Melarsoprol
,
Nifurtimox
💬 | - | - | 1件: 65 65 💬 |
1628 | Meloxicam 0.125 mg/kg | 1件: Meloxicam Meloxicam | 1件: Meloxicam
Meloxicam
💬 | 1件: PTGS2 PTGS2 💬 | 22件: Alzheimer disease Alzheimer disease, Arachidonic acid metabolism, C-type lectin receptor signaling pathway, Chemical carcinogenesis - DNA adducts, Human cytomegalovirus infection, Human papillomavirus infection, IL-17 signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Metabolic pathways, MicroRNAs in cancer, NF-kappa B signaling pathway, Ovarian steroidogenesis, Oxytocin signaling pathway, Pathways in cancer, Pathways of neurodegeneration - multiple diseases, Regulation of lipolysis in adipocytes, Retrograde endocannabinoid signaling, Serotonergic synapse, Small cell lung cancer, TNF signaling pathway, VEGF signaling pathway 💬 | 1件: 46 46 💬 |
1629 | Meloxicam 0.25 mg/kg | 1件: Meloxicam Meloxicam | 1件: Meloxicam
Meloxicam
💬 | 1件: PTGS2 PTGS2 💬 | 22件: Alzheimer disease Alzheimer disease, Arachidonic acid metabolism, C-type lectin receptor signaling pathway, Chemical carcinogenesis - DNA adducts, Human cytomegalovirus infection, Human papillomavirus infection, IL-17 signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Metabolic pathways, MicroRNAs in cancer, NF-kappa B signaling pathway, Ovarian steroidogenesis, Oxytocin signaling pathway, Pathways in cancer, Pathways of neurodegeneration - multiple diseases, Regulation of lipolysis in adipocytes, Retrograde endocannabinoid signaling, Serotonergic synapse, Small cell lung cancer, TNF signaling pathway, VEGF signaling pathway 💬 | 1件: 46 46 💬 |
1630 | Mercaptopurine (Puri-Nethol) | 1件: Mercaptopurine Mercaptopurine | 2件: Mercaptopurine
Mercaptopurine
,
Mercaptopurine
💬 | 1件: HPRT1 HPRT1 💬 | 4件: Drug metabolism - other enzymes Drug metabolism - other enzymes, Metabolic pathways, Nucleotide metabolism, Purine metabolism 💬 | 1件: 97 97 💬 |
1631 | Mesalamine Delayed Release Tablets 400mg | 2件: Manganese citrate Manganese citrate, Mesalazine | 1件: Mesalamine
Mesalamine
💬 | - | - | 1件: 97 97 💬 |
1632 | Mesalazine (3,600 mg) | 1件: Mesalazine Mesalazine | 1件: Mesalamine
Mesalamine
💬 | - | - | 1件: 97 97 💬 |
1633 | Mesalazine 250Mg Tablet and nitazoxanide 500Mg Oral Tablet | 2件: Mesalazine Mesalazine, Nitazoxanide | 2件: Mesalamine
Mesalamine
,
Nitazoxanide
💬 | - | - | 1件: 97 97 💬 |
1634 | Mesalazine 4G Enema | 1件: Mesalazine Mesalazine | 1件: Mesalamine
Mesalamine
💬 | - | - | 1件: 97 97 💬 |
1635 | Mesencephalic Neuronal Precursor Cells | - | - | - | - | 1件: 6 6 💬 |
1636 | Mesenchymal stem cell 0.5 | - | - | - | - | 1件: 228 228 💬 |
1637 | Mesenchymal stem cell 1.0 | - | - | - | - | 1件: 228 228 💬 |
1638 | Metformin 500 Mg Oral Tablet, up to 4 tablets a day | 1件: Metformin Metformin | 1件: Metformin
Metformin
💬 | 2件: PRKAA1 PRKAA1, PRKAA2 💬 | 20件: AMPK signaling pathway AMPK signaling pathway, Adipocytokine signaling pathway, Alcoholic liver disease, Apelin signaling pathway, Autophagy - animal, Circadian rhythm, Fluid shear stress and atherosclerosis, FoxO signaling pathway, Glucagon signaling pathway, Hypertrophic cardiomyopathy, Insulin resistance, Insulin signaling pathway, Longevity regulating pathway, Longevity regulating pathway - multiple species, Non-alcoholic fatty liver disease, Oxytocin signaling pathway, PI3K-Akt signaling pathway, Thermogenesis, Tight junction, mTOR signaling pathway 💬 | 1件: 13 13 💬 |
1639 | Metformin/CP-690,550 | 1件: Metformin Metformin | 1件: Metformin
Metformin
💬 | 2件: PRKAA1 PRKAA1, PRKAA2 💬 | 20件: AMPK signaling pathway AMPK signaling pathway, Adipocytokine signaling pathway, Alcoholic liver disease, Apelin signaling pathway, Autophagy - animal, Circadian rhythm, Fluid shear stress and atherosclerosis, FoxO signaling pathway, Glucagon signaling pathway, Hypertrophic cardiomyopathy, Insulin resistance, Insulin signaling pathway, Longevity regulating pathway, Longevity regulating pathway - multiple species, Non-alcoholic fatty liver disease, Oxytocin signaling pathway, PI3K-Akt signaling pathway, Thermogenesis, Tight junction, mTOR signaling pathway 💬 | 1件: 46 46 💬 |
1640 | Metformine Sandoz 850 mg filmomhulde tabletten | 1件: Metformin Metformin | 1件: Metformin
Metformin
💬 | 2件: PRKAA1 PRKAA1, PRKAA2 💬 | 20件: AMPK signaling pathway AMPK signaling pathway, Adipocytokine signaling pathway, Alcoholic liver disease, Apelin signaling pathway, Autophagy - animal, Circadian rhythm, Fluid shear stress and atherosclerosis, FoxO signaling pathway, Glucagon signaling pathway, Hypertrophic cardiomyopathy, Insulin resistance, Insulin signaling pathway, Longevity regulating pathway, Longevity regulating pathway - multiple species, Non-alcoholic fatty liver disease, Oxytocin signaling pathway, PI3K-Akt signaling pathway, Thermogenesis, Tight junction, mTOR signaling pathway 💬 | 1件: 81 81 💬 |
1641 | METHOTREXATE - 20 MG/0.8 ML SOLUZIONE INIETTABILE 4 SIRINGHE PRERIEMPITE MONOUSO DA 1.25 ML | 1件: Methotrexate Methotrexate | 1件: Methotrexate
Methotrexate
💬 | 2件: DHFR DHFR, DHFR2 💬 | 5件: Antifolate resistance Antifolate resistance, Biosynthesis of cofactors, Folate biosynthesis, Metabolic pathways, One carbon pool by folate 💬 | 1件: 96 96 💬 |
1642 | Methotrexate plus ERB-041 for 12 weeks | 1件: Methotrexate Methotrexate | 1件: Methotrexate
Methotrexate
💬 | 2件: DHFR DHFR, DHFR2 💬 | 5件: Antifolate resistance Antifolate resistance, Biosynthesis of cofactors, Folate biosynthesis, Metabolic pathways, One carbon pool by folate 💬 | 1件: 46 46 💬 |
1643 | Methotrexate(MTX) administration is at the discretion of the rheumatologist and no tradename is fixed by the protocol | 1件: Methotrexate Methotrexate | 1件: Methotrexate
Methotrexate
💬 | 2件: DHFR DHFR, DHFR2 💬 | 5件: Antifolate resistance Antifolate resistance, Biosynthesis of cofactors, Folate biosynthesis, Metabolic pathways, One carbon pool by folate 💬 | 1件: 46 46 💬 |
1644 | Methotrexate(MTX) administration is at the discretion of the rheumatologist and no tradename is fixed by the protocol. | 1件: Methotrexate Methotrexate | 1件: Methotrexate
Methotrexate
💬 | 2件: DHFR DHFR, DHFR2 💬 | 5件: Antifolate resistance Antifolate resistance, Biosynthesis of cofactors, Folate biosynthesis, Metabolic pathways, One carbon pool by folate 💬 | 1件: 46 46 💬 |
1645 | Methotrexate(necessary) | 1件: Methotrexate Methotrexate | 1件: Methotrexate
Methotrexate
💬 | 2件: DHFR DHFR, DHFR2 💬 | 5件: Antifolate resistance Antifolate resistance, Biosynthesis of cofactors, Folate biosynthesis, Metabolic pathways, One carbon pool by folate 💬 | 1件: 46 46 💬 |
1646 | METHOTREXATE*10MG/1,33ML 4S | 1件: Methotrexate Methotrexate | 1件: Methotrexate
Methotrexate
💬 | 2件: DHFR DHFR, DHFR2 💬 | 5件: Antifolate resistance Antifolate resistance, Biosynthesis of cofactors, Folate biosynthesis, Metabolic pathways, One carbon pool by folate 💬 | 1件: 46 46 💬 |
1647 | METHOTREXATE*15MG/2ML 4SIR | 1件: Methotrexate Methotrexate | 1件: Methotrexate
Methotrexate
💬 | 2件: DHFR DHFR, DHFR2 💬 | 5件: Antifolate resistance Antifolate resistance, Biosynthesis of cofactors, Folate biosynthesis, Metabolic pathways, One carbon pool by folate 💬 | 1件: 46 46 💬 |
1648 | METHOTREXATE*20MG/2,66ML 4S | 1件: Methotrexate Methotrexate | 1件: Methotrexate
Methotrexate
💬 | 2件: DHFR DHFR, DHFR2 💬 | 5件: Antifolate resistance Antifolate resistance, Biosynthesis of cofactors, Folate biosynthesis, Metabolic pathways, One carbon pool by folate 💬 | 1件: 46 46 💬 |
1649 | METHOTREXATE*7,5MG/ML 4SIR. | 1件: Methotrexate Methotrexate | 1件: Methotrexate
Methotrexate
💬 | 2件: DHFR DHFR, DHFR2 💬 | 5件: Antifolate resistance Antifolate resistance, Biosynthesis of cofactors, Folate biosynthesis, Metabolic pathways, One carbon pool by folate 💬 | 1件: 46 46 💬 |
1650 | Methyl 1-[N6-(3-iodobenzyl)-adenin-9-yl]-beta-Dribofuronamide | 1件: Adenine Adenine | 1件: Adenine
Adenine
💬 | - | - | 1件: 46 46 💬 |
1651 | Methyl 1-[N6-(3-iodobenzyl)-adenin-9-yl]-ß-Dribofuronamide | 1件: Adenine Adenine | 1件: Adenine
Adenine
💬 | - | - | 1件: 46 46 💬 |
1652 | Methyl 4,6-diamino-2-[1-(2-fluorobenzyl)-1H-pyrazolo | - | - | - | - | 1件: 86 86 💬 |
1653 | Methyl 4,6-diamino-2-[1-(2-fluorobenzyl)-1H-pyrazolo [3,4-b]pyridine-3-yl]-5-pyrimidinyl(methyl)carb | - | - | - | - | 2件: 86 86, 88 💬 |
1654 | Methyl [4,6-diamino-2-[1-[(2-fluorophenyl)methyl]-1H-pyrazolo[3,4-b]pyridin-3-yl]-5-pyrimidinyl]meth | - | - | - | - | 2件: 86 86, 88 💬 |
1655 | Methylphenidate modified release 40 mg | 1件: Methylphenidate Methylphenidate | 1件: Methylphenidate
Methylphenidate
💬 | 2件: SLC6A2 SLC6A2, SLC6A3 💬 | 7件: Alcoholism Alcoholism, Amphetamine addiction, Cocaine addiction, Dopaminergic synapse, Parkinson disease, Pathways of neurodegeneration - multiple diseases, Synaptic vesicle cycle 💬 | 1件: 13 13 💬 |
1656 | Methylprednisolon-21-hydrogensuccinat, Natriumsalz | 1件: Methylprednisolone Methylprednisolone | 1件: Methylprednisolone
Methylprednisolone
💬 | 1件: NR3C1 NR3C1 💬 | 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 1件: 13 13 💬 |
1657 | METHYLPREDNISOLONE MYLAN Générique | 1件: Methylprednisolone Methylprednisolone | 1件: Methylprednisolone
Methylprednisolone
💬 | 1件: NR3C1 NR3C1 💬 | 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 1件: 66 66 💬 |
1658 | Methylprednisoloni natrii succinas | - | - | - | - | 1件: 50 50 💬 |
1659 | MetoHEXAL® Succ ® 47,5 mg Retardtabletten | - | - | - | - | 1件: 113 113 💬 |
1660 | MH004 Ia(0.1%) | - | - | - | - | 1件: 46 46 💬 |
1661 | MH004 Ia(0.3%) | - | - | - | - | 1件: 46 46 💬 |
1662 | MH004 Ib-1(0.1%) | - | - | - | - | 1件: 46 46 💬 |
1663 | MH004 Ib-1(0.3%) | - | - | - | - | 1件: 46 46 💬 |
1664 | MH004 Ib-2(0.3%) | - | - | - | - | 1件: 46 46 💬 |
1665 | MIB-626 | - | - | - | - | 1件: 18 18 💬 |
1666 | Minibody against CD8 conjugated to desferrioxamine labeled with zirconium Zr 89 | 1件: Deferoxamine Deferoxamine | 1件: Deferoxamine
Deferoxamine
💬 | - | - | 2件: 51 51, 53 💬 |
1667 | MIRAPEXIN*30CPR 0,7MG | 1件: Pramipexole Pramipexole | 1件: Pramipexole
Pramipexole
💬 | 3件: DRD2 DRD2, DRD3, DRD4 💬 | 8件: Alcoholism Alcoholism, Cocaine addiction, Dopaminergic synapse, Gap junction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway 💬 | 1件: 6 6 💬 |
1668 | Mirdametinib (PD-0325901) oral capsule or dispersible tablet | 1件: Mirdametinib Mirdametinib | 1件: Mirdametinib
Mirdametinib
💬 | 2件: MAP2K1 MAP2K1, MAP2K2 💬 | 89件: Acute myeloid leukemia Acute myeloid leukemia, Alcoholism, Alzheimer disease, Apelin signaling pathway, Apoptosis, Autophagy - animal, B cell receptor signaling pathway, Bladder cancer, Breast cancer, Cellular senescence, Central carbon metabolism in cancer, Chemical carcinogenesis - reactive oxygen species, Chemical carcinogenesis - receptor activation, Chemokine signaling pathway, Choline metabolism in cancer, Cholinergic synapse, Chronic myeloid leukemia, Colorectal cancer, Cushing syndrome, EGFR tyrosine kinase inhibitor resistance, Endocrine resistance, Endometrial cancer, ErbB signaling pathway, Estrogen signaling pathway, Fc epsilon RI signaling pathway, Fc gamma R-mediated phagocytosis, Focal adhesion, FoxO signaling pathway, Gap junction, Gastric cancer, Glioma, GnRH secretion, GnRH signaling pathway, Growth hormone synthesis, secretion and action, HIF-1 signaling pathway, Hepatitis B, Hepatitis C, Hepatocellular carcinoma, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Influenza A, Insulin signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Long-term depression, Long-term potentiation, MAPK signaling pathway, Melanogenesis, Melanoma, MicroRNAs in cancer, Natural killer cell mediated cytotoxicity, Neurotrophin signaling pathway, Neutrophil extracellular trap formation, Non-small cell lung cancer, Oocyte meiosis, Osteoclast differentiation, Oxytocin signaling pathway, PD-L1 expression and PD-1 checkpoint pathway in cancer, PI3K-Akt signaling pathway, Pancreatic cancer, Parathyroid hormone synthesis, secretion and action, Pathways in cancer, Pathways of neurodegeneration - multiple diseases, Phospholipase D signaling pathway, Progesterone-mediated oocyte maturation, Prolactin signaling pathway, Prostate cancer, Proteoglycans in cancer, Rap1 signaling pathway, Ras signaling pathway, Regulation of actin cytoskeleton, Relaxin signaling pathway, Renal cell carcinoma, Salmonella infection, Serotonergic synapse, Signaling pathways regulating pluripotency of stem cells, Sphingolipid signaling pathway, T cell receptor signaling pathway, TNF signaling pathway, Thyroid cancer, Thyroid hormone signaling pathway, Toll-like receptor signaling pathway, VEGF signaling pathway, Vascular smooth muscle contraction, Yersinia infection, cAMP signaling pathway, cGMP-PKG signaling pathway, mTOR signaling pathway 💬 | 1件: 34 34 💬 |
1669 | MK-0653 | - | - | - | - | 1件: 260 260 💬 |
1670 | MK-0663 | - | - | - | - | 2件: 46 46, 271 💬 |
1671 | MK-0859 | - | - | - | - | 1件: 79 79 💬 |
1672 | MK-0873 | 1件: MK-0873 MK-0873 | - | - | - | 1件: 46 46 💬 |
1673 | MK-4836 | - | - | - | - | 2件: 86 86, 88 💬 |
1674 | MK-6194 | - | - | - | - | 1件: 97 97 💬 |
1675 | MK-8259 | - | - | - | - | 1件: 97 97 💬 |
1676 | MK-8457 | - | - | - | - | 1件: 46 46 💬 |
1677 | MK-8457 (free acid) | - | - | - | - | 1件: 46 46 💬 |
1678 | MK-8457 100 mg | - | - | - | - | 1件: 46 46 💬 |
1679 | MK-8808 | - | - | - | - | 1件: 46 46 💬 |
1680 | MK-8892 | - | - | - | - | 1件: 86 86 💬 |
1681 | MM-093 | 1件: MM-093 MM-093 | - | - | - | 1件: 46 46 💬 |
1682 | MN-001 | - | - | - | - | 1件: 226 226 💬 |
1683 | MN-001 BID | - | - | - | - | 1件: 226 226 💬 |
1684 | MN-08 24 mg/day | - | - | - | - | 1件: 86 86 💬 |
1685 | MN-08 60 mg/day | - | - | - | - | 1件: 86 86 💬 |
1686 | MOD-4023 | - | - | - | - | 1件: 78 78 💬 |
1687 | Modified Oral Glucose Tolerance Test (50g 4-hours) | 1件: Dextrose, unspecified form Dextrose, unspecified form | - | - | - | 1件: 299 299 💬 |
1688 | Modified recombinant human C-type natriuretic peptide | - | - | - | - | 1件: 276 276 💬 |
1689 | Modopar 62,5 | - | - | - | - | 1件: 6 6 💬 |
1690 | MODULEN IBD (R) (specific Enteral Nutrition) | - | - | - | - | 1件: 96 96 💬 |
1691 | Molgramostim 300 mcg nebuliser solution | 1件: Molgramostim Molgramostim | 1件: Molgramostim
Molgramostim
💬 | 1件: CSF2RA CSF2RA 💬 | 4件: Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, Hematopoietic cell lineage, JAK-STAT signaling pathway, Pathways in cancer 💬 | 1件: 229 229 💬 |
1692 | Molgramostim 300 µg nebulizer solution | 1件: Molgramostim Molgramostim | 1件: Molgramostim
Molgramostim
💬 | 1件: CSF2RA CSF2RA 💬 | 4件: Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, Hematopoietic cell lineage, JAK-STAT signaling pathway, Pathways in cancer 💬 | 1件: 229 229 💬 |
1693 | Molgramostim Nebuliser solution 300 mcg | 1件: Molgramostim Molgramostim | 1件: Molgramostim
Molgramostim
💬 | 1件: CSF2RA CSF2RA 💬 | 4件: Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, Hematopoietic cell lineage, JAK-STAT signaling pathway, Pathways in cancer 💬 | 1件: 229 229 💬 |
1694 | Molgramostim nebulizer solution | 1件: Molgramostim Molgramostim | 1件: Molgramostim
Molgramostim
💬 | 1件: CSF2RA CSF2RA 💬 | 4件: Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, Hematopoietic cell lineage, JAK-STAT signaling pathway, Pathways in cancer 💬 | 1件: 299 299 💬 |
1695 | Mono Nuclear Cell (MNC) transplantation | - | - | - | - | 1件: 57 57 💬 |
1696 | MORAb-022 | - | - | - | - | 1件: 46 46 💬 |
1697 | MORF-057 | - | - | - | - | 1件: 97 97 💬 |
1698 | Moxifloxacin 400 mg | 1件: Moxifloxacin Moxifloxacin | 1件: Moxifloxacin
Moxifloxacin
💬 | - | - | 1件: 86 86 💬 |
1699 | MP-435(dose1) + Methotrexate | 1件: Methotrexate Methotrexate | 1件: Methotrexate
Methotrexate
💬 | 2件: DHFR DHFR, DHFR2 💬 | 5件: Antifolate resistance Antifolate resistance, Biosynthesis of cofactors, Folate biosynthesis, Metabolic pathways, One carbon pool by folate 💬 | 1件: 46 46 💬 |
1700 | MR-MC-01 | - | - | - | - | 1件: 226 226 💬 |
1701 | MRA 003 US | - | - | - | - | 1件: 49 49 💬 |
1702 | MRNA che codifica l’enzima umano deramificante del glicogeno formulato in una nanopaticella lipidica | - | - | - | - | 1件: 257 257 💬 |
1703 | MRNA encoding the human glycogen debranching enzyme formulated in a lipid nanoparticle delivery | - | - | - | - | 1件: 257 257 💬 |
1704 | MSC injection 01 | - | - | - | - | 1件: 96 96 💬 |
1705 | MSC injection 02 | - | - | - | - | 1件: 96 96 💬 |
1706 | MSC treatment 01 | - | - | - | - | 1件: 96 96 💬 |
1707 | MSC treatment 02 | - | - | - | - | 1件: 96 96 💬 |
1708 | MSC-NTF cells transplantation (IM) | - | - | - | - | 1件: 2 2 💬 |
1709 | MSC-NTF cells transplantation (IT) | - | - | - | - | 1件: 2 2 💬 |
1710 | MSC2430913A or ONO-4641 (to be used as synonyms) | - | - | - | - | 1件: 13 13 💬 |
1711 | MSTC-001 (MS-STAT) | - | - | - | - | 1件: 13 13 💬 |
1712 | MT-1303 [0.1] | - | - | - | - | 1件: 13 13 💬 |
1713 | MT-1303 [0.2] | - | - | - | - | 1件: 13 13 💬 |
1714 | MT-1303 [0.4] | - | - | - | - | 1件: 13 13 💬 |
1715 | MTC TRx0014-001 capsules | - | - | - | - | 1件: 127 127 💬 |
1716 | Multiple (4 autologous subcutaneous T cell vaccinations with T cell lines reactive to nine myelin peptides) | 1件: Myelin basic protein Myelin basic protein | - | - | - | 1件: 13 13 💬 |
1717 | MXB-8025 | - | - | - | - | 1件: 93 93 💬 |
1718 | Mycophenolat-Natrium | - | - | - | - | 1件: 66 66 💬 |
1719 | Mycophénolate mofétil | - | - | - | - | 1件: 44 44 💬 |
1720 | MYELOSTIM - 34 1 FLACONCINO LIOFILIZZATO 33.6 MIU + SIRINGA PRERIEMPITA SOLVENTE 1 ML | - | - | - | - | 2件: 19 19, 65 💬 |
1721 | MYK-461 | - | - | - | - | 1件: 58 58 💬 |
1722 | MYO-029 | 1件: Stamulumab Stamulumab | 1件: Stamulumab
Stamulumab
💬 | 1件: MSTN MSTN 💬 | 1件: Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction 💬 | 1件: 113 113 💬 |
1723 | N(4,5Bis methanesulfonyl2methylbenzoyl) guanidine hydrochloride monohydrate | 1件: Guanidine Guanidine | - | - | - | 1件: 113 113 💬 |
1724 | N,N,N',N'-tetramethyl-10H-phenothiazine-3,7-diaminium bis(methanesulfonate) | 1件: Phenothiazine Phenothiazine | 1件: Phenothiazine
Phenothiazine
💬 | - | - | 1件: 127 127 💬 |
1725 | N,N,N?,N?-tetramethyl-10H-phenothiazine-3,7-diaminium bis(methanesulfonate) | 1件: Phenothiazine Phenothiazine | 1件: Phenothiazine
Phenothiazine
💬 | - | - | 1件: 127 127 💬 |
1726 | N,N,N’,N’-tetramethyl-10H-phenothiazine-3,7-diaminium bis(methanesulfonate) | 1件: Phenothiazine Phenothiazine | 1件: Phenothiazine
Phenothiazine
💬 | - | - | 1件: 127 127 💬 |
1727 | N-(4,5-Bis methanesulfonyl-2-methyl-benzoyl)guanidine hydrochloride monohydrate | 1件: Guanidine Guanidine | - | - | - | 1件: 113 113 💬 |
1728 | N-(5-hydroxy-2,4- bis(trimethylsilyl)phenyl)-4-oxo- 1,4-dihydroquinoline-3-carboxamide | - | - | - | - | 1件: 299 299 💬 |
1729 | N-(5-hydroxy-2,4-bis(trimethylsilyl)phenyl)-4-oxo-1,4-dihydroquinoline-3-carboxamide | - | - | - | - | 1件: 299 299 💬 |
1730 | N-(5-{4-[(3,3-dimethyl-1-azetidinyl)carbonyl]phenyl}[1,2,4]triazolo[1,5-a]pyridin-2-yl)cyclopropanecarboxamide | - | - | - | - | 1件: 49 49 💬 |
1731 | N-(trans-3-(5-((R)-1-hydroxyethyl)-1,3,4-oxadiazol-2-yl)cyclobutyl)-3-phenylisoxazole-5-carboxamide | - | - | - | - | 1件: 299 299 💬 |
1732 | N-0923 | - | - | - | - | 1件: 6 6 💬 |
1733 | N-[1-((5-cyanopyridin-2-yl)methyl)-1H-pyrazol-3-yl]-2-[4-(1-(trifluoromethyl)cyclopropyl)phenyl]acetamide | 2件: Acetamide Acetamide, Pyrazole | - | - | - | 1件: 154 154 💬 |
1734 | N-Acetyl Cysteine (NAC) | 1件: Cysteine Cysteine | - | - | - | 1件: 90 90 💬 |
1735 | N-acetylcysteine (NAC) | 1件: Acetylcysteine Acetylcysteine | 1件: Acetylcysteine
Acetylcysteine
💬 | - | - | 2件: 51 51, 299 💬 |
1736 | N-Acetylcysteine, (NAC) | 1件: Acetylcysteine Acetylcysteine | 1件: Acetylcysteine
Acetylcysteine
💬 | - | - | 1件: 85 85 💬 |
1737 | N-acetylgalactosamine 4-sulfatase | - | - | - | - | 1件: 19 19 💬 |
1738 | N-methyl D-(2,3,4,5,6-pentahydroxy-hexyl)-ammonium | - | - | - | - | 1件: 28 28 💬 |
1739 | N-methyl-3-phenyl-3-[4-(trifluoromethyl)phenoxy]propan-1-amine | - | - | - | - | 1件: 13 13 💬 |
1740 | N-trans-3-Hexenoyl] Human Growth Hormone Releasing Factor (1-44) Acetate | 2件: Acetate Acetate, Somatotropin | - | - | - | 1件: 265 265 💬 |
1741 | N-{4-Chloro-2-[(1-oxido-4-pyridinyl)carbonyl]phenyl}-4-(1,1-dimethylethyl)benzenesulfonamide, sodium | - | - | - | - | 1件: 96 96 💬 |
1742 | N-{4-Chloro-2-[(1-oxido-4-pyridinyl)carbonyl]phenyl}-4-(1,1-dimethylethyl)benzenesulfonamidesodium | - | - | - | - | 1件: 96 96 💬 |
1743 | N1,N3-BIS(2-MERCAPTOETHYL) ISOPHTHALAMIDE | - | - | - | - | 2件: 5 5, 17 💬 |
1744 | Nab-sirolimus (also known as ABI-009, nab-rapamycin, albumin-bound rapamycin) | 1件: Sirolimus Sirolimus | 1件: Sirolimus
Sirolimus
💬 | 1件: MTOR MTOR 💬 | 51件: AMPK signaling pathway AMPK signaling pathway, Acute myeloid leukemia, Adipocytokine signaling pathway, Alzheimer disease, Amyotrophic lateral sclerosis, Apelin signaling pathway, Autophagy - animal, Autophagy - other, Breast cancer, Cellular senescence, Central carbon metabolism in cancer, Chemical carcinogenesis - receptor activation, Choline metabolism in cancer, Colorectal cancer, Diabetic cardiomyopathy, EGFR tyrosine kinase inhibitor resistance, Endocrine resistance, ErbB signaling pathway, Gastric cancer, Glioma, Growth hormone synthesis, secretion and action, HIF-1 signaling pathway, Hepatocellular carcinoma, Herpes simplex virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Huntington disease, Insulin resistance, Insulin signaling pathway, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Longevity regulating pathway, Longevity regulating pathway - multiple species, MicroRNAs in cancer, Neutrophil extracellular trap formation, PD-L1 expression and PD-1 checkpoint pathway in cancer, PI3K-Akt signaling pathway, Pancreatic cancer, Pathways in cancer, Pathways of neurodegeneration - multiple diseases, Phospholipase D signaling pathway, Prostate cancer, Proteoglycans in cancer, Shigellosis, Spinocerebellar ataxia, Th17 cell differentiation, Thermogenesis, Thyroid hormone signaling pathway, Type II diabetes mellitus, mTOR signaling pathway 💬 | 1件: 86 86 💬 |
1745 | Nabilone 0.25 mg | 1件: Nabilone Nabilone | 1件: Nabilone
Nabilone
💬 | 2件: CNR1 CNR1, CNR2 💬 | 4件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Rap1 signaling pathway, Retrograde endocannabinoid signaling, Thermogenesis 💬 | 1件: 6 6 💬 |
1746 | NaCl 0.9% | - | - | - | - | 1件: 39 39 💬 |
1747 | NAND (Neoandrographolide) | - | - | - | - | 1件: 97 97 💬 |
1748 | Naproxen (EC-Narosyn) Delayed Release Tables, 375 (Syntex (USA), Inc.) | 1件: Naproxen Naproxen | 1件: Naproxen
Naproxen
💬 | 2件: PTGS1 PTGS1, PTGS2 💬 | 23件: Alzheimer disease Alzheimer disease, Arachidonic acid metabolism, C-type lectin receptor signaling pathway, Chemical carcinogenesis - DNA adducts, Human cytomegalovirus infection, Human papillomavirus infection, IL-17 signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Metabolic pathways, MicroRNAs in cancer, NF-kappa B signaling pathway, Ovarian steroidogenesis, Oxytocin signaling pathway, Pathways in cancer, Pathways of neurodegeneration - multiple diseases, Platelet activation, Regulation of lipolysis in adipocytes, Retrograde endocannabinoid signaling, Serotonergic synapse, Small cell lung cancer, TNF signaling pathway, VEGF signaling pathway 💬 | 1件: 46 46 💬 |
1749 | Natalizumab (NTZ) | 1件: Natalizumab Natalizumab | 1件: Natalizumab
Natalizumab
💬 | 1件: ITGA4 ITGA4 💬 | 14件: Arrhythmogenic right ventricular cardiomyopathy Arrhythmogenic right ventricular cardiomyopathy, Cell adhesion molecules, Dilated cardiomyopathy, ECM-receptor interaction, Focal adhesion, Hematopoietic cell lineage, Human papillomavirus infection, Hypertrophic cardiomyopathy, Intestinal immune network for IgA production, Leishmaniasis, Leukocyte transendothelial migration, PI3K-Akt signaling pathway, Regulation of actin cytoskeleton, Yersinia infection 💬 | 1件: 13 13 💬 |
1750 | National Drug Code: 59762-0074 | - | - | - | - | 1件: 81 81 💬 |
1751 | NATPARA/NATPAR | 1件: Parathyroid hormone Parathyroid hormone | 1件: Parathyroid hormone
Parathyroid hormone
💬 | 2件: PTH1R PTH1R, PTH2R 💬 | 3件: Endocrine and other factor-regulated calcium reabsorption Endocrine and other factor-regulated calcium reabsorption, Neuroactive ligand-receptor interaction, Parathyroid hormone synthesis, secretion and action 💬 | 1件: 235 235 💬 |
1752 | Natriumchlorid 0,9 % | 1件: Sodium chloride Sodium chloride | 1件: Sodium chloride
Sodium chloride
💬 | - | - | 1件: 288 288 💬 |
1753 | NBI-827104 | - | - | - | - | 1件: 154 154 💬 |
1754 | NBT-NM108 | - | - | - | - | 1件: 193 193 💬 |
1755 | NBT-NM108 (60 g/day) | - | - | - | - | 1件: 13 13 💬 |
1756 | NBTX-001 | - | - | - | - | 1件: 6 6 💬 |
1757 | NDC0009-0436-01 | - | - | - | - | 1件: 78 78 💬 |
1758 | NEB/01-07 | - | - | - | - | 1件: 299 299 💬 |
1759 | Nebido® Testosterone Undecanoate 1000 Mg/4 mL Solution for Injection | 3件: Testosterone Testosterone, Testosterone undecanoate, Undecanoic acid | 2件: Testosterone
Testosterone
,
Testosterone undecanoate
💬 | 1件: AR AR 💬 | 4件: Chemical carcinogenesis - receptor activation Chemical carcinogenesis - receptor activation, Oocyte meiosis, Pathways in cancer, Prostate cancer 💬 | 1件: 13 13 💬 |
1760 | Nebulization of Amikacin during NIV (RR: 15 cycles/minute) | 1件: Amikacin Amikacin | 1件: Amikacin
Amikacin
💬 | - | - | 1件: 299 299 💬 |
1761 | Nebulization of Amikacin during NIV (RR: 25 cycles/minute) | 1件: Amikacin Amikacin | 1件: Amikacin
Amikacin
💬 | - | - | 1件: 299 299 💬 |
1762 | NEUPRO 4 mg/24 h parche transdérmico | 1件: Rotigotine Rotigotine | 1件: Rotigotine
Rotigotine
💬 | 1件: DRD2 DRD2 💬 | 8件: Alcoholism Alcoholism, Cocaine addiction, Dopaminergic synapse, Gap junction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway 💬 | 1件: 6 6 💬 |
1763 | Neupro 4 mg/24 h transdermal patch | 1件: Rotigotine Rotigotine | 1件: Rotigotine
Rotigotine
💬 | 1件: DRD2 DRD2 💬 | 8件: Alcoholism Alcoholism, Cocaine addiction, Dopaminergic synapse, Gap junction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway 💬 | 1件: 6 6 💬 |
1764 | Neupro 4mg/24 h transdermal patch | 1件: Rotigotine Rotigotine | 1件: Rotigotine
Rotigotine
💬 | 1件: DRD2 DRD2 💬 | 8件: Alcoholism Alcoholism, Cocaine addiction, Dopaminergic synapse, Gap junction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway 💬 | 1件: 6 6 💬 |
1765 | Neupro 4mg/24h transdermal patch | 1件: Rotigotine Rotigotine | 1件: Rotigotine
Rotigotine
💬 | 1件: DRD2 DRD2 💬 | 8件: Alcoholism Alcoholism, Cocaine addiction, Dopaminergic synapse, Gap junction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway 💬 | 1件: 6 6 💬 |
1766 | Neupro 4Mg/24Hr Transdermal Patch | 1件: Rotigotine Rotigotine | 1件: Rotigotine
Rotigotine
💬 | 1件: DRD2 DRD2 💬 | 8件: Alcoholism Alcoholism, Cocaine addiction, Dopaminergic synapse, Gap junction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway 💬 | 1件: 6 6 💬 |
1767 | NEUPRO 6 mg/24 h parche transdérmico | 1件: Rotigotine Rotigotine | 1件: Rotigotine
Rotigotine
💬 | 1件: DRD2 DRD2 💬 | 8件: Alcoholism Alcoholism, Cocaine addiction, Dopaminergic synapse, Gap junction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway 💬 | 1件: 6 6 💬 |
1768 | Neupro 6 mg/24 h transdermal patch | 1件: Rotigotine Rotigotine | 1件: Rotigotine
Rotigotine
💬 | 1件: DRD2 DRD2 💬 | 8件: Alcoholism Alcoholism, Cocaine addiction, Dopaminergic synapse, Gap junction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway 💬 | 1件: 6 6 💬 |
1769 | Neupro 6mg/24 h transdermal patch | 1件: Rotigotine Rotigotine | 1件: Rotigotine
Rotigotine
💬 | 1件: DRD2 DRD2 💬 | 8件: Alcoholism Alcoholism, Cocaine addiction, Dopaminergic synapse, Gap junction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway 💬 | 1件: 6 6 💬 |
1770 | Neupro 6mg/24h transdermal patch | 1件: Rotigotine Rotigotine | 1件: Rotigotine
Rotigotine
💬 | 1件: DRD2 DRD2 💬 | 8件: Alcoholism Alcoholism, Cocaine addiction, Dopaminergic synapse, Gap junction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway 💬 | 1件: 6 6 💬 |
1771 | NEUPRO 8 mg/24 h parche transdérmico | 1件: Rotigotine Rotigotine | 1件: Rotigotine
Rotigotine
💬 | 1件: DRD2 DRD2 💬 | 8件: Alcoholism Alcoholism, Cocaine addiction, Dopaminergic synapse, Gap junction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway 💬 | 1件: 6 6 💬 |
1772 | Neupro 8 mg/24 h transdermal patch | 1件: Rotigotine Rotigotine | 1件: Rotigotine
Rotigotine
💬 | 1件: DRD2 DRD2 💬 | 8件: Alcoholism Alcoholism, Cocaine addiction, Dopaminergic synapse, Gap junction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway 💬 | 1件: 6 6 💬 |
1773 | Neupro 8mg/24h transdermal patch | 1件: Rotigotine Rotigotine | 1件: Rotigotine
Rotigotine
💬 | 1件: DRD2 DRD2 💬 | 8件: Alcoholism Alcoholism, Cocaine addiction, Dopaminergic synapse, Gap junction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway 💬 | 1件: 6 6 💬 |
1774 | NEUPRO*28CER 4MG/24H | 1件: Rotigotine Rotigotine | 1件: Rotigotine
Rotigotine
💬 | 1件: DRD2 DRD2 💬 | 8件: Alcoholism Alcoholism, Cocaine addiction, Dopaminergic synapse, Gap junction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway 💬 | 1件: 6 6 💬 |
1775 | NEUPRO*28CER 6MG/24H | 1件: Rotigotine Rotigotine | 1件: Rotigotine
Rotigotine
💬 | 1件: DRD2 DRD2 💬 | 8件: Alcoholism Alcoholism, Cocaine addiction, Dopaminergic synapse, Gap junction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway 💬 | 1件: 6 6 💬 |
1776 | NEUPRO*28CER 8MG/24H | 1件: Rotigotine Rotigotine | 1件: Rotigotine
Rotigotine
💬 | 1件: DRD2 DRD2 💬 | 8件: Alcoholism Alcoholism, Cocaine addiction, Dopaminergic synapse, Gap junction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway 💬 | 1件: 6 6 💬 |
1777 | NEUPRO*7CER 4MG/24H | 1件: Rotigotine Rotigotine | 1件: Rotigotine
Rotigotine
💬 | 1件: DRD2 DRD2 💬 | 8件: Alcoholism Alcoholism, Cocaine addiction, Dopaminergic synapse, Gap junction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway 💬 | 1件: 6 6 💬 |
1778 | NEUPRO*7CER 6MG/24H | 1件: Rotigotine Rotigotine | 1件: Rotigotine
Rotigotine
💬 | 1件: DRD2 DRD2 💬 | 8件: Alcoholism Alcoholism, Cocaine addiction, Dopaminergic synapse, Gap junction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway 💬 | 1件: 6 6 💬 |
1779 | NEUPRO*7CER 8MG/24H | 1件: Rotigotine Rotigotine | 1件: Rotigotine
Rotigotine
💬 | 1件: DRD2 DRD2 💬 | 8件: Alcoholism Alcoholism, Cocaine addiction, Dopaminergic synapse, Gap junction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway 💬 | 1件: 6 6 💬 |
1780 | Neupro® 8 mg/24 h | 1件: Rotigotine Rotigotine | 1件: Rotigotine
Rotigotine
💬 | 1件: DRD2 DRD2 💬 | 8件: Alcoholism Alcoholism, Cocaine addiction, Dopaminergic synapse, Gap junction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway 💬 | 1件: 6 6 💬 |
1781 | Nexavar (BAY 43-9006) (Sorafenib) | 1件: Sorafenib Sorafenib | 1件: Sorafenib
Sorafenib
💬 | 8件: BRAF BRAF, FLT3, FLT4, KDR, KIT, PDGFRB, RAF1, RET 💬 | 89件: Acute myeloid leukemia Acute myeloid leukemia, Alcoholism, Alzheimer disease, Apelin signaling pathway, Apoptosis, Autophagy - animal, Axon guidance, B cell receptor signaling pathway, Bladder cancer, Breast cancer, C-type lectin receptor signaling pathway, Calcium signaling pathway, Cellular senescence, Central carbon metabolism in cancer, Chemical carcinogenesis - reactive oxygen species, Chemical carcinogenesis - receptor activation, Chemokine signaling pathway, Choline metabolism in cancer, Chronic myeloid leukemia, Colorectal cancer, Cushing syndrome, EGFR tyrosine kinase inhibitor resistance, Endocrine resistance, Endometrial cancer, ErbB signaling pathway, Estrogen signaling pathway, Fc epsilon RI signaling pathway, Fc gamma R-mediated phagocytosis, Fluid shear stress and atherosclerosis, Focal adhesion, FoxO signaling pathway, Gap junction, Gastric cancer, Glioma, GnRH secretion, GnRH signaling pathway, Growth hormone synthesis, secretion and action, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Hepatocellular carcinoma, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Influenza A, Insulin signaling pathway, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Long-term depression, Long-term potentiation, MAPK signaling pathway, Melanogenesis, Melanoma, MicroRNAs in cancer, Natural killer cell mediated cytotoxicity, Neurotrophin signaling pathway, Neutrophil extracellular trap formation, Non-small cell lung cancer, Oxytocin signaling pathway, PD-L1 expression and PD-1 checkpoint pathway in cancer, PI3K-Akt signaling pathway, Pancreatic cancer, Parathyroid hormone synthesis, secretion and action, Pathways in cancer, Pathways of neurodegeneration - multiple diseases, Phospholipase D signaling pathway, Progesterone-mediated oocyte maturation, Prolactin signaling pathway, Prostate cancer, Proteoglycans in cancer, Rap1 signaling pathway, Ras signaling pathway, Regulation of actin cytoskeleton, Relaxin signaling pathway, Renal cell carcinoma, Salmonella infection, Serotonergic synapse, Signaling pathways regulating pluripotency of stem cells, Sphingolipid signaling pathway, T cell receptor signaling pathway, Thyroid cancer, Thyroid hormone signaling pathway, Transcriptional misregulation in cancer, Tuberculosis, VEGF signaling pathway, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway, mTOR signaling pathway 💬 | 1件: 34 34 💬 |
1782 | NI-0101 | - | - | - | - | 1件: 46 46 💬 |
1783 | NI-03 | - | - | - | - | 1件: 298 298 💬 |
1784 | NI-0401 (anti-CD3 mAB) | 1件: Muromonab Muromonab | - | - | - | 1件: 96 96 💬 |
1785 | NI-0501 | - | - | - | - | 1件: 107 107 💬 |
1786 | NI-071 | - | - | - | - | 1件: 46 46 💬 |
1787 | NI-0801 | - | - | - | - | 1件: 93 93 💬 |
1788 | Nicotine Nasal Spray 10 MG/ML (0.5 MG/SPRAY) | 1件: Nicotine Nicotine | 1件: Nicotine
Nicotine
💬 | 16件: CHRNA1 CHRNA1, CHRNA10, CHRNA2, CHRNA3, CHRNA4, CHRNA5, CHRNA6, CHRNA7, CHRNA9, CHRNB1, CHRNB2, CHRNB3, CHRNB4, CHRND, CHRNE, CHRNG 💬 | 8件: Alzheimer disease Alzheimer disease, Calcium signaling pathway, Chemical carcinogenesis - receptor activation, Cholinergic synapse, Neuroactive ligand-receptor interaction, Nicotine addiction, Pathways of neurodegeneration - multiple diseases, Virion - Lyssavirus 💬 | 1件: 6 6 💬 |
1789 | Nifurtimox 15/20 mg/kg/d 10d + eflornithine 400 mg/kg/d 7d | 2件: Eflornithine Eflornithine, Nifurtimox | 2件: Nifurtimox
Nifurtimox
,
Eflornithine
💬 | 1件: ODC1 ODC1 💬 | 3件: Arginine and proline metabolism Arginine and proline metabolism, Glutathione metabolism, Metabolic pathways 💬 | 1件: 65 65 💬 |
1790 | Nifurtimox-Eflronithine Combination Treatment (NECT) | 1件: Nifurtimox Nifurtimox | 1件: Nifurtimox
Nifurtimox
💬 | - | - | 1件: 65 65 💬 |
1791 | Nitric Oxide generated by the GeNO nitrosyl delivery system | 1件: Nitric Oxide Nitric Oxide | 1件: Nitric oxide
Nitric oxide
💬 | - | - | 1件: 86 86 💬 |
1792 | Nle4,D-Phe7]-a-melanocyte stimulating hormone or NDP-a-MSH | - | - | - | - | 1件: 254 254 💬 |
1793 | NNC 0109-0000-0012 | - | - | - | - | 1件: 46 46 💬 |
1794 | NNC 0141-0000-0100 | - | - | - | - | 1件: 46 46 💬 |
1795 | NNC 0142-0000-0002 | - | - | - | - | 2件: 46 46, 96 💬 |
1796 | NNC 0151-0000-0000 | - | - | - | - | 2件: 46 46, 49 💬 |
1797 | NNC 126-0083 | - | - | - | - | 1件: 78 78 💬 |
1798 | NNC 142-0002 | - | - | - | - | 1件: 46 46 💬 |
1799 | NNC0109-0012 | - | - | - | - | 1件: 46 46 💬 |
1800 | NNC0114-0000-0005 | - | - | - | - | 1件: 46 46 💬 |
1801 | NNC0114-0006 | - | - | - | - | 3件: 46 46, 49, 96 💬 |
1802 | NNC0142-0000-0002 | - | - | - | - | 1件: 96 96 💬 |
1803 | NNC0142-0002 | - | - | - | - | 1件: 46 46 💬 |
1804 | NNC0151-0000-0000 | - | - | - | - | 1件: 46 46 💬 |
1805 | NNC0195-0092 | - | - | - | - | 1件: 78 78 💬 |
1806 | NNC0195-0092 10 mg/1.5 ml PDS290-10 | - | - | - | - | 1件: 78 78 💬 |
1807 | NNC0195-0092 15 mg/1.5 ml PDS290-15 | - | - | - | - | 1件: 78 78 💬 |
1808 | NNC0195-0092 5 mg/1.5 ml PDS290-10 | - | - | - | - | 1件: 78 78 💬 |
1809 | NNC0195-0092 DP 6.7 mg ml 3 ml cartridge | - | - | - | - | 1件: 78 78 💬 |
1810 | NNC0195-0092 PDS290 10 mg-1.5 ml | - | - | - | - | 1件: 78 78 💬 |
1811 | NNC0195-0092 PDS290 10 mg/1.5 ml | - | - | - | - | 1件: 78 78 💬 |
1812 | NNC0215-0384 | - | - | - | - | 2件: 46 46, 162 💬 |
1813 | NNC109-0012 | - | - | - | - | 1件: 46 46 💬 |
1814 | NNC126-0083 | 1件: Somatropin pegol Somatropin pegol | - | - | - | 1件: 78 78 💬 |
1815 | NNC142-0002 | - | - | - | - | 1件: 96 96 💬 |
1816 | NNC151-0000 | - | - | - | - | 1件: 46 46 💬 |
1817 | NON PROPIETRY, THEREFORE N/A | - | - | - | - | 1件: 51 51 💬 |
1818 | Non-nucleoside reverse transcriptase inhibitors | - | - | - | - | 1件: 265 265 💬 |
1819 | Non-steroidal anti-inflammatory drug (NSAID) | - | - | - | - | 1件: 46 46 💬 |
1820 | Non-steroidal anti-inflammatory drugs (NSAIDs) | - | - | - | - | 1件: 107 107 💬 |
1821 | Norditropin NordiFlex® | - | - | - | - | 1件: 78 78 💬 |
1822 | Norditropin NordiFlex® 10 mg/1.5 ml | 1件: Somatotropin Somatotropin | - | - | - | 1件: 78 78 💬 |
1823 | Norditropin NordiFlex® 10mg/1.5 ml | 1件: Somatotropin Somatotropin | - | - | - | 1件: 78 78 💬 |
1824 | Normal Saline 0.9% Infusion Solution | - | - | - | - | 1件: 22 22 💬 |
1825 | Norovirus -specific T-cell (NST) therapy | - | - | - | - | 1件: 65 65 💬 |
1826 | Norucholic acid (NCA) 500 mg | 1件: norUrsodeoxycholic acid norUrsodeoxycholic acid | - | - | - | 1件: 93 93 💬 |
1827 | NorUDCA (Norursodeoxycholic acid) | 1件: norUrsodeoxycholic acid norUrsodeoxycholic acid | - | - | - | 1件: 94 94 💬 |
1828 | Norursodeoxycholic acid, NCA | 1件: norUrsodeoxycholic acid norUrsodeoxycholic acid | - | - | - | 1件: 94 94 💬 |
1829 | Novo Rapid Insulin (Novonordisk) | - | - | - | - | 1件: 299 299 💬 |
1830 | NovoNorm 0.5 mg | - | - | - | - | 1件: 299 299 💬 |
1831 | NovoRapid 100 U/ml, solution for injection in a vial. NovoRapid Penfill 100 U/ml, solution for injection in a cartridge. NovoRapid FlexPen 100 U/ml, solution for injection in a pre-filled pen. | - | - | - | - | 1件: 299 299 💬 |
1832 | NOXAFIL - 40 mg/ml oral suspension | 1件: Posaconazole Posaconazole | 1件: Posaconazole
Posaconazole
💬 | - | - | 1件: 299 299 💬 |
1833 | NOXAFIL - 40 MG/ML SOSPENSIONE ORALE USO ORALE FLACONE (VETRO) 105 ML 1 FLACONE | 1件: Posaconazole Posaconazole | 1件: Posaconazole
Posaconazole
💬 | - | - | 1件: 299 299 💬 |
1834 | NOXAFIL - oral suspension 40 mg/ml | 1件: Posaconazole Posaconazole | 1件: Posaconazole
Posaconazole
💬 | - | - | 1件: 299 299 💬 |
1835 | Noxafil 40 mg/ml oral solution | 1件: Posaconazole Posaconazole | 1件: Posaconazole
Posaconazole
💬 | - | - | 1件: 65 65 💬 |
1836 | NP031112 600mg | - | - | - | - | 1件: 5 5 💬 |
1837 | NP031112 800mg | - | - | - | - | 1件: 5 5 💬 |
1838 | NPB-01 | - | - | - | - | 3件: 13 13, 14, 162 💬 |
1839 | NPC-02 | - | - | - | - | 1件: 171 171 💬 |
1840 | NPC-09 | - | - | - | - | 1件: 30 30 💬 |
1841 | NPI-001 | - | - | - | - | 2件: 90 90, 303 💬 |
1842 | NPLATE 500 microgramos polvo para solución inyectable | 1件: Romiplostim Romiplostim | 1件: Romiplostim
Romiplostim
💬 | 1件: MPL MPL 💬 | 2件: Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, JAK-STAT signaling pathway 💬 | 1件: 63 63 💬 |
1843 | NR2B NMDA Antagonist CP-101,606 (traxoprodil) | 1件: Ketamine Ketamine | 1件: Ketamine
Ketamine
💬 | 5件: GRIN1 GRIN1, GRIN2A, GRIN2B, GRIN2C, GRIN2D 💬 | 20件: Alcoholism Alcoholism, Alzheimer disease, Amphetamine addiction, Amyotrophic lateral sclerosis, Calcium signaling pathway, Circadian entrainment, Cocaine addiction, Dopaminergic synapse, Glutamatergic synapse, Huntington disease, Long-term potentiation, Neuroactive ligand-receptor interaction, Nicotine addiction, Pathways of neurodegeneration - multiple diseases, Prion disease, Rap1 signaling pathway, Ras signaling pathway, Spinocerebellar ataxia, Systemic lupus erythematosus, cAMP signaling pathway 💬 | 1件: 6 6 💬 |
1844 | NS-065/NCNP-01 | - | - | - | - | 1件: 113 113 💬 |
1845 | NS-089/NCNP-02 | - | - | - | - | 1件: 113 113 💬 |
1846 | NSAIDs (permitted,not necessary) | - | - | - | - | 1件: 46 46 💬 |
1847 | NT-KO-003 | - | - | - | - | 1件: 13 13 💬 |
1848 | NurOwn (MSC-NTF cells) | - | - | - | - | 2件: 2 2, 13 💬 |
1849 | NurOwn® (MSC-NTF cells) | - | - | - | - | 1件: 2 2 💬 |
1850 | NUTROPINAq 10 mg/2 ml (30 UI), solución inyectable | 1件: Somatotropin Somatotropin | - | - | - | 1件: 78 78 💬 |
1851 | NYX-458 | - | - | - | - | 1件: 6 6 💬 |
1852 | Obatoclax mesylate (GX15-070MS) | 1件: Obatoclax Obatoclax | - | - | - | 1件: 60 60 💬 |
1853 | OCA 0.1 mg | - | - | - | - | 1件: 296 296 💬 |
1854 | OCA 0.1mg | - | - | - | - | 1件: 296 296 💬 |
1855 | OCH-NCNP1 | - | - | - | - | 1件: 13 13 💬 |
1856 | Ocrelizumab 600 mg | 1件: Ocrelizumab Ocrelizumab | 1件: Ocrelizumab
Ocrelizumab
💬 | 1件: MS4A1 MS4A1 💬 | 1件: Hematopoietic cell lineage Hematopoietic cell lineage 💬 | 1件: 13 13 💬 |
1857 | Octreotide a azione pronta 0,1 mg | 1件: Octreotide Octreotide | 1件: Octreotide
Octreotide
💬 | 1件: SSTR2 SSTR2 💬 | 4件: Gastric acid secretion Gastric acid secretion, Growth hormone synthesis, secretion and action, Neuroactive ligand-receptor interaction, cAMP signaling pathway 💬 | 1件: 227 227 💬 |
1858 | ODM-101 65mg Carbidopa | 1件: Carbidopa Carbidopa | 1件: Carbidopa
Carbidopa
💬 | 1件: DDC DDC 💬 | 9件: Alcoholism Alcoholism, Amphetamine addiction, Cocaine addiction, Dopaminergic synapse, Metabolic pathways, Phenylalanine metabolism, Serotonergic synapse, Tryptophan metabolism, Tyrosine metabolism 💬 | 1件: 6 6 💬 |
1859 | ODSH at 0.125 mg/kg/h | - | - | - | - | 1件: 210 210 💬 |
1860 | ODSH at 0.250 mg/kg/h | - | - | - | - | 1件: 210 210 💬 |
1861 | ODSH at 0.375 mg/kg/h | - | - | - | - | 1件: 210 210 💬 |
1862 | Ofatumumab 60mg | 1件: Ofatumumab Ofatumumab | 1件: Ofatumumab
Ofatumumab
💬 | 1件: MS4A1 MS4A1 💬 | 1件: Hematopoietic cell lineage Hematopoietic cell lineage 💬 | 1件: 13 13 💬 |
1863 | Okrido 6mg/mL oral solution | - | - | - | - | 1件: 3 3 💬 |
1864 | OL adalimumab 40 mg | 1件: Adalimumab Adalimumab | 1件: Adalimumab
Adalimumab
💬 | 1件: TNF TNF 💬 | 67件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Dilated cardiomyopathy, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease, Osteoclast differentiation, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway 💬 | 1件: 96 96 💬 |
1865 | Oleovit D3 14.400 IU/ml oral drops, solution | - | - | - | - | 1件: 13 13 💬 |
1866 | OligoG (60 mg/ml) | - | - | - | - | 1件: 299 299 💬 |
1867 | Oligomero morfolino fosforodiamidato per skipping dell’esone 45 | - | - | - | - | 1件: 113 113 💬 |
1868 | Olokizumab 60 mg | 1件: Olokizumab Olokizumab | 1件: Olokizumab
Olokizumab
💬 | 1件: IL6 IL6 💬 | 51件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, African trypanosomiasis, Alcoholic liver disease, Alzheimer disease, Amoebiasis, Antifolate resistance, C-type lectin receptor signaling pathway, Cellular senescence, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Cytosolic DNA-sensing pathway, EGFR tyrosine kinase inhibitor resistance, Epstein-Barr virus infection, FoxO signaling pathway, Graft-versus-host disease, HIF-1 signaling pathway, Hematopoietic cell lineage, Hepatitis B, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Intestinal immune network for IgA production, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Legionellosis, Lipid and atherosclerosis, Malaria, Measles, NOD-like receptor signaling pathway, Non-alcoholic fatty liver disease, PI3K-Akt signaling pathway, Pathogenic Escherichia coli infection, Pathways in cancer, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Rheumatoid arthritis, Salmonella infection, TNF signaling pathway, Th17 cell differentiation, Toll-like receptor signaling pathway, Transcriptional misregulation in cancer, Tuberculosis, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection 💬 | 1件: 46 46 💬 |
1869 | Olokizumab 64 mg SC q2w | 1件: Olokizumab Olokizumab | 1件: Olokizumab
Olokizumab
💬 | 1件: IL6 IL6 💬 | 51件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, African trypanosomiasis, Alcoholic liver disease, Alzheimer disease, Amoebiasis, Antifolate resistance, C-type lectin receptor signaling pathway, Cellular senescence, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Cytosolic DNA-sensing pathway, EGFR tyrosine kinase inhibitor resistance, Epstein-Barr virus infection, FoxO signaling pathway, Graft-versus-host disease, HIF-1 signaling pathway, Hematopoietic cell lineage, Hepatitis B, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Intestinal immune network for IgA production, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Legionellosis, Lipid and atherosclerosis, Malaria, Measles, NOD-like receptor signaling pathway, Non-alcoholic fatty liver disease, PI3K-Akt signaling pathway, Pathogenic Escherichia coli infection, Pathways in cancer, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Rheumatoid arthritis, Salmonella infection, TNF signaling pathway, Th17 cell differentiation, Toll-like receptor signaling pathway, Transcriptional misregulation in cancer, Tuberculosis, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection 💬 | 1件: 46 46 💬 |
1870 | Olokizumab 64 mg SC q4w | 1件: Olokizumab Olokizumab | 1件: Olokizumab
Olokizumab
💬 | 1件: IL6 IL6 💬 | 51件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, African trypanosomiasis, Alcoholic liver disease, Alzheimer disease, Amoebiasis, Antifolate resistance, C-type lectin receptor signaling pathway, Cellular senescence, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Cytosolic DNA-sensing pathway, EGFR tyrosine kinase inhibitor resistance, Epstein-Barr virus infection, FoxO signaling pathway, Graft-versus-host disease, HIF-1 signaling pathway, Hematopoietic cell lineage, Hepatitis B, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Intestinal immune network for IgA production, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Legionellosis, Lipid and atherosclerosis, Malaria, Measles, NOD-like receptor signaling pathway, Non-alcoholic fatty liver disease, PI3K-Akt signaling pathway, Pathogenic Escherichia coli infection, Pathways in cancer, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Rheumatoid arthritis, Salmonella infection, TNF signaling pathway, Th17 cell differentiation, Toll-like receptor signaling pathway, Transcriptional misregulation in cancer, Tuberculosis, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection 💬 | 1件: 46 46 💬 |
1871 | Olokizumab 64mg q2w | 1件: Olokizumab Olokizumab | 1件: Olokizumab
Olokizumab
💬 | 1件: IL6 IL6 💬 | 51件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, African trypanosomiasis, Alcoholic liver disease, Alzheimer disease, Amoebiasis, Antifolate resistance, C-type lectin receptor signaling pathway, Cellular senescence, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Cytosolic DNA-sensing pathway, EGFR tyrosine kinase inhibitor resistance, Epstein-Barr virus infection, FoxO signaling pathway, Graft-versus-host disease, HIF-1 signaling pathway, Hematopoietic cell lineage, Hepatitis B, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Intestinal immune network for IgA production, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Legionellosis, Lipid and atherosclerosis, Malaria, Measles, NOD-like receptor signaling pathway, Non-alcoholic fatty liver disease, PI3K-Akt signaling pathway, Pathogenic Escherichia coli infection, Pathways in cancer, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Rheumatoid arthritis, Salmonella infection, TNF signaling pathway, Th17 cell differentiation, Toll-like receptor signaling pathway, Transcriptional misregulation in cancer, Tuberculosis, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection 💬 | 1件: 46 46 💬 |
1872 | Olokizumab 64mg q4w | 1件: Olokizumab Olokizumab | 1件: Olokizumab
Olokizumab
💬 | 1件: IL6 IL6 💬 | 51件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, African trypanosomiasis, Alcoholic liver disease, Alzheimer disease, Amoebiasis, Antifolate resistance, C-type lectin receptor signaling pathway, Cellular senescence, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Cytosolic DNA-sensing pathway, EGFR tyrosine kinase inhibitor resistance, Epstein-Barr virus infection, FoxO signaling pathway, Graft-versus-host disease, HIF-1 signaling pathway, Hematopoietic cell lineage, Hepatitis B, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Intestinal immune network for IgA production, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Legionellosis, Lipid and atherosclerosis, Malaria, Measles, NOD-like receptor signaling pathway, Non-alcoholic fatty liver disease, PI3K-Akt signaling pathway, Pathogenic Escherichia coli infection, Pathways in cancer, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Rheumatoid arthritis, Salmonella infection, TNF signaling pathway, Th17 cell differentiation, Toll-like receptor signaling pathway, Transcriptional misregulation in cancer, Tuberculosis, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection 💬 | 1件: 46 46 💬 |
1873 | Olumiant - EU/1/16/1170/001-008 | 1件: Baricitinib Baricitinib | 1件: Baricitinib
Baricitinib
💬 | 2件: JAK1 JAK1, JAK2 💬 | 35件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, Chemical carcinogenesis - receptor activation, Chemokine signaling pathway, Cholinergic synapse, Coronavirus disease - COVID-19, EGFR tyrosine kinase inhibitor resistance, Epstein-Barr virus infection, Growth hormone synthesis, secretion and action, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Lipid and atherosclerosis, Measles, NOD-like receptor signaling pathway, Necroptosis, Osteoclast differentiation, PD-L1 expression and PD-1 checkpoint pathway in cancer, PI3K-Akt signaling pathway, Pancreatic cancer, Pathways in cancer, Prolactin signaling pathway, Signaling pathways regulating pluripotency of stem cells, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toxoplasmosis, Tuberculosis, Viral carcinogenesis 💬 | 1件: 49 49 💬 |
1874 | Olumiant - EU/1/16/1170/009-016 | 1件: Baricitinib Baricitinib | 1件: Baricitinib
Baricitinib
💬 | 2件: JAK1 JAK1, JAK2 💬 | 35件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, Chemical carcinogenesis - receptor activation, Chemokine signaling pathway, Cholinergic synapse, Coronavirus disease - COVID-19, EGFR tyrosine kinase inhibitor resistance, Epstein-Barr virus infection, Growth hormone synthesis, secretion and action, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Lipid and atherosclerosis, Measles, NOD-like receptor signaling pathway, Necroptosis, Osteoclast differentiation, PD-L1 expression and PD-1 checkpoint pathway in cancer, PI3K-Akt signaling pathway, Pancreatic cancer, Pathways in cancer, Prolactin signaling pathway, Signaling pathways regulating pluripotency of stem cells, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toxoplasmosis, Tuberculosis, Viral carcinogenesis 💬 | 1件: 49 49 💬 |
1875 | OLUMIANT 4 mg | 1件: Baricitinib Baricitinib | 1件: Baricitinib
Baricitinib
💬 | 2件: JAK1 JAK1, JAK2 💬 | 35件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, Chemical carcinogenesis - receptor activation, Chemokine signaling pathway, Cholinergic synapse, Coronavirus disease - COVID-19, EGFR tyrosine kinase inhibitor resistance, Epstein-Barr virus infection, Growth hormone synthesis, secretion and action, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Lipid and atherosclerosis, Measles, NOD-like receptor signaling pathway, Necroptosis, Osteoclast differentiation, PD-L1 expression and PD-1 checkpoint pathway in cancer, PI3K-Akt signaling pathway, Pancreatic cancer, Pathways in cancer, Prolactin signaling pathway, Signaling pathways regulating pluripotency of stem cells, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toxoplasmosis, Tuberculosis, Viral carcinogenesis 💬 | 1件: 46 46 💬 |
1876 | OLUMIANT 4mg | 1件: Baricitinib Baricitinib | 1件: Baricitinib
Baricitinib
💬 | 2件: JAK1 JAK1, JAK2 💬 | 35件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, Chemical carcinogenesis - receptor activation, Chemokine signaling pathway, Cholinergic synapse, Coronavirus disease - COVID-19, EGFR tyrosine kinase inhibitor resistance, Epstein-Barr virus infection, Growth hormone synthesis, secretion and action, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Lipid and atherosclerosis, Measles, NOD-like receptor signaling pathway, Necroptosis, Osteoclast differentiation, PD-L1 expression and PD-1 checkpoint pathway in cancer, PI3K-Akt signaling pathway, Pancreatic cancer, Pathways in cancer, Prolactin signaling pathway, Signaling pathways regulating pluripotency of stem cells, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toxoplasmosis, Tuberculosis, Viral carcinogenesis 💬 | 1件: 46 46 💬 |
1877 | OM 89. | - | - | - | - | 1件: 46 46 💬 |
1878 | Omadacycline Injection [Nuzyra] | 1件: Omadacycline Omadacycline | 1件: Omadacycline
Omadacycline
💬 | - | - | 1件: 299 299 💬 |
1879 | Omadacycline Oral Tablet [Nuzyra] | 1件: Omadacycline Omadacycline | 1件: Omadacycline
Omadacycline
💬 | - | - | 1件: 299 299 💬 |
1880 | Omaveloxolone Capsules, 40 mg | 1件: Omaveloxolone Omaveloxolone | 1件: Omaveloxolone
Omaveloxolone
💬 | 1件: NFE2L2 NFE2L2 💬 | 7件: Chemical carcinogenesis - reactive oxygen species Chemical carcinogenesis - reactive oxygen species, Fluid shear stress and atherosclerosis, Hepatocellular carcinoma, Lipid and atherosclerosis, Parkinson disease, Pathways in cancer, Protein processing in endoplasmic reticulum 💬 | 1件: 18 18 💬 |
1881 | Omaveloxolone Capsules, 80 mg | 1件: Omaveloxolone Omaveloxolone | 1件: Omaveloxolone
Omaveloxolone
💬 | 1件: NFE2L2 NFE2L2 💬 | 7件: Chemical carcinogenesis - reactive oxygen species Chemical carcinogenesis - reactive oxygen species, Fluid shear stress and atherosclerosis, Hepatocellular carcinoma, Lipid and atherosclerosis, Parkinson disease, Pathways in cancer, Protein processing in endoplasmic reticulum 💬 | 1件: 18 18 💬 |
1882 | Omeprazole 40 mg | 1件: Omeprazole Omeprazole | 1件: Omeprazole
Omeprazole
💬 | 2件: ATP4A ATP4A, ATP4B 💬 | 4件: Collecting duct acid secretion Collecting duct acid secretion, Gastric acid secretion, Metabolic pathways, Oxidative phosphorylation 💬 | 1件: 96 96 💬 |
1883 | Omeprazole 40mg Capsule | 1件: Omeprazole Omeprazole | 1件: Omeprazole
Omeprazole
💬 | 2件: ATP4A ATP4A, ATP4B 💬 | 4件: Collecting duct acid secretion Collecting duct acid secretion, Gastric acid secretion, Metabolic pathways, Oxidative phosphorylation 💬 | 1件: 299 299 💬 |
1884 | OMS721 (narsoplimab) | 1件: Narsoplimab Narsoplimab | 1件: Narsoplimab
Narsoplimab
💬 | 1件: MASP2 MASP2 💬 | 3件: Complement and coagulation cascades Complement and coagulation cascades, Coronavirus disease - COVID-19, Staphylococcus aureus infection 💬 | 2件: 66 66, 222 💬 |
1885 | ON 01910.NA | - | - | - | - | 1件: 36 36 💬 |
1886 | Ondansetron 8 mg film-coated tablets | 1件: Ondansetron Ondansetron | 1件: Ondansetron
Ondansetron
💬 | 5件: HTR3A HTR3A, HTR3B, HTR3C, HTR3D, HTR3E 💬 | 2件: Serotonergic synapse Serotonergic synapse, Taste transduction 💬 | 1件: 6 6 💬 |
1887 | ONO-4059 | - | - | - | - | 1件: 35 35 💬 |
1888 | ONO-4641 | - | - | - | - | 1件: 13 13 💬 |
1889 | ONO-4641/ MSC2430913A | - | - | - | - | 1件: 13 13 💬 |
1890 | ONO-4641/MSC2430913A | - | - | - | - | 1件: 13 13 💬 |
1891 | OPC-41061 | - | - | - | - | 1件: 67 67 💬 |
1892 | OPC-41061 (tolvaptan) | 1件: Tolvaptan Tolvaptan | 1件: Tolvaptan
Tolvaptan
💬 | 1件: AVPR2 AVPR2 💬 | 3件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Phospholipase D signaling pathway, Vasopressin-regulated water reabsorption 💬 | 1件: 67 67 💬 |
1893 | OPC-6535 | - | - | - | - | 2件: 96 96, 97 💬 |
1894 | OPC-6535 Tablets (drug) | - | - | - | - | 1件: 97 97 💬 |
1895 | OPC-6535(Tetomilast) | 1件: Tetomilast Tetomilast | - | - | - | 2件: 96 96, 97 💬 |
1896 | Open label Namilumab | 1件: Namilumab Namilumab | - | - | - | 1件: 84 84 💬 |
1897 | Open-label PTH(1-84) | - | - | - | - | 1件: 235 235 💬 |
1898 | OPRX-106 (plant cells expressing TNFR-Fc) 8mg | - | - | - | - | 1件: 97 97 💬 |
1899 | OPS-2071 600 mg | - | - | - | - | 1件: 96 96 💬 |
1900 | Oral Methylprednisolone 625 mg/24h x3 days | 1件: Methylprednisolone Methylprednisolone | 1件: Methylprednisolone
Methylprednisolone
💬 | 1件: NR3C1 NR3C1 💬 | 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 1件: 13 13 💬 |
1901 | Oral nutritional supplementation | - | - | - | - | 1件: 2 2 💬 |
1902 | Oral SCIO-469 capsule | - | - | - | - | 1件: 46 46 💬 |
1903 | Orencia (trade name) | 1件: Abatacept Abatacept | 1件: Abatacept
Abatacept
💬 | 2件: CD80 CD80, CD86 💬 | 13件: Allograft rejection Allograft rejection, Autoimmune thyroid disease, Cell adhesion molecules, Graft-versus-host disease, Intestinal immune network for IgA production, Kaposi sarcoma-associated herpesvirus infection, Rheumatoid arthritis, Systemic lupus erythematosus, Toll-like receptor signaling pathway, Transcriptional misregulation in cancer, Type I diabetes mellitus, Viral myocarditis, Virion - Adenovirus 💬 | 1件: 50 50 💬 |
1904 | ORENCIA 250 mg polvo para concentrado para sol. para perfusión | 1件: Abatacept Abatacept | 1件: Abatacept
Abatacept
💬 | 2件: CD80 CD80, CD86 💬 | 13件: Allograft rejection Allograft rejection, Autoimmune thyroid disease, Cell adhesion molecules, Graft-versus-host disease, Intestinal immune network for IgA production, Kaposi sarcoma-associated herpesvirus infection, Rheumatoid arthritis, Systemic lupus erythematosus, Toll-like receptor signaling pathway, Transcriptional misregulation in cancer, Type I diabetes mellitus, Viral myocarditis, Virion - Adenovirus 💬 | 1件: 46 46 💬 |
1905 | Orfadin oral suspension 4mg/ml | 1件: Nitisinone Nitisinone | 1件: Nitisinone
Nitisinone
💬 | 1件: HPD HPD 💬 | 5件: Biosynthesis of cofactors Biosynthesis of cofactors, Metabolic pathways, Phenylalanine metabolism, Tyrosine metabolism, Ubiquinone and other terpenoid-quinone biosynthesis 💬 | 1件: 241 241 💬 |
1906 | Ortho-cyclen, Ethinyl estradiol/norgestimate, 0.035 mg/0.250 mg | 3件: Estradiol Estradiol, Ethinylestradiol, Norgestimate | 3件: Estradiol
Estradiol
,
Ethinyl estradiol
,
Norgestimate
💬 | 3件: ESR1 ESR1, ESR2, PGR 💬 | 12件: Breast cancer Breast cancer, Chemical carcinogenesis - receptor activation, Endocrine and other factor-regulated calcium reabsorption, Endocrine resistance, Estrogen signaling pathway, GnRH secretion, Oocyte meiosis, Pathways in cancer, Progesterone-mediated oocyte maturation, Prolactin signaling pathway, Proteoglycans in cancer, Thyroid hormone signaling pathway 💬 | 1件: 299 299 💬 |
1907 | Ortho-novum | 1件: Mestranol Mestranol | 1件: Mestranol
Mestranol
💬 | 2件: ESR1 ESR1, ESR2 💬 | 10件: Breast cancer Breast cancer, Chemical carcinogenesis - receptor activation, Endocrine and other factor-regulated calcium reabsorption, Endocrine resistance, Estrogen signaling pathway, GnRH secretion, Pathways in cancer, Prolactin signaling pathway, Proteoglycans in cancer, Thyroid hormone signaling pathway 💬 | 2件: 46 46, 49 💬 |
1908 | Ortho-Novum 777 | 1件: Mestranol Mestranol | 1件: Mestranol
Mestranol
💬 | 2件: ESR1 ESR1, ESR2 💬 | 10件: Breast cancer Breast cancer, Chemical carcinogenesis - receptor activation, Endocrine and other factor-regulated calcium reabsorption, Endocrine resistance, Estrogen signaling pathway, GnRH secretion, Pathways in cancer, Prolactin signaling pathway, Proteoglycans in cancer, Thyroid hormone signaling pathway 💬 | 1件: 49 49 💬 |
1909 | Ortho-Novum® 1/35 | 1件: Mestranol Mestranol | 1件: Mestranol
Mestranol
💬 | 2件: ESR1 ESR1, ESR2 💬 | 10件: Breast cancer Breast cancer, Chemical carcinogenesis - receptor activation, Endocrine and other factor-regulated calcium reabsorption, Endocrine resistance, Estrogen signaling pathway, GnRH secretion, Pathways in cancer, Prolactin signaling pathway, Proteoglycans in cancer, Thyroid hormone signaling pathway 💬 | 1件: 46 46 💬 |
1910 | OsrhAAT 40 mg/kg IV | - | - | - | - | 1件: 231 231 💬 |
1911 | OsrhAAT 60 mg/kg IV | - | - | - | - | 1件: 231 231 💬 |
1912 | Ossido Nitrico | - | - | - | - | 1件: 86 86 💬 |
1913 | OSSM-001 | - | - | - | - | 1件: 96 96 💬 |
1914 | OSU 6162 similar to (-)-OSU 6162 | - | - | - | - | 1件: 6 6 💬 |
1915 | OSU6162 similar to (-)-OSU 6162 | - | - | - | - | 2件: 6 6, 8 💬 |
1916 | OTEZLA - 10 MG + 20 MG + 30 MG COMPRESSA RIVESTITA CON FILM USO ORALE - BLISTER (PVC/ALU) IN UN ASTUCCIO - 4 COMPRESSE DA 10 MG + 4 COMPRESSE DA 20 MG +19 COMPRESSE DA 30 MG | 1件: Apremilast Apremilast | 1件: Apremilast
Apremilast
💬 | 4件: PDE4A PDE4A, PDE4B, PDE4C, PDE4D 💬 | 5件: Metabolic pathways Metabolic pathways, Morphine addiction, Parathyroid hormone synthesis, secretion and action, Purine metabolism, cAMP signaling pathway 💬 | 2件: 56 56, 107 💬 |
1917 | OTHER NERVOUS SYSTEM DRUGS | - | - | - | - | 2件: 6 6, 13 💬 |
1918 | Other Non Steroidal Anti-Inflammatory Drugs (NSAIDs) except etodolac | 1件: Etodolac Etodolac | 1件: Etodolac
Etodolac
💬 | 1件: PTGS2 PTGS2 💬 | 22件: Alzheimer disease Alzheimer disease, Arachidonic acid metabolism, C-type lectin receptor signaling pathway, Chemical carcinogenesis - DNA adducts, Human cytomegalovirus infection, Human papillomavirus infection, IL-17 signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Metabolic pathways, MicroRNAs in cancer, NF-kappa B signaling pathway, Ovarian steroidogenesis, Oxytocin signaling pathway, Pathways in cancer, Pathways of neurodegeneration - multiple diseases, Regulation of lipolysis in adipocytes, Retrograde endocannabinoid signaling, Serotonergic synapse, Small cell lung cancer, TNF signaling pathway, VEGF signaling pathway 💬 | 1件: 46 46 💬 |
1919 | Other Non-selective NSAIDs | - | - | - | - | 1件: 271 271 💬 |
1920 | Other non-sponsor pancreatic enzyme replacement therapy | - | - | - | - | 1件: 299 299 💬 |
1921 | Outer membrane vesicles (OMV) from Neisseria meningitidis group B strain NZ98/254measured as amount of total protein containing the PorA P1.4 | - | - | - | - | 1件: 11 11 💬 |
1922 | Oxycodone naloxone prolonged release tablets | 2件: Naloxone Naloxone, Oxycodone | 2件: Oxycodone
Oxycodone
,
Naloxone
💬 | 3件: OPRD1 OPRD1, OPRK1, OPRM1 💬 | 5件: Estrogen signaling pathway Estrogen signaling pathway, Morphine addiction, Neuroactive ligand-receptor interaction, Sphingolipid signaling pathway, cGMP-PKG signaling pathway 💬 | 1件: 226 226 💬 |
1923 | Oxycodone/naloxone prolonged release t | 3件: Manganese citrate Manganese citrate, Naloxone, Oxycodone | 2件: Oxycodone
Oxycodone
,
Naloxone
💬 | 3件: OPRD1 OPRD1, OPRK1, OPRM1 💬 | 5件: Estrogen signaling pathway Estrogen signaling pathway, Morphine addiction, Neuroactive ligand-receptor interaction, Sphingolipid signaling pathway, cGMP-PKG signaling pathway 💬 | 1件: 226 226 💬 |
1924 | Oxycodone/Naloxone Prolonged Release tablets | 2件: Naloxone Naloxone, Oxycodone | 2件: Oxycodone
Oxycodone
,
Naloxone
💬 | 3件: OPRD1 OPRD1, OPRK1, OPRM1 💬 | 5件: Estrogen signaling pathway Estrogen signaling pathway, Morphine addiction, Neuroactive ligand-receptor interaction, Sphingolipid signaling pathway, cGMP-PKG signaling pathway 💬 | 1件: 6 6 💬 |
1925 | Oxycodone/naloxone prolonged release tablets 10 mg /5 mg | 3件: Manganese citrate Manganese citrate, Naloxone, Oxycodone | 2件: Oxycodone
Oxycodone
,
Naloxone
💬 | 3件: OPRD1 OPRD1, OPRK1, OPRM1 💬 | 5件: Estrogen signaling pathway Estrogen signaling pathway, Morphine addiction, Neuroactive ligand-receptor interaction, Sphingolipid signaling pathway, cGMP-PKG signaling pathway 💬 | 1件: 6 6 💬 |
1926 | Oxycodone/naloxone prolonged release tablets 10/5 mg | 3件: Manganese citrate Manganese citrate, Naloxone, Oxycodone | 2件: Oxycodone
Oxycodone
,
Naloxone
💬 | 3件: OPRD1 OPRD1, OPRK1, OPRM1 💬 | 5件: Estrogen signaling pathway Estrogen signaling pathway, Morphine addiction, Neuroactive ligand-receptor interaction, Sphingolipid signaling pathway, cGMP-PKG signaling pathway 💬 | 1件: 226 226 💬 |
1927 | Oxycodone/naloxone prolonged release tablets 20 mg /10 mg | 3件: Manganese citrate Manganese citrate, Naloxone, Oxycodone | 2件: Oxycodone
Oxycodone
,
Naloxone
💬 | 3件: OPRD1 OPRD1, OPRK1, OPRM1 💬 | 5件: Estrogen signaling pathway Estrogen signaling pathway, Morphine addiction, Neuroactive ligand-receptor interaction, Sphingolipid signaling pathway, cGMP-PKG signaling pathway 💬 | 1件: 6 6 💬 |
1928 | Oxycodone/naloxone prolonged release tablets 20/10 mg | 3件: Manganese citrate Manganese citrate, Naloxone, Oxycodone | 2件: Oxycodone
Oxycodone
,
Naloxone
💬 | 3件: OPRD1 OPRD1, OPRK1, OPRM1 💬 | 5件: Estrogen signaling pathway Estrogen signaling pathway, Morphine addiction, Neuroactive ligand-receptor interaction, Sphingolipid signaling pathway, cGMP-PKG signaling pathway 💬 | 1件: 226 226 💬 |
1929 | Oxycodone/naloxone prolonged release tablets 5 mg /2.5 mg | 3件: Manganese citrate Manganese citrate, Naloxone, Oxycodone | 2件: Oxycodone
Oxycodone
,
Naloxone
💬 | 3件: OPRD1 OPRD1, OPRK1, OPRM1 💬 | 5件: Estrogen signaling pathway Estrogen signaling pathway, Morphine addiction, Neuroactive ligand-receptor interaction, Sphingolipid signaling pathway, cGMP-PKG signaling pathway 💬 | 1件: 6 6 💬 |
1930 | Oxycodone/naloxone prolonged release tablets 5/2.5 mg | 3件: Manganese citrate Manganese citrate, Naloxone, Oxycodone | 2件: Oxycodone
Oxycodone
,
Naloxone
💬 | 3件: OPRD1 OPRD1, OPRK1, OPRM1 💬 | 5件: Estrogen signaling pathway Estrogen signaling pathway, Morphine addiction, Neuroactive ligand-receptor interaction, Sphingolipid signaling pathway, cGMP-PKG signaling pathway 💬 | 1件: 226 226 💬 |
1931 | Oxygen 40 % | 1件: Oxygen Oxygen | 1件: Oxygen
Oxygen
💬 | - | - | 1件: 85 85 💬 |
1932 | Oxytocin 48IU | 1件: Oxytocin Oxytocin | 1件: Oxytocin
Oxytocin
💬 | 1件: OXTR OXTR 💬 | 4件: Calcium signaling pathway Calcium signaling pathway, Neuroactive ligand-receptor interaction, Oxytocin signaling pathway, cAMP signaling pathway 💬 | 1件: 206 206 💬 |
1933 | Oxytocin nasal spray | 1件: Oxytocin Oxytocin | 1件: Oxytocin
Oxytocin
💬 | 1件: OXTR OXTR 💬 | 4件: Calcium signaling pathway Calcium signaling pathway, Neuroactive ligand-receptor interaction, Oxytocin signaling pathway, cAMP signaling pathway 💬 | 2件: 72 72, 193 💬 |
1934 | Ozanimod 0.5 mg | 1件: Ozanimod Ozanimod | 1件: Ozanimod
Ozanimod
💬 | 5件: S1PR1 S1PR1, S1PR2, S1PR3, S1PR4, S1PR5 💬 | 3件: FoxO signaling pathway FoxO signaling pathway, Neuroactive ligand-receptor interaction, Sphingolipid signaling pathway 💬 | 1件: 13 13 💬 |
1935 | P-188 NF | - | - | - | - | 1件: 113 113 💬 |
1936 | P2B001 once daily (pramipexole 0.3 mg / rasagiline 0.75 mg), | 2件: Pramipexole Pramipexole, Rasagiline | 3件: Pramipexole
Pramipexole
,
Rasagiline
,
Rasagiline tartrate
💬 | 4件: DRD2 DRD2, DRD3, DRD4, MAOB 💬 | 18件: Alcoholism Alcoholism, Amphetamine addiction, Arginine and proline metabolism, Cocaine addiction, Dopaminergic synapse, Drug metabolism - cytochrome P450, Gap junction, Glycine, serine and threonine metabolism, Histidine metabolism, Metabolic pathways, Neuroactive ligand-receptor interaction, Parkinson disease, Phenylalanine metabolism, Rap1 signaling pathway, Serotonergic synapse, Tryptophan metabolism, Tyrosine metabolism, cAMP signaling pathway 💬 | 1件: 6 6 💬 |
1937 | P2B001 once daily (pramipexole 0.6 mg / rasagiline 0.75 mg), | 2件: Pramipexole Pramipexole, Rasagiline | 3件: Pramipexole
Pramipexole
,
Rasagiline
,
Rasagiline tartrate
💬 | 4件: DRD2 DRD2, DRD3, DRD4, MAOB 💬 | 18件: Alcoholism Alcoholism, Amphetamine addiction, Arginine and proline metabolism, Cocaine addiction, Dopaminergic synapse, Drug metabolism - cytochrome P450, Gap junction, Glycine, serine and threonine metabolism, Histidine metabolism, Metabolic pathways, Neuroactive ligand-receptor interaction, Parkinson disease, Phenylalanine metabolism, Rap1 signaling pathway, Serotonergic synapse, Tryptophan metabolism, Tyrosine metabolism, cAMP signaling pathway 💬 | 1件: 6 6 💬 |
1938 | P38 (4) Map Kinase Inhibitor | - | - | - | - | 1件: 46 46 💬 |
1939 | P38 Inhibitor (4) | - | - | - | - | 1件: 46 46 💬 |
1940 | P38 Inhibitor (4) 150mg | - | - | - | - | 1件: 46 46 💬 |
1941 | P38 Inhibitor (4) 25mg | - | - | - | - | 1件: 46 46 💬 |
1942 | P38 Inhibitor (4) 300mg | - | - | - | - | 1件: 46 46 💬 |
1943 | P38 Inhibitor (4) 50mg | - | - | - | - | 1件: 46 46 💬 |
1944 | P38 Inhibitor (4) 75mg | - | - | - | - | 1件: 46 46 💬 |
1945 | P38(4) Map Kinase Inhibitor | - | - | - | - | 1件: 46 46 💬 |
1946 | PALOVAROTENE - 4 mg | 1件: Palovarotene Palovarotene | 1件: Palovarotene
Palovarotene
💬 | 1件: RARG RARG 💬 | - | 1件: 272 272 💬 |
1947 | Palovarotene dose level 4 | 1件: Palovarotene Palovarotene | 1件: Palovarotene
Palovarotene
💬 | 1件: RARG RARG 💬 | - | 1件: 272 272 💬 |
1948 | PALOVAROTENE-4 mg | 1件: Palovarotene Palovarotene | 1件: Palovarotene
Palovarotene
💬 | 1件: RARG RARG 💬 | - | 1件: 272 272 💬 |
1949 | PANCREATINA (Páncreas Polvo | - | - | - | - | 1件: 299 299 💬 |
1950 | PANCREATINA (Páncreas Polvo) | - | - | - | - | 1件: 299 299 💬 |
1951 | Panzytrat 25.000 | - | - | - | - | 1件: 298 298 💬 |
1952 | Panzytrat 25.000 FIP-E units of Lipase | - | - | - | - | 1件: 298 298 💬 |
1953 | Panzytrat® 25,000 | - | - | - | - | 1件: 299 299 💬 |
1954 | PARACETAMOLO NOVA ARGENTIA - 500 MG COMPRESSE 20 COMPRESSE | - | - | - | - | 1件: 300 300 💬 |
1955 | Parathyroid hormon 1-84 | - | - | - | - | 1件: 235 235 💬 |
1956 | Parathyroid Hormone (1-84) Human Recombinant | 1件: Parathyroid hormone Parathyroid hormone | 1件: Parathyroid hormone
Parathyroid hormone
💬 | 2件: PTH1R PTH1R, PTH2R 💬 | 3件: Endocrine and other factor-regulated calcium reabsorption Endocrine and other factor-regulated calcium reabsorption, Neuroactive ligand-receptor interaction, Parathyroid hormone synthesis, secretion and action 💬 | 1件: 235 235 💬 |
1957 | Part 1, JM-010 component Group A | - | - | - | - | 1件: 6 6 💬 |
1958 | Part 1, JM-010 component Group B | - | - | - | - | 1件: 6 6 💬 |
1959 | Part 1, JM-010 component Group C | - | - | - | - | 1件: 6 6 💬 |
1960 | Part 2, JM-010 combination Group A | - | - | - | - | 1件: 6 6 💬 |
1961 | Part 2, JM-010 combination Group B | - | - | - | - | 1件: 6 6 💬 |
1962 | Part 2, JM-010 component Group C | - | - | - | - | 1件: 6 6 💬 |
1963 | Part I - etoricoxib 60 mg | 1件: Etoricoxib Etoricoxib | 1件: Etoricoxib
Etoricoxib
💬 | 1件: PTGS2 PTGS2 💬 | 22件: Alzheimer disease Alzheimer disease, Arachidonic acid metabolism, C-type lectin receptor signaling pathway, Chemical carcinogenesis - DNA adducts, Human cytomegalovirus infection, Human papillomavirus infection, IL-17 signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Metabolic pathways, MicroRNAs in cancer, NF-kappa B signaling pathway, Ovarian steroidogenesis, Oxytocin signaling pathway, Pathways in cancer, Pathways of neurodegeneration - multiple diseases, Regulation of lipolysis in adipocytes, Retrograde endocannabinoid signaling, Serotonergic synapse, Small cell lung cancer, TNF signaling pathway, VEGF signaling pathway 💬 | 1件: 271 271 💬 |
1964 | Part I- naproxen 1000 mg | 1件: Naproxen Naproxen | 1件: Naproxen
Naproxen
💬 | 2件: PTGS1 PTGS1, PTGS2 💬 | 23件: Alzheimer disease Alzheimer disease, Arachidonic acid metabolism, C-type lectin receptor signaling pathway, Chemical carcinogenesis - DNA adducts, Human cytomegalovirus infection, Human papillomavirus infection, IL-17 signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Metabolic pathways, MicroRNAs in cancer, NF-kappa B signaling pathway, Ovarian steroidogenesis, Oxytocin signaling pathway, Pathways in cancer, Pathways of neurodegeneration - multiple diseases, Platelet activation, Regulation of lipolysis in adipocytes, Retrograde endocannabinoid signaling, Serotonergic synapse, Small cell lung cancer, TNF signaling pathway, VEGF signaling pathway 💬 | 1件: 271 271 💬 |
1965 | Part II- etoricoxib 60 mg | 1件: Etoricoxib Etoricoxib | 1件: Etoricoxib
Etoricoxib
💬 | 1件: PTGS2 PTGS2 💬 | 22件: Alzheimer disease Alzheimer disease, Arachidonic acid metabolism, C-type lectin receptor signaling pathway, Chemical carcinogenesis - DNA adducts, Human cytomegalovirus infection, Human papillomavirus infection, IL-17 signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Metabolic pathways, MicroRNAs in cancer, NF-kappa B signaling pathway, Ovarian steroidogenesis, Oxytocin signaling pathway, Pathways in cancer, Pathways of neurodegeneration - multiple diseases, Regulation of lipolysis in adipocytes, Retrograde endocannabinoid signaling, Serotonergic synapse, Small cell lung cancer, TNF signaling pathway, VEGF signaling pathway 💬 | 1件: 271 271 💬 |
1966 | Part II- naproxen 1000 mg | 1件: Naproxen Naproxen | 1件: Naproxen
Naproxen
💬 | 2件: PTGS1 PTGS1, PTGS2 💬 | 23件: Alzheimer disease Alzheimer disease, Arachidonic acid metabolism, C-type lectin receptor signaling pathway, Chemical carcinogenesis - DNA adducts, Human cytomegalovirus infection, Human papillomavirus infection, IL-17 signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Metabolic pathways, MicroRNAs in cancer, NF-kappa B signaling pathway, Ovarian steroidogenesis, Oxytocin signaling pathway, Pathways in cancer, Pathways of neurodegeneration - multiple diseases, Platelet activation, Regulation of lipolysis in adipocytes, Retrograde endocannabinoid signaling, Serotonergic synapse, Small cell lung cancer, TNF signaling pathway, VEGF signaling pathway 💬 | 1件: 271 271 💬 |
1967 | Partial Enteral Nutrition | - | - | - | - | 1件: 96 96 💬 |
1968 | Pasireotida 600 | 1件: Pasireotide Pasireotide | 1件: Pasireotide
Pasireotide
💬 | 4件: SSTR1 SSTR1, SSTR2, SSTR3, SSTR5 💬 | 4件: Gastric acid secretion Gastric acid secretion, Growth hormone synthesis, secretion and action, Neuroactive ligand-receptor interaction, cAMP signaling pathway 💬 | 1件: 75 75 💬 |
1969 | Pasireotide 0.3mg | 1件: Pasireotide Pasireotide | 1件: Pasireotide
Pasireotide
💬 | 4件: SSTR1 SSTR1, SSTR2, SSTR3, SSTR5 💬 | 4件: Gastric acid secretion Gastric acid secretion, Growth hormone synthesis, secretion and action, Neuroactive ligand-receptor interaction, cAMP signaling pathway 💬 | 1件: 75 75 💬 |
1970 | Pasireotide 0.6 MG/ML | 1件: Pasireotide Pasireotide | 1件: Pasireotide
Pasireotide
💬 | 4件: SSTR1 SSTR1, SSTR2, SSTR3, SSTR5 💬 | 4件: Gastric acid secretion Gastric acid secretion, Growth hormone synthesis, secretion and action, Neuroactive ligand-receptor interaction, cAMP signaling pathway 💬 | 1件: 75 75 💬 |
1971 | Pasireotide 0.6mg | 1件: Pasireotide Pasireotide | 1件: Pasireotide
Pasireotide
💬 | 4件: SSTR1 SSTR1, SSTR2, SSTR3, SSTR5 💬 | 4件: Gastric acid secretion Gastric acid secretion, Growth hormone synthesis, secretion and action, Neuroactive ligand-receptor interaction, cAMP signaling pathway 💬 | 1件: 75 75 💬 |
1972 | Pasireotide 0.9 mg | 1件: Pasireotide Pasireotide | 1件: Pasireotide
Pasireotide
💬 | 4件: SSTR1 SSTR1, SSTR2, SSTR3, SSTR5 💬 | 4件: Gastric acid secretion Gastric acid secretion, Growth hormone synthesis, secretion and action, Neuroactive ligand-receptor interaction, cAMP signaling pathway 💬 | 1件: 75 75 💬 |
1973 | Pasireotide 40mg | 1件: Pasireotide Pasireotide | 1件: Pasireotide
Pasireotide
💬 | 4件: SSTR1 SSTR1, SSTR2, SSTR3, SSTR5 💬 | 4件: Gastric acid secretion Gastric acid secretion, Growth hormone synthesis, secretion and action, Neuroactive ligand-receptor interaction, cAMP signaling pathway 💬 | 1件: 75 75 💬 |
1974 | Pasireotide 60mg | 1件: Pasireotide Pasireotide | 1件: Pasireotide
Pasireotide
💬 | 4件: SSTR1 SSTR1, SSTR2, SSTR3, SSTR5 💬 | 4件: Gastric acid secretion Gastric acid secretion, Growth hormone synthesis, secretion and action, Neuroactive ligand-receptor interaction, cAMP signaling pathway 💬 | 1件: 75 75 💬 |
1975 | PAT-001, 0.1% | - | - | - | - | 1件: 160 160 💬 |
1976 | PAT-001, 0.2% | - | - | - | - | 1件: 160 160 💬 |
1977 | Patients' existing non-steroidal anti-inflammatory drug (NSAID) at approved doses | - | - | - | - | 1件: 46 46 💬 |
1978 | PBF-677 | - | - | - | - | 1件: 97 97 💬 |
1979 | PD 0299685 | - | - | - | - | 1件: 226 226 💬 |
1980 | PD 0299685 at 15mg BID | - | - | - | - | 1件: 226 226 💬 |
1981 | PD 0299685 at 30mg BID | - | - | - | - | 1件: 226 226 💬 |
1982 | PD 0360324 | - | - | - | - | 2件: 46 46, 84 💬 |
1983 | PD-0299685 | 1件: PD-0299685 PD-0299685 | - | - | - | 1件: 226 226 💬 |
1984 | PD-0325901 | 1件: Mirdametinib Mirdametinib | 1件: Mirdametinib
Mirdametinib
💬 | 2件: MAP2K1 MAP2K1, MAP2K2 💬 | 89件: Acute myeloid leukemia Acute myeloid leukemia, Alcoholism, Alzheimer disease, Apelin signaling pathway, Apoptosis, Autophagy - animal, B cell receptor signaling pathway, Bladder cancer, Breast cancer, Cellular senescence, Central carbon metabolism in cancer, Chemical carcinogenesis - reactive oxygen species, Chemical carcinogenesis - receptor activation, Chemokine signaling pathway, Choline metabolism in cancer, Cholinergic synapse, Chronic myeloid leukemia, Colorectal cancer, Cushing syndrome, EGFR tyrosine kinase inhibitor resistance, Endocrine resistance, Endometrial cancer, ErbB signaling pathway, Estrogen signaling pathway, Fc epsilon RI signaling pathway, Fc gamma R-mediated phagocytosis, Focal adhesion, FoxO signaling pathway, Gap junction, Gastric cancer, Glioma, GnRH secretion, GnRH signaling pathway, Growth hormone synthesis, secretion and action, HIF-1 signaling pathway, Hepatitis B, Hepatitis C, Hepatocellular carcinoma, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Influenza A, Insulin signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Long-term depression, Long-term potentiation, MAPK signaling pathway, Melanogenesis, Melanoma, MicroRNAs in cancer, Natural killer cell mediated cytotoxicity, Neurotrophin signaling pathway, Neutrophil extracellular trap formation, Non-small cell lung cancer, Oocyte meiosis, Osteoclast differentiation, Oxytocin signaling pathway, PD-L1 expression and PD-1 checkpoint pathway in cancer, PI3K-Akt signaling pathway, Pancreatic cancer, Parathyroid hormone synthesis, secretion and action, Pathways in cancer, Pathways of neurodegeneration - multiple diseases, Phospholipase D signaling pathway, Progesterone-mediated oocyte maturation, Prolactin signaling pathway, Prostate cancer, Proteoglycans in cancer, Rap1 signaling pathway, Ras signaling pathway, Regulation of actin cytoskeleton, Relaxin signaling pathway, Renal cell carcinoma, Salmonella infection, Serotonergic synapse, Signaling pathways regulating pluripotency of stem cells, Sphingolipid signaling pathway, T cell receptor signaling pathway, TNF signaling pathway, Thyroid cancer, Thyroid hormone signaling pathway, Toll-like receptor signaling pathway, VEGF signaling pathway, Vascular smooth muscle contraction, Yersinia infection, cAMP signaling pathway, cGMP-PKG signaling pathway, mTOR signaling pathway 💬 | 1件: 34 34 💬 |
1985 | PD00377 Na-salt | - | - | - | - | 1件: 85 85 💬 |
1986 | Pentasa Compact 4g, granulate with prolonged release | 2件: Manganese citrate Manganese citrate, Mesalazine | 1件: Mesalamine
Mesalamine
💬 | - | - | 1件: 97 97 💬 |
1987 | Pentoxifylline 400 MG | 1件: Pentoxifylline Pentoxifylline | 1件: Pentoxifylline
Pentoxifylline
💬 | - | - | 1件: 97 97 💬 |
1988 | Peri-neural Dexamethasone 1 mg | 1件: Dexamethasone Dexamethasone | 1件: Dexamethasone
Dexamethasone
💬 | 1件: NR3C1 NR3C1 💬 | 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 1件: 46 46 💬 |
1989 | Personalized extended interval dosing of natalizumab | 1件: Natalizumab Natalizumab | 1件: Natalizumab
Natalizumab
💬 | 1件: ITGA4 ITGA4 💬 | 14件: Arrhythmogenic right ventricular cardiomyopathy Arrhythmogenic right ventricular cardiomyopathy, Cell adhesion molecules, Dilated cardiomyopathy, ECM-receptor interaction, Focal adhesion, Hematopoietic cell lineage, Human papillomavirus infection, Hypertrophic cardiomyopathy, Intestinal immune network for IgA production, Leishmaniasis, Leukocyte transendothelial migration, PI3K-Akt signaling pathway, Regulation of actin cytoskeleton, Yersinia infection 💬 | 1件: 13 13 💬 |
1990 | PF 06687234 | - | - | - | - | 2件: 96 96, 97 💬 |
1991 | PF-00489791 | 1件: PF-00489791 PF-00489791 | - | - | - | 1件: 86 86 💬 |
1992 | PF-00547659 | - | - | - | - | 2件: 96 96, 97 💬 |
1993 | PF-00547659 SC injection | - | - | - | - | 2件: 96 96, 97 💬 |
1994 | PF-02545920 | - | - | - | - | 1件: 8 8 💬 |
1995 | PF-04171327 | - | - | - | - | 1件: 46 46 💬 |
1996 | PF-04171327 10 mg | - | - | - | - | 1件: 46 46 💬 |
1997 | PF-04171327 25 mg | - | - | - | - | 1件: 46 46 💬 |
1998 | PF-04236921 | - | - | - | - | 2件: 49 49, 96 💬 |
1999 | PF-04236921 SC injection | - | - | - | - | 1件: 96 96 💬 |
2000 | PF-04383119 | - | - | - | - | 1件: 226 226 💬 |
2001 | PF-05208763 | - | - | - | - | 1件: 67 67 💬 |
2002 | PF-05230917 | - | - | - | - | 1件: 97 97 💬 |
2003 | PF-05280586 | - | - | - | - | 1件: 46 46 💬 |
2004 | PF-05285401 | - | - | - | - | 1件: 97 97 💬 |
2005 | PF-06252616 | 1件: Domagrozumab Domagrozumab | 1件: Domagrozumab
Domagrozumab
💬 | 1件: MSTN MSTN 💬 | 1件: Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction 💬 | 1件: 113 113 💬 |
2006 | PF-06291826-83/Fx-1006A | 1件: Fx-1006A Fx-1006A | - | - | - | 1件: 28 28 💬 |
2007 | PF-06342674 0.25 mg/kg | - | - | - | - | 1件: 13 13 💬 |
2008 | PF-06342674 1.5 mg/kg | - | - | - | - | 1件: 13 13 💬 |
2009 | PF-06342674 6.0 mg/kg | - | - | - | - | 1件: 13 13 💬 |
2010 | PF-06410293 | - | - | - | - | 1件: 46 46 💬 |
2011 | PF-06412562 | - | - | - | - | 1件: 6 6 💬 |
2012 | PF-06438179 | - | - | - | - | 1件: 46 46 💬 |
2013 | PF-06462700 | - | - | - | - | 1件: 60 60 💬 |
2014 | PF-06480605 | - | - | - | - | 1件: 97 97 💬 |
2015 | PF-06480605 100 mg/ml | - | - | - | - | 1件: 97 97 💬 |
2016 | PF-06649751 | 1件: Tavapadon Tavapadon | 1件: Tavapadon
Tavapadon
💬 | 2件: DRD1 DRD1, DRD5 💬 | 10件: Alcoholism Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, cAMP signaling pathway 💬 | 1件: 6 6 💬 |
2017 | PF-06649751 - 15mg | 1件: Tavapadon Tavapadon | 1件: Tavapadon
Tavapadon
💬 | 2件: DRD1 DRD1, DRD5 💬 | 10件: Alcoholism Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, cAMP signaling pathway 💬 | 1件: 6 6 💬 |
2018 | PF-06649751 - 1mg | 1件: Tavapadon Tavapadon | 1件: Tavapadon
Tavapadon
💬 | 2件: DRD1 DRD1, DRD5 💬 | 10件: Alcoholism Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, cAMP signaling pathway 💬 | 1件: 6 6 💬 |
2019 | PF-06649751 - 5mg | 1件: Tavapadon Tavapadon | 1件: Tavapadon
Tavapadon
💬 | 2件: DRD1 DRD1, DRD5 💬 | 10件: Alcoholism Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, cAMP signaling pathway 💬 | 1件: 6 6 💬 |
2020 | PF-06649751 high dose (15 mg QD) | 1件: Tavapadon Tavapadon | 1件: Tavapadon
Tavapadon
💬 | 2件: DRD1 DRD1, DRD5 💬 | 10件: Alcoholism Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, cAMP signaling pathway 💬 | 1件: 6 6 💬 |
2021 | PF-06649751 low dose (1 mg QD) | 1件: Tavapadon Tavapadon | 1件: Tavapadon
Tavapadon
💬 | 2件: DRD1 DRD1, DRD5 💬 | 10件: Alcoholism Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, cAMP signaling pathway 💬 | 1件: 6 6 💬 |
2022 | PF-06649751 middle dose 1 (3 mg QD) | 1件: Tavapadon Tavapadon | 1件: Tavapadon
Tavapadon
💬 | 2件: DRD1 DRD1, DRD5 💬 | 10件: Alcoholism Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, cAMP signaling pathway 💬 | 1件: 6 6 💬 |
2023 | PF-06649751 middle dose 2 (7 mg QD) | 1件: Tavapadon Tavapadon | 1件: Tavapadon
Tavapadon
💬 | 2件: DRD1 DRD1, DRD5 💬 | 10件: Alcoholism Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, cAMP signaling pathway 💬 | 1件: 6 6 💬 |
2024 | PF-06650833 | 1件: PF-06650833 PF-06650833 | - | - | - | 1件: 46 46 💬 |
2025 | PF-06650833 100 mg | 1件: PF-06650833 PF-06650833 | - | - | - | 1件: 46 46 💬 |
2026 | PF-06650833 20 mg | 1件: PF-06650833 PF-06650833 | - | - | - | 1件: 46 46 💬 |
2027 | PF-06651600 | 1件: PF-06651600 PF-06651600 | - | - | - | 3件: 46 46, 96, 97 💬 |
2028 | PF-06651600 10 mg | 1件: PF-06651600 PF-06651600 | - | - | - | 1件: 97 97 💬 |
2029 | PF-06651600 50 mg | 1件: PF-06651600 PF-06651600 | - | - | - | 2件: 96 96, 97 💬 |
2030 | PF-06651600 50mg | 1件: PF-06651600 PF-06651600 | - | - | - | 1件: 96 96 💬 |
2031 | PF-06651600-15 | 1件: PF-06651600 PF-06651600 | - | - | - | 2件: 96 96, 97 💬 |
2032 | PF-06669571 | - | - | - | - | 1件: 6 6 💬 |
2033 | PF-06687234 | - | - | - | - | 1件: 97 97 💬 |
2034 | PF-06700841 | 1件: PF-06700841 PF-06700841 | - | - | - | 3件: 49 49, 96, 97 💬 |
2035 | PF-06700841 15 mg | 1件: PF-06700841 PF-06700841 | - | - | - | 1件: 49 49 💬 |
2036 | PF-06700841 25 mg | 1件: PF-06700841 PF-06700841 | - | - | - | 2件: 96 96, 97 💬 |
2037 | PF-06700841 25mg | 1件: PF-06700841 PF-06700841 | - | - | - | 1件: 49 49 💬 |
2038 | PF-06700841 30 mg | 1件: PF-06700841 PF-06700841 | - | - | - | 1件: 49 49 💬 |
2039 | PF-06700841 45 mg | 1件: PF-06700841 PF-06700841 | - | - | - | 1件: 49 49 💬 |
2040 | PF-06700841 5 mg | 1件: PF-06700841 PF-06700841 | - | - | - | 3件: 49 49, 96, 97 💬 |
2041 | PF-06700841 5mg | 1件: PF-06700841 PF-06700841 | - | - | - | 1件: 49 49 💬 |
2042 | PF-06700841-15 | 1件: PF-06700841 PF-06700841 | - | - | - | 3件: 49 49, 96, 97 💬 |
2043 | PF-06730512 | - | - | - | - | 1件: 222 222 💬 |
2044 | PF-06755347 intravenous healthy participant | - | - | - | - | 1件: 63 63 💬 |
2045 | PF-06755347 subcutaneous healthy participant | - | - | - | - | 1件: 63 63 💬 |
2046 | PF-06755347 subcutaneous ITP | - | - | - | - | 1件: 63 63 💬 |
2047 | PF-06823859 | - | - | - | - | 1件: 50 50 💬 |
2048 | PF-06823859 high | - | - | - | - | 1件: 50 50 💬 |
2049 | PF-06823859 low | - | - | - | - | 1件: 50 50 💬 |
2050 | PF-06826647 | - | - | - | - | 1件: 97 97 💬 |
2051 | PF-06826647 100 mg QD | - | - | - | - | 1件: 97 97 💬 |
2052 | PF-06826647 300 mg QD | - | - | - | - | 1件: 97 97 💬 |
2053 | PF-06826647 600 mg QD | - | - | - | - | 1件: 97 97 💬 |
2054 | PF-06835375 | - | - | - | - | 3件: 46 46, 49, 63 💬 |
2055 | PF-06836922 | - | - | - | - | 1件: 78 78 💬 |
2056 | PF-06939926 | - | - | - | - | 1件: 113 113 💬 |
2057 | PF-07054894 | - | - | - | - | 1件: 97 97 💬 |
2058 | PF-07256472 | - | - | - | - | 1件: 276 276 💬 |
2059 | PF-6826647 400 mg QD | - | - | - | - | 1件: 97 97 💬 |
2060 | Ph. Eur.: (2S)-2-amino-3-(3,4-dihydroxyphenyl)propanoic acid | 1件: Propanoic acid Propanoic acid | - | - | - | 1件: 6 6 💬 |
2061 | Ph. Eur.: (2S)-3-(3,4-dihydroxyphenyl)-2hydrazino-2methylprop acid | - | - | - | - | 1件: 6 6 💬 |
2062 | PHA-022121 | - | - | - | - | 1件: 65 65 💬 |
2063 | PHA-022121 high dose | - | - | - | - | 1件: 65 65 💬 |
2064 | PHA-022121 low dose | - | - | - | - | 1件: 65 65 💬 |
2065 | PHA-022121 medium dose | - | - | - | - | 1件: 65 65 💬 |
2066 | PHA-022121 selected dose | - | - | - | - | 1件: 65 65 💬 |
2067 | PHA-794,428 | - | - | - | - | 1件: 78 78 💬 |
2068 | PhEur.: (2S)-2-amino-3-(3,4-dihydroxyphenyl)propanoic acid | 1件: Propanoic acid Propanoic acid | - | - | - | 1件: 6 6 💬 |
2069 | PhEur.: (2S)-3-(3,4-dihydroxyphenyl)-2hydrazino-2methylpropanoic acid | - | - | - | - | 1件: 6 6 💬 |
2070 | Phosphorodiamidate morpholino oligomer for exon 45 skipping | - | - | - | - | 1件: 113 113 💬 |
2071 | Physiologic serum nebulized nasally | - | - | - | - | 1件: 299 299 💬 |
2072 | PI-0824 | 1件: PI-0824 PI-0824 | - | - | - | 1件: 35 35 💬 |
2073 | Pilocarpine Nitrate 5% | 2件: Nitrate Nitrate, Pilocarpine | 2件: Pilocarpine
Pilocarpine
,
Nitric acid
💬 | 2件: CHRM2 CHRM2, CHRM3 💬 | 13件: Alzheimer disease Alzheimer disease, Calcium signaling pathway, Cholinergic synapse, Gastric acid secretion, Insulin secretion, Neuroactive ligand-receptor interaction, PI3K-Akt signaling pathway, Pancreatic secretion, Pathways of neurodegeneration - multiple diseases, Regulation of actin cytoskeleton, Salivary secretion, Taste transduction, cAMP signaling pathway 💬 | 1件: 299 299 💬 |
2074 | Pimozide 2mg/day (current) or 4 mg/day (study initiation) | 1件: Pimozide Pimozide | 1件: Pimozide
Pimozide
💬 | 2件: ADRA2A ADRA2A, DRD2 💬 | 9件: Alcoholism Alcoholism, Cocaine addiction, Dopaminergic synapse, Gap junction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway, cGMP-PKG signaling pathway 💬 | 1件: 2 2 💬 |
2075 | Pimozide 4 mg per day | 1件: Pimozide Pimozide | 1件: Pimozide
Pimozide
💬 | 2件: ADRA2A ADRA2A, DRD2 💬 | 9件: Alcoholism Alcoholism, Cocaine addiction, Dopaminergic synapse, Gap junction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway, cGMP-PKG signaling pathway 💬 | 1件: 2 2 💬 |
2076 | Piperacilline/Tazobactam Fresenius Kabi 2 g/0,25 g poeder voor oplossing voor infusie | 1件: Tazobactam Tazobactam | 1件: Tazobactam
Tazobactam
💬 | - | - | 1件: 299 299 💬 |
2077 | Piperacilline/Tazobactam Fresenius Kabi 4 g/0,5 g poeder voor oplossing voor infusie | 1件: Tazobactam Tazobactam | 1件: Tazobactam
Tazobactam
💬 | - | - | 1件: 299 299 💬 |
2078 | Pirfenidone and nintedanib | 2件: Nintedanib Nintedanib, Pirfenidone | 2件: Pirfenidone
Pirfenidone
,
Nintedanib
💬 | 14件: CCL2 CCL2, FGFR1, FGFR2, FGFR3, FLT1, FLT4, IL10, IL1A, IL1B, IL6, KDR, PDGFRA, PDGFRB, TNF 💬 | 106件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adherens junction, Adipocytokine signaling pathway, African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, Autoimmune thyroid disease, Bladder cancer, Breast cancer, C-type lectin receptor signaling pathway, Calcium signaling pathway, Cellular senescence, Central carbon metabolism in cancer, Chagas disease, Chemokine signaling pathway, Choline metabolism in cancer, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Cytosolic DNA-sensing pathway, Dilated cardiomyopathy, EGFR tyrosine kinase inhibitor resistance, Endocytosis, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Focal adhesion, FoxO signaling pathway, Gap junction, Gastric cancer, Glioma, Graft-versus-host disease, HIF-1 signaling pathway, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Inflammatory mediator regulation of TRP channels, Influenza A, Insulin resistance, Intestinal immune network for IgA production, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, MAPK signaling pathway, Malaria, Measles, Melanoma, MicroRNAs in cancer, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease, Osteoclast differentiation, PI3K-Akt signaling pathway, Parathyroid hormone synthesis, secretion and action, Pathogenic Escherichia coli infection, Pathways in cancer, Pathways of neurodegeneration - multiple diseases, Pertussis, Phospholipase D signaling pathway, Prion disease, Prostate cancer, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rap1 signaling pathway, Ras signaling pathway, Regulation of actin cytoskeleton, Rheumatoid arthritis, Salmonella infection, Shigellosis, Signaling pathways regulating pluripotency of stem cells, Sphingolipid signaling pathway, Staphylococcus aureus infection, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Th17 cell differentiation, Thermogenesis, Toll-like receptor signaling pathway, Toxoplasmosis, Transcriptional misregulation in cancer, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, VEGF signaling pathway, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway 💬 | 1件: 85 85 💬 |
2079 | Pirfenidone or nintedanib | 2件: Nintedanib Nintedanib, Pirfenidone | 2件: Pirfenidone
Pirfenidone
,
Nintedanib
💬 | 14件: CCL2 CCL2, FGFR1, FGFR2, FGFR3, FLT1, FLT4, IL10, IL1A, IL1B, IL6, KDR, PDGFRA, PDGFRB, TNF 💬 | 106件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adherens junction, Adipocytokine signaling pathway, African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, Autoimmune thyroid disease, Bladder cancer, Breast cancer, C-type lectin receptor signaling pathway, Calcium signaling pathway, Cellular senescence, Central carbon metabolism in cancer, Chagas disease, Chemokine signaling pathway, Choline metabolism in cancer, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Cytosolic DNA-sensing pathway, Dilated cardiomyopathy, EGFR tyrosine kinase inhibitor resistance, Endocytosis, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Focal adhesion, FoxO signaling pathway, Gap junction, Gastric cancer, Glioma, Graft-versus-host disease, HIF-1 signaling pathway, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Inflammatory mediator regulation of TRP channels, Influenza A, Insulin resistance, Intestinal immune network for IgA production, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, MAPK signaling pathway, Malaria, Measles, Melanoma, MicroRNAs in cancer, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease, Osteoclast differentiation, PI3K-Akt signaling pathway, Parathyroid hormone synthesis, secretion and action, Pathogenic Escherichia coli infection, Pathways in cancer, Pathways of neurodegeneration - multiple diseases, Pertussis, Phospholipase D signaling pathway, Prion disease, Prostate cancer, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rap1 signaling pathway, Ras signaling pathway, Regulation of actin cytoskeleton, Rheumatoid arthritis, Salmonella infection, Shigellosis, Signaling pathways regulating pluripotency of stem cells, Sphingolipid signaling pathway, Staphylococcus aureus infection, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Th17 cell differentiation, Thermogenesis, Toll-like receptor signaling pathway, Toxoplasmosis, Transcriptional misregulation in cancer, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, VEGF signaling pathway, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway 💬 | 1件: 85 85 💬 |
2080 | PK-Merz® 200mg/500ml inj(Amantadine) , Normal saline 500ml inj | 1件: Amantadine Amantadine | 1件: Amantadine
Amantadine
💬 | 5件: GRIN1 GRIN1, GRIN2A, GRIN2B, GRIN2C, GRIN2D 💬 | 20件: Alcoholism Alcoholism, Alzheimer disease, Amphetamine addiction, Amyotrophic lateral sclerosis, Calcium signaling pathway, Circadian entrainment, Cocaine addiction, Dopaminergic synapse, Glutamatergic synapse, Huntington disease, Long-term potentiation, Neuroactive ligand-receptor interaction, Nicotine addiction, Pathways of neurodegeneration - multiple diseases, Prion disease, Rap1 signaling pathway, Ras signaling pathway, Spinocerebellar ataxia, Systemic lupus erythematosus, cAMP signaling pathway 💬 | 1件: 6 6 💬 |
2081 | PL 00095/5079R | - | - | - | - | 1件: 46 46 💬 |
2082 | PL 0010/0211 | - | - | - | - | 1件: 299 299 💬 |
2083 | PL 00512/0150 | - | - | - | - | 1件: 298 298 💬 |
2084 | PL 04515/0127 | - | - | - | - | 1件: 13 13 💬 |
2085 | PL 12185/0002 & PL 12185/0005(WATER FOR INJECTION) | 1件: Water Water | 1件: Water
Water
💬 | - | - | 1件: 57 57 💬 |
2086 | PL 12762/0049 | - | - | - | - | 1件: 13 13 💬 |
2087 | PL 17901/0122 | - | - | - | - | 1件: 96 96 💬 |
2088 | PL 20532/0012 | - | - | - | - | 1件: 96 96 💬 |
2089 | PLA-695 | - | - | - | - | 1件: 46 46 💬 |
2090 | PLACENTEX ¿ Polydeoxyribonucleotide 5.625 mg/3 ml | - | - | - | - | 1件: 51 51 💬 |
2091 | PLACENTEX ¿5.625 mg/3 ml soluzione iniettabile¿ | - | - | - | - | 1件: 51 51 💬 |
2092 | Plantain NSP | - | - | - | - | 1件: 96 96 💬 |
2093 | PLEGRIDY - 125 MCG - SOLUZIONE INIETTABILE - USO SOTTOCUTANEO - PENNA PRERIEMPITA - 0,5 ML - 6 PENNE PRERIEMPITE | 1件: Peginterferon beta-1a Peginterferon beta-1a | 1件: Peginterferon beta-1a
Peginterferon beta-1a
💬 | 2件: IFNAR1 IFNAR1, IFNAR2 💬 | 18件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Measles, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Osteoclast differentiation, PI3K-Akt signaling pathway, Pathways in cancer, Toll-like receptor signaling pathway 💬 | 1件: 13 13 💬 |
2094 | Plegridy 63 micrograms | 1件: Peginterferon beta-1a Peginterferon beta-1a | 1件: Peginterferon beta-1a
Peginterferon beta-1a
💬 | 2件: IFNAR1 IFNAR1, IFNAR2 💬 | 18件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Measles, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Osteoclast differentiation, PI3K-Akt signaling pathway, Pathways in cancer, Toll-like receptor signaling pathway 💬 | 1件: 13 13 💬 |
2095 | Pleneva TM BGC20-0134 | - | - | - | - | 1件: 13 13 💬 |
2096 | PLF with NeoFuse | - | - | - | - | 1件: 70 70 💬 |
2097 | PLN-74809-000 | 1件: PLN-74809 PLN-74809 | - | - | - | 1件: 85 85 💬 |
2098 | PLN-74809-020 | 1件: PLN-74809 PLN-74809 | - | - | - | 1件: 85 85 💬 |
2099 | Plovamer acetate 0.5 milligram (mg) | 1件: Acetate Acetate | - | - | - | 1件: 13 13 💬 |
2100 | PMG1015 Dose 4 | - | - | - | - | 1件: 85 85 💬 |
2101 | PMG1015 Dose 6 | - | - | - | - | 1件: 85 85 💬 |
2102 | PN 200 tablets (500 mg naproxen and 20 mg omeprazole) | 2件: Naproxen Naproxen, Omeprazole | 2件: Naproxen
Naproxen
,
Omeprazole
💬 | 4件: ATP4A ATP4A, ATP4B, PTGS1, PTGS2 💬 | 26件: Alzheimer disease Alzheimer disease, Arachidonic acid metabolism, C-type lectin receptor signaling pathway, Chemical carcinogenesis - DNA adducts, Collecting duct acid secretion, Gastric acid secretion, Human cytomegalovirus infection, Human papillomavirus infection, IL-17 signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Metabolic pathways, MicroRNAs in cancer, NF-kappa B signaling pathway, Ovarian steroidogenesis, Oxidative phosphorylation, Oxytocin signaling pathway, Pathways in cancer, Pathways of neurodegeneration - multiple diseases, Platelet activation, Regulation of lipolysis in adipocytes, Retrograde endocannabinoid signaling, Serotonergic synapse, Small cell lung cancer, TNF signaling pathway, VEGF signaling pathway 💬 | 2件: 46 46, 271 💬 |
2103 | Pneumococcal polysaccharide serotype 1, 2, 3, 4, 5, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15B, 17F, 18C, 19A, 19F, 20, 22F, 23F and 33F | - | - | - | - | 1件: 46 46 💬 |
2104 | Pneumococcal polysaccharide serotype 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F and 23F | - | - | - | - | 1件: 46 46 💬 |
2105 | Pneumococcal polysaccharide serotype 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, 23F | - | - | - | - | 1件: 222 222 💬 |
2106 | PNEUMOVAX – Soluzione iniettabile in siringa preriempita da 0,5 ml | - | - | - | - | 2件: 62 62, 66 💬 |
2107 | POLY(OXY-1,2-ETHANEDIYL), ALPHA-HYDRO-OMEGA-METHOXY, ETHER WITH N-[[[2- | 1件: Diethyl ether Diethyl ether | 1件: Ether
Ether
💬 | - | - | 1件: 235 235 💬 |
2108 | POLY(OXY-1,2-ETHANEDIYL), ALPHA-HYDRO-OMEGA-METHOXY, ETHER WITH N-[[[2-[[6-[[1-[3-[[3-(2,3-DIHYDROXYPROPOXY)PROPYL]AMINO]-3-OXOPROPYL]-2,5-DI | 1件: Diethyl ether Diethyl ether | 1件: Ether
Ether
💬 | - | - | 1件: 235 235 💬 |
2109 | POLY(OXY-1,2-ETHANEDIYL), ALPHA-HYDRO-OMEGA-METHOXY, ETHER WITH N-[[[2-[[6-[[1-[3-[[3-(2,3-DIHYDROXYPROPOXY)PROPYL]AMINO]-3-OXOPROPYL]-2,5-DIOXO-3-PYRROLIDINYL]THIO]HEXYL]AMINO]ETHYL]AMINO]CARBONYL]-2-METHYLALANYL-TERIPARATIDE (2:1) | 2件: Diethyl ether Diethyl ether, Teriparatide | 2件: Ether
Ether
,
Teriparatide
💬 | 1件: PTH1R PTH1R 💬 | 3件: Endocrine and other factor-regulated calcium reabsorption Endocrine and other factor-regulated calcium reabsorption, Neuroactive ligand-receptor interaction, Parathyroid hormone synthesis, secretion and action 💬 | 1件: 235 235 💬 |
2110 | Pomalidomide (CC-4047 | 1件: Pomalidomide Pomalidomide | 1件: Pomalidomide
Pomalidomide
💬 | 2件: IL6 IL6, TNF 💬 | 80件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Cellular senescence, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Cytosolic DNA-sensing pathway, Dilated cardiomyopathy, EGFR tyrosine kinase inhibitor resistance, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, FoxO signaling pathway, Graft-versus-host disease, HIF-1 signaling pathway, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Intestinal immune network for IgA production, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, MAPK signaling pathway, Malaria, Measles, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease, Osteoclast differentiation, PI3K-Akt signaling pathway, Pathogenic Escherichia coli infection, Pathways in cancer, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Th17 cell differentiation, Toll-like receptor signaling pathway, Toxoplasmosis, Transcriptional misregulation in cancer, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway 💬 | 1件: 85 85 💬 |
2111 | Pomalidomide (CC-4047) | 1件: Pomalidomide Pomalidomide | 1件: Pomalidomide
Pomalidomide
💬 | 2件: IL6 IL6, TNF 💬 | 80件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Cellular senescence, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Cytosolic DNA-sensing pathway, Dilated cardiomyopathy, EGFR tyrosine kinase inhibitor resistance, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, FoxO signaling pathway, Graft-versus-host disease, HIF-1 signaling pathway, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Intestinal immune network for IgA production, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, MAPK signaling pathway, Malaria, Measles, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease, Osteoclast differentiation, PI3K-Akt signaling pathway, Pathogenic Escherichia coli infection, Pathways in cancer, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Th17 cell differentiation, Toll-like receptor signaling pathway, Toxoplasmosis, Transcriptional misregulation in cancer, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway 💬 | 1件: 51 51 💬 |
2112 | Ponesimod 40 mg | 1件: Ponesimod Ponesimod | 1件: Ponesimod
Ponesimod
💬 | 1件: S1PR1 S1PR1 💬 | 3件: FoxO signaling pathway FoxO signaling pathway, Neuroactive ligand-receptor interaction, Sphingolipid signaling pathway 💬 | 1件: 13 13 💬 |
2113 | Posaconazole 100 MG [Noxafil] | 1件: Posaconazole Posaconazole | 1件: Posaconazole
Posaconazole
💬 | - | - | 1件: 299 299 💬 |
2114 | Posaconazole 40 MG/ML | 1件: Posaconazole Posaconazole | 1件: Posaconazole
Posaconazole
💬 | - | - | 1件: 299 299 💬 |
2115 | Positron Emission Tomography using [11 Carbon]-3-amino-4-(2-dimethylaminomethylphenylsulfanyl)-benzonitrile ([11C]-DASB) and [18 Fluorine]-altanserin ([18F]-altanserin) | 1件: Activated charcoal Activated charcoal | - | - | - | 1件: 6 6 💬 |
2116 | Postoperative 3-month exclusive enteral nutrition | - | - | - | - | 1件: 96 96 💬 |
2117 | PR-06410293 | - | - | - | - | 1件: 46 46 💬 |
2118 | PRALIA 60 mg Subcutaneous Injection Syringe(denosumab) | 1件: Denosumab Denosumab | 1件: Denosumab
Denosumab
💬 | 1件: TNFSF11 TNFSF11 💬 | 8件: Breast cancer Breast cancer, Chemical carcinogenesis - receptor activation, Cytokine-cytokine receptor interaction, NF-kappa B signaling pathway, Osteoclast differentiation, Parathyroid hormone synthesis, secretion and action, Prolactin signaling pathway, Rheumatoid arthritis 💬 | 1件: 46 46 💬 |
2119 | PRALIA 60mg Subcutaneous Injection Syringe(denosumab) | 1件: Denosumab Denosumab | 1件: Denosumab
Denosumab
💬 | 1件: TNFSF11 TNFSF11 💬 | 8件: Breast cancer Breast cancer, Chemical carcinogenesis - receptor activation, Cytokine-cytokine receptor interaction, NF-kappa B signaling pathway, Osteoclast differentiation, Parathyroid hormone synthesis, secretion and action, Prolactin signaling pathway, Rheumatoid arthritis 💬 | 1件: 46 46 💬 |
2120 | Pramipexole 0.125 mg tablets | 1件: Pramipexole Pramipexole | 1件: Pramipexole
Pramipexole
💬 | 3件: DRD2 DRD2, DRD3, DRD4 💬 | 8件: Alcoholism Alcoholism, Cocaine addiction, Dopaminergic synapse, Gap junction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway 💬 | 1件: 6 6 💬 |
2121 | Pramipexole 0.5 mg tablets | 1件: Pramipexole Pramipexole | 1件: Pramipexole
Pramipexole
💬 | 3件: DRD2 DRD2, DRD3, DRD4 💬 | 8件: Alcoholism Alcoholism, Cocaine addiction, Dopaminergic synapse, Gap junction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway 💬 | 1件: 6 6 💬 |
2122 | Pramipexole hydrochloride sustained-release tablet (Siforl®) Specification: 0.26mg/ tablet (in pramipexole) | 1件: Pramipexole Pramipexole | 1件: Pramipexole
Pramipexole
💬 | 3件: DRD2 DRD2, DRD3, DRD4 💬 | 8件: Alcoholism Alcoholism, Cocaine addiction, Dopaminergic synapse, Gap junction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway 💬 | 1件: 6 6 💬 |
2123 | Praxol hydrochloride sustained release tablet Specification: 0.375mg/ tablet (in pramipexole hydrochloride) | 1件: Pramipexole Pramipexole | 1件: Pramipexole
Pramipexole
💬 | 3件: DRD2 DRD2, DRD3, DRD4 💬 | 8件: Alcoholism Alcoholism, Cocaine addiction, Dopaminergic synapse, Gap junction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway 💬 | 1件: 6 6 💬 |
2124 | Prednisolone 40 mg | 1件: Prednisolone Prednisolone | 1件: Prednisolone
Prednisolone
💬 | 1件: NR3C1 NR3C1 💬 | 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 1件: 46 46 💬 |
2125 | PREDNISON 5, 20 Léciva por. tablet nob | - | - | - | - | 1件: 50 50 💬 |
2126 | Prednison 5, 20 Léciva por. tablet nob. | - | - | - | - | 1件: 50 50 💬 |
2127 | Prednisone 0,5 mg/kg orally on alternate days | 1件: Prednisone Prednisone | 1件: Prednisone
Prednisone
💬 | 1件: NR3C1 NR3C1 💬 | 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 1件: 222 222 💬 |
2128 | Prednisone 4 mg | 1件: Prednisone Prednisone | 1件: Prednisone
Prednisone
💬 | 1件: NR3C1 NR3C1 💬 | 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 1件: 46 46 💬 |
2129 | Preparative regimen 4-6 weeks after Leukapheresis | - | - | - | - | 1件: 96 96 💬 |
2130 | Prescribe N-acetylcysteine tablets | 1件: Acetylcysteine Acetylcysteine | 1件: Acetylcysteine
Acetylcysteine
💬 | - | - | 1件: 90 90 💬 |
2131 | PREVENAR 13 - 0.5 ML SOSPENSIONE INIETTABILE - USO INTRAMUSCOLARE - FLACONCINO MONODOSE (0,5 ML VETRO TIPO I) - 1 FLACONCINO MONODOSE | 12件: Streptococcus pneumoniae type 1 capsular polysaccharide antigen Streptococcus pneumoniae type 1 capsular polysaccharide antigen, Streptococcus pneumoniae type 14 capsular polysaccharide antigen, Streptococcus pneumoniae type 18c capsular polysaccharide antigen, Streptococcus pneumoniae type 19a capsular polysaccharide antigen, Streptococcus pneumoniae type 19f capsular polysaccharide antigen, Streptococcus pneumoniae type 23f capsular polysaccharide antigen, Streptococcus pneumoniae type 3 capsular polysaccharide antigen, Streptococcus pneumoniae type 4 capsular polysaccharide antigen, Streptococcus pneumoniae type 5 capsular polysaccharide antigen, Streptococcus pneumoniae type 6b capsular polysaccharide antigen, Streptococcus pneumoniae type 7f capsular polysaccharide antigen, Streptococcus pneumoniae type 9v capsular polysaccharide antigen | - | - | - | 1件: 222 222 💬 |
2132 | PRO044 IV 6 mg/kg | - | - | - | - | 1件: 113 113 💬 |
2133 | PRO044 SC 6 mg/kg | - | - | - | - | 1件: 113 113 💬 |
2134 | PRO045, 0.15 mg/kg/week | 1件: BMN-045 BMN-045 | - | - | - | 1件: 113 113 💬 |
2135 | PRO045, 1.0 mg/kg/week | 1件: BMN-045 BMN-045 | - | - | - | 1件: 113 113 💬 |
2136 | PRO045, 3.0 mg/kg/week | 1件: BMN-045 BMN-045 | - | - | - | 1件: 113 113 💬 |
2137 | PRO045, 6.0 mg/kg/week | 1件: BMN-045 BMN-045 | - | - | - | 1件: 113 113 💬 |
2138 | PRO045, 9.0 mg/kg/week | 1件: BMN-045 BMN-045 | - | - | - | 1件: 113 113 💬 |
2139 | PROCAPTAN - 10 MG COMPRESSE RIVESTITE CON FILM 60 COMPRESSE IN CONTENITORE PER COMPRESSE PP | - | - | - | - | 1件: 58 58 💬 |
2140 | Products containing azathioprine or 6-mercaptopurine | 2件: Azathioprine Azathioprine, Mercaptopurine | 3件: Mercaptopurine
Mercaptopurine
,
Azathioprine
,
Mercaptopurine
💬 | 1件: HPRT1 HPRT1 💬 | 4件: Drug metabolism - other enzymes Drug metabolism - other enzymes, Metabolic pathways, Nucleotide metabolism, Purine metabolism 💬 | 1件: 97 97 💬 |
2141 | Prolastin-C, 60 mg/kg | 1件: Alpha-1-proteinase inhibitor Alpha-1-proteinase inhibitor | - | - | - | 1件: 231 231 💬 |
2142 | Promixin 1 million International Units (IU) Powder for Nebuliser Solution | - | - | - | - | 1件: 299 299 💬 |
2143 | PROMIXIN*NEBUL 30MONOD 1MUI | - | - | - | - | 1件: 299 299 💬 |
2144 | Promixin, 1 million International Units (IU) Powder for Nebuliser Solution | - | - | - | - | 1件: 299 299 💬 |
2145 | Promixin,1 millón de Unidades Internacionales,polvo para solución para inhalación por nebulizador | - | - | - | - | 1件: 299 299 💬 |
2146 | Propranolol HCl CF 40 mg tablet | 1件: Propranolol Propranolol | 1件: Propranolol
Propranolol
💬 | 3件: ADRB1 ADRB1, ADRB2, ADRB3 💬 | 12件: Adrenergic signaling in cardiomyocytes Adrenergic signaling in cardiomyocytes, Calcium signaling pathway, Chemical carcinogenesis - receptor activation, Dilated cardiomyopathy, Gap junction, Neuroactive ligand-receptor interaction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Thermogenesis, cAMP signaling pathway, cGMP-PKG signaling pathway 💬 | 1件: 6 6 💬 |
2147 | Proteína recombinante estimulante de la megacariopoyesis | - | - | - | - | 1件: 63 63 💬 |
2148 | Prototype capsule GDC-0134 | 1件: GDC-0134 GDC-0134 | - | - | - | 1件: 2 2 💬 |
2149 | PRTX-100 at 12.0 mcg/kg | - | - | - | - | 1件: 46 46 💬 |
2150 | PRTX-100 at 3.0 mcg/kg | - | - | - | - | 1件: 46 46 💬 |
2151 | PRTX-100 at 420 mcg | - | - | - | - | 1件: 46 46 💬 |
2152 | PRTX-100 at 6.0 mcg/kg | - | - | - | - | 1件: 46 46 💬 |
2153 | PRV-6527 | - | - | - | - | 1件: 96 96 💬 |
2154 | PRV-6527 (JNJ-40346527) | 1件: JNJ-40346527 JNJ-40346527 | - | - | - | 1件: 96 96 💬 |
2155 | PRV-6527(JNJ-40346527) | 1件: JNJ-40346527 JNJ-40346527 | - | - | - | 1件: 96 96 💬 |
2156 | PRX-102 2 mg/kg every 4 weeks | - | - | - | - | 1件: 19 19 💬 |
2157 | Pseudoephedrine + 480 ml water | 2件: Pseudoephedrine Pseudoephedrine, Water | 2件: Water
Water
,
Pseudoephedrine
💬 | 9件: ADRA1A ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C, ADRB1, ADRB2, ADRB3 💬 | 14件: AMPK signaling pathway AMPK signaling pathway, Adrenergic signaling in cardiomyocytes, Calcium signaling pathway, Chemical carcinogenesis - receptor activation, Dilated cardiomyopathy, Gap junction, Neuroactive ligand-receptor interaction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Thermogenesis, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway 💬 | 1件: 17 17 💬 |
2158 | PT320 2.0 mg | - | - | - | - | 1件: 6 6 💬 |
2159 | PTC-0161480 | - | - | - | - | 2件: 246 246, 299 💬 |
2160 | PTH1-84 in parent study | - | - | - | - | 1件: 235 235 💬 |
2161 | PTI-428 | 1件: PTI-428 PTI-428 | - | - | - | 1件: 299 299 💬 |
2162 | PTI-801 | 1件: PTI-801 PTI-801 | - | - | - | 1件: 299 299 💬 |
2163 | PTI-808 | - | - | - | - | 1件: 299 299 💬 |
2164 | PTR-01 | - | - | - | - | 1件: 36 36 💬 |
2165 | PTW-002 10 mg/g gel | - | - | - | - | 1件: 36 36 💬 |
2166 | Puerarin injection 400 mg | 1件: Puerarin Puerarin | - | - | - | 1件: 46 46 💬 |
2167 | PUR 0110 | - | - | - | - | 1件: 97 97 💬 |
2168 | PUR 0110 Rectal Enema | - | - | - | - | 1件: 97 97 💬 |
2169 | PUR 0110 Rectal Enema 1000 mg | - | - | - | - | 1件: 97 97 💬 |
2170 | PUR 0110 Rectal Enema 250 mg | - | - | - | - | 1件: 97 97 💬 |
2171 | PUR 0110 Rectal Enema 500 mg | - | - | - | - | 1件: 97 97 💬 |
2172 | Puri Nethol | - | - | - | - | 1件: 96 96 💬 |
2173 | Puri-Nethol | - | - | - | - | 3件: 86 86, 96, 97 💬 |
2174 | Puri-Nethol 50 mg | - | - | - | - | 1件: 96 96 💬 |
2175 | Pyruvate, creatine, niacinamide | 2件: Creatine Creatine, Nicotinamide | 1件: Niacinamide
Niacinamide
💬 | - | - | 1件: 5 5 💬 |
2176 | PZN 8881655(RochePharma AG) | - | - | - | - | 1件: 85 85 💬 |
2177 | Q4W GMA301 IV injections (600 mg) | - | - | - | - | 1件: 86 86 💬 |
2178 | QCC374 0.015 mg | - | - | - | - | 1件: 86 86 💬 |
2179 | QCC374 0.06 mg | - | - | - | - | 1件: 86 86 💬 |
2180 | Qingkailing injection 40 ml | - | - | - | - | 1件: 46 46 💬 |
2181 | QLS-101 ophthalmic solution, 2.0 % | - | - | - | - | 1件: 157 157 💬 |
2182 | QOL assessment, Neuropsychological | - | - | - | - | 1件: 34 34 💬 |
2183 | QR-010 | - | - | - | - | 1件: 299 299 💬 |
2184 | QR-421a | - | - | - | - | 2件: 90 90, 303 💬 |
2185 | QRL-201 - Dose 4 | - | - | - | - | 1件: 2 2 💬 |
2186 | QRL-201 - Dose 6 | - | - | - | - | 1件: 2 2 💬 |
2187 | QRL-201- Dose 8 | - | - | - | - | 1件: 2 2 💬 |
2188 | QTXEW2-04-AF, EW2, GC-1, QRX-431 | - | - | - | - | 1件: 20 20 💬 |
2189 | Qutenza (8% capsaicin) | 1件: Capsaicin Capsaicin | 1件: Capsaicin
Capsaicin
💬 | 1件: TRPV1 TRPV1 💬 | 2件: Inflammatory mediator regulation of TRP channels Inflammatory mediator regulation of TRP channels, Neuroactive ligand-receptor interaction 💬 | 1件: 86 86 💬 |
2190 | R-021 | - | - | - | - | 1件: 222 222 💬 |
2191 | R788 sodium hexahydrate, RIG2-01, RIG-G | - | - | - | - | 1件: 46 46 💬 |
2192 | R788 Sodium, R788 Na, R788 | - | - | - | - | 1件: 46 46 💬 |
2193 | RAAV 2/6 hIDS DONOR | - | - | - | - | 1件: 19 19 💬 |
2194 | RAAV2-ND4 | - | - | - | - | 1件: 302 302 💬 |
2195 | RAAV2/2-ND4 VECTOR | - | - | - | - | 1件: 302 302 💬 |
2196 | RAAV2/5-PBGD vector dosage 4 | - | - | - | - | 1件: 254 254 💬 |
2197 | RAAV2/6 Left ZFN Vector | - | - | - | - | 1件: 19 19 💬 |
2198 | RAAV2/6 Right ZFN Vector | - | - | - | - | 1件: 19 19 💬 |
2199 | Radiolabelled OligoG CF-5/20 6% Solution | - | - | - | - | 1件: 299 299 💬 |
2200 | Radiolabelled OligoG CF-5/20 6% Solution for Nebulisation | - | - | - | - | 1件: 299 299 💬 |
2201 | RANEXA - 750 MG - COMPRESSA A RILASCIO PROLUNGATO- USO ORALE - BLISTER (PVC/PVDC/ALLUMINIO) 60 COMPRESSE | 1件: Ranolazine Ranolazine | 1件: Ranolazine
Ranolazine
💬 | - | - | 1件: 58 58 💬 |
2202 | RANEXA*60CPR 500MG R.P. | 1件: Ranolazine Ranolazine | 1件: Ranolazine
Ranolazine
💬 | - | - | 1件: 58 58 💬 |
2203 | RANEXA*60CPR 750MG R.P. | 1件: Ranolazine Ranolazine | 1件: Ranolazine
Ranolazine
💬 | - | - | 1件: 58 58 💬 |
2204 | Ranibizumab injection (0.5 mg) | 1件: Ranibizumab Ranibizumab | 1件: Ranibizumab
Ranibizumab
💬 | 1件: VEGFA VEGFA 💬 | 24件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Bladder cancer, Calcium signaling pathway, Chemical carcinogenesis - reactive oxygen species, Chemical carcinogenesis - receptor activation, EGFR tyrosine kinase inhibitor resistance, Fluid shear stress and atherosclerosis, Focal adhesion, HIF-1 signaling pathway, Human cytomegalovirus infection, Human papillomavirus infection, Kaposi sarcoma-associated herpesvirus infection, MAPK signaling pathway, MicroRNAs in cancer, PI3K-Akt signaling pathway, Pancreatic cancer, Pathways in cancer, Proteoglycans in cancer, Rap1 signaling pathway, Ras signaling pathway, Relaxin signaling pathway, Renal cell carcinoma, Rheumatoid arthritis, VEGF signaling pathway 💬 | 2件: 166 166, 301 💬 |
2205 | Rapamune 1 mg/ml solución oral | 1件: Sirolimus Sirolimus | 1件: Sirolimus
Sirolimus
💬 | 1件: MTOR MTOR 💬 | 51件: AMPK signaling pathway AMPK signaling pathway, Acute myeloid leukemia, Adipocytokine signaling pathway, Alzheimer disease, Amyotrophic lateral sclerosis, Apelin signaling pathway, Autophagy - animal, Autophagy - other, Breast cancer, Cellular senescence, Central carbon metabolism in cancer, Chemical carcinogenesis - receptor activation, Choline metabolism in cancer, Colorectal cancer, Diabetic cardiomyopathy, EGFR tyrosine kinase inhibitor resistance, Endocrine resistance, ErbB signaling pathway, Gastric cancer, Glioma, Growth hormone synthesis, secretion and action, HIF-1 signaling pathway, Hepatocellular carcinoma, Herpes simplex virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Huntington disease, Insulin resistance, Insulin signaling pathway, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Longevity regulating pathway, Longevity regulating pathway - multiple species, MicroRNAs in cancer, Neutrophil extracellular trap formation, PD-L1 expression and PD-1 checkpoint pathway in cancer, PI3K-Akt signaling pathway, Pancreatic cancer, Pathways in cancer, Pathways of neurodegeneration - multiple diseases, Phospholipase D signaling pathway, Prostate cancer, Proteoglycans in cancer, Shigellosis, Spinocerebellar ataxia, Th17 cell differentiation, Thermogenesis, Thyroid hormone signaling pathway, Type II diabetes mellitus, mTOR signaling pathway 💬 | 1件: 158 158 💬 |
2206 | Rapamycin cream, topical, 0.5%, 1.0% w/w | 1件: Sirolimus Sirolimus | 1件: Sirolimus
Sirolimus
💬 | 1件: MTOR MTOR 💬 | 51件: AMPK signaling pathway AMPK signaling pathway, Acute myeloid leukemia, Adipocytokine signaling pathway, Alzheimer disease, Amyotrophic lateral sclerosis, Apelin signaling pathway, Autophagy - animal, Autophagy - other, Breast cancer, Cellular senescence, Central carbon metabolism in cancer, Chemical carcinogenesis - receptor activation, Choline metabolism in cancer, Colorectal cancer, Diabetic cardiomyopathy, EGFR tyrosine kinase inhibitor resistance, Endocrine resistance, ErbB signaling pathway, Gastric cancer, Glioma, Growth hormone synthesis, secretion and action, HIF-1 signaling pathway, Hepatocellular carcinoma, Herpes simplex virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Huntington disease, Insulin resistance, Insulin signaling pathway, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Longevity regulating pathway, Longevity regulating pathway - multiple species, MicroRNAs in cancer, Neutrophil extracellular trap formation, PD-L1 expression and PD-1 checkpoint pathway in cancer, PI3K-Akt signaling pathway, Pancreatic cancer, Pathways in cancer, Pathways of neurodegeneration - multiple diseases, Phospholipase D signaling pathway, Prostate cancer, Proteoglycans in cancer, Shigellosis, Spinocerebellar ataxia, Th17 cell differentiation, Thermogenesis, Thyroid hormone signaling pathway, Type II diabetes mellitus, mTOR signaling pathway 💬 | 1件: 158 158 💬 |
2207 | Rasagiline mesylate 1.0 mg | 1件: Rasagiline Rasagiline | 2件: Rasagiline
Rasagiline
,
Rasagiline tartrate
💬 | 1件: MAOB MAOB 💬 | 14件: Alcoholism Alcoholism, Amphetamine addiction, Arginine and proline metabolism, Cocaine addiction, Dopaminergic synapse, Drug metabolism - cytochrome P450, Glycine, serine and threonine metabolism, Histidine metabolism, Metabolic pathways, Parkinson disease, Phenylalanine metabolism, Serotonergic synapse, Tryptophan metabolism, Tyrosine metabolism 💬 | 1件: 6 6 💬 |
2208 | RAvPAL-PEG 0.001 mg/kg | 1件: Pegvaliase Pegvaliase | 1件: Pegvaliase
Pegvaliase
💬 | 1件: PAH PAH 💬 | 5件: Biosynthesis of amino acids Biosynthesis of amino acids, Folate biosynthesis, Metabolic pathways, Phenylalanine metabolism, Phenylalanine, tyrosine and tryptophan biosynthesis 💬 | 1件: 240 240 💬 |
2209 | RAvPAL-PEG 0.003 mg/kg | 1件: Pegvaliase Pegvaliase | 1件: Pegvaliase
Pegvaliase
💬 | 1件: PAH PAH 💬 | 5件: Biosynthesis of amino acids Biosynthesis of amino acids, Folate biosynthesis, Metabolic pathways, Phenylalanine metabolism, Phenylalanine, tyrosine and tryptophan biosynthesis 💬 | 1件: 240 240 💬 |
2210 | RAvPAL-PEG 0.01 mg/kg | 1件: Pegvaliase Pegvaliase | 1件: Pegvaliase
Pegvaliase
💬 | 1件: PAH PAH 💬 | 5件: Biosynthesis of amino acids Biosynthesis of amino acids, Folate biosynthesis, Metabolic pathways, Phenylalanine metabolism, Phenylalanine, tyrosine and tryptophan biosynthesis 💬 | 1件: 240 240 💬 |
2211 | RAvPAL-PEG 0.03 mg/kg | 1件: Pegvaliase Pegvaliase | 1件: Pegvaliase
Pegvaliase
💬 | 1件: PAH PAH 💬 | 5件: Biosynthesis of amino acids Biosynthesis of amino acids, Folate biosynthesis, Metabolic pathways, Phenylalanine metabolism, Phenylalanine, tyrosine and tryptophan biosynthesis 💬 | 1件: 240 240 💬 |
2212 | RAvPAL-PEG 0.1 mg/kg | 1件: Pegvaliase Pegvaliase | 1件: Pegvaliase
Pegvaliase
💬 | 1件: PAH PAH 💬 | 5件: Biosynthesis of amino acids Biosynthesis of amino acids, Folate biosynthesis, Metabolic pathways, Phenylalanine metabolism, Phenylalanine, tyrosine and tryptophan biosynthesis 💬 | 1件: 240 240 💬 |
2213 | RC18 80 mg plus standard therapy | - | - | - | - | 1件: 49 49 💬 |
2214 | Rcombinant Human Parathyroid Hormone [rhPTH(1-84)] | 1件: Parathyroid hormone Parathyroid hormone | 1件: Parathyroid hormone
Parathyroid hormone
💬 | 2件: PTH1R PTH1R, PTH2R 💬 | 3件: Endocrine and other factor-regulated calcium reabsorption Endocrine and other factor-regulated calcium reabsorption, Neuroactive ligand-receptor interaction, Parathyroid hormone synthesis, secretion and action 💬 | 1件: 235 235 💬 |
2215 | RCTB-401 | - | - | - | - | 1件: 96 96 💬 |
2216 | RE-021 | - | - | - | - | 3件: 66 66, 218, 222 💬 |
2217 | RE-021 (Sparsentan) | 1件: Sparsentan Sparsentan | 1件: Sparsentan
Sparsentan
💬 | 2件: AGTR1 AGTR1, EDNRA 💬 | 17件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adrenergic signaling in cardiomyocytes, Aldosterone synthesis and secretion, Apelin signaling pathway, Calcium signaling pathway, Coronavirus disease - COVID-19, Cortisol synthesis and secretion, Cushing syndrome, Diabetic cardiomyopathy, Neuroactive ligand-receptor interaction, Pathways in cancer, Phospholipase D signaling pathway, Renin secretion, Renin-angiotensin system, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway 💬 | 1件: 222 222 💬 |
2218 | RE-024 | - | - | - | - | 1件: 120 120 💬 |
2219 | REBIF - 44 MCG(12 MILIONI UI) -SOLUZ INIETTABILE- USO SOTTOCUTANEO-PENNA PRERIEMPITA 0.5 ML (24 MILIONI UI/ML)12 PENNE PRERIEMPITE | 1件: Interferon beta-1a Interferon beta-1a | 1件: Interferon beta-1a
Interferon beta-1a
💬 | 2件: IFNAR1 IFNAR1, IFNAR2 💬 | 18件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Measles, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Osteoclast differentiation, PI3K-Akt signaling pathway, Pathways in cancer, Toll-like receptor signaling pathway 💬 | 1件: 13 13 💬 |
2220 | Rebif 22 y 44 mcg | 1件: Interferon beta-1a Interferon beta-1a | 1件: Interferon beta-1a
Interferon beta-1a
💬 | 2件: IFNAR1 IFNAR1, IFNAR2 💬 | 18件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Measles, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Osteoclast differentiation, PI3K-Akt signaling pathway, Pathways in cancer, Toll-like receptor signaling pathway 💬 | 1件: 13 13 💬 |
2221 | Rebif 44 | 1件: Interferon beta-1a Interferon beta-1a | 1件: Interferon beta-1a
Interferon beta-1a
💬 | 2件: IFNAR1 IFNAR1, IFNAR2 💬 | 18件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Measles, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Osteoclast differentiation, PI3K-Akt signaling pathway, Pathways in cancer, Toll-like receptor signaling pathway 💬 | 1件: 13 13 💬 |
2222 | Rebif 44 microgrammi/0.5ml soluzione iniettabile in cartuccia | 1件: Interferon beta-1a Interferon beta-1a | 1件: Interferon beta-1a
Interferon beta-1a
💬 | 2件: IFNAR1 IFNAR1, IFNAR2 💬 | 18件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Measles, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Osteoclast differentiation, PI3K-Akt signaling pathway, Pathways in cancer, Toll-like receptor signaling pathway 💬 | 1件: 13 13 💬 |
2223 | REBIF 44 microgramos solución inyectable | 1件: Interferon beta-1a Interferon beta-1a | 1件: Interferon beta-1a
Interferon beta-1a
💬 | 2件: IFNAR1 IFNAR1, IFNAR2 💬 | 18件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Measles, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Osteoclast differentiation, PI3K-Akt signaling pathway, Pathways in cancer, Toll-like receptor signaling pathway 💬 | 1件: 13 13 💬 |
2224 | REBIF 44 microgramos solución inyectable en jeringa precargada | 1件: Interferon beta-1a Interferon beta-1a | 1件: Interferon beta-1a
Interferon beta-1a
💬 | 2件: IFNAR1 IFNAR1, IFNAR2 💬 | 18件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Measles, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Osteoclast differentiation, PI3K-Akt signaling pathway, Pathways in cancer, Toll-like receptor signaling pathway 💬 | 1件: 13 13 💬 |
2225 | Rebif 44 micrograms | 1件: Interferon beta-1a Interferon beta-1a | 1件: Interferon beta-1a
Interferon beta-1a
💬 | 2件: IFNAR1 IFNAR1, IFNAR2 💬 | 18件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Measles, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Osteoclast differentiation, PI3K-Akt signaling pathway, Pathways in cancer, Toll-like receptor signaling pathway 💬 | 1件: 13 13 💬 |
2226 | Rebif 44 micrograms solution for injection | 1件: Interferon beta-1a Interferon beta-1a | 1件: Interferon beta-1a
Interferon beta-1a
💬 | 2件: IFNAR1 IFNAR1, IFNAR2 💬 | 18件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Measles, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Osteoclast differentiation, PI3K-Akt signaling pathway, Pathways in cancer, Toll-like receptor signaling pathway 💬 | 1件: 13 13 💬 |
2227 | Rebif 44 micrograms solution for injection in pre-filled syringe | 1件: Interferon beta-1a Interferon beta-1a | 1件: Interferon beta-1a
Interferon beta-1a
💬 | 2件: IFNAR1 IFNAR1, IFNAR2 💬 | 18件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Measles, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Osteoclast differentiation, PI3K-Akt signaling pathway, Pathways in cancer, Toll-like receptor signaling pathway 💬 | 1件: 13 13 💬 |
2228 | Rebif 44 µg | 1件: Interferon beta-1a Interferon beta-1a | 1件: Interferon beta-1a
Interferon beta-1a
💬 | 2件: IFNAR1 IFNAR1, IFNAR2 💬 | 18件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Measles, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Osteoclast differentiation, PI3K-Akt signaling pathway, Pathways in cancer, Toll-like receptor signaling pathway 💬 | 1件: 13 13 💬 |
2229 | Rebif 44® | 1件: Interferon beta-1a Interferon beta-1a | 1件: Interferon beta-1a
Interferon beta-1a
💬 | 2件: IFNAR1 IFNAR1, IFNAR2 💬 | 18件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Measles, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Osteoclast differentiation, PI3K-Akt signaling pathway, Pathways in cancer, Toll-like receptor signaling pathway 💬 | 1件: 13 13 💬 |
2230 | Rebif 8,8 µg, Rebif 22µg | 1件: Interferon beta-1a Interferon beta-1a | 1件: Interferon beta-1a
Interferon beta-1a
💬 | 2件: IFNAR1 IFNAR1, IFNAR2 💬 | 18件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Measles, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Osteoclast differentiation, PI3K-Akt signaling pathway, Pathways in cancer, Toll-like receptor signaling pathway 💬 | 1件: 13 13 💬 |
2231 | Rebif 8.8 micrograms and 22 micrograms solution for injection in pre-filled syringe initiation pack | 1件: Interferon beta-1a Interferon beta-1a | 1件: Interferon beta-1a
Interferon beta-1a
💬 | 2件: IFNAR1 IFNAR1, IFNAR2 💬 | 18件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Measles, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Osteoclast differentiation, PI3K-Akt signaling pathway, Pathways in cancer, Toll-like receptor signaling pathway 💬 | 1件: 13 13 💬 |
2232 | Rebif 8.8 micrograms and 22 micrograms solution for injection in pre-filled syringe initiation pack. | 1件: Interferon beta-1a Interferon beta-1a | 1件: Interferon beta-1a
Interferon beta-1a
💬 | 2件: IFNAR1 IFNAR1, IFNAR2 💬 | 18件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Measles, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Osteoclast differentiation, PI3K-Akt signaling pathway, Pathways in cancer, Toll-like receptor signaling pathway 💬 | 1件: 13 13 💬 |
2233 | Rebif New Formulation + ibuprofen PRN | 1件: Ibuprofen Ibuprofen | 1件: Ibuprofen
Ibuprofen
💬 | 2件: PTGS1 PTGS1, PTGS2 💬 | 23件: Alzheimer disease Alzheimer disease, Arachidonic acid metabolism, C-type lectin receptor signaling pathway, Chemical carcinogenesis - DNA adducts, Human cytomegalovirus infection, Human papillomavirus infection, IL-17 signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Metabolic pathways, MicroRNAs in cancer, NF-kappa B signaling pathway, Ovarian steroidogenesis, Oxytocin signaling pathway, Pathways in cancer, Pathways of neurodegeneration - multiple diseases, Platelet activation, Regulation of lipolysis in adipocytes, Retrograde endocannabinoid signaling, Serotonergic synapse, Small cell lung cancer, TNF signaling pathway, VEGF signaling pathway 💬 | 1件: 13 13 💬 |
2234 | Rebif New Formulation + prophylactic Ibuprofen | 1件: Ibuprofen Ibuprofen | 1件: Ibuprofen
Ibuprofen
💬 | 2件: PTGS1 PTGS1, PTGS2 💬 | 23件: Alzheimer disease Alzheimer disease, Arachidonic acid metabolism, C-type lectin receptor signaling pathway, Chemical carcinogenesis - DNA adducts, Human cytomegalovirus infection, Human papillomavirus infection, IL-17 signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Metabolic pathways, MicroRNAs in cancer, NF-kappa B signaling pathway, Ovarian steroidogenesis, Oxytocin signaling pathway, Pathways in cancer, Pathways of neurodegeneration - multiple diseases, Platelet activation, Regulation of lipolysis in adipocytes, Retrograde endocannabinoid signaling, Serotonergic synapse, Small cell lung cancer, TNF signaling pathway, VEGF signaling pathway 💬 | 1件: 13 13 💬 |
2235 | Rebif New Formulation 44mcg multidose cartridge | 1件: Interferon beta-1a Interferon beta-1a | 1件: Interferon beta-1a
Interferon beta-1a
💬 | 2件: IFNAR1 IFNAR1, IFNAR2 💬 | 18件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Measles, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Osteoclast differentiation, PI3K-Akt signaling pathway, Pathways in cancer, Toll-like receptor signaling pathway 💬 | 1件: 13 13 💬 |
2236 | Rebif New Formulation Non Titrated | 1件: Interferon beta-1a Interferon beta-1a | 1件: Interferon beta-1a
Interferon beta-1a
💬 | 2件: IFNAR1 IFNAR1, IFNAR2 💬 | 18件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Measles, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Osteoclast differentiation, PI3K-Akt signaling pathway, Pathways in cancer, Toll-like receptor signaling pathway 💬 | 1件: 13 13 💬 |
2237 | Rebif New Formulation Titrated | 1件: Interferon beta-1a Interferon beta-1a | 1件: Interferon beta-1a
Interferon beta-1a
💬 | 2件: IFNAR1 IFNAR1, IFNAR2 💬 | 18件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Measles, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Osteoclast differentiation, PI3K-Akt signaling pathway, Pathways in cancer, Toll-like receptor signaling pathway 💬 | 1件: 13 13 💬 |
2238 | REBIF SC 12SIR 6000000UI 22MCG | 1件: Interferon beta-1a Interferon beta-1a | 1件: Interferon beta-1a
Interferon beta-1a
💬 | 2件: IFNAR1 IFNAR1, IFNAR2 💬 | 18件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Measles, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Osteoclast differentiation, PI3K-Akt signaling pathway, Pathways in cancer, Toll-like receptor signaling pathway 💬 | 1件: 13 13 💬 |
2239 | REBIF*SC 12SIR 6000000UI 22MCG | 1件: Interferon beta-1a Interferon beta-1a | 1件: Interferon beta-1a
Interferon beta-1a
💬 | 2件: IFNAR1 IFNAR1, IFNAR2 💬 | 18件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Measles, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Osteoclast differentiation, PI3K-Akt signaling pathway, Pathways in cancer, Toll-like receptor signaling pathway 💬 | 1件: 13 13 💬 |
2240 | Rebif® (clone 484-39) | 1件: Interferon beta-1a Interferon beta-1a | 1件: Interferon beta-1a
Interferon beta-1a
💬 | 2件: IFNAR1 IFNAR1, IFNAR2 💬 | 18件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Measles, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Osteoclast differentiation, PI3K-Akt signaling pathway, Pathways in cancer, Toll-like receptor signaling pathway 💬 | 1件: 13 13 💬 |
2241 | Rebif® New Formulation | 1件: Interferon beta-1a Interferon beta-1a | 1件: Interferon beta-1a
Interferon beta-1a
💬 | 2件: IFNAR1 IFNAR1, IFNAR2 💬 | 18件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Measles, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Osteoclast differentiation, PI3K-Akt signaling pathway, Pathways in cancer, Toll-like receptor signaling pathway 💬 | 1件: 13 13 💬 |
2242 | Rebif® New Formulation (IFN-beta-1a, RNF) | 1件: Interferon beta-1a Interferon beta-1a | 1件: Interferon beta-1a
Interferon beta-1a
💬 | 2件: IFNAR1 IFNAR1, IFNAR2 💬 | 18件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Measles, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Osteoclast differentiation, PI3K-Akt signaling pathway, Pathways in cancer, Toll-like receptor signaling pathway 💬 | 1件: 13 13 💬 |
2243 | Rebif® new formulation (RNF) | 1件: Interferon beta-1a Interferon beta-1a | 1件: Interferon beta-1a
Interferon beta-1a
💬 | 2件: IFNAR1 IFNAR1, IFNAR2 💬 | 18件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Measles, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Osteoclast differentiation, PI3K-Akt signaling pathway, Pathways in cancer, Toll-like receptor signaling pathway 💬 | 1件: 13 13 💬 |
2244 | Rebif® New Formulation (RNF) using RebiSmartTM | 1件: Interferon beta-1a Interferon beta-1a | 1件: Interferon beta-1a
Interferon beta-1a
💬 | 2件: IFNAR1 IFNAR1, IFNAR2 💬 | 18件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Measles, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Osteoclast differentiation, PI3K-Akt signaling pathway, Pathways in cancer, Toll-like receptor signaling pathway 💬 | 1件: 13 13 💬 |
2245 | Recombinant AAV vector serotype 2 containing the human wild type mitochondrial ND4 gene | - | - | - | - | 1件: 302 302 💬 |
2246 | Recombinant AAV vector serotype 2 containing the human wild typemitochondrial ND4 gene | - | - | - | - | 1件: 302 302 💬 |
2247 | Recombinant Adeno-Associated Viral vector, serotype 2 (rAAV2/2) containing the human wild-type mitochondrial NADH Dehydrogenase 4 gene (ND4) | 1件: NADH NADH | - | - | - | 1件: 302 302 💬 |
2248 | Recombinant Adeno-associated virus 2/6 vector encoding the cDNA for human alpha galactosidase A | - | - | - | - | 1件: 19 19 💬 |
2249 | Recombinant antihumanized anti-human monoclonal antibody directed against the IL-6R | - | - | - | - | 1件: 107 107 💬 |
2250 | Recombinant form of human nerve growth factor produced in Escherichia Coli. | 2件: Escherichia coli Escherichia coli, Nerve Growth Factor | - | - | - | 1件: 53 53 💬 |
2251 | RECOMBINANT HUMAN ?-GLUCOSIDASE CONJUGATED WITH SYNTHETIC BISMANNOSE-6-PHOSPHATE-MAN6 GLYCAN | 1件: Phosphate ion Phosphate ion | - | - | - | 1件: 256 256 💬 |
2252 | Recombinant human a-glucosidase conjugated with multiple copies of synthetic bis-mannose-6-phosphate-tetra-mannose glycan (NEOGAA) | 3件: Avalglucosidase alfa Avalglucosidase alfa, Mannose, Phosphate ion | 1件: Avalglucosidase alfa
Avalglucosidase alfa
💬 | 1件: GAA GAA 💬 | 4件: Galactose metabolism Galactose metabolism, Lysosome, Metabolic pathways, Starch and sucrose metabolism 💬 | 1件: 256 256 💬 |
2253 | Recombinant human a-glucosidase conjugated with multiple copies of synthetic bis-mannose-6-phosphate-tetra-mannose glycan Avalglucosidase Alfa (NeoGAA) | 3件: Avalglucosidase alfa Avalglucosidase alfa, Mannose, Phosphate ion | 1件: Avalglucosidase alfa
Avalglucosidase alfa
💬 | 1件: GAA GAA 💬 | 4件: Galactose metabolism Galactose metabolism, Lysosome, Metabolic pathways, Starch and sucrose metabolism 💬 | 1件: 256 256 💬 |
2254 | RECOMBINANT HUMAN ALFA-GLUCOSIDASE CONJUGATED WITH SYNTHETIC BISMANNOSE-6-PHOSPHATE-MAN6 GLYCAN | 1件: Phosphate ion Phosphate ion | - | - | - | 1件: 256 256 💬 |
2255 | Recombinant Human Alpha-N-Acetylglucosaminidase (rhNAGLU) | - | - | - | - | 1件: 19 19 💬 |
2256 | Recombinant human anti-GDF-8 antibody | - | - | - | - | 1件: 113 113 💬 |
2257 | Recombinant human Arysulfatase B, recombinant human N-acetylgalactosamine 4-sulfatase | - | - | - | - | 1件: 19 19 💬 |
2258 | Recombinant human brain natriuretic peptide (rhBNP) | - | - | - | - | 1件: 215 215 💬 |
2259 | Recombinant human Cerebral Dopamine Neurotrophic Factor | 1件: Dopamine Dopamine | 1件: Dopamine
Dopamine
💬 | 5件: DRD1 DRD1, DRD2, DRD3, DRD4, DRD5 💬 | 11件: Alcoholism Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway 💬 | 1件: 6 6 💬 |
2260 | Recombinant human heparan N-sulfatase | - | - | - | - | 1件: 19 19 💬 |
2261 | Recombinant human heparan N-sulfatase (rhHNS) | - | - | - | - | 1件: 19 19 💬 |
2262 | Recombinant human heparan N-sulfatase [rhHNS] | - | - | - | - | 1件: 19 19 💬 |
2263 | Recombinant human heparan Nsulfatase (rhHNS) | - | - | - | - | 1件: 19 19 💬 |
2264 | Recombinant human N-acetylgalactosamine 4-sulfatase | - | - | - | - | 1件: 19 19 💬 |
2265 | Recombinant human N-acetylgalactosamine 6-sulfatase, BMN 110 | - | - | - | - | 1件: 19 19 💬 |
2266 | Recombinant human N-acetylgalactosamine 6-sulfatase, BMN 110 drug substance | - | - | - | - | 1件: 19 19 💬 |
2267 | Recombinant human N-acetylgalactosamine-6-sulfatase | 1件: Elosulfase alfa Elosulfase alfa | 1件: Elosulfase alfa
Elosulfase alfa
💬 | 1件: GALNS GALNS 💬 | 3件: Glycosaminoglycan degradation Glycosaminoglycan degradation, Lysosome, Metabolic pathways 💬 | 1件: 19 19 💬 |
2268 | Recombinant human N-acetylgalactosamine-6-sulfatase (rhGALNS) | 1件: Elosulfase alfa Elosulfase alfa | 1件: Elosulfase alfa
Elosulfase alfa
💬 | 1件: GALNS GALNS 💬 | 3件: Glycosaminoglycan degradation Glycosaminoglycan degradation, Lysosome, Metabolic pathways 💬 | 1件: 19 19 💬 |
2269 | Recombinant human N-acetylgalactosamine-6-sulfatase, BMN 110 | 1件: Elosulfase alfa Elosulfase alfa | 1件: Elosulfase alfa
Elosulfase alfa
💬 | 1件: GALNS GALNS 💬 | 3件: Glycosaminoglycan degradation Glycosaminoglycan degradation, Lysosome, Metabolic pathways 💬 | 1件: 19 19 💬 |
2270 | Recombinant human N-acetylgalactosamine-6-sulfatase, BMN 110 drug substance | 1件: Elosulfase alfa Elosulfase alfa | 1件: Elosulfase alfa
Elosulfase alfa
💬 | 1件: GALNS GALNS 💬 | 3件: Glycosaminoglycan degradation Glycosaminoglycan degradation, Lysosome, Metabolic pathways 💬 | 1件: 19 19 💬 |
2271 | Recombinant human Nacetylgalactosamine- | - | - | - | - | 1件: 19 19 💬 |
2272 | Recombinant Human Nerve Growth Factor (rhNGF) | 2件: Cenegermin Cenegermin, Nerve Growth Factor | 1件: Cenegermin
Cenegermin
💬 | 1件: NGFR NGFR 💬 | 9件: Apoptosis - multiple species Apoptosis - multiple species, Cytokine-cytokine receptor interaction, MAPK signaling pathway, Neurotrophin signaling pathway, PI3K-Akt signaling pathway, Rap1 signaling pathway, Ras signaling pathway, Transcriptional misregulation in cancer, Virion - Lyssavirus 💬 | 2件: 53 53, 90 💬 |
2273 | RECOMBINANT HUMAN PARATHYROID HORMONE (1-84) | 1件: Parathyroid hormone Parathyroid hormone | 1件: Parathyroid hormone
Parathyroid hormone
💬 | 2件: PTH1R PTH1R, PTH2R 💬 | 3件: Endocrine and other factor-regulated calcium reabsorption Endocrine and other factor-regulated calcium reabsorption, Neuroactive ligand-receptor interaction, Parathyroid hormone synthesis, secretion and action 💬 | 1件: 235 235 💬 |
2274 | Recombinant Human Parathyroid Hormone [rhPTH(1-84)] | 1件: Parathyroid hormone Parathyroid hormone | 1件: Parathyroid hormone
Parathyroid hormone
💬 | 2件: PTH1R PTH1R, PTH2R 💬 | 3件: Endocrine and other factor-regulated calcium reabsorption Endocrine and other factor-regulated calcium reabsorption, Neuroactive ligand-receptor interaction, Parathyroid hormone synthesis, secretion and action 💬 | 1件: 235 235 💬 |
2275 | Recombinant humanised anti-human monoclonal antibody directed against the IL-6R | - | - | - | - | 1件: 46 46 💬 |
2276 | Recombinant humanized anti-alpha 4 integrin antibody | - | - | - | - | 1件: 13 13 💬 |
2277 | Recombinant humanized anti-human Interleukin 6-Receptor (IL-6R) monoclonal | - | - | - | - | 1件: 46 46 💬 |
2278 | Recombinant humanized anti-human Interleukin 6-Receptor (IL-6R) monoclonal antibody | - | - | - | - | 1件: 46 46 💬 |
2279 | Recombinant humanized anti-human Interleukin-6 | - | - | - | - | 1件: 46 46 💬 |
2280 | Recombinant humanized anti-human Interleukin-6 Receptor (IL-6R) monoclonal antibody | - | - | - | - | 1件: 46 46 💬 |
2281 | Recombinant humanized anti-human monoclonal antibody directed against the IL-6R | - | - | - | - | 3件: 46 46, 51, 107 💬 |
2282 | Recombinant Humanized Anti-interleukin-6 Receptor Monoclonal Antibody Injection 4mg/kg | - | - | - | - | 1件: 331 331 💬 |
2283 | Recombinant Humanized Anti-interleukin-6 Receptor Monoclonal Antibody Injection 6mg/kg | - | - | - | - | 1件: 331 331 💬 |
2284 | Recombinant Humanized Anti-interleukin-6 Receptor Monoclonal Antibody Injection 8mg/kg | - | - | - | - | 1件: 331 331 💬 |
2285 | RECOMBINANT NEISSERIA | - | - | - | - | 1件: 11 11 💬 |
2286 | RECOMBINANT NEISSERIA MENINGITIDIS GROUP B FHBP FUSION PROTEIN PRODUCED IN E.COLI CELLS BY RECOMBINANT DNA TECHNOLOGY ADSORBED ON ALUMINIUM HYDROXIDE | 5件: Aluminium Aluminium, Aluminum hydroxide, Hydroxide ion, Iron polymaltose, Lactobacillus casei | 2件: Aluminum hydroxide
Aluminum hydroxide
,
Lactobacillus casei
💬 | - | - | 1件: 11 11 💬 |
2287 | RECOMBINANT NEISSERIA MENINGITIDIS GROUP B NADA PROTEIN | - | - | - | - | 1件: 11 11 💬 |
2288 | RECOMBINANT NEISSERIA MENINGITIDIS GROUP B NHBA FUSION PROTEIN | 2件: Iron polymaltose Iron polymaltose, Lactobacillus casei | 1件: Lactobacillus casei
Lactobacillus casei
💬 | - | - | 2件: 11 11, 13 💬 |
2289 | Recombinant von Willebrand Factor 650IU | 1件: Von Willebrand factor human Von Willebrand factor human | - | - | - | 1件: 288 288 💬 |
2290 | Recombinant-methionyl human glial cell line-derived neurotrophic factor | - | - | - | - | 1件: 6 6 💬 |
2291 | REF CRUZADA PEI Nº 12-088 | - | - | - | - | 1件: 274 274 💬 |
2292 | Reference capsule GDC-0134 | 1件: GDC-0134 GDC-0134 | - | - | - | 1件: 2 2 💬 |
2293 | REGN1500 250 mg SC/15 mg/kg IV/450 mg SC | - | - | - | - | 1件: 79 79 💬 |
2294 | Regular Novolin R | - | - | - | - | 1件: 6 6 💬 |
2295 | Reldesemtiv 450 mg | 1件: Reldesemtiv Reldesemtiv | 1件: Reldesemtiv
Reldesemtiv
💬 | 1件: TNNC2 TNNC2 💬 | 1件: Calcium signaling pathway Calcium signaling pathway 💬 | 1件: 3 3 💬 |
2296 | Remicade (anti tumor necrosis factor inhibitor) | 1件: Infliximab Infliximab | 1件: Infliximab
Infliximab
💬 | 1件: TNF TNF 💬 | 67件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Dilated cardiomyopathy, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease, Osteoclast differentiation, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway 💬 | 1件: 40 40 💬 |
2297 | REMICADE 100 mg polvo para concentrado para solución para perfusión | 1件: Infliximab Infliximab | 1件: Infliximab
Infliximab
💬 | 1件: TNF TNF 💬 | 67件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Dilated cardiomyopathy, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease, Osteoclast differentiation, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway 💬 | 2件: 46 46, 271 💬 |
2298 | Repatha 420 mg solution for injection in cartridge | 1件: Evolocumab Evolocumab | 1件: Evolocumab
Evolocumab
💬 | 1件: PCSK9 PCSK9 💬 | 1件: Cholesterol metabolism Cholesterol metabolism 💬 | 1件: 79 79 💬 |
2299 | Repatha 420 mg soluzione per iniezione in cartuccia | 1件: Evolocumab Evolocumab | 1件: Evolocumab
Evolocumab
💬 | 1件: PCSK9 PCSK9 💬 | 1件: Cholesterol metabolism Cholesterol metabolism 💬 | 1件: 79 79 💬 |
2300 | REQUIP 21 CPR 0,25 MG | 1件: Ropinirole Ropinirole | 1件: Ropinirole
Ropinirole
💬 | 3件: DRD2 DRD2, DRD3, DRD4 💬 | 8件: Alcoholism Alcoholism, Cocaine addiction, Dopaminergic synapse, Gap junction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway 💬 | 1件: 6 6 💬 |
2301 | REQUIP 21 CPR 0,5 MG | 1件: Ropinirole Ropinirole | 1件: Ropinirole
Ropinirole
💬 | 3件: DRD2 DRD2, DRD3, DRD4 💬 | 8件: Alcoholism Alcoholism, Cocaine addiction, Dopaminergic synapse, Gap junction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway 💬 | 1件: 6 6 💬 |
2302 | Requip Modutab, 4mg | 1件: Ropinirole Ropinirole | 1件: Ropinirole
Ropinirole
💬 | 3件: DRD2 DRD2, DRD3, DRD4 💬 | 8件: Alcoholism Alcoholism, Cocaine addiction, Dopaminergic synapse, Gap junction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway 💬 | 1件: 6 6 💬 |
2303 | Requip Modutab, 8mg | 1件: Ropinirole Ropinirole | 1件: Ropinirole
Ropinirole
💬 | 3件: DRD2 DRD2, DRD3, DRD4 💬 | 8件: Alcoholism Alcoholism, Cocaine addiction, Dopaminergic synapse, Gap junction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway 💬 | 1件: 6 6 💬 |
2304 | REQUIP*21CPR 0,25MG | 1件: Ropinirole Ropinirole | 1件: Ropinirole
Ropinirole
💬 | 3件: DRD2 DRD2, DRD3, DRD4 💬 | 8件: Alcoholism Alcoholism, Cocaine addiction, Dopaminergic synapse, Gap junction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway 💬 | 1件: 6 6 💬 |
2305 | REQUIP*21CPR 0,5MG | 1件: Ropinirole Ropinirole | 1件: Ropinirole
Ropinirole
💬 | 3件: DRD2 DRD2, DRD3, DRD4 💬 | 8件: Alcoholism Alcoholism, Cocaine addiction, Dopaminergic synapse, Gap junction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway 💬 | 1件: 6 6 💬 |
2306 | REQUIP*28CPR 8MG R.P. | 1件: Ropinirole Ropinirole | 1件: Ropinirole
Ropinirole
💬 | 3件: DRD2 DRD2, DRD3, DRD4 💬 | 8件: Alcoholism Alcoholism, Cocaine addiction, Dopaminergic synapse, Gap junction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway 💬 | 1件: 6 6 💬 |
2307 | REQUIP-MODUTAB , 4mg | 1件: Ropinirole Ropinirole | 1件: Ropinirole
Ropinirole
💬 | 3件: DRD2 DRD2, DRD3, DRD4 💬 | 8件: Alcoholism Alcoholism, Cocaine addiction, Dopaminergic synapse, Gap junction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway 💬 | 1件: 6 6 💬 |
2308 | REQUIP-MODUTAB , 8mg | 1件: Ropinirole Ropinirole | 1件: Ropinirole
Ropinirole
💬 | 3件: DRD2 DRD2, DRD3, DRD4 💬 | 8件: Alcoholism Alcoholism, Cocaine addiction, Dopaminergic synapse, Gap junction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway 💬 | 1件: 6 6 💬 |
2309 | REQUIP-MODUTAB, 4mg | 1件: Ropinirole Ropinirole | 1件: Ropinirole
Ropinirole
💬 | 3件: DRD2 DRD2, DRD3, DRD4 💬 | 8件: Alcoholism Alcoholism, Cocaine addiction, Dopaminergic synapse, Gap junction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway 💬 | 1件: 6 6 💬 |
2310 | REQUIP-MODUTAB, 8mg | 1件: Ropinirole Ropinirole | 1件: Ropinirole
Ropinirole
💬 | 3件: DRD2 DRD2, DRD3, DRD4 💬 | 8件: Alcoholism Alcoholism, Cocaine addiction, Dopaminergic synapse, Gap junction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway 💬 | 1件: 6 6 💬 |
2311 | REVATIO - 0.8 MG/ML - SOLUZIONE INIETTABILE - USO ENDOVENOSO - FLACONCINO(VETRO) 1 FLACONCINO DA 20 ML | 1件: Sildenafil Sildenafil | 1件: Sildenafil
Sildenafil
💬 | 1件: PDE5A PDE5A 💬 | 3件: Metabolic pathways Metabolic pathways, Purine metabolism, cGMP-PKG signaling pathway 💬 | 1件: 294 294 💬 |
2312 | Revatio 0.8mg/ml solution for injection | 1件: Sildenafil Sildenafil | 1件: Sildenafil
Sildenafil
💬 | 1件: PDE5A PDE5A 💬 | 3件: Metabolic pathways Metabolic pathways, Purine metabolism, cGMP-PKG signaling pathway 💬 | 1件: 294 294 💬 |
2313 | REYATAZ 150MG 60 CPS BL | 1件: Atazanavir Atazanavir | 1件: Atazanavir
Atazanavir
💬 | - | - | 1件: 265 265 💬 |
2314 | RG-012 | - | - | - | - | 1件: 218 218 💬 |
2315 | RG6042, formerly ISIS 443139, IONIS-HTTRx | - | - | - | - | 1件: 8 8 💬 |
2316 | RGB-03 | - | - | - | - | 1件: 46 46 💬 |
2317 | RhGH Norditropin® pen (34 µg/kg) | 1件: Somatotropin Somatotropin | - | - | - | 1件: 78 78 💬 |
2318 | RhHNS-45 mg | - | - | - | - | 1件: 19 19 💬 |
2319 | RhNGF 60 µg/ml eye drops solution | 1件: Cenegermin Cenegermin | 1件: Cenegermin
Cenegermin
💬 | 1件: NGFR NGFR 💬 | 9件: Apoptosis - multiple species Apoptosis - multiple species, Cytokine-cytokine receptor interaction, MAPK signaling pathway, Neurotrophin signaling pathway, PI3K-Akt signaling pathway, Rap1 signaling pathway, Ras signaling pathway, Transcriptional misregulation in cancer, Virion - Lyssavirus 💬 | 1件: 90 90 💬 |
2320 | RhPTH (1-84) | 1件: Parathyroid hormone Parathyroid hormone | 1件: Parathyroid hormone
Parathyroid hormone
💬 | 2件: PTH1R PTH1R, PTH2R 💬 | 3件: Endocrine and other factor-regulated calcium reabsorption Endocrine and other factor-regulated calcium reabsorption, Neuroactive ligand-receptor interaction, Parathyroid hormone synthesis, secretion and action 💬 | 1件: 235 235 💬 |
2321 | RhPTH(1-84) | 1件: Parathyroid hormone Parathyroid hormone | 1件: Parathyroid hormone
Parathyroid hormone
💬 | 2件: PTH1R PTH1R, PTH2R 💬 | 3件: Endocrine and other factor-regulated calcium reabsorption Endocrine and other factor-regulated calcium reabsorption, Neuroactive ligand-receptor interaction, Parathyroid hormone synthesis, secretion and action 💬 | 1件: 235 235 💬 |
2322 | RhuDex 50 mg (63.5 mg RhuDex choline salt) granules | 1件: Choline Choline | 1件: Choline
Choline
💬 | - | - | 1件: 93 93 💬 |
2323 | RI-002 | - | - | - | - | 1件: 65 65 💬 |
2324 | Rifampin 300mg BID + istradefylline 40mg Day 8 only | 2件: Istradefylline Istradefylline, Rifampicin | 2件: Rifampin
Rifampin
,
Istradefylline
💬 | 1件: ADORA2A ADORA2A 💬 | 7件: Alcoholism Alcoholism, Calcium signaling pathway, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, Vascular smooth muscle contraction, cAMP signaling pathway 💬 | 1件: 6 6 💬 |
2325 | Rifaximin delayed release 400 mg film coated tablet | 1件: Rifaximin Rifaximin | 1件: Rifaximin
Rifaximin
💬 | - | - | 1件: 96 96 💬 |
2326 | Riociguat coated tablet 0.5 mg | 1件: Riociguat Riociguat | 1件: Riociguat
Riociguat
💬 | 3件: GUCY1A1 GUCY1A1, GUCY1A2, GUCY1B1 💬 | 11件: Circadian entrainment Circadian entrainment, Gap junction, Long-term depression, Metabolic pathways, Oxytocin signaling pathway, Platelet activation, Purine metabolism, Renin secretion, Salivary secretion, Vascular smooth muscle contraction, cGMP-PKG signaling pathway 💬 | 1件: 51 51 💬 |
2327 | Riociguat coated tablet 1.0 mg | 1件: Riociguat Riociguat | 1件: Riociguat
Riociguat
💬 | 3件: GUCY1A1 GUCY1A1, GUCY1A2, GUCY1B1 💬 | 11件: Circadian entrainment Circadian entrainment, Gap junction, Long-term depression, Metabolic pathways, Oxytocin signaling pathway, Platelet activation, Purine metabolism, Renin secretion, Salivary secretion, Vascular smooth muscle contraction, cGMP-PKG signaling pathway 💬 | 1件: 51 51 💬 |
2328 | Riociguat coated tablet 2.0 mg | 1件: Riociguat Riociguat | 1件: Riociguat
Riociguat
💬 | 3件: GUCY1A1 GUCY1A1, GUCY1A2, GUCY1B1 💬 | 11件: Circadian entrainment Circadian entrainment, Gap junction, Long-term depression, Metabolic pathways, Oxytocin signaling pathway, Platelet activation, Purine metabolism, Renin secretion, Salivary secretion, Vascular smooth muscle contraction, cGMP-PKG signaling pathway 💬 | 1件: 51 51 💬 |
2329 | Riociguat granules 0.3% for oral application | 1件: Riociguat Riociguat | 1件: Riociguat
Riociguat
💬 | 3件: GUCY1A1 GUCY1A1, GUCY1A2, GUCY1B1 💬 | 11件: Circadian entrainment Circadian entrainment, Gap junction, Long-term depression, Metabolic pathways, Oxytocin signaling pathway, Platelet activation, Purine metabolism, Renin secretion, Salivary secretion, Vascular smooth muscle contraction, cGMP-PKG signaling pathway 💬 | 1件: 86 86 💬 |
2330 | Risankizumab 600 mg IV | 1件: Risankizumab Risankizumab | 1件: Risankizumab
Risankizumab
💬 | 1件: IL23A IL23A 💬 | 9件: C-type lectin receptor signaling pathway C-type lectin receptor signaling pathway, Cytokine-cytokine receptor interaction, Inflammatory bowel disease, JAK-STAT signaling pathway, Pathways in cancer, Pertussis, Rheumatoid arthritis, Th17 cell differentiation, Tuberculosis 💬 | 1件: 96 96 💬 |
2331 | Ritalin LA 40mg capsules | 1件: Methylphenidate Methylphenidate | 1件: Methylphenidate
Methylphenidate
💬 | 2件: SLC6A2 SLC6A2, SLC6A3 💬 | 7件: Alcoholism Alcoholism, Amphetamine addiction, Cocaine addiction, Dopaminergic synapse, Parkinson disease, Pathways of neurodegeneration - multiple diseases, Synaptic vesicle cycle 💬 | 1件: 13 13 💬 |
2332 | Ritonavir (Norvir) | 1件: Ritonavir Ritonavir | 1件: Ritonavir
Ritonavir
💬 | - | - | 1件: 265 265 💬 |
2333 | Rituxan (INN: Rituximab), brand name in the United States | 1件: Rituximab Rituximab | 1件: Rituximab
Rituximab
💬 | 1件: MS4A1 MS4A1 💬 | 1件: Hematopoietic cell lineage Hematopoietic cell lineage 💬 | 1件: 46 46 💬 |
2334 | Rituxan (INN: Rituximab), brand name in the US | 1件: Rituximab Rituximab | 1件: Rituximab
Rituximab
💬 | 1件: MS4A1 MS4A1 💬 | 1件: Hematopoietic cell lineage Hematopoietic cell lineage 💬 | 1件: 46 46 💬 |
2335 | Rituximab-Pfizer (PF-05280586) x 3 courses | 1件: Rituximab Rituximab | 1件: Rituximab
Rituximab
💬 | 1件: MS4A1 MS4A1 💬 | 1件: Hematopoietic cell lineage Hematopoietic cell lineage 💬 | 1件: 46 46 💬 |
2336 | Rivastigmin Luye Transdermal Patches - 4.6mg/24h | - | - | - | - | 1件: 6 6 💬 |
2337 | RM-493 | - | - | - | - | 2件: 193 193, 202 💬 |
2338 | Ro 001-9265 | - | - | - | - | 1件: 41 41 💬 |
2339 | Ro 001-9265/F02 | - | - | - | - | 1件: 41 41 💬 |
2340 | RO 001-9265/F02-01 | - | - | - | - | 1件: 46 46 💬 |
2341 | Ro 001-9265/F03 | - | - | - | - | 1件: 41 41 💬 |
2342 | Ro 001-9265/F04 | - | - | - | - | 1件: 41 41 💬 |
2343 | Ro 002-9893/F02 | - | - | - | - | 1件: 46 46 💬 |
2344 | Ro 45-2294 | - | - | - | - | 1件: 46 46 💬 |
2345 | Ro 47-0203 | - | - | - | - | 4件: 51 51, 85, 86, 88 💬 |
2346 | Ro 47-0203 / ACT-050088 | - | - | - | - | 1件: 86 86 💬 |
2347 | Ro 48-77533 | - | - | - | - | 1件: 46 46 💬 |
2348 | Ro 487-533/F01 | - | - | - | - | 1件: 271 271 💬 |
2349 | Ro 487-5733/F01 | - | - | - | - | 1件: 271 271 💬 |
2350 | RO 487-7533 | - | - | - | - | 1件: 46 46 💬 |
2351 | Ro 487-7533/F01 | - | - | - | - | 3件: 46 46, 107, 271 💬 |
2352 | Ro 487-7533/F10 | - | - | - | - | 2件: 46 46, 107 💬 |
2353 | Ro 487-7533/F10-02 | - | - | - | - | 1件: 46 46 💬 |
2354 | Ro 487-7533/F10-04 | - | - | - | - | 4件: 41 41, 46, 51, 107 💬 |
2355 | Ro 491-7523/F18 | - | - | - | - | 1件: 206 206 💬 |
2356 | Ro 491-7523/F19 | - | - | - | - | 1件: 206 206 💬 |
2357 | RO 496-4913 | - | - | - | - | 2件: 46 46, 49 💬 |
2358 | Ro 496-4913/F03 | - | - | - | - | 2件: 13 13, 46 💬 |
2359 | Ro 496-4913/F07 | - | - | - | - | 1件: 13 13 💬 |
2360 | Ro 533-3787/F01- 06 | - | - | - | - | 1件: 13 13 💬 |
2361 | Ro 533-3787/F01-06 | - | - | - | - | 1件: 11 11 💬 |
2362 | Ro 549-0261/F04 | - | - | - | - | 1件: 97 97 💬 |
2363 | Ro 549-0261/F04-02 | - | - | - | - | 1件: 96 96 💬 |
2364 | Ro 549-0261/F08-02 | - | - | - | - | 1件: 96 96 💬 |
2365 | RO 551-6922 | - | - | - | - | 1件: 46 46 💬 |
2366 | Ro 723-4292/F02 | - | - | - | - | 1件: 8 8 💬 |
2367 | Ro-47-0203 | - | - | - | - | 1件: 86 86 💬 |
2368 | Ro-47-0203/029 | - | - | - | - | 1件: 86 86 💬 |
2369 | RO-496-4913 | - | - | - | - | 1件: 46 46 💬 |
2370 | Ro47-0203 | - | - | - | - | 1件: 86 86 💬 |
2371 | Ro47-0203 / ACT-050088 | - | - | - | - | 2件: 51 51, 86 💬 |
2372 | RO487-7533/F10-04 | - | - | - | - | 2件: 46 46, 51 💬 |
2373 | RO4917523 0.5 mg | - | - | - | - | 1件: 206 206 💬 |
2374 | RO496-4913 | - | - | - | - | 1件: 46 46 💬 |
2375 | RO4964913/F07-01 | - | - | - | - | 1件: 13 13 💬 |
2376 | Ro549-0261/F04-02 | - | - | - | - | 1件: 96 96 💬 |
2377 | RO5490255/F01-02 | - | - | - | - | 1件: 85 85 💬 |
2378 | RO5490261/F04-02 | - | - | - | - | 1件: 97 97 💬 |
2379 | RO7112689/F03-01 | - | - | - | - | 2件: 62 62, 109 💬 |
2380 | RO7123520/F03-01 | - | - | - | - | 1件: 46 46 💬 |
2381 | RO7204239/F01-01 | - | - | - | - | 1件: 3 3 💬 |
2382 | RO7239361 Injections, 15 mg/Syringe (21.4 mg/mL) | - | - | - | - | 1件: 113 113 💬 |
2383 | RO7239361 Injections, 50 mg/Syringe (71.4 mg/mL) | - | - | - | - | 1件: 113 113 💬 |
2384 | RO7248824/F02-01 | - | - | - | - | 1件: 201 201 💬 |
2385 | RO7248824/F03-01 (Diluent for RO7248824/F02-01 | - | - | - | - | 1件: 201 201 💬 |
2386 | RO7490677 160 mg/8 ml | - | - | - | - | 1件: 85 85 💬 |
2387 | RO7490677 160 mg/8mL | - | - | - | - | 1件: 85 85 💬 |
2388 | RO7490677 160mg/8mL | - | - | - | - | 1件: 85 85 💬 |
2389 | RO7490677/ F01-02 | - | - | - | - | 1件: 85 85 💬 |
2390 | RO7490677/F01-01 | - | - | - | - | 1件: 85 85 💬 |
2391 | RO7490677/F01-02 | - | - | - | - | 1件: 85 85 💬 |
2392 | RO7490677/F01-03 | - | - | - | - | 1件: 85 85 💬 |
2393 | ROACTEMRA - 162 MG - SOLUZIONE INIETTABILE - USO SOTTOCUTANEO - SIRINGA PRERIEMPITA 0,9ML (VETRO) - 4 SIRINGHE PRERIEMPITE | 1件: Tocilizumab Tocilizumab | 1件: Tocilizumab
Tocilizumab
💬 | 1件: IL6R IL6R 💬 | 12件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, EGFR tyrosine kinase inhibitor resistance, HIF-1 signaling pathway, Hematopoietic cell lineage, Human cytomegalovirus infection, JAK-STAT signaling pathway, Non-alcoholic fatty liver disease, PI3K-Akt signaling pathway, Pathways in cancer, Th17 cell differentiation, Viral protein interaction with cytokine and cytokine receptor 💬 | 2件: 46 46, 51 💬 |
2394 | ROACTEMRA - 20 MG/ML CONCENTRATO PER SOLUZIONE PER INFUSIONE - USO ENDOVENOSO - FLACONCINO (VETRO) 4ML 1 FLACONCINO | 1件: Tocilizumab Tocilizumab | 1件: Tocilizumab
Tocilizumab
💬 | 1件: IL6R IL6R 💬 | 12件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, EGFR tyrosine kinase inhibitor resistance, HIF-1 signaling pathway, Hematopoietic cell lineage, Human cytomegalovirus infection, JAK-STAT signaling pathway, Non-alcoholic fatty liver disease, PI3K-Akt signaling pathway, Pathways in cancer, Th17 cell differentiation, Viral protein interaction with cytokine and cytokine receptor 💬 | 1件: 46 46 💬 |
2395 | RoActemra 20 mg/ml concentrado para solución para perfusión | 1件: Tocilizumab Tocilizumab | 1件: Tocilizumab
Tocilizumab
💬 | 1件: IL6R IL6R 💬 | 12件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, EGFR tyrosine kinase inhibitor resistance, HIF-1 signaling pathway, Hematopoietic cell lineage, Human cytomegalovirus infection, JAK-STAT signaling pathway, Non-alcoholic fatty liver disease, PI3K-Akt signaling pathway, Pathways in cancer, Th17 cell differentiation, Viral protein interaction with cytokine and cytokine receptor 💬 | 1件: 46 46 💬 |
2396 | ROACTEMRA 20 mg/ml, concentrado para solución para perfusión | 1件: Tocilizumab Tocilizumab | 1件: Tocilizumab
Tocilizumab
💬 | 1件: IL6R IL6R 💬 | 12件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, EGFR tyrosine kinase inhibitor resistance, HIF-1 signaling pathway, Hematopoietic cell lineage, Human cytomegalovirus infection, JAK-STAT signaling pathway, Non-alcoholic fatty liver disease, PI3K-Akt signaling pathway, Pathways in cancer, Th17 cell differentiation, Viral protein interaction with cytokine and cytokine receptor 💬 | 3件: 46 46, 107, 271 💬 |
2397 | Rob 803 | - | - | - | - | 1件: 46 46 💬 |
2398 | Rob 803 (9-Chloro-2,3-dimethyl-6-(N,N-dimethylaminoethylamino-2-oxoethyl)-6H-indolo[2,3-b] quinoxali | - | - | - | - | 1件: 46 46 💬 |
2399 | Rob 803 (capsules 12.5 mg) | - | - | - | - | 1件: 46 46 💬 |
2400 | Rob 803 (capsules 15 mg) | - | - | - | - | 1件: 46 46 💬 |
2401 | Rob 803 (capsules 25 mg) | - | - | - | - | 1件: 46 46 💬 |
2402 | Rob 803 (capsules 6.25 mg) | - | - | - | - | 1件: 46 46 💬 |
2403 | Rob 803 12.5mg capsule | - | - | - | - | 1件: 46 46 💬 |
2404 | Rob 803 15mg capsule | - | - | - | - | 1件: 46 46 💬 |
2405 | Rob 803 25mg capsule | - | - | - | - | 1件: 46 46 💬 |
2406 | Rob 803 6.25mg capsule | - | - | - | - | 1件: 46 46 💬 |
2407 | Rob 803 6.5mg capsule | - | - | - | - | 1件: 46 46 💬 |
2408 | Rodatristat ethyl 600 mg BID | - | - | - | - | 1件: 86 86 💬 |
2409 | Roferon-A, 4.5miu | 1件: Interferon alfa-2a Interferon alfa-2a | 1件: Interferon alfa-2a
Interferon alfa-2a
💬 | 2件: IFNAR1 IFNAR1, IFNAR2 💬 | 18件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Measles, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Osteoclast differentiation, PI3K-Akt signaling pathway, Pathways in cancer, Toll-like receptor signaling pathway 💬 | 1件: 56 56 💬 |
2410 | Roferon-A, 6miu | 1件: Interferon alfa-2a Interferon alfa-2a | 1件: Interferon alfa-2a
Interferon alfa-2a
💬 | 2件: IFNAR1 IFNAR1, IFNAR2 💬 | 18件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Measles, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Osteoclast differentiation, PI3K-Akt signaling pathway, Pathways in cancer, Toll-like receptor signaling pathway 💬 | 1件: 56 56 💬 |
2411 | Rokan (r) Novo 120 mg | - | - | - | - | 1件: 18 18 💬 |
2412 | Ropinirole CR 8mg tablet | 1件: Ropinirole Ropinirole | 1件: Ropinirole
Ropinirole
💬 | 3件: DRD2 DRD2, DRD3, DRD4 💬 | 8件: Alcoholism Alcoholism, Cocaine addiction, Dopaminergic synapse, Gap junction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway 💬 | 1件: 6 6 💬 |
2413 | Ropivacaine plus normal saline | 1件: Ropivacaine Ropivacaine | 1件: Ropivacaine
Ropivacaine
💬 | 5件: SCN1A SCN1A, SCN2A, SCN3A, SCN5A, SCN9A 💬 | 3件: Adrenergic signaling in cardiomyocytes Adrenergic signaling in cardiomyocytes, Dopaminergic synapse, Taste transduction 💬 | 1件: 70 70 💬 |
2414 | Rosuvastatin calcium 40mg | 2件: Calcium Calcium, Rosuvastatin | 1件: Rosuvastatin
Rosuvastatin
💬 | 1件: HMGCR HMGCR 💬 | 4件: AMPK signaling pathway AMPK signaling pathway, Bile secretion, Metabolic pathways, Terpenoid backbone biosynthesis 💬 | 1件: 56 56 💬 |
2415 | ROT-TDS 8 mg/24 h | - | - | - | - | 1件: 6 6 💬 |
2416 | Rotigotine Nasal Spray | 1件: Rotigotine Rotigotine | 1件: Rotigotine
Rotigotine
💬 | 1件: DRD2 DRD2 💬 | 8件: Alcoholism Alcoholism, Cocaine addiction, Dopaminergic synapse, Gap junction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway 💬 | 1件: 6 6 💬 |
2417 | Rotigotine transdermal patch 4mg/24h (20cm2) | 1件: Rotigotine Rotigotine | 1件: Rotigotine
Rotigotine
💬 | 1件: DRD2 DRD2 💬 | 8件: Alcoholism Alcoholism, Cocaine addiction, Dopaminergic synapse, Gap junction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway 💬 | 1件: 6 6 💬 |
2418 | Rotigotine transdermal patch 6mg/24h (30cm2) | 1件: Rotigotine Rotigotine | 1件: Rotigotine
Rotigotine
💬 | 1件: DRD2 DRD2 💬 | 8件: Alcoholism Alcoholism, Cocaine addiction, Dopaminergic synapse, Gap junction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway 💬 | 1件: 6 6 💬 |
2419 | Rotigotine transdermal patch 8mg/24h (40cm2) | 1件: Rotigotine Rotigotine | 1件: Rotigotine
Rotigotine
💬 | 1件: DRD2 DRD2 💬 | 8件: Alcoholism Alcoholism, Cocaine addiction, Dopaminergic synapse, Gap junction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway 💬 | 1件: 6 6 💬 |
2420 | RQ-00000010 | - | - | - | - | 1件: 6 6 💬 |
2421 | RST-001 | - | - | - | - | 1件: 90 90 💬 |
2422 | RTA 402 | - | - | - | - | 3件: 67 67, 86, 218 💬 |
2423 | RVG 03820 | - | - | - | - | 1件: 3 3 💬 |
2424 | RVG 05565 | - | - | - | - | 1件: 96 96 💬 |
2425 | RVG 07151 | - | - | - | - | 1件: 96 96 💬 |
2426 | RVG 08740 | - | - | - | - | 1件: 6 6 💬 |
2427 | RVG 08938 | - | - | - | - | 1件: 75 75 💬 |
2428 | RWJ-445380 100 mg | - | - | - | - | 1件: 46 46 💬 |
2429 | RWJ-445380 200 mg | - | - | - | - | 1件: 46 46 💬 |
2430 | RWJ-445380 300 mg | - | - | - | - | 1件: 46 46 💬 |
2431 | RWJ-445380 capsule 100 mg | - | - | - | - | 1件: 46 46 💬 |
2432 | RWJ-445380 capsules 150 mg | - | - | - | - | 1件: 46 46 💬 |
2433 | RWJ-445380 Capsules 50 mg | - | - | - | - | 1件: 46 46 💬 |
2434 | RWJ-445380-002 | - | - | - | - | 1件: 46 46 💬 |
2435 | S(-)-3-[3-bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxopyridin-1(2H)-yl]-N,4-dimethylbenzamide | - | - | - | - | 1件: 46 46 💬 |
2436 | SA-001 | - | - | - | - | 1件: 298 298 💬 |
2437 | SAIZEN - 1 FLACONCINO POLV. 8 MG + 1 CARTUCCIA. SOLV. INSERITI IN UN DISPOSITIVO PER LA RICOSTITUZIONE | 1件: Somatotropin Somatotropin | - | - | - | 1件: 78 78 💬 |
2438 | Saizen 8mg click.easy powder for solution for injection | 1件: Somatotropin Somatotropin | - | - | - | 1件: 78 78 💬 |
2439 | Saizen 8mg click.easy power for solution for injection | 1件: Somatotropin Somatotropin | - | - | - | 1件: 78 78 💬 |
2440 | Salbutamol 4Mg Tablet | 1件: Salbutamol Salbutamol | 1件: Albuterol
Albuterol
💬 | 1件: ADRB2 ADRB2 💬 | 9件: Adrenergic signaling in cardiomyocytes Adrenergic signaling in cardiomyocytes, Calcium signaling pathway, Chemical carcinogenesis - receptor activation, Neuroactive ligand-receptor interaction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, cAMP signaling pathway, cGMP-PKG signaling pathway 💬 | 1件: 11 11 💬 |
2441 | Salbutamol WZF 4 mg | 1件: Salbutamol Salbutamol | 1件: Albuterol
Albuterol
💬 | 1件: ADRB2 ADRB2 💬 | 9件: Adrenergic signaling in cardiomyocytes Adrenergic signaling in cardiomyocytes, Calcium signaling pathway, Chemical carcinogenesis - receptor activation, Neuroactive ligand-receptor interaction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, cAMP signaling pathway, cGMP-PKG signaling pathway 💬 | 1件: 11 11 💬 |
2442 | Salbutamol-ratiopharm® N metered-dose aerosol inhaler | 1件: Salbutamol Salbutamol | 1件: Albuterol
Albuterol
💬 | 1件: ADRB2 ADRB2 💬 | 9件: Adrenergic signaling in cardiomyocytes Adrenergic signaling in cardiomyocytes, Calcium signaling pathway, Chemical carcinogenesis - receptor activation, Neuroactive ligand-receptor interaction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, cAMP signaling pathway, cGMP-PKG signaling pathway 💬 | 1件: 299 299 💬 |
2443 | Salbutamol-ratiopharm® N metereddose aerosol inhaler | 1件: Salbutamol Salbutamol | 1件: Albuterol
Albuterol
💬 | 1件: ADRB2 ADRB2 💬 | 9件: Adrenergic signaling in cardiomyocytes Adrenergic signaling in cardiomyocytes, Calcium signaling pathway, Chemical carcinogenesis - receptor activation, Neuroactive ligand-receptor interaction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, cAMP signaling pathway, cGMP-PKG signaling pathway 💬 | 1件: 299 299 💬 |
2444 | Saline 0.9% inhalation solution | - | - | - | - | 1件: 299 299 💬 |
2445 | Saline 0.9% NaCl | - | - | - | - | 1件: 235 235 💬 |
2446 | Saline Nasal Mist | - | - | - | - | 1件: 127 127 💬 |
2447 | Salofalk 4g/60ml Klysma | 1件: Mesalazine Mesalazine | 1件: Mesalamine
Mesalamine
💬 | - | - | 1件: 97 97 💬 |
2448 | SAN-300 0.5 mg/kg QW | - | - | - | - | 1件: 46 46 💬 |
2449 | SAN-300 1.0 mg/kg QW | - | - | - | - | 1件: 46 46 💬 |
2450 | SAN-300 2.0 mg/kg QOW | - | - | - | - | 1件: 46 46 💬 |
2451 | SAN-300 4.0 mg/kg QOW | - | - | - | - | 1件: 46 46 💬 |
2452 | SAN-300 4.0 mg/kg QW | - | - | - | - | 1件: 46 46 💬 |
2453 | Sandimmun Neoral | 1件: Cyclosporine Cyclosporine | 1件: Cyclosporine
Cyclosporine
💬 | 5件: PPP3CA PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 💬 | 33件: Alzheimer disease Alzheimer disease, Amphetamine addiction, Amyotrophic lateral sclerosis, Axon guidance, B cell receptor signaling pathway, C-type lectin receptor signaling pathway, Calcium signaling pathway, Cellular senescence, Dopaminergic synapse, Glucagon signaling pathway, Glutamatergic synapse, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Lipid and atherosclerosis, Long-term potentiation, MAPK signaling pathway, Natural killer cell mediated cytotoxicity, Oocyte meiosis, Osteoclast differentiation, Oxytocin signaling pathway, PD-L1 expression and PD-1 checkpoint pathway in cancer, Pathways of neurodegeneration - multiple diseases, Prion disease, Renin secretion, T cell receptor signaling pathway, Th1 and Th2 cell differentiation, Th17 cell differentiation, Tuberculosis, VEGF signaling pathway, Wnt signaling pathway, cGMP-PKG signaling pathway 💬 | 3件: 60 60, 97, 226 💬 |
2454 | SANDIMMUN NEORAL - 10 MG CAPSULE MOLLI 50 CAPSULE | 1件: Cyclosporine Cyclosporine | 1件: Cyclosporine
Cyclosporine
💬 | 5件: PPP3CA PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 💬 | 33件: Alzheimer disease Alzheimer disease, Amphetamine addiction, Amyotrophic lateral sclerosis, Axon guidance, B cell receptor signaling pathway, C-type lectin receptor signaling pathway, Calcium signaling pathway, Cellular senescence, Dopaminergic synapse, Glucagon signaling pathway, Glutamatergic synapse, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Lipid and atherosclerosis, Long-term potentiation, MAPK signaling pathway, Natural killer cell mediated cytotoxicity, Oocyte meiosis, Osteoclast differentiation, Oxytocin signaling pathway, PD-L1 expression and PD-1 checkpoint pathway in cancer, Pathways of neurodegeneration - multiple diseases, Prion disease, Renin secretion, T cell receptor signaling pathway, Th1 and Th2 cell differentiation, Th17 cell differentiation, Tuberculosis, VEGF signaling pathway, Wnt signaling pathway, cGMP-PKG signaling pathway 💬 | 1件: 60 60 💬 |
2455 | SANDIMMUN NEORAL - 100 MG CAPSULE MOLLI 30 CAPSULE | 1件: Cyclosporine Cyclosporine | 1件: Cyclosporine
Cyclosporine
💬 | 5件: PPP3CA PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 💬 | 33件: Alzheimer disease Alzheimer disease, Amphetamine addiction, Amyotrophic lateral sclerosis, Axon guidance, B cell receptor signaling pathway, C-type lectin receptor signaling pathway, Calcium signaling pathway, Cellular senescence, Dopaminergic synapse, Glucagon signaling pathway, Glutamatergic synapse, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Lipid and atherosclerosis, Long-term potentiation, MAPK signaling pathway, Natural killer cell mediated cytotoxicity, Oocyte meiosis, Osteoclast differentiation, Oxytocin signaling pathway, PD-L1 expression and PD-1 checkpoint pathway in cancer, Pathways of neurodegeneration - multiple diseases, Prion disease, Renin secretion, T cell receptor signaling pathway, Th1 and Th2 cell differentiation, Th17 cell differentiation, Tuberculosis, VEGF signaling pathway, Wnt signaling pathway, cGMP-PKG signaling pathway 💬 | 1件: 60 60 💬 |
2456 | SANDIMMUN NEORAL - 25 MG CAPSULE MOLLI 50 CAPSULE | 1件: Cyclosporine Cyclosporine | 1件: Cyclosporine
Cyclosporine
💬 | 5件: PPP3CA PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 💬 | 33件: Alzheimer disease Alzheimer disease, Amphetamine addiction, Amyotrophic lateral sclerosis, Axon guidance, B cell receptor signaling pathway, C-type lectin receptor signaling pathway, Calcium signaling pathway, Cellular senescence, Dopaminergic synapse, Glucagon signaling pathway, Glutamatergic synapse, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Lipid and atherosclerosis, Long-term potentiation, MAPK signaling pathway, Natural killer cell mediated cytotoxicity, Oocyte meiosis, Osteoclast differentiation, Oxytocin signaling pathway, PD-L1 expression and PD-1 checkpoint pathway in cancer, Pathways of neurodegeneration - multiple diseases, Prion disease, Renin secretion, T cell receptor signaling pathway, Th1 and Th2 cell differentiation, Th17 cell differentiation, Tuberculosis, VEGF signaling pathway, Wnt signaling pathway, cGMP-PKG signaling pathway 💬 | 1件: 60 60 💬 |
2457 | SANDIMMUN NEORAL - 50 MG CAPSULE MOLLI 50 CAPSULE | 1件: Cyclosporine Cyclosporine | 1件: Cyclosporine
Cyclosporine
💬 | 5件: PPP3CA PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 💬 | 33件: Alzheimer disease Alzheimer disease, Amphetamine addiction, Amyotrophic lateral sclerosis, Axon guidance, B cell receptor signaling pathway, C-type lectin receptor signaling pathway, Calcium signaling pathway, Cellular senescence, Dopaminergic synapse, Glucagon signaling pathway, Glutamatergic synapse, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Lipid and atherosclerosis, Long-term potentiation, MAPK signaling pathway, Natural killer cell mediated cytotoxicity, Oocyte meiosis, Osteoclast differentiation, Oxytocin signaling pathway, PD-L1 expression and PD-1 checkpoint pathway in cancer, Pathways of neurodegeneration - multiple diseases, Prion disease, Renin secretion, T cell receptor signaling pathway, Th1 and Th2 cell differentiation, Th17 cell differentiation, Tuberculosis, VEGF signaling pathway, Wnt signaling pathway, cGMP-PKG signaling pathway 💬 | 1件: 60 60 💬 |
2458 | SANDIMMUN NEORAL*30CPS 100MG | 1件: Cyclosporine Cyclosporine | 1件: Cyclosporine
Cyclosporine
💬 | 5件: PPP3CA PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 💬 | 33件: Alzheimer disease Alzheimer disease, Amphetamine addiction, Amyotrophic lateral sclerosis, Axon guidance, B cell receptor signaling pathway, C-type lectin receptor signaling pathway, Calcium signaling pathway, Cellular senescence, Dopaminergic synapse, Glucagon signaling pathway, Glutamatergic synapse, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Lipid and atherosclerosis, Long-term potentiation, MAPK signaling pathway, Natural killer cell mediated cytotoxicity, Oocyte meiosis, Osteoclast differentiation, Oxytocin signaling pathway, PD-L1 expression and PD-1 checkpoint pathway in cancer, Pathways of neurodegeneration - multiple diseases, Prion disease, Renin secretion, T cell receptor signaling pathway, Th1 and Th2 cell differentiation, Th17 cell differentiation, Tuberculosis, VEGF signaling pathway, Wnt signaling pathway, cGMP-PKG signaling pathway 💬 | 1件: 46 46 💬 |
2459 | SANDIMMUN NEORAL*50CPS 25MG | 1件: Cyclosporine Cyclosporine | 1件: Cyclosporine
Cyclosporine
💬 | 5件: PPP3CA PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 💬 | 33件: Alzheimer disease Alzheimer disease, Amphetamine addiction, Amyotrophic lateral sclerosis, Axon guidance, B cell receptor signaling pathway, C-type lectin receptor signaling pathway, Calcium signaling pathway, Cellular senescence, Dopaminergic synapse, Glucagon signaling pathway, Glutamatergic synapse, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Lipid and atherosclerosis, Long-term potentiation, MAPK signaling pathway, Natural killer cell mediated cytotoxicity, Oocyte meiosis, Osteoclast differentiation, Oxytocin signaling pathway, PD-L1 expression and PD-1 checkpoint pathway in cancer, Pathways of neurodegeneration - multiple diseases, Prion disease, Renin secretion, T cell receptor signaling pathway, Th1 and Th2 cell differentiation, Th17 cell differentiation, Tuberculosis, VEGF signaling pathway, Wnt signaling pathway, cGMP-PKG signaling pathway 💬 | 1件: 46 46 💬 |
2460 | Sapropterin dihydrochloride (6R-BH4) | 1件: Sapropterin Sapropterin | 1件: Sapropterin
Sapropterin
💬 | - | - | 1件: 86 86 💬 |
2461 | Sapropterin dihydrochloride, 6R-BH4, tetrahydrobiopterin | 1件: Sapropterin Sapropterin | 1件: Sapropterin
Sapropterin
💬 | - | - | 1件: 240 240 💬 |
2462 | Saroglitazar magnesium 4 mg | 2件: Magnesium Magnesium, Saroglitazar | - | - | - | 1件: 93 93 💬 |
2463 | Sativex Oromucosal Spray (non-marketed) | 2件: Cannabidiol Cannabidiol, Dronabinol | 2件: Dronabinol
Dronabinol
,
Cannabidiol
💬 | 2件: CNR1 CNR1, CNR2 💬 | 4件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Rap1 signaling pathway, Retrograde endocannabinoid signaling, Thermogenesis 💬 | 1件: 13 13 💬 |
2464 | Satralizumab (120 mg/PFS with NSD) | 1件: Satralizumab Satralizumab | 1件: Satralizumab
Satralizumab
💬 | 1件: IL6R IL6R 💬 | 12件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, EGFR tyrosine kinase inhibitor resistance, HIF-1 signaling pathway, Hematopoietic cell lineage, Human cytomegalovirus infection, JAK-STAT signaling pathway, Non-alcoholic fatty liver disease, PI3K-Akt signaling pathway, Pathways in cancer, Th17 cell differentiation, Viral protein interaction with cytokine and cytokine receptor 💬 | 1件: 13 13 💬 |
2465 | SB 681323 | - | - | - | - | 1件: 46 46 💬 |
2466 | SB-47171 | - | - | - | - | 1件: 19 19 💬 |
2467 | SB-47898 | - | - | - | - | 1件: 19 19 💬 |
2468 | SB-497115 | - | - | - | - | 1件: 63 63 💬 |
2469 | SB-497115-GR | - | - | - | - | 1件: 63 63 💬 |
2470 | SB-497115-GR 12.5mg | - | - | - | - | 1件: 63 63 💬 |
2471 | SB-497115-GR 25mg | - | - | - | - | 1件: 63 63 💬 |
2472 | SB-497115-GR 50 mg | - | - | - | - | 1件: 63 63 💬 |
2473 | SB-656933 | - | - | - | - | 1件: 97 97 💬 |
2474 | SB-656933 Tablets | - | - | - | - | 2件: 97 97, 299 💬 |
2475 | SB-656933-AAA | - | - | - | - | 1件: 299 299 💬 |
2476 | SB-681323 | - | - | - | - | 1件: 46 46 💬 |
2477 | SB-681323 oral tablets | - | - | - | - | 1件: 46 46 💬 |
2478 | SB-681323 Tablets | - | - | - | - | 1件: 46 46 💬 |
2479 | SB-683699 | - | - | - | - | 1件: 13 13 💬 |
2480 | SBI-087 | - | - | - | - | 2件: 46 46, 49 💬 |
2481 | SBT-020 | - | - | - | - | 1件: 8 8 💬 |
2482 | SC12267 (4SC-101) | 1件: SC12267 SC12267 | - | - | - | 3件: 46 46, 96, 97 💬 |
2483 | SCH 420814 | - | - | - | - | 1件: 6 6 💬 |
2484 | SCH 420814 10 mg | - | - | - | - | 1件: 6 6 💬 |
2485 | SCH 420814 100 mg | - | - | - | - | 1件: 6 6 💬 |
2486 | SCIO-469 | - | - | - | - | 1件: 46 46 💬 |
2487 | SCM-010 | - | - | - | - | 1件: 13 13 💬 |
2488 | SD-101 Dermal Cream (6%) | - | - | - | - | 1件: 36 36 💬 |
2489 | SD-101-6.0 cream | - | - | - | - | 1件: 36 36 💬 |
2490 | SD-809 | - | - | - | - | 1件: 8 8 💬 |
2491 | Search for exocrine pancreatic insufficiency at week 0 and 12 | - | - | - | - | 1件: 96 96 💬 |
2492 | Sebelipase alfa 0.35 mg/kg | 1件: Sebelipase alfa Sebelipase alfa | 1件: Sebelipase alfa
Sebelipase alfa
💬 | 1件: LIPA LIPA 💬 | 3件: Cholesterol metabolism Cholesterol metabolism, Lysosome, Steroid biosynthesis 💬 | 1件: 19 19 💬 |
2493 | Secukinumab 150 mg provided in 1.0 mL pre-filled syringes (PFSs) for sc injection. | 1件: Secukinumab Secukinumab | 1件: Secukinumab
Secukinumab
💬 | 1件: IL17A IL17A 💬 | 6件: Alcoholic liver disease Alcoholic liver disease, Cytokine-cytokine receptor interaction, IL-17 signaling pathway, Inflammatory bowel disease, Rheumatoid arthritis, Th17 cell differentiation 💬 | 1件: 271 271 💬 |
2494 | Secukinumab 75 mg/0.5 ml Solution for injection | 1件: Secukinumab Secukinumab | 1件: Secukinumab
Secukinumab
💬 | 1件: IL17A IL17A 💬 | 6件: Alcoholic liver disease Alcoholic liver disease, Cytokine-cytokine receptor interaction, IL-17 signaling pathway, Inflammatory bowel disease, Rheumatoid arthritis, Th17 cell differentiation 💬 | 1件: 271 271 💬 |
2495 | See D.3.9.3 'Other descriptive name' below | - | - | - | - | 1件: 46 46 💬 |
2496 | Selective Nerve Root Block | - | - | - | - | 1件: 70 70 💬 |
2497 | Selexipag, ACT-293987 (NS-304) | 1件: Selexipag Selexipag | 1件: Selexipag
Selexipag
💬 | 1件: PTGIR PTGIR 💬 | 3件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Platelet activation, Vascular smooth muscle contraction 💬 | 1件: 86 86 💬 |
2498 | Serum physiologique 0.9 % | - | - | - | - | 1件: 96 96 💬 |
2499 | Sezione * D.3.6.2.1 - valore: 400mg alla settimana 0, in seguito 200mg ogni due settimane | - | - | - | - | 1件: 96 96 💬 |
2500 | SGT-001 | - | - | - | - | 1件: 113 113 💬 |
2501 | SHP 655 (BAX 930) | - | - | - | - | 1件: 64 64 💬 |
2502 | Sialic acid, N-acetylneuraminic acid | - | - | - | - | 1件: 30 30 💬 |
2503 | Sifalimumab 600 mg | 1件: Sifalimumab Sifalimumab | 1件: Sifalimumab
Sifalimumab
💬 | 13件: IFNA1 IFNA1, IFNA10, IFNA13, IFNA14, IFNA16, IFNA17, IFNA2, IFNA21, IFNA4, IFNA5, IFNA6, IFNA7, IFNA8 💬 | 25件: Alcoholic liver disease Alcoholic liver disease, Autoimmune thyroid disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Cytosolic DNA-sensing pathway, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Lipid and atherosclerosis, Measles, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, PI3K-Akt signaling pathway, Pathways in cancer, RIG-I-like receptor signaling pathway, Toll-like receptor signaling pathway, Tuberculosis 💬 | 1件: 49 49 💬 |
2504 | Sifrol 0,088 | 1件: Pramipexole Pramipexole | 1件: Pramipexole
Pramipexole
💬 | 3件: DRD2 DRD2, DRD3, DRD4 💬 | 8件: Alcoholism Alcoholism, Cocaine addiction, Dopaminergic synapse, Gap junction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway 💬 | 1件: 6 6 💬 |
2505 | Sifrol 0,18 | 1件: Pramipexole Pramipexole | 1件: Pramipexole
Pramipexole
💬 | 3件: DRD2 DRD2, DRD3, DRD4 💬 | 8件: Alcoholism Alcoholism, Cocaine addiction, Dopaminergic synapse, Gap junction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway 💬 | 1件: 6 6 💬 |
2506 | Sifrol 0,35 | 1件: Pramipexole Pramipexole | 1件: Pramipexole
Pramipexole
💬 | 3件: DRD2 DRD2, DRD3, DRD4 💬 | 8件: Alcoholism Alcoholism, Cocaine addiction, Dopaminergic synapse, Gap junction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway 💬 | 1件: 6 6 💬 |
2507 | Sifrol 0,7 | 1件: Pramipexole Pramipexole | 1件: Pramipexole
Pramipexole
💬 | 3件: DRD2 DRD2, DRD3, DRD4 💬 | 8件: Alcoholism Alcoholism, Cocaine addiction, Dopaminergic synapse, Gap junction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway 💬 | 1件: 6 6 💬 |
2508 | Sifrol, 0,35 mg Tablette | 1件: Pramipexole Pramipexole | 1件: Pramipexole
Pramipexole
💬 | 3件: DRD2 DRD2, DRD3, DRD4 💬 | 8件: Alcoholism Alcoholism, Cocaine addiction, Dopaminergic synapse, Gap junction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway 💬 | 1件: 6 6 💬 |
2509 | Sifrol, 0,70 mg Tablette | 1件: Pramipexole Pramipexole | 1件: Pramipexole
Pramipexole
💬 | 3件: DRD2 DRD2, DRD3, DRD4 💬 | 8件: Alcoholism Alcoholism, Cocaine addiction, Dopaminergic synapse, Gap junction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway 💬 | 1件: 6 6 💬 |
2510 | Sildenafil (Subchronic-4 weeks) | 1件: Sildenafil Sildenafil | 1件: Sildenafil
Sildenafil
💬 | 1件: PDE5A PDE5A 💬 | 3件: Metabolic pathways Metabolic pathways, Purine metabolism, cGMP-PKG signaling pathway 💬 | 1件: 299 299 💬 |
2511 | Sildenafil 20mg and Bosentan 62.5mg | 2件: Bosentan Bosentan, Sildenafil | 3件: Bosentan
Bosentan
,
Bosentan
,
Sildenafil
💬 | 3件: EDNRA EDNRA, EDNRB, PDE5A 💬 | 11件: Calcium signaling pathway Calcium signaling pathway, Melanogenesis, Metabolic pathways, Neuroactive ligand-receptor interaction, Pathways in cancer, Purine metabolism, Relaxin signaling pathway, Renin secretion, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway 💬 | 2件: 51 51, 86 💬 |
2512 | Sildenafil 40mg oral capsule | 1件: Sildenafil Sildenafil | 1件: Sildenafil
Sildenafil
💬 | 1件: PDE5A PDE5A 💬 | 3件: Metabolic pathways Metabolic pathways, Purine metabolism, cGMP-PKG signaling pathway 💬 | 1件: 299 299 💬 |
2513 | Sildenafil citrate (UK-92,480) | 1件: Sildenafil Sildenafil | 1件: Sildenafil
Sildenafil
💬 | 1件: PDE5A PDE5A 💬 | 3件: Metabolic pathways Metabolic pathways, Purine metabolism, cGMP-PKG signaling pathway 💬 | 1件: 86 86 💬 |
2514 | SIMPONI - 50 MG-SOLUZIONE PER INIEZIONE IN PENNA PRERIEMPITA-USO SOTTOCUTANEO-PENNA PRERIEMPITA(VETRO) -0.5 ML 3 (3X1) PENNE PRERIEMPITE | 1件: Golimumab Golimumab | 1件: Golimumab
Golimumab
💬 | 1件: TNF TNF 💬 | 67件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Dilated cardiomyopathy, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease, Osteoclast differentiation, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway 💬 | 1件: 46 46 💬 |
2515 | SIMPONI 50 mg solución inyectable en pluma precargada | 1件: Golimumab Golimumab | 1件: Golimumab
Golimumab
💬 | 1件: TNF TNF 💬 | 67件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Dilated cardiomyopathy, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease, Osteoclast differentiation, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway 💬 | 1件: 46 46 💬 |
2516 | SimvaHEXAL® 40 mg Filmtabletten | - | - | - | - | 1件: 13 13 💬 |
2517 | Simvastatin 40 mg | 1件: Simvastatin Simvastatin | 1件: Simvastatin
Simvastatin
💬 | 1件: HMGCR HMGCR 💬 | 4件: AMPK signaling pathway AMPK signaling pathway, Bile secretion, Metabolic pathways, Terpenoid backbone biosynthesis 💬 | 1件: 86 86 💬 |
2518 | Simvastatin 40 mg film-coated tablets | 1件: Simvastatin Simvastatin | 1件: Simvastatin
Simvastatin
💬 | 1件: HMGCR HMGCR 💬 | 4件: AMPK signaling pathway AMPK signaling pathway, Bile secretion, Metabolic pathways, Terpenoid backbone biosynthesis 💬 | 1件: 13 13 💬 |
2519 | Simvastatin 40 mg tablets | 1件: Simvastatin Simvastatin | 1件: Simvastatin
Simvastatin
💬 | 1件: HMGCR HMGCR 💬 | 4件: AMPK signaling pathway AMPK signaling pathway, Bile secretion, Metabolic pathways, Terpenoid backbone biosynthesis 💬 | 1件: 86 86 💬 |
2520 | Simvastatin 40mg | 1件: Simvastatin Simvastatin | 1件: Simvastatin
Simvastatin
💬 | 1件: HMGCR HMGCR 💬 | 4件: AMPK signaling pathway AMPK signaling pathway, Bile secretion, Metabolic pathways, Terpenoid backbone biosynthesis 💬 | 1件: 94 94 💬 |
2521 | Simvastatina Sandoz 40 mg comprimidos recubiertos con película EFG | 1件: Simvastatin Simvastatin | 1件: Simvastatin
Simvastatin
💬 | 1件: HMGCR HMGCR 💬 | 4件: AMPK signaling pathway AMPK signaling pathway, Bile secretion, Metabolic pathways, Terpenoid backbone biosynthesis 💬 | 1件: 13 13 💬 |
2522 | Simvastatine Sandoz 40 mg filmomhulde tabletten | 1件: Simvastatin Simvastatin | 1件: Simvastatin
Simvastatin
💬 | 1件: HMGCR HMGCR 💬 | 4件: AMPK signaling pathway AMPK signaling pathway, Bile secretion, Metabolic pathways, Terpenoid backbone biosynthesis 💬 | 1件: 13 13 💬 |
2523 | Simvastatine Sandoz 40mg deelbare filmomhulde tabletten | 1件: Simvastatin Simvastatin | 1件: Simvastatin
Simvastatin
💬 | 1件: HMGCR HMGCR 💬 | 4件: AMPK signaling pathway AMPK signaling pathway, Bile secretion, Metabolic pathways, Terpenoid backbone biosynthesis 💬 | 1件: 13 13 💬 |
2524 | Single dose C2N-8E12 | - | - | - | - | 1件: 5 5 💬 |
2525 | Sinvastatina Sandoz 40 mg comprimidos revestidos por película | - | - | - | - | 1件: 13 13 💬 |
2526 | Siponimod 0,25 mg | 1件: Siponimod Siponimod | 1件: Siponimod
Siponimod
💬 | 2件: S1PR1 S1PR1, S1PR5 💬 | 3件: FoxO signaling pathway FoxO signaling pathway, Neuroactive ligand-receptor interaction, Sphingolipid signaling pathway 💬 | 1件: 13 13 💬 |
2527 | Siponimod 0.25 mg tablet | 1件: Siponimod Siponimod | 1件: Siponimod
Siponimod
💬 | 2件: S1PR1 S1PR1, S1PR5 💬 | 3件: FoxO signaling pathway FoxO signaling pathway, Neuroactive ligand-receptor interaction, Sphingolipid signaling pathway 💬 | 2件: 13 13, 50 💬 |
2528 | Siponimod 0.5 mg tablet | 1件: Siponimod Siponimod | 1件: Siponimod
Siponimod
💬 | 2件: S1PR1 S1PR1, S1PR5 💬 | 3件: FoxO signaling pathway FoxO signaling pathway, Neuroactive ligand-receptor interaction, Sphingolipid signaling pathway 💬 | 2件: 13 13, 50 💬 |
2529 | Sirolimus 0,1% crème | 1件: Sirolimus Sirolimus | 1件: Sirolimus
Sirolimus
💬 | 1件: MTOR MTOR 💬 | 51件: AMPK signaling pathway AMPK signaling pathway, Acute myeloid leukemia, Adipocytokine signaling pathway, Alzheimer disease, Amyotrophic lateral sclerosis, Apelin signaling pathway, Autophagy - animal, Autophagy - other, Breast cancer, Cellular senescence, Central carbon metabolism in cancer, Chemical carcinogenesis - receptor activation, Choline metabolism in cancer, Colorectal cancer, Diabetic cardiomyopathy, EGFR tyrosine kinase inhibitor resistance, Endocrine resistance, ErbB signaling pathway, Gastric cancer, Glioma, Growth hormone synthesis, secretion and action, HIF-1 signaling pathway, Hepatocellular carcinoma, Herpes simplex virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Huntington disease, Insulin resistance, Insulin signaling pathway, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Longevity regulating pathway, Longevity regulating pathway - multiple species, MicroRNAs in cancer, Neutrophil extracellular trap formation, PD-L1 expression and PD-1 checkpoint pathway in cancer, PI3K-Akt signaling pathway, Pancreatic cancer, Pathways in cancer, Pathways of neurodegeneration - multiple diseases, Phospholipase D signaling pathway, Prostate cancer, Proteoglycans in cancer, Shigellosis, Spinocerebellar ataxia, Th17 cell differentiation, Thermogenesis, Thyroid hormone signaling pathway, Type II diabetes mellitus, mTOR signaling pathway 💬 | 2件: 278 278, 280 💬 |
2530 | Sirolimus 0.2% | 1件: Sirolimus Sirolimus | 1件: Sirolimus
Sirolimus
💬 | 1件: MTOR MTOR 💬 | 51件: AMPK signaling pathway AMPK signaling pathway, Acute myeloid leukemia, Adipocytokine signaling pathway, Alzheimer disease, Amyotrophic lateral sclerosis, Apelin signaling pathway, Autophagy - animal, Autophagy - other, Breast cancer, Cellular senescence, Central carbon metabolism in cancer, Chemical carcinogenesis - receptor activation, Choline metabolism in cancer, Colorectal cancer, Diabetic cardiomyopathy, EGFR tyrosine kinase inhibitor resistance, Endocrine resistance, ErbB signaling pathway, Gastric cancer, Glioma, Growth hormone synthesis, secretion and action, HIF-1 signaling pathway, Hepatocellular carcinoma, Herpes simplex virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Huntington disease, Insulin resistance, Insulin signaling pathway, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Longevity regulating pathway, Longevity regulating pathway - multiple species, MicroRNAs in cancer, Neutrophil extracellular trap formation, PD-L1 expression and PD-1 checkpoint pathway in cancer, PI3K-Akt signaling pathway, Pancreatic cancer, Pathways in cancer, Pathways of neurodegeneration - multiple diseases, Phospholipase D signaling pathway, Prostate cancer, Proteoglycans in cancer, Shigellosis, Spinocerebellar ataxia, Th17 cell differentiation, Thermogenesis, Thyroid hormone signaling pathway, Type II diabetes mellitus, mTOR signaling pathway 💬 | 1件: 158 158 💬 |
2531 | Sirolimus 0.4% | 1件: Sirolimus Sirolimus | 1件: Sirolimus
Sirolimus
💬 | 1件: MTOR MTOR 💬 | 51件: AMPK signaling pathway AMPK signaling pathway, Acute myeloid leukemia, Adipocytokine signaling pathway, Alzheimer disease, Amyotrophic lateral sclerosis, Apelin signaling pathway, Autophagy - animal, Autophagy - other, Breast cancer, Cellular senescence, Central carbon metabolism in cancer, Chemical carcinogenesis - receptor activation, Choline metabolism in cancer, Colorectal cancer, Diabetic cardiomyopathy, EGFR tyrosine kinase inhibitor resistance, Endocrine resistance, ErbB signaling pathway, Gastric cancer, Glioma, Growth hormone synthesis, secretion and action, HIF-1 signaling pathway, Hepatocellular carcinoma, Herpes simplex virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Huntington disease, Insulin resistance, Insulin signaling pathway, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Longevity regulating pathway, Longevity regulating pathway - multiple species, MicroRNAs in cancer, Neutrophil extracellular trap formation, PD-L1 expression and PD-1 checkpoint pathway in cancer, PI3K-Akt signaling pathway, Pancreatic cancer, Pathways in cancer, Pathways of neurodegeneration - multiple diseases, Phospholipase D signaling pathway, Prostate cancer, Proteoglycans in cancer, Shigellosis, Spinocerebellar ataxia, Th17 cell differentiation, Thermogenesis, Thyroid hormone signaling pathway, Type II diabetes mellitus, mTOR signaling pathway 💬 | 1件: 158 158 💬 |
2532 | Sirolimus and Hydroxychloroquine 400 mg | 2件: Hydroxychloroquine Hydroxychloroquine, Sirolimus | 2件: Sirolimus
Sirolimus
,
Hydroxychloroquine
💬 | 1件: MTOR MTOR 💬 | 51件: AMPK signaling pathway AMPK signaling pathway, Acute myeloid leukemia, Adipocytokine signaling pathway, Alzheimer disease, Amyotrophic lateral sclerosis, Apelin signaling pathway, Autophagy - animal, Autophagy - other, Breast cancer, Cellular senescence, Central carbon metabolism in cancer, Chemical carcinogenesis - receptor activation, Choline metabolism in cancer, Colorectal cancer, Diabetic cardiomyopathy, EGFR tyrosine kinase inhibitor resistance, Endocrine resistance, ErbB signaling pathway, Gastric cancer, Glioma, Growth hormone synthesis, secretion and action, HIF-1 signaling pathway, Hepatocellular carcinoma, Herpes simplex virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Huntington disease, Insulin resistance, Insulin signaling pathway, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Longevity regulating pathway, Longevity regulating pathway - multiple species, MicroRNAs in cancer, Neutrophil extracellular trap formation, PD-L1 expression and PD-1 checkpoint pathway in cancer, PI3K-Akt signaling pathway, Pancreatic cancer, Pathways in cancer, Pathways of neurodegeneration - multiple diseases, Phospholipase D signaling pathway, Prostate cancer, Proteoglycans in cancer, Shigellosis, Spinocerebellar ataxia, Th17 cell differentiation, Thermogenesis, Thyroid hormone signaling pathway, Type II diabetes mellitus, mTOR signaling pathway 💬 | 1件: 89 89 💬 |
2533 | Sivatin 40 mg film-coated tablets | - | - | - | - | 1件: 13 13 💬 |
2534 | SKI-606 | - | - | - | - | 1件: 67 67 💬 |
2535 | SLS-005 | - | - | - | - | 1件: 2 2 💬 |
2536 | SLS-005 Trehalose | 1件: Trehalose Trehalose | - | - | - | 1件: 2 2 💬 |
2537 | SMOFKABIVEN - EMULSIONE PER INFUSIONE SENZA ELETTROLITI 1 SACCA BIOFINE MULTICOMPARTIMENTATE DA 493 ML | 2件: Medium-chain triglycerides Medium-chain triglycerides, Sodium glycerophosphate | 1件: Sodium glycerophosphate
Sodium glycerophosphate
💬 | - | - | 1件: 66 66 💬 |
2538 | Sobetirome (NV1205) | 1件: Sobetirome Sobetirome | 1件: Sobetirome
Sobetirome
💬 | 1件: THRB THRB 💬 | 2件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Thyroid hormone signaling pathway 💬 | 1件: 20 20 💬 |
2539 | Sodium (R)-8-methyl-2-(3-methylbenzofuran-2-yl)-5-(1-(tetrahydro-2H-pyran-4-yl)ethoxy)quinoline-4-ca | - | - | - | - | 1件: 299 299 💬 |
2540 | Sodium (S)-3-(4-hydroxyphenyl)-2-(2-((S)-1-((S)-1-palmitoylpyrrolidine-2-carbonyl)pyrrolidine-2-carboxamido)acetamido)propanoate | 1件: Pyrrolidine Pyrrolidine | - | - | - | 1件: 97 97 💬 |
2541 | Sodium 4-Phenylbutyrate | 1件: Phenylbutyric acid Phenylbutyric acid | - | - | - | 1件: 299 299 💬 |
2542 | Sodium 4-Phenylbutyrate (4PBA) | 1件: Phenylbutyric acid Phenylbutyric acid | - | - | - | 1件: 299 299 💬 |
2543 | Sodium chloride (NaCl) | 2件: Chloride ion Chloride ion, Sodium chloride | 1件: Sodium chloride
Sodium chloride
💬 | - | - | 1件: 67 67 💬 |
2544 | Sodium chloride 0,9% | 2件: Chloride ion Chloride ion, Sodium chloride | 1件: Sodium chloride
Sodium chloride
💬 | - | - | 1件: 299 299 💬 |
2545 | Sodium Chloride 0.9% | 2件: Chloride ion Chloride ion, Sodium chloride | 1件: Sodium chloride
Sodium chloride
💬 | - | - | 2件: 14 14, 227 💬 |
2546 | Sodium chloride 6% | 2件: Chloride ion Chloride ion, Sodium chloride | 1件: Sodium chloride
Sodium chloride
💬 | - | - | 1件: 299 299 💬 |
2547 | SODIUM CHLORIDE SOLUTION 0.9% | 2件: Chloride ion Chloride ion, Sodium chloride | 1件: Sodium chloride
Sodium chloride
💬 | - | - | 4件: 51 51, 60, 288, 299 💬 |
2548 | Sodium Nitrate | 2件: Nitrate Nitrate, Sodium nitrate | 1件: Nitric acid
Nitric acid
💬 | - | - | 2件: 58 58, 113 💬 |
2549 | Sodium Nitrate - double dose | 2件: Nitrate Nitrate, Sodium nitrate | 1件: Nitric acid
Nitric acid
💬 | - | - | 1件: 113 113 💬 |
2550 | SODIUM NITRITE | 1件: Nitrite Nitrite | - | - | - | 1件: 86 86 💬 |
2551 | Sodium Nitrite Inhalation Solution | 1件: Nitrite Nitrite | - | - | - | 1件: 86 86 💬 |
2552 | SODIUM NITROPRUSSIDE | 1件: Nitroprusside Nitroprusside | - | - | - | 1件: 51 51 💬 |
2553 | Sodium phenylbutyrate (NaPB) | 1件: Phenylbutyric acid Phenylbutyric acid | - | - | - | 1件: 3 3 💬 |
2554 | Sodium Pyruvate in 0.9% Sodium Chloride Solution | 2件: Chloride ion Chloride ion, Sodium chloride | 1件: Sodium chloride
Sodium chloride
💬 | - | - | 1件: 299 299 💬 |
2555 | Sodium-[o-[(2,6-dichlorophenyl)-amino]- phenyl]-acetate | 1件: Acetate Acetate | - | - | - | 1件: 46 46 💬 |
2556 | Sodium-[o-[(2,6-dichlorophenyl)-amino]-phenyl]-acetate | 1件: Acetate Acetate | - | - | - | 1件: 46 46 💬 |
2557 | SOLIRIS 300 mg concentrado para solución para perfusión | 1件: Eculizumab Eculizumab | 1件: Eculizumab
Eculizumab
💬 | 1件: C5 C5 💬 | 11件: Alcoholic liver disease Alcoholic liver disease, Complement and coagulation cascades, Coronavirus disease - COVID-19, Herpes simplex virus 1 infection, Neuroactive ligand-receptor interaction, Neutrophil extracellular trap formation, Pertussis, Prion disease, Regulation of actin cytoskeleton, Staphylococcus aureus infection, Systemic lupus erythematosus 💬 | 1件: 109 109 💬 |
2558 | SOLU MEDROL - 40 MG/ML POLVERE E SOLVENTE PER SOLUZIONE INIETTABILE 1 FLACONE A DOPPIA CAMERA DA 40 MG/ML | - | - | - | - | 1件: 56 56 💬 |
2559 | SOLU MEDROL - 500 MG/8 ML POLVERE E SOLVENTE PER SOLUZIONE INIETTABILE 1 FLACONE DI POLVERE DA 500 MG+ FIALA SOLVENTE DA 8 ML | - | - | - | - | 1件: 56 56 💬 |
2560 | Solu-medrol inj. PSO LQF 40mg | 1件: Methylprednisolone hemisuccinate Methylprednisolone hemisuccinate | 1件: Methylprednisolone hemisuccinate
Methylprednisolone hemisuccinate
💬 | 1件: NR3C1 NR3C1 💬 | 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 1件: 50 50 💬 |
2561 | SOM230 600µg | - | - | - | - | 1件: 75 75 💬 |
2562 | SOM230, 600 micrograms | - | - | - | - | 1件: 75 75 💬 |
2563 | Somatropin - GH naïve pediatric cohort | 1件: Somatotropin Somatotropin | - | - | - | 1件: 193 193 💬 |
2564 | Sotatercept - 45 mg/vial | 1件: Sotatercept Sotatercept | 1件: Sotatercept
Sotatercept
💬 | 1件: ACVR2A ACVR2A 💬 | 4件: Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, Fluid shear stress and atherosclerosis, Signaling pathways regulating pluripotency of stem cells, TGF-beta signaling pathway 💬 | 1件: 86 86 💬 |
2565 | Sotatercept - 60 mg/vial | 1件: Sotatercept Sotatercept | 1件: Sotatercept
Sotatercept
💬 | 1件: ACVR2A ACVR2A 💬 | 4件: Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, Fluid shear stress and atherosclerosis, Signaling pathways regulating pluripotency of stem cells, TGF-beta signaling pathway 💬 | 1件: 86 86 💬 |
2566 | SPI-62 | - | - | - | - | 1件: 75 75 💬 |
2567 | SPI-62 dose 2 | - | - | - | - | 1件: 75 75 💬 |
2568 | SPI-62 dose 3 | - | - | - | - | 1件: 75 75 💬 |
2569 | SPI-62 dose 4 | - | - | - | - | 1件: 75 75 💬 |
2570 | SPI-62 dose1 | - | - | - | - | 1件: 75 75 💬 |
2571 | SPP-004 | - | - | - | - | 1件: 21 21 💬 |
2572 | SRK-015 | - | - | - | - | 1件: 3 3 💬 |
2573 | SRP-4045 | - | - | - | - | 1件: 113 113 💬 |
2574 | SRP-4053 | - | - | - | - | 1件: 113 113 💬 |
2575 | SSGJ-613 | - | - | - | - | 1件: 107 107 💬 |
2576 | SSP-004184 100 mg | - | - | - | - | 1件: 284 284 💬 |
2577 | SSP-004184 100 mg Capsule | - | - | - | - | 1件: 284 284 💬 |
2578 | SSP-004184 250 mg | - | - | - | - | 1件: 284 284 💬 |
2579 | SSP-004184 250 mg Capsule | - | - | - | - | 1件: 284 284 💬 |
2580 | SSP-004184 375 mg | - | - | - | - | 1件: 284 284 💬 |
2581 | SSP-004184 375 mg Capsule | - | - | - | - | 1件: 284 284 💬 |
2582 | SSP-004184 50 mg | - | - | - | - | 1件: 284 284 💬 |
2583 | SSP-004184 50 mg Capsule | - | - | - | - | 1件: 284 284 💬 |
2584 | SSP-004184 500 mg | - | - | - | - | 1件: 284 284 💬 |
2585 | SSP-004184 500 mg Capsule | - | - | - | - | 1件: 284 284 💬 |
2586 | SSP-004184AQ 100 mg | - | - | - | - | 1件: 284 284 💬 |
2587 | SSP-004184AQ 100 mg Capsule | - | - | - | - | 1件: 284 284 💬 |
2588 | SSP-004184AQ 200 mg | - | - | - | - | 1件: 284 284 💬 |
2589 | SSP-004184AQ 200 mg Capsule | - | - | - | - | 1件: 284 284 💬 |
2590 | SSP-004184AQ 250 mg | - | - | - | - | 1件: 284 284 💬 |
2591 | SSP-004184AQ 250 mg Capsule | - | - | - | - | 1件: 284 284 💬 |
2592 | SSP-004184AQ 375 mg | - | - | - | - | 1件: 284 284 💬 |
2593 | SSP-004184AQ 375 mg Capsule | - | - | - | - | 1件: 284 284 💬 |
2594 | SSP-004184AQ 50 mg | - | - | - | - | 1件: 284 284 💬 |
2595 | SSP-004184AQ 50 mg Capsule | - | - | - | - | 1件: 284 284 💬 |
2596 | ST-0529 | - | - | - | - | 1件: 97 97 💬 |
2597 | ST10-021 | - | - | - | - | 2件: 96 96, 97 💬 |
2598 | STA-6838, STA-5326 m, S38 | - | - | - | - | 1件: 96 96 💬 |
2599 | Standard Dose YPT-01 | - | - | - | - | 1件: 299 299 💬 |
2600 | Standard Nutritional Supplement + PERT | - | - | - | - | 1件: 299 299 💬 |
2601 | Standard-dose vitamin D (400IU per day) | 1件: Vitamin D Vitamin D | - | - | - | 1件: 274 274 💬 |
2602 | STELARA - 45 MG SOLUZIONE INIETTABILE - USO SOTTOCUTANEO - FLACONCINO (VETRO) 0.5 ML (90 MG/ML) 1 FLACONCINO | 1件: Ustekinumab Ustekinumab | 1件: Ustekinumab
Ustekinumab
💬 | 3件: IL12A IL12A, IL12B, IL23A 💬 | 28件: African trypanosomiasis African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Amoebiasis, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Herpes simplex virus 1 infection, Inflammatory bowel disease, Influenza A, JAK-STAT signaling pathway, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, Malaria, Measles, Pathways in cancer, Pertussis, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus 💬 | 1件: 96 96 💬 |
2603 | STELARA - 90 MG SOLUZIONE INIETTABILE - USO SOTTOCUTANEO - FLACONCINO (VETRO) 1.0 ML (90 MG/ML) 1 FLACONCINO | 1件: Ustekinumab Ustekinumab | 1件: Ustekinumab
Ustekinumab
💬 | 3件: IL12A IL12A, IL12B, IL23A 💬 | 28件: African trypanosomiasis African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Amoebiasis, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Herpes simplex virus 1 infection, Inflammatory bowel disease, Influenza A, JAK-STAT signaling pathway, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, Malaria, Measles, Pathways in cancer, Pertussis, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus 💬 | 2件: 96 96, 97 💬 |
2604 | Sterile Normal Saline (0.9% NaCl) | - | - | - | - | 2件: 62 62, 254 💬 |
2605 | STERILE PYROGEN-FREE ISOTONIC NACL SOLUTE (0.9% W / V) | - | - | - | - | 1件: 299 299 💬 |
2606 | STG-001 | 1件: STG-001 STG-001 | - | - | - | 1件: 301 301 💬 |
2607 | STI-6129 | - | - | - | - | 1件: 28 28 💬 |
2608 | STK-001 | 1件: Zorevunersen Zorevunersen | - | - | - | 1件: 140 140 💬 |
2609 | STK-001 - Multiple Ascending Doses | 1件: Zorevunersen Zorevunersen | - | - | - | 1件: 140 140 💬 |
2610 | STK-001 - Single Ascending Doses | 1件: Zorevunersen Zorevunersen | - | - | - | 1件: 140 140 💬 |
2611 | STNM01 1.84 mg | - | - | - | - | 1件: 97 97 💬 |
2612 | STW5-II (Iberogast N, BAY98-7410) | - | - | - | - | 1件: 97 97 💬 |
2613 | Sub-Study: Nintedanib | 1件: Nintedanib Nintedanib | 1件: Nintedanib
Nintedanib
💬 | 8件: FGFR1 FGFR1, FGFR2, FGFR3, FLT1, FLT4, KDR, PDGFRA, PDGFRB 💬 | 34件: Adherens junction Adherens junction, Bladder cancer, Breast cancer, Calcium signaling pathway, Central carbon metabolism in cancer, Choline metabolism in cancer, EGFR tyrosine kinase inhibitor resistance, Endocytosis, Fluid shear stress and atherosclerosis, Focal adhesion, Gap junction, Gastric cancer, Glioma, HIF-1 signaling pathway, Human cytomegalovirus infection, Human papillomavirus infection, JAK-STAT signaling pathway, MAPK signaling pathway, Melanoma, MicroRNAs in cancer, PI3K-Akt signaling pathway, Parathyroid hormone synthesis, secretion and action, Pathways in cancer, Phospholipase D signaling pathway, Prostate cancer, Proteoglycans in cancer, Rap1 signaling pathway, Ras signaling pathway, Regulation of actin cytoskeleton, Rheumatoid arthritis, Signaling pathways regulating pluripotency of stem cells, Thermogenesis, Transcriptional misregulation in cancer, VEGF signaling pathway 💬 | 1件: 85 85 💬 |
2614 | Sublingual nitroglycerine | 1件: Nitroglycerin Nitroglycerin | 1件: Nitroglycerin
Nitroglycerin
💬 | - | - | 1件: 46 46 💬 |
2615 | Sulindac (HLX-0201), dose strength 1 | 1件: Sulindac Sulindac | 1件: Sulindac
Sulindac
💬 | 2件: PTGS1 PTGS1, PTGS2 💬 | 23件: Alzheimer disease Alzheimer disease, Arachidonic acid metabolism, C-type lectin receptor signaling pathway, Chemical carcinogenesis - DNA adducts, Human cytomegalovirus infection, Human papillomavirus infection, IL-17 signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Metabolic pathways, MicroRNAs in cancer, NF-kappa B signaling pathway, Ovarian steroidogenesis, Oxytocin signaling pathway, Pathways in cancer, Pathways of neurodegeneration - multiple diseases, Platelet activation, Regulation of lipolysis in adipocytes, Retrograde endocannabinoid signaling, Serotonergic synapse, Small cell lung cancer, TNF signaling pathway, VEGF signaling pathway 💬 | 1件: 206 206 💬 |
2616 | Sulindac (HLX-0201), dose strength 2 | 1件: Sulindac Sulindac | 1件: Sulindac
Sulindac
💬 | 2件: PTGS1 PTGS1, PTGS2 💬 | 23件: Alzheimer disease Alzheimer disease, Arachidonic acid metabolism, C-type lectin receptor signaling pathway, Chemical carcinogenesis - DNA adducts, Human cytomegalovirus infection, Human papillomavirus infection, IL-17 signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Metabolic pathways, MicroRNAs in cancer, NF-kappa B signaling pathway, Ovarian steroidogenesis, Oxytocin signaling pathway, Pathways in cancer, Pathways of neurodegeneration - multiple diseases, Platelet activation, Regulation of lipolysis in adipocytes, Retrograde endocannabinoid signaling, Serotonergic synapse, Small cell lung cancer, TNF signaling pathway, VEGF signaling pathway 💬 | 1件: 206 206 💬 |
2617 | Supplement nutritional supporting | - | - | - | - | 1件: 291 291 💬 |
2618 | Surgical infusion of AAV-GAD into the subthalamic nucleus | - | - | - | - | 1件: 6 6 💬 |
2619 | Survival of Motor Neuron 2 (SMN2) Splicing Modulator Antisense Oligonucleotide | - | - | - | - | 1件: 3 3 💬 |
2620 | SYN115 Tablets, 60 mg | - | - | - | - | 1件: 6 6 💬 |
2621 | Syntocinon 40 IU/ml nasal spray | 1件: Oxytocin Oxytocin | 1件: Oxytocin
Oxytocin
💬 | 1件: OXTR OXTR 💬 | 4件: Calcium signaling pathway Calcium signaling pathway, Neuroactive ligand-receptor interaction, Oxytocin signaling pathway, cAMP signaling pathway 💬 | 1件: 6 6 💬 |
2622 | Syntocinon nasal spray | 1件: Oxytocin Oxytocin | 1件: Oxytocin
Oxytocin
💬 | 1件: OXTR OXTR 💬 | 4件: Calcium signaling pathway Calcium signaling pathway, Neuroactive ligand-receptor interaction, Oxytocin signaling pathway, cAMP signaling pathway 💬 | 1件: 193 193 💬 |
2623 | Systemic non-biological treatments | - | - | - | - | 2件: 46 46, 271 💬 |
2624 | T 614 | - | - | - | - | 1件: 300 300 💬 |
2625 | T-614 | - | - | - | - | 1件: 46 46 💬 |
2626 | T-817MA | - | - | - | - | 1件: 149 149 💬 |
2627 | TA-46 | - | - | - | - | 1件: 276 276 💬 |
2628 | TA-650 | - | - | - | - | 4件: 37 37, 56, 96, 97 💬 |
2629 | TA-650 (Infliximab) | 1件: Infliximab Infliximab | 1件: Infliximab
Infliximab
💬 | 1件: TNF TNF 💬 | 67件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Dilated cardiomyopathy, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease, Osteoclast differentiation, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway 💬 | 3件: 46 46, 97, 271 💬 |
2630 | TA-650 10 mg/kg | - | - | - | - | 1件: 46 46 💬 |
2631 | TA-650 3 mg/kg | - | - | - | - | 1件: 46 46 💬 |
2632 | TA-650 6 mg/kg | - | - | - | - | 1件: 46 46 💬 |
2633 | TACHIPIRINA - 1000 MG COMPRESSE 8 COMPRESSE | - | - | - | - | 1件: 14 14 💬 |
2634 | TAD 600 | - | - | - | - | 1件: 299 299 💬 |
2635 | Tadalafil 40 mg | 1件: Tadalafil Tadalafil | 1件: Tadalafil
Tadalafil
💬 | 1件: PDE5A PDE5A 💬 | 3件: Metabolic pathways Metabolic pathways, Purine metabolism, cGMP-PKG signaling pathway 💬 | 1件: 86 86 💬 |
2636 | TAK-018 | - | - | - | - | 1件: 96 96 💬 |
2637 | TAK-071 | - | - | - | - | 1件: 6 6 💬 |
2638 | TAK-079 | - | - | - | - | 3件: 11 11, 49, 63 💬 |
2639 | TAK-079, TSF-021, TSF79 | - | - | - | - | 1件: 11 11 💬 |
2640 | TAK-475 | 1件: TAK-475 TAK-475 | - | - | - | 1件: 79 79 💬 |
2641 | TAK-625 | - | - | - | - | 2件: 297 297, 338 💬 |
2642 | TAK-672 | - | - | - | - | 1件: 288 288 💬 |
2643 | TAK-831 | 1件: TAK-831 TAK-831 | - | - | - | 1件: 18 18 💬 |
2644 | Taltz (80 mg solution for injection in pre-filled syringe) | 1件: Ixekizumab Ixekizumab | 1件: Ixekizumab
Ixekizumab
💬 | 1件: IL17A IL17A 💬 | 6件: Alcoholic liver disease Alcoholic liver disease, Cytokine-cytokine receptor interaction, IL-17 signaling pathway, Inflammatory bowel disease, Rheumatoid arthritis, Th17 cell differentiation 💬 | 2件: 107 107, 271 💬 |
2645 | Taltz 80mg | 1件: Ixekizumab Ixekizumab | 1件: Ixekizumab
Ixekizumab
💬 | 1件: IL17A IL17A 💬 | 6件: Alcoholic liver disease Alcoholic liver disease, Cytokine-cytokine receptor interaction, IL-17 signaling pathway, Inflammatory bowel disease, Rheumatoid arthritis, Th17 cell differentiation 💬 | 1件: 36 36 💬 |
2646 | Tamoxifen 40 mg daily for one year | 1件: Tamoxifen Tamoxifen | 1件: Tamoxifen
Tamoxifen
💬 | 2件: ESR1 ESR1, ESR2 💬 | 10件: Breast cancer Breast cancer, Chemical carcinogenesis - receptor activation, Endocrine and other factor-regulated calcium reabsorption, Endocrine resistance, Estrogen signaling pathway, GnRH secretion, Pathways in cancer, Prolactin signaling pathway, Proteoglycans in cancer, Thyroid hormone signaling pathway 💬 | 1件: 2 2 💬 |
2647 | Target Sequencing by NGS ( Next-generation sequencing) | - | - | - | - | 1件: 65 65 💬 |
2648 | Tauroursoursodeoxycholic acid, brand name Tudcabil | - | - | - | - | 1件: 97 97 💬 |
2649 | Tavapadon 0.25 mg | 1件: Tavapadon Tavapadon | 1件: Tavapadon
Tavapadon
💬 | 2件: DRD1 DRD1, DRD5 💬 | 10件: Alcoholism Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, cAMP signaling pathway 💬 | 1件: 6 6 💬 |
2650 | Tavapadon 0.25mg | 1件: Tavapadon Tavapadon | 1件: Tavapadon
Tavapadon
💬 | 2件: DRD1 DRD1, DRD5 💬 | 10件: Alcoholism Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, cAMP signaling pathway 💬 | 1件: 6 6 💬 |
2651 | Tears Naturale Forte | - | - | - | - | 1件: 53 53 💬 |
2652 | Teduglutide (ALX-0600) | 1件: Teduglutide Teduglutide | 1件: Teduglutide
Teduglutide
💬 | 1件: GLP2R GLP2R 💬 | 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 1件: 96 96 💬 |
2653 | Teduglutide 0.05 | 1件: Teduglutide Teduglutide | 1件: Teduglutide
Teduglutide
💬 | 1件: GLP2R GLP2R 💬 | 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 1件: 96 96 💬 |
2654 | Teduglutide 0.05 dose | 1件: Teduglutide Teduglutide | 1件: Teduglutide
Teduglutide
💬 | 1件: GLP2R GLP2R 💬 | 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 1件: 96 96 💬 |
2655 | Teduglutide 0.1 mg dose | 1件: Teduglutide Teduglutide | 1件: Teduglutide
Teduglutide
💬 | 1件: GLP2R GLP2R 💬 | 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 1件: 96 96 💬 |
2656 | Teduglutide 0.2 mg | 1件: Teduglutide Teduglutide | 1件: Teduglutide
Teduglutide
💬 | 1件: GLP2R GLP2R 💬 | 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 1件: 96 96 💬 |
2657 | Telitacicept 80 mg | - | - | - | - | 1件: 53 53 💬 |
2658 | Terguride 0,5mg tablet | 1件: Terguride Terguride | 1件: Terguride
Terguride
💬 | 2件: DRD2 DRD2, PRL 💬 | 12件: Alcoholism Alcoholism, Cocaine addiction, Cytokine-cytokine receptor interaction, Dopaminergic synapse, Gap junction, JAK-STAT signaling pathway, Neuroactive ligand-receptor interaction, PI3K-Akt signaling pathway, Parkinson disease, Prolactin signaling pathway, Rap1 signaling pathway, cAMP signaling pathway 💬 | 1件: 86 86 💬 |
2659 | Terguride 0.5 mg tablet | 1件: Terguride Terguride | 1件: Terguride
Terguride
💬 | 2件: DRD2 DRD2, PRL 💬 | 12件: Alcoholism Alcoholism, Cocaine addiction, Cytokine-cytokine receptor interaction, Dopaminergic synapse, Gap junction, JAK-STAT signaling pathway, Neuroactive ligand-receptor interaction, PI3K-Akt signaling pathway, Parkinson disease, Prolactin signaling pathway, Rap1 signaling pathway, cAMP signaling pathway 💬 | 1件: 86 86 💬 |
2660 | TETA 4HCL | 1件: Triethylenetetramine Triethylenetetramine | - | - | - | 1件: 171 171 💬 |
2661 | TETA.4HCI | 1件: Triethylenetetramine Triethylenetetramine | - | - | - | 1件: 171 171 💬 |
2662 | TETA.4HCl | 1件: Triethylenetetramine Triethylenetetramine | - | - | - | 1件: 171 171 💬 |
2663 | TETRACT-HIB - 1 SIRINGA PRECARICATA 0.5 ML | - | - | - | - | 1件: 222 222 💬 |
2664 | Tetrahydro-6,6,9-tri methyl-3-penthyl-6 H-dibenzo[ b,d ]pyran-1-ol | - | - | - | - | 1件: 298 298 💬 |
2665 | TEV-48574 | - | - | - | - | 2件: 96 96, 97 💬 |
2666 | TEV-48574 Dose Regimen A | - | - | - | - | 2件: 96 96, 97 💬 |
2667 | TEV-48574 Dose Regiment B | - | - | - | - | 2件: 96 96, 97 💬 |
2668 | The 0.5 mL dose of vaccine contains 25 micrograms of each of the following 23 pneumococcal polysaccharide | - | - | - | - | 1件: 222 222 💬 |
2669 | The generic name is warfarin and many producers will be involved | 1件: Warfarin Warfarin | 1件: Warfarin
Warfarin
💬 | 2件: NQO1 NQO1, VKORC1 💬 | 7件: Biosynthesis of cofactors Biosynthesis of cofactors, Chemical carcinogenesis - reactive oxygen species, Fluid shear stress and atherosclerosis, Hepatocellular carcinoma, Metabolic pathways, Pathways in cancer, Ubiquinone and other terpenoid-quinone biosynthesis 💬 | 1件: 49 49 💬 |
2670 | The investigational medicinal product (IMP) may be labelled as either PF-04236921 106 mg/vial, Clonal SC lyophilized form” or PF-04236921 Powder for Injection, 106 mg/vial”. Supplies labelled with either nomenclature are equivalent. | - | - | - | - | 1件: 96 96 💬 |
2671 | The investigational medicinal product (IMP) will be labeled as PF-04236921 106 mg/vial, Clonal SC lyophilized form, which is equivalent to PF-04236921 Powder for Injection, 106 mg/vial as described in the enclosed CTA | - | - | - | - | 1件: 96 96 💬 |
2672 | The investigational medicinal product (IMP) will be labeled as PF-04236921 106 mg/vial, Clonal SC lyophilized form, which is equivalent to PF-04236921 Powder for Injection, 106 mg/vial as described in the enclosed CTA. | - | - | - | - | 1件: 96 96 💬 |
2673 | There is no recommended INN | - | - | - | - | 1件: 65 65 💬 |
2674 | Thymosin Beta 4 | 1件: Thymosin beta-4 Thymosin beta-4 | - | - | - | 2件: 36 36, 53 💬 |
2675 | Thymosin Beta 4 eye drops | 1件: Thymosin beta-4 Thymosin beta-4 | - | - | - | 1件: 53 53 💬 |
2676 | Timolol Alcon 0.5% collyre | 1件: Timolol Timolol | 2件: Timolol
Timolol
,
Timolol
💬 | 2件: ADRB1 ADRB1, ADRB2 💬 | 11件: Adrenergic signaling in cardiomyocytes Adrenergic signaling in cardiomyocytes, Calcium signaling pathway, Chemical carcinogenesis - receptor activation, Dilated cardiomyopathy, Gap junction, Neuroactive ligand-receptor interaction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, cAMP signaling pathway, cGMP-PKG signaling pathway 💬 | 1件: 227 227 💬 |
2677 | Timolol nasal spray | 1件: Timolol Timolol | 2件: Timolol
Timolol
,
Timolol
💬 | 2件: ADRB1 ADRB1, ADRB2 💬 | 11件: Adrenergic signaling in cardiomyocytes Adrenergic signaling in cardiomyocytes, Calcium signaling pathway, Chemical carcinogenesis - receptor activation, Dilated cardiomyopathy, Gap junction, Neuroactive ligand-receptor interaction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, cAMP signaling pathway, cGMP-PKG signaling pathway 💬 | 1件: 227 227 💬 |
2678 | TJ-68 | - | - | - | - | 1件: 2 2 💬 |
2679 | TJ301 600mg | - | - | - | - | 1件: 97 97 💬 |
2680 | TLL-018 | - | - | - | - | 1件: 46 46 💬 |
2681 | TLR7/8 Antagonist (10mg) | - | - | - | - | 1件: 49 49 💬 |
2682 | TLR7/8 Antagonist (2.5mg) | - | - | - | - | 1件: 49 49 💬 |
2683 | TMI-005 | - | - | - | - | 1件: 46 46 💬 |
2684 | TMI-005 (WAY-177005) | - | - | - | - | 1件: 46 46 💬 |
2685 | TMI-005 WAY-177005 | - | - | - | - | 1件: 46 46 💬 |
2686 | TNF-a antagonists, non-TNFs, DMARD non-biologics | - | - | - | - | 2件: 46 46, 271 💬 |
2687 | TNR-001 | - | - | - | - | 2件: 46 46, 271 💬 |
2688 | TNR-001, TNFR:FC | - | - | - | - | 1件: 271 271 💬 |
2689 | TNX-650, rhuMAb anti-IL13, aIL-13, MILR1444A | - | - | - | - | 1件: 85 85 💬 |
2690 | TOBI 300 mg / 5 mL nebuliser solution | 1件: Tobramycin Tobramycin | 1件: Tobramycin
Tobramycin
💬 | - | - | 1件: 299 299 💬 |
2691 | TOBI 300 mg/5 ml Nebuliser Solution | 1件: Tobramycin Tobramycin | 1件: Tobramycin
Tobramycin
💬 | - | - | 1件: 299 299 💬 |
2692 | TOBI 300 mg/5 ml solución para inhalación por nebulizador | 1件: Tobramycin Tobramycin | 1件: Tobramycin
Tobramycin
💬 | - | - | 1件: 299 299 💬 |
2693 | TOBI 300 mg/5 ml, solution pour inhalation par nébuliseur | 1件: Tobramycin Tobramycin | 1件: Tobramycin
Tobramycin
💬 | - | - | 1件: 299 299 💬 |
2694 | TOBI 300mg/ 5ml solución para inhalación con nebulizador | 1件: Tobramycin Tobramycin | 1件: Tobramycin
Tobramycin
💬 | - | - | 1件: 299 299 💬 |
2695 | TOBI 300mg/5mL Nebuliser Solution | 1件: Tobramycin Tobramycin | 1件: Tobramycin
Tobramycin
💬 | - | - | 1件: 299 299 💬 |
2696 | Tobi 300mg/5ml Nebuliser solution. | 1件: Tobramycin Tobramycin | 1件: Tobramycin
Tobramycin
💬 | - | - | 1件: 299 299 💬 |
2697 | Tobi 300mg/5ml Solución para inhalación por nebulizador. | 1件: Tobramycin Tobramycin | 1件: Tobramycin
Tobramycin
💬 | - | - | 1件: 299 299 💬 |
2698 | Tobi Nebcinal | - | - | - | - | 1件: 299 299 💬 |
2699 | TOBI Podhaler 28 mg inhalációs por, kemény kapszula | 1件: Tobramycin Tobramycin | 1件: Tobramycin
Tobramycin
💬 | - | - | 1件: 299 299 💬 |
2700 | TOBI PODHALER*448CPS 28MG+10IN | 1件: Tobramycin Tobramycin | 1件: Tobramycin
Tobramycin
💬 | - | - | 1件: 299 299 💬 |
2701 | TOBI*NEBUL 56F 1D 300MG/5ML | 1件: Tobramycin Tobramycin | 1件: Tobramycin
Tobramycin
💬 | - | - | 1件: 299 299 💬 |
2702 | Tobramycin inhalation solution using a PARI LC® Plus nebulizer. | 1件: Tobramycin Tobramycin | 1件: Tobramycin
Tobramycin
💬 | - | - | 1件: 299 299 💬 |
2703 | Tobramycin injection 40mg/1ml | 1件: Tobramycin Tobramycin | 1件: Tobramycin
Tobramycin
💬 | - | - | 1件: 299 299 💬 |
2704 | Tobramycin nebulized nasally | 1件: Tobramycin Tobramycin | 1件: Tobramycin
Tobramycin
💬 | - | - | 1件: 299 299 💬 |
2705 | Tobramycin Steri-Neb 300 mg/5 ml, inhalation solution | 1件: Tobramycin Tobramycin | 1件: Tobramycin
Tobramycin
💬 | - | - | 1件: 299 299 💬 |
2706 | Tocilizumab 162Mg/0.9Ml Autoinjector | 1件: Tocilizumab Tocilizumab | 1件: Tocilizumab
Tocilizumab
💬 | 1件: IL6R IL6R 💬 | 12件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, EGFR tyrosine kinase inhibitor resistance, HIF-1 signaling pathway, Hematopoietic cell lineage, Human cytomegalovirus infection, JAK-STAT signaling pathway, Non-alcoholic fatty liver disease, PI3K-Akt signaling pathway, Pathways in cancer, Th17 cell differentiation, Viral protein interaction with cytokine and cytokine receptor 💬 | 1件: 41 41 💬 |
2707 | Tocilizumab 162mg/0.9ml jeringa SC | 1件: Tocilizumab Tocilizumab | 1件: Tocilizumab
Tocilizumab
💬 | 1件: IL6R IL6R 💬 | 12件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, EGFR tyrosine kinase inhibitor resistance, HIF-1 signaling pathway, Hematopoietic cell lineage, Human cytomegalovirus infection, JAK-STAT signaling pathway, Non-alcoholic fatty liver disease, PI3K-Akt signaling pathway, Pathways in cancer, Th17 cell differentiation, Viral protein interaction with cytokine and cytokine receptor 💬 | 1件: 46 46 💬 |
2708 | Tocilizumab 162mg/0.9ml SC PFS SC | 1件: Tocilizumab Tocilizumab | 1件: Tocilizumab
Tocilizumab
💬 | 1件: IL6R IL6R 💬 | 12件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, EGFR tyrosine kinase inhibitor resistance, HIF-1 signaling pathway, Hematopoietic cell lineage, Human cytomegalovirus infection, JAK-STAT signaling pathway, Non-alcoholic fatty liver disease, PI3K-Akt signaling pathway, Pathways in cancer, Th17 cell differentiation, Viral protein interaction with cytokine and cytokine receptor 💬 | 1件: 46 46 💬 |
2709 | Tocilizumab 162mg/0.9ml syringe SC | 1件: Tocilizumab Tocilizumab | 1件: Tocilizumab
Tocilizumab
💬 | 1件: IL6R IL6R 💬 | 12件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, EGFR tyrosine kinase inhibitor resistance, HIF-1 signaling pathway, Hematopoietic cell lineage, Human cytomegalovirus infection, JAK-STAT signaling pathway, Non-alcoholic fatty liver disease, PI3K-Akt signaling pathway, Pathways in cancer, Th17 cell differentiation, Viral protein interaction with cytokine and cytokine receptor 💬 | 1件: 46 46 💬 |
2710 | Tocilizumab Injection 8mg/kg | 1件: Tocilizumab Tocilizumab | 1件: Tocilizumab
Tocilizumab
💬 | 1件: IL6R IL6R 💬 | 12件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, EGFR tyrosine kinase inhibitor resistance, HIF-1 signaling pathway, Hematopoietic cell lineage, Human cytomegalovirus infection, JAK-STAT signaling pathway, Non-alcoholic fatty liver disease, PI3K-Akt signaling pathway, Pathways in cancer, Th17 cell differentiation, Viral protein interaction with cytokine and cytokine receptor 💬 | 1件: 46 46 💬 |
2711 | Tocilizumab SC 162 mg/0.9 ml disposable auto-injector (AI) | 1件: Tocilizumab Tocilizumab | 1件: Tocilizumab
Tocilizumab
💬 | 1件: IL6R IL6R 💬 | 12件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, EGFR tyrosine kinase inhibitor resistance, HIF-1 signaling pathway, Hematopoietic cell lineage, Human cytomegalovirus infection, JAK-STAT signaling pathway, Non-alcoholic fatty liver disease, PI3K-Akt signaling pathway, Pathways in cancer, Th17 cell differentiation, Viral protein interaction with cytokine and cytokine receptor 💬 | 1件: 46 46 💬 |
2712 | Tocilizumab SC 162 mg/0.9 ml pre-filled syringe with safety device (PFS) | 1件: Tocilizumab Tocilizumab | 1件: Tocilizumab
Tocilizumab
💬 | 1件: IL6R IL6R 💬 | 12件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, EGFR tyrosine kinase inhibitor resistance, HIF-1 signaling pathway, Hematopoietic cell lineage, Human cytomegalovirus infection, JAK-STAT signaling pathway, Non-alcoholic fatty liver disease, PI3K-Akt signaling pathway, Pathways in cancer, Th17 cell differentiation, Viral protein interaction with cytokine and cytokine receptor 💬 | 1件: 46 46 💬 |
2713 | Tocilizumab SC 162 mg/0.9 ml prefilled syringe with safety device (PFS) | 1件: Tocilizumab Tocilizumab | 1件: Tocilizumab
Tocilizumab
💬 | 1件: IL6R IL6R 💬 | 12件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, EGFR tyrosine kinase inhibitor resistance, HIF-1 signaling pathway, Hematopoietic cell lineage, Human cytomegalovirus infection, JAK-STAT signaling pathway, Non-alcoholic fatty liver disease, PI3K-Akt signaling pathway, Pathways in cancer, Th17 cell differentiation, Viral protein interaction with cytokine and cytokine receptor 💬 | 1件: 51 51 💬 |
2714 | Tofacitinib (CP-690,550) | 1件: Tofacitinib Tofacitinib | 1件: Tofacitinib
Tofacitinib
💬 | 4件: JAK1 JAK1, JAK2, JAK3, TYK2 💬 | 37件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, Chemical carcinogenesis - receptor activation, Chemokine signaling pathway, Cholinergic synapse, Coronavirus disease - COVID-19, EGFR tyrosine kinase inhibitor resistance, Epstein-Barr virus infection, Growth hormone synthesis, secretion and action, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Lipid and atherosclerosis, Measles, NOD-like receptor signaling pathway, Necroptosis, Non-small cell lung cancer, Osteoclast differentiation, PD-L1 expression and PD-1 checkpoint pathway in cancer, PI3K-Akt signaling pathway, Pancreatic cancer, Pathways in cancer, Primary immunodeficiency, Prolactin signaling pathway, Signaling pathways regulating pluripotency of stem cells, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toxoplasmosis, Tuberculosis, Viral carcinogenesis 💬 | 1件: 96 96 💬 |
2715 | TOFACITINIB CITRATE CP-690550 | 1件: Tofacitinib Tofacitinib | 1件: Tofacitinib
Tofacitinib
💬 | 4件: JAK1 JAK1, JAK2, JAK3, TYK2 💬 | 37件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, Chemical carcinogenesis - receptor activation, Chemokine signaling pathway, Cholinergic synapse, Coronavirus disease - COVID-19, EGFR tyrosine kinase inhibitor resistance, Epstein-Barr virus infection, Growth hormone synthesis, secretion and action, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Lipid and atherosclerosis, Measles, NOD-like receptor signaling pathway, Necroptosis, Non-small cell lung cancer, Osteoclast differentiation, PD-L1 expression and PD-1 checkpoint pathway in cancer, PI3K-Akt signaling pathway, Pancreatic cancer, Pathways in cancer, Primary immunodeficiency, Prolactin signaling pathway, Signaling pathways regulating pluripotency of stem cells, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toxoplasmosis, Tuberculosis, Viral carcinogenesis 💬 | 1件: 46 46 💬 |
2716 | Tolebrutinib 60mg | - | - | - | - | 1件: 13 13 💬 |
2717 | TOLVAPTAN (OPC-41061) | 1件: Tolvaptan Tolvaptan | 1件: Tolvaptan
Tolvaptan
💬 | 1件: AVPR2 AVPR2 💬 | 3件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Phospholipase D signaling pathway, Vasopressin-regulated water reabsorption 💬 | 1件: 67 67 💬 |
2718 | TOLVAPTAN 45/15 | 1件: Tolvaptan Tolvaptan | 1件: Tolvaptan
Tolvaptan
💬 | 1件: AVPR2 AVPR2 💬 | 3件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Phospholipase D signaling pathway, Vasopressin-regulated water reabsorption 💬 | 1件: 67 67 💬 |
2719 | TOLVAPTAN 60/30 | 1件: Tolvaptan Tolvaptan | 1件: Tolvaptan
Tolvaptan
💬 | 1件: AVPR2 AVPR2 💬 | 3件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Phospholipase D signaling pathway, Vasopressin-regulated water reabsorption 💬 | 1件: 67 67 💬 |
2720 | Tominersen 60 mg | - | - | - | - | 1件: 8 8 💬 |
2721 | Topical 0.1% Sirolimus | 1件: Sirolimus Sirolimus | 1件: Sirolimus
Sirolimus
💬 | 1件: MTOR MTOR 💬 | 51件: AMPK signaling pathway AMPK signaling pathway, Acute myeloid leukemia, Adipocytokine signaling pathway, Alzheimer disease, Amyotrophic lateral sclerosis, Apelin signaling pathway, Autophagy - animal, Autophagy - other, Breast cancer, Cellular senescence, Central carbon metabolism in cancer, Chemical carcinogenesis - receptor activation, Choline metabolism in cancer, Colorectal cancer, Diabetic cardiomyopathy, EGFR tyrosine kinase inhibitor resistance, Endocrine resistance, ErbB signaling pathway, Gastric cancer, Glioma, Growth hormone synthesis, secretion and action, HIF-1 signaling pathway, Hepatocellular carcinoma, Herpes simplex virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Huntington disease, Insulin resistance, Insulin signaling pathway, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Longevity regulating pathway, Longevity regulating pathway - multiple species, MicroRNAs in cancer, Neutrophil extracellular trap formation, PD-L1 expression and PD-1 checkpoint pathway in cancer, PI3K-Akt signaling pathway, Pancreatic cancer, Pathways in cancer, Pathways of neurodegeneration - multiple diseases, Phospholipase D signaling pathway, Prostate cancer, Proteoglycans in cancer, Shigellosis, Spinocerebellar ataxia, Th17 cell differentiation, Thermogenesis, Thyroid hormone signaling pathway, Type II diabetes mellitus, mTOR signaling pathway 💬 | 1件: 278 278 💬 |
2722 | Topical AmphiMatrix with nitroglycerin (MQX-503) | 1件: Nitroglycerin Nitroglycerin | 1件: Nitroglycerin
Nitroglycerin
💬 | - | - | 1件: 51 51 💬 |
2723 | Topical BPM31510 3.0% Cream | - | - | - | - | 1件: 36 36 💬 |
2724 | Topical calcipotriene 0.005% ointment | 1件: Calcipotriol Calcipotriol | 1件: Calcipotriene
Calcipotriene
💬 | 1件: VDR VDR 💬 | 5件: Chemical carcinogenesis - receptor activation Chemical carcinogenesis - receptor activation, Endocrine and other factor-regulated calcium reabsorption, Mineral absorption, Parathyroid hormone synthesis, secretion and action, Tuberculosis 💬 | 1件: 51 51 💬 |
2725 | Topical organogel with nitroglycerin | 1件: Nitroglycerin Nitroglycerin | 1件: Nitroglycerin
Nitroglycerin
💬 | - | - | 1件: 51 51 💬 |
2726 | Tozadenant (SYN115) 60 mg BID | 1件: Tozadenant Tozadenant | 1件: Tozadenant
Tozadenant
💬 | 1件: ADORA2A ADORA2A 💬 | 7件: Alcoholism Alcoholism, Calcium signaling pathway, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, Vascular smooth muscle contraction, cAMP signaling pathway 💬 | 1件: 6 6 💬 |
2727 | TPI-287 6.3 mg/m2 | 1件: TPI-287 TPI-287 | - | - | - | 2件: 5 5, 7 💬 |
2728 | TPN-101, 400 mg/day | - | - | - | - | 2件: 2 2, 127 💬 |
2729 | TRACLEER 62,5 mg comprimidos recubiertos con película | 1件: Bosentan Bosentan | 2件: Bosentan
Bosentan
,
Bosentan
💬 | 2件: EDNRA EDNRA, EDNRB 💬 | 9件: Calcium signaling pathway Calcium signaling pathway, Melanogenesis, Neuroactive ligand-receptor interaction, Pathways in cancer, Relaxin signaling pathway, Renin secretion, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway 💬 | 1件: 86 86 💬 |
2730 | TRACLEER 62,5MG 56CPR RIV. | 1件: Bosentan Bosentan | 2件: Bosentan
Bosentan
,
Bosentan
💬 | 2件: EDNRA EDNRA, EDNRB 💬 | 9件: Calcium signaling pathway Calcium signaling pathway, Melanogenesis, Neuroactive ligand-receptor interaction, Pathways in cancer, Relaxin signaling pathway, Renin secretion, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway 💬 | 1件: 86 86 💬 |
2731 | Trade name depends on the source of the product | - | - | - | - | 1件: 76 76 💬 |
2732 | Trade name depends on the source of the product’ | - | - | - | - | 1件: 76 76 💬 |
2733 | Trade Name Xarelto | 1件: Rivaroxaban Rivaroxaban | 1件: Rivaroxaban
Rivaroxaban
💬 | 1件: F10 F10 💬 | 1件: Complement and coagulation cascades Complement and coagulation cascades 💬 | 1件: 49 49 💬 |
2734 | Trametinib (0.5 mg) | 1件: Trametinib Trametinib | 1件: Trametinib
Trametinib
💬 | 2件: MAP2K1 MAP2K1, MAP2K2 💬 | 89件: Acute myeloid leukemia Acute myeloid leukemia, Alcoholism, Alzheimer disease, Apelin signaling pathway, Apoptosis, Autophagy - animal, B cell receptor signaling pathway, Bladder cancer, Breast cancer, Cellular senescence, Central carbon metabolism in cancer, Chemical carcinogenesis - reactive oxygen species, Chemical carcinogenesis - receptor activation, Chemokine signaling pathway, Choline metabolism in cancer, Cholinergic synapse, Chronic myeloid leukemia, Colorectal cancer, Cushing syndrome, EGFR tyrosine kinase inhibitor resistance, Endocrine resistance, Endometrial cancer, ErbB signaling pathway, Estrogen signaling pathway, Fc epsilon RI signaling pathway, Fc gamma R-mediated phagocytosis, Focal adhesion, FoxO signaling pathway, Gap junction, Gastric cancer, Glioma, GnRH secretion, GnRH signaling pathway, Growth hormone synthesis, secretion and action, HIF-1 signaling pathway, Hepatitis B, Hepatitis C, Hepatocellular carcinoma, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Influenza A, Insulin signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Long-term depression, Long-term potentiation, MAPK signaling pathway, Melanogenesis, Melanoma, MicroRNAs in cancer, Natural killer cell mediated cytotoxicity, Neurotrophin signaling pathway, Neutrophil extracellular trap formation, Non-small cell lung cancer, Oocyte meiosis, Osteoclast differentiation, Oxytocin signaling pathway, PD-L1 expression and PD-1 checkpoint pathway in cancer, PI3K-Akt signaling pathway, Pancreatic cancer, Parathyroid hormone synthesis, secretion and action, Pathways in cancer, Pathways of neurodegeneration - multiple diseases, Phospholipase D signaling pathway, Progesterone-mediated oocyte maturation, Prolactin signaling pathway, Prostate cancer, Proteoglycans in cancer, Rap1 signaling pathway, Ras signaling pathway, Regulation of actin cytoskeleton, Relaxin signaling pathway, Renal cell carcinoma, Salmonella infection, Serotonergic synapse, Signaling pathways regulating pluripotency of stem cells, Sphingolipid signaling pathway, T cell receptor signaling pathway, TNF signaling pathway, Thyroid cancer, Thyroid hormone signaling pathway, Toll-like receptor signaling pathway, VEGF signaling pathway, Vascular smooth muscle contraction, Yersinia infection, cAMP signaling pathway, cGMP-PKG signaling pathway, mTOR signaling pathway 💬 | 1件: 2 2 💬 |
2735 | TransCon hGH (ACP-011) | - | - | - | - | 1件: 78 78 💬 |
2736 | TransCon hGH (ACP-011) - 12,1mg | - | - | - | - | 1件: 78 78 💬 |
2737 | TransCon hGH (ACP-011) - 12.1mg | - | - | - | - | 1件: 78 78 💬 |
2738 | TransCon hGH (ACP-011) - 24.2mg | - | - | - | - | 1件: 78 78 💬 |
2739 | TransCon hGH CT-301 (ACP-011) - 12,1mg | - | - | - | - | 1件: 78 78 💬 |
2740 | Transdermal flumazenil (Added 4/2020) | 1件: Flumazenil Flumazenil | 1件: Flumazenil
Flumazenil
💬 | 16件: GABRA1 GABRA1, GABRA2, GABRA3, GABRA4, GABRA5, GABRA6, GABRB1, GABRB2, GABRB3, GABRD, GABRE, GABRG1, GABRG2, GABRG3, GABRP, GABRQ 💬 | 7件: GABAergic synapse GABAergic synapse, Morphine addiction, Neuroactive ligand-receptor interaction, Nicotine addiction, Retrograde endocannabinoid signaling, Serotonergic synapse, Taste transduction 💬 | 1件: 6 6 💬 |
2741 | Transdermal nicotine | 1件: Nicotine Nicotine | 1件: Nicotine
Nicotine
💬 | 16件: CHRNA1 CHRNA1, CHRNA10, CHRNA2, CHRNA3, CHRNA4, CHRNA5, CHRNA6, CHRNA7, CHRNA9, CHRNB1, CHRNB2, CHRNB3, CHRNB4, CHRND, CHRNE, CHRNG 💬 | 8件: Alzheimer disease Alzheimer disease, Calcium signaling pathway, Chemical carcinogenesis - receptor activation, Cholinergic synapse, Neuroactive ligand-receptor interaction, Nicotine addiction, Pathways of neurodegeneration - multiple diseases, Virion - Lyssavirus 💬 | 1件: 6 6 💬 |
2742 | Treatment Phase Group 4 | - | - | - | - | 1件: 113 113 💬 |
2743 | Treatment with polyethylene glycol (Macrogol 4000) | 1件: Polyethylene glycol Polyethylene glycol | 1件: Polyethylene glycol 3350
Polyethylene glycol 3350
💬 | - | - | 1件: 299 299 💬 |
2744 | Treprostinil, UT-15, LRX-15, 15AU81, BW A15AU, U-62, 840 | 1件: Treprostinil Treprostinil | 1件: Treprostinil
Treprostinil
💬 | 1件: PTGIR PTGIR 💬 | 3件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Platelet activation, Vascular smooth muscle contraction 💬 | 1件: 86 86 💬 |
2745 | Triam 40 mg Lichtenstein | - | - | - | - | 1件: 46 46 💬 |
2746 | Triamcinolone 40 milligrams (Kenacort, Bristol Myers Squip) | 1件: Triamcinolone Triamcinolone | 1件: Triamcinolone
Triamcinolone
💬 | 1件: NR3C1 NR3C1 💬 | 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 1件: 46 46 💬 |
2747 | Triamcinolone Acetonide and normal saline solution | 1件: Triamcinolone Triamcinolone | 1件: Triamcinolone
Triamcinolone
💬 | 1件: NR3C1 NR3C1 💬 | 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 1件: 70 70 💬 |
2748 | TRU-015 | 1件: TRU-015 TRU-015 | - | - | - | 3件: 46 46, 49, 222 💬 |
2749 | Trulicity 0,75 mg injekcný roztok naplnený v injekcnom pere | 1件: Dulaglutide Dulaglutide | 1件: Dulaglutide
Dulaglutide
💬 | 1件: GLP1R GLP1R 💬 | 3件: Insulin secretion Insulin secretion, Neuroactive ligand-receptor interaction, cAMP signaling pathway 💬 | 1件: 13 13 💬 |
2750 | Trulicity 0,75 mg injekcný roztok naplnený v injekcnom pere. | 1件: Dulaglutide Dulaglutide | 1件: Dulaglutide
Dulaglutide
💬 | 1件: GLP1R GLP1R 💬 | 3件: Insulin secretion Insulin secretion, Neuroactive ligand-receptor interaction, cAMP signaling pathway 💬 | 1件: 13 13 💬 |
2751 | Tumor Necrosis Factor Inhibitor (etanercept, infliximab, adalimumab, and golimumab) | 4件: Adalimumab Adalimumab, Etanercept, Golimumab, Infliximab | 4件: Etanercept
Etanercept
,
Adalimumab
,
Infliximab
,
Golimumab
💬 | 2件: LTA LTA, TNF 💬 | 67件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Dilated cardiomyopathy, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease, Osteoclast differentiation, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway 💬 | 1件: 46 46 💬 |
2752 | Tumor Necrosis Factor Inhibitors | - | - | - | - | 1件: 46 46 💬 |
2753 | TV-4710 | - | - | - | - | 1件: 49 49 💬 |
2754 | TVP-1012 0.5mg | - | - | - | - | 1件: 6 6 💬 |
2755 | Twice-daily dosage with 0.5% cyclosporine-A eyedrops | 1件: Cyclosporine Cyclosporine | 1件: Cyclosporine
Cyclosporine
💬 | 5件: PPP3CA PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 💬 | 33件: Alzheimer disease Alzheimer disease, Amphetamine addiction, Amyotrophic lateral sclerosis, Axon guidance, B cell receptor signaling pathway, C-type lectin receptor signaling pathway, Calcium signaling pathway, Cellular senescence, Dopaminergic synapse, Glucagon signaling pathway, Glutamatergic synapse, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Lipid and atherosclerosis, Long-term potentiation, MAPK signaling pathway, Natural killer cell mediated cytotoxicity, Oocyte meiosis, Osteoclast differentiation, Oxytocin signaling pathway, PD-L1 expression and PD-1 checkpoint pathway in cancer, Pathways of neurodegeneration - multiple diseases, Prion disease, Renin secretion, T cell receptor signaling pathway, Th1 and Th2 cell differentiation, Th17 cell differentiation, Tuberculosis, VEGF signaling pathway, Wnt signaling pathway, cGMP-PKG signaling pathway 💬 | 1件: 90 90 💬 |
2756 | TY-0305 | - | - | - | - | 1件: 58 58 💬 |
2757 | TYSABRI 300 mg concentrado para solución para perfusión | 1件: Natalizumab Natalizumab | 1件: Natalizumab
Natalizumab
💬 | 1件: ITGA4 ITGA4 💬 | 14件: Arrhythmogenic right ventricular cardiomyopathy Arrhythmogenic right ventricular cardiomyopathy, Cell adhesion molecules, Dilated cardiomyopathy, ECM-receptor interaction, Focal adhesion, Hematopoietic cell lineage, Human papillomavirus infection, Hypertrophic cardiomyopathy, Intestinal immune network for IgA production, Leishmaniasis, Leukocyte transendothelial migration, PI3K-Akt signaling pathway, Regulation of actin cytoskeleton, Yersinia infection 💬 | 1件: 13 13 💬 |
2758 | Tysabri ® (Natalizumab) | 1件: Natalizumab Natalizumab | 1件: Natalizumab
Natalizumab
💬 | 1件: ITGA4 ITGA4 💬 | 14件: Arrhythmogenic right ventricular cardiomyopathy Arrhythmogenic right ventricular cardiomyopathy, Cell adhesion molecules, Dilated cardiomyopathy, ECM-receptor interaction, Focal adhesion, Hematopoietic cell lineage, Human papillomavirus infection, Hypertrophic cardiomyopathy, Intestinal immune network for IgA production, Leishmaniasis, Leukocyte transendothelial migration, PI3K-Akt signaling pathway, Regulation of actin cytoskeleton, Yersinia infection 💬 | 1件: 13 13 💬 |
2759 | Tysabri® (natalizumab) | 1件: Natalizumab Natalizumab | 1件: Natalizumab
Natalizumab
💬 | 1件: ITGA4 ITGA4 💬 | 14件: Arrhythmogenic right ventricular cardiomyopathy Arrhythmogenic right ventricular cardiomyopathy, Cell adhesion molecules, Dilated cardiomyopathy, ECM-receptor interaction, Focal adhesion, Hematopoietic cell lineage, Human papillomavirus infection, Hypertrophic cardiomyopathy, Intestinal immune network for IgA production, Leishmaniasis, Leukocyte transendothelial migration, PI3K-Akt signaling pathway, Regulation of actin cytoskeleton, Yersinia infection 💬 | 1件: 13 13 💬 |
2760 | UF-021 | - | - | - | - | 1件: 90 90 💬 |
2761 | UF-021 (isopropyl unoprostone) | 1件: Unoprostone Unoprostone | 1件: Unoprostone
Unoprostone
💬 | 1件: PTGFR PTGFR 💬 | 3件: Calcium signaling pathway Calcium signaling pathway, Neuroactive ligand-receptor interaction, Phospholipase D signaling pathway 💬 | 1件: 90 90 💬 |
2762 | UF-021(isopropyl unoprostone) | 1件: Unoprostone Unoprostone | 1件: Unoprostone
Unoprostone
💬 | 1件: PTGFR PTGFR 💬 | 3件: Calcium signaling pathway Calcium signaling pathway, Neuroactive ligand-receptor interaction, Phospholipase D signaling pathway 💬 | 1件: 90 90 💬 |
2763 | UK 092480 | - | - | - | - | 1件: 86 86 💬 |
2764 | UK-427,857 | - | - | - | - | 1件: 46 46 💬 |
2765 | UK-92,480 | - | - | - | - | 1件: 86 86 💬 |
2766 | UK-92,480-10 | - | - | - | - | 1件: 86 86 💬 |
2767 | Ultrasound-guided Suprascapular Nerve Block | - | - | - | - | 1件: 149 149 💬 |
2768 | UN-ALPHA-R 0.25µg | - | - | - | - | 1件: 235 235 💬 |
2769 | Unconjugated Isoflavones 100 (PTI G-4660, 87% Genistein) | 1件: Genistein Genistein | 1件: Genistein
Genistein
💬 | - | - | 1件: 299 299 💬 |
2770 | Upadacitinib (ABT-494) | 1件: Upadacitinib Upadacitinib | 1件: Upadacitinib
Upadacitinib
💬 | 1件: JAK1 JAK1 💬 | 27件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, EGFR tyrosine kinase inhibitor resistance, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Measles, NOD-like receptor signaling pathway, Necroptosis, Osteoclast differentiation, PD-L1 expression and PD-1 checkpoint pathway in cancer, PI3K-Akt signaling pathway, Pancreatic cancer, Pathways in cancer, Signaling pathways regulating pluripotency of stem cells, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toxoplasmosis, Tuberculosis, Viral carcinogenesis 💬 | 1件: 97 97 💬 |
2771 | Updacitinib (ABT-494) | - | - | - | - | 1件: 97 97 💬 |
2772 | Urbason 40 mg | - | - | - | - | 1件: 13 13 💬 |
2773 | URBASON 40 mg comprimidos | - | - | - | - | 1件: 13 13 💬 |
2774 | Ustekinumab (approximately 6 mg/kg) | 1件: Ustekinumab Ustekinumab | 1件: Ustekinumab
Ustekinumab
💬 | 3件: IL12A IL12A, IL12B, IL23A 💬 | 28件: African trypanosomiasis African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Amoebiasis, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Herpes simplex virus 1 infection, Inflammatory bowel disease, Influenza A, JAK-STAT signaling pathway, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, Malaria, Measles, Pathways in cancer, Pertussis, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus 💬 | 1件: 49 49 💬 |
2775 | Ustekinumab 4.5 mg/kg | 1件: Ustekinumab Ustekinumab | 1件: Ustekinumab
Ustekinumab
💬 | 3件: IL12A IL12A, IL12B, IL23A 💬 | 28件: African trypanosomiasis African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Amoebiasis, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Herpes simplex virus 1 infection, Inflammatory bowel disease, Influenza A, JAK-STAT signaling pathway, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, Malaria, Measles, Pathways in cancer, Pertussis, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus 💬 | 1件: 96 96 💬 |
2776 | Ustekinumab 45 mg | 1件: Ustekinumab Ustekinumab | 1件: Ustekinumab
Ustekinumab
💬 | 3件: IL12A IL12A, IL12B, IL23A 💬 | 28件: African trypanosomiasis African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Amoebiasis, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Herpes simplex virus 1 infection, Inflammatory bowel disease, Influenza A, JAK-STAT signaling pathway, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, Malaria, Measles, Pathways in cancer, Pertussis, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus 💬 | 1件: 93 93 💬 |
2777 | Ustekinumab 6 mg/kg (IP) | 1件: Ustekinumab Ustekinumab | 1件: Ustekinumab
Ustekinumab
💬 | 3件: IL12A IL12A, IL12B, IL23A 💬 | 28件: African trypanosomiasis African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Amoebiasis, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Herpes simplex virus 1 infection, Inflammatory bowel disease, Influenza A, JAK-STAT signaling pathway, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, Malaria, Measles, Pathways in cancer, Pertussis, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus 💬 | 1件: 96 96 💬 |
2778 | Ustekinumab approximately 6 mg/kg (IV) | 1件: Ustekinumab Ustekinumab | 1件: Ustekinumab
Ustekinumab
💬 | 3件: IL12A IL12A, IL12B, IL23A 💬 | 28件: African trypanosomiasis African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Amoebiasis, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Herpes simplex virus 1 infection, Inflammatory bowel disease, Influenza A, JAK-STAT signaling pathway, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, Malaria, Measles, Pathways in cancer, Pertussis, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus 💬 | 1件: 96 96 💬 |
2779 | Ustekinumab IV - Nonresponder - Ustekinumab 90mg SC (MP) | 1件: Ustekinumab Ustekinumab | 1件: Ustekinumab
Ustekinumab
💬 | 3件: IL12A IL12A, IL12B, IL23A 💬 | 28件: African trypanosomiasis African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Amoebiasis, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Herpes simplex virus 1 infection, Inflammatory bowel disease, Influenza A, JAK-STAT signaling pathway, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, Malaria, Measles, Pathways in cancer, Pertussis, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus 💬 | 1件: 96 96 💬 |
2780 | UT-15C 0.25 mg | - | - | - | - | 1件: 86 86 💬 |
2781 | UVEDOSE 100 000 UI | - | - | - | - | 1件: 13 13 💬 |
2782 | UVEDOSE 100 000 UI, solution buvable en ampoule | - | - | - | - | 1件: 13 13 💬 |
2783 | UX701 (1.0 × 10^13 genome copies/kg) | - | - | - | - | 1件: 171 171 💬 |
2784 | UX701 (2.0 × 10^13 genome copies/kg) | - | - | - | - | 1件: 171 171 💬 |
2785 | UX701 (5.0 × 10^12 genome copies/kg) | - | - | - | - | 1件: 171 171 💬 |
2786 | Vamorolone 0.25 mg/day/day | 1件: Vamorolone Vamorolone | 1件: Vamorolone
Vamorolone
💬 | 1件: NR3C1 NR3C1 💬 | 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 1件: 113 113 💬 |
2787 | Vamorolone 0.25 mg/kg/day | 1件: Vamorolone Vamorolone | 1件: Vamorolone
Vamorolone
💬 | 1件: NR3C1 NR3C1 💬 | 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 1件: 113 113 💬 |
2788 | Vamorolone 0.75 mg/day/day | 1件: Vamorolone Vamorolone | 1件: Vamorolone
Vamorolone
💬 | 1件: NR3C1 NR3C1 💬 | 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 1件: 113 113 💬 |
2789 | Vamorolone 0.75 mg/kg/day | 1件: Vamorolone Vamorolone | 1件: Vamorolone
Vamorolone
💬 | 1件: NR3C1 NR3C1 💬 | 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 1件: 113 113 💬 |
2790 | Vamorolone 2.0 mg/day/day | 1件: Vamorolone Vamorolone | 1件: Vamorolone
Vamorolone
💬 | 1件: NR3C1 NR3C1 💬 | 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 1件: 113 113 💬 |
2791 | Vamorolone 2.0 mg/kg/day | 1件: Vamorolone Vamorolone | 1件: Vamorolone
Vamorolone
💬 | 1件: NR3C1 NR3C1 💬 | 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 1件: 113 113 💬 |
2792 | Vamorolone 4% suspension for oral dosing | 1件: Vamorolone Vamorolone | 1件: Vamorolone
Vamorolone
💬 | 1件: NR3C1 NR3C1 💬 | 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 1件: 97 97 💬 |
2793 | Vamorolone 6.0 mg/day/day | 1件: Vamorolone Vamorolone | 1件: Vamorolone
Vamorolone
💬 | 1件: NR3C1 NR3C1 💬 | 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 1件: 113 113 💬 |
2794 | Vamorolone 6.0 mg/kg/day | 1件: Vamorolone Vamorolone | 1件: Vamorolone
Vamorolone
💬 | 1件: NR3C1 NR3C1 💬 | 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 1件: 113 113 💬 |
2795 | Varenicline Nasal Spray | 1件: Varenicline Varenicline | 1件: Varenicline
Varenicline
💬 | 2件: CHRNA4 CHRNA4, CHRNB2 💬 | 4件: Chemical carcinogenesis - receptor activation Chemical carcinogenesis - receptor activation, Cholinergic synapse, Neuroactive ligand-receptor interaction, Nicotine addiction 💬 | 1件: 53 53 💬 |
2796 | Vedolizumab-800CW | 1件: Vedolizumab Vedolizumab | 1件: Vedolizumab
Vedolizumab
💬 | 2件: ITGA4 ITGA4, ITGB7 💬 | 15件: Arrhythmogenic right ventricular cardiomyopathy Arrhythmogenic right ventricular cardiomyopathy, Cell adhesion molecules, Dilated cardiomyopathy, ECM-receptor interaction, Focal adhesion, Hematopoietic cell lineage, Human papillomavirus infection, Hypertrophic cardiomyopathy, Intestinal immune network for IgA production, Leishmaniasis, Leukocyte transendothelial migration, PI3K-Akt signaling pathway, Regulation of actin cytoskeleton, Transcriptional misregulation in cancer, Yersinia infection 💬 | 1件: 96 96 💬 |
2797 | Vehicle (SD-101 0%) | - | - | - | - | 1件: 36 36 💬 |
2798 | Venetoclax Oral Tablet, 400 mg | 1件: Venetoclax Venetoclax | 1件: Venetoclax
Venetoclax
💬 | 1件: BCL2 BCL2 💬 | 43件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adrenergic signaling in cardiomyocytes, Amyotrophic lateral sclerosis, Apoptosis, Apoptosis - multiple species, Autophagy - animal, Chemical carcinogenesis - receptor activation, Cholinergic synapse, Colorectal cancer, EGFR tyrosine kinase inhibitor resistance, Endocrine resistance, Epstein-Barr virus infection, Estrogen signaling pathway, Fluid shear stress and atherosclerosis, Focal adhesion, Gastric cancer, HIF-1 signaling pathway, Hedgehog signaling pathway, Hepatitis B, Herpes simplex virus 1 infection, Human immunodeficiency virus 1 infection, JAK-STAT signaling pathway, Lipid and atherosclerosis, Measles, MicroRNAs in cancer, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Necroptosis, Neurotrophin signaling pathway, PI3K-Akt signaling pathway, Parathyroid hormone synthesis, secretion and action, Pathways in cancer, Pathways of neurodegeneration - multiple diseases, Platinum drug resistance, Prostate cancer, Protein processing in endoplasmic reticulum, Salmonella infection, Shigellosis, Small cell lung cancer, Sphingolipid signaling pathway, Toxoplasmosis, Tuberculosis, p53 signaling pathway 💬 | 1件: 28 28 💬 |
2799 | Ventoline oral solution 0,4mg/ml | - | - | - | - | 1件: 111 111 💬 |
2800 | VEYONDI 650IU powder and solvent for solution for injection | - | - | - | - | 1件: 288 288 💬 |
2801 | VEYVONDI 650IU powder and solvent for solution for injection | 1件: Vonicog alfa Vonicog alfa | 1件: Vonicog alfa
Vonicog alfa
💬 | - | - | 1件: 288 288 💬 |
2802 | VFEND 40 mg/ml powder for oral suspension | 1件: Voriconazole Voriconazole | 1件: Voriconazole
Voriconazole
💬 | - | - | 1件: 299 299 💬 |
2803 | Vigabatrin: Vigabatrin new ST formulation then Sabril® | 1件: Vigabatrin Vigabatrin | 1件: Vigabatrin
Vigabatrin
💬 | 1件: ABAT ABAT 💬 | 7件: Alanine, aspartate and glutamate metabolism Alanine, aspartate and glutamate metabolism, Butanoate metabolism, GABAergic synapse, Metabolic pathways, Propanoate metabolism, Valine, leucine and isoleucine degradation, beta-Alanine metabolism 💬 | 1件: 145 145 💬 |
2804 | Vigantol® Öl 20.000 I.E./ml | - | - | - | - | 1件: 13 13 💬 |
2805 | Viokase 16 (pancrelipase) + Nexium | 2件: Esomeprazole Esomeprazole, Pancrelipase | 2件: Pancrelipase
Pancrelipase
,
Esomeprazole
💬 | 2件: ATP4A ATP4A, ATP4B 💬 | 4件: Collecting duct acid secretion Collecting duct acid secretion, Gastric acid secretion, Metabolic pathways, Oxidative phosphorylation 💬 | 1件: 298 298 💬 |
2806 | Visilizumab (Nuvion) | 1件: Visilizumab Visilizumab | 1件: Visilizumab
Visilizumab
💬 | 3件: CD3D CD3D, CD3E, CD3G 💬 | 11件: Chagas disease Chagas disease, Epstein-Barr virus infection, Hematopoietic cell lineage, Human T-cell leukemia virus 1 infection, Human immunodeficiency virus 1 infection, Measles, PD-L1 expression and PD-1 checkpoint pathway in cancer, Primary immunodeficiency, T cell receptor signaling pathway, Th1 and Th2 cell differentiation, Th17 cell differentiation 💬 | 1件: 97 97 💬 |
2807 | Visilizumab (Nuvion® | 1件: Visilizumab Visilizumab | 1件: Visilizumab
Visilizumab
💬 | 3件: CD3D CD3D, CD3E, CD3G 💬 | 11件: Chagas disease Chagas disease, Epstein-Barr virus infection, Hematopoietic cell lineage, Human T-cell leukemia virus 1 infection, Human immunodeficiency virus 1 infection, Measles, PD-L1 expression and PD-1 checkpoint pathway in cancer, Primary immunodeficiency, T cell receptor signaling pathway, Th1 and Th2 cell differentiation, Th17 cell differentiation 💬 | 1件: 97 97 💬 |
2808 | Vitamin D3 400 IU | 1件: Cholecalciferol Cholecalciferol | 1件: Cholecalciferol
Cholecalciferol
💬 | 1件: VDR VDR 💬 | 5件: Chemical carcinogenesis - receptor activation Chemical carcinogenesis - receptor activation, Endocrine and other factor-regulated calcium reabsorption, Mineral absorption, Parathyroid hormone synthesis, secretion and action, Tuberculosis 💬 | 1件: 49 49 💬 |
2809 | Vitamin D3 4000 UI daily | 1件: Cholecalciferol Cholecalciferol | 1件: Cholecalciferol
Cholecalciferol
💬 | 1件: VDR VDR 💬 | 5件: Chemical carcinogenesis - receptor activation Chemical carcinogenesis - receptor activation, Endocrine and other factor-regulated calcium reabsorption, Mineral absorption, Parathyroid hormone synthesis, secretion and action, Tuberculosis 💬 | 1件: 96 96 💬 |
2810 | Vitamin D3 6000 IU | 1件: Cholecalciferol Cholecalciferol | 1件: Cholecalciferol
Cholecalciferol
💬 | 1件: VDR VDR 💬 | 5件: Chemical carcinogenesis - receptor activation Chemical carcinogenesis - receptor activation, Endocrine and other factor-regulated calcium reabsorption, Mineral absorption, Parathyroid hormone synthesis, secretion and action, Tuberculosis 💬 | 1件: 49 49 💬 |
2811 | Vitamin D3 800 UI/day then 800 UI/day | 1件: Cholecalciferol Cholecalciferol | 1件: Cholecalciferol
Cholecalciferol
💬 | 1件: VDR VDR 💬 | 5件: Chemical carcinogenesis - receptor activation Chemical carcinogenesis - receptor activation, Endocrine and other factor-regulated calcium reabsorption, Mineral absorption, Parathyroid hormone synthesis, secretion and action, Tuberculosis 💬 | 1件: 96 96 💬 |
2812 | Vitamin D3: 3000 or 4000 UI/day then 2,000 UI/day | 1件: Cholecalciferol Cholecalciferol | 1件: Cholecalciferol
Cholecalciferol
💬 | 1件: VDR VDR 💬 | 5件: Chemical carcinogenesis - receptor activation Chemical carcinogenesis - receptor activation, Endocrine and other factor-regulated calcium reabsorption, Mineral absorption, Parathyroid hormone synthesis, secretion and action, Tuberculosis 💬 | 1件: 96 96 💬 |
2813 | Vitamin E 800IU | 1件: Vitamin E Vitamin E | 1件: Vitamin E
Vitamin E
💬 | - | - | 2件: 96 96, 97 💬 |
2814 | VITAMINA D3 KERN PHARMA SOLUCIÓN OLEOSA | - | - | - | - | 1件: 13 13 💬 |
2815 | VOLMAX*30CPR 4MG R.P. | - | - | - | - | 1件: 3 3 💬 |
2816 | VPRIV - 400 U - POLVERE PER SOLUZIONE PER INFUSIONE - USO ENDOVENOSO - FLACONCINO(VETRO) 1 FLACONCINO | 1件: Velaglucerase alfa Velaglucerase alfa | 1件: Velaglucerase alfa
Velaglucerase alfa
💬 | 1件: GBA1 GBA1 💬 | 4件: Lysosome Lysosome, Metabolic pathways, Other glycan degradation, Sphingolipid metabolism 💬 | 1件: 19 19 💬 |
2817 | VPRIV 400 Units powder for solution of infusion | 1件: Velaglucerase alfa Velaglucerase alfa | 1件: Velaglucerase alfa
Velaglucerase alfa
💬 | 1件: GBA1 GBA1 💬 | 4件: Lysosome Lysosome, Metabolic pathways, Other glycan degradation, Sphingolipid metabolism 💬 | 1件: 19 19 💬 |
2818 | VRT-813077 | - | - | - | - | 1件: 299 299 💬 |
2819 | VRT-826809 | - | - | - | - | 1件: 299 299 💬 |
2820 | VRT-893661 | - | - | - | - | 1件: 299 299 💬 |
2821 | VRT-893661 VRT-0893661 | - | - | - | - | 1件: 299 299 💬 |
2822 | VT-001 | - | - | - | - | 1件: 66 66 💬 |
2823 | VTX-801 | - | - | - | - | 1件: 171 171 💬 |
2824 | VTX002 is not biologic | - | - | - | - | 1件: 97 97 💬 |
2825 | VX-440 | - | - | - | - | 1件: 299 299 💬 |
2826 | VX-445 | - | - | - | - | 1件: 299 299 💬 |
2827 | VX-445 / TEZ / IVA | - | - | - | - | 1件: 299 299 💬 |
2828 | VX-445 / TEZ / IVA FDC | - | - | - | - | 1件: 299 299 💬 |
2829 | VX-445 /TEZ/IVA | - | - | - | - | 1件: 299 299 💬 |
2830 | VX-445/TEZ/IVA | - | - | - | - | 1件: 299 299 💬 |
2831 | VX-561 (CTP-656) | - | - | - | - | 1件: 299 299 💬 |
2832 | VX-634 | - | - | - | - | 1件: 231 231 💬 |
2833 | VX-659 | 1件: VX-659 VX-659 | - | - | - | 1件: 299 299 💬 |
2834 | VX-659/ TEZ/IVA | 1件: VX-659 VX-659 | - | - | - | 1件: 299 299 💬 |
2835 | VX-659/TEZ/IVA | 1件: VX-659 VX-659 | - | - | - | 1件: 299 299 💬 |
2836 | VX-659/Tezacaftor/Ivacaftor | 3件: Ivacaftor Ivacaftor, Tezacaftor, VX-659 | 2件: Ivacaftor
Ivacaftor
,
Tezacaftor
💬 | 1件: CFTR CFTR 💬 | 8件: ABC transporters ABC transporters, AMPK signaling pathway, Bile secretion, Gastric acid secretion, Pancreatic secretion, Tight junction, Vibrio cholerae infection, cAMP signaling pathway 💬 | 1件: 299 299 💬 |
2837 | VX-661 | - | - | - | - | 1件: 299 299 💬 |
2838 | VX-661 / VX-770 | - | - | - | - | 1件: 299 299 💬 |
2839 | VX-661 Plus Ivacaftor Combination | 1件: Ivacaftor Ivacaftor | 1件: Ivacaftor
Ivacaftor
💬 | 1件: CFTR CFTR 💬 | 8件: ABC transporters ABC transporters, AMPK signaling pathway, Bile secretion, Gastric acid secretion, Pancreatic secretion, Tight junction, Vibrio cholerae infection, cAMP signaling pathway 💬 | 1件: 299 299 💬 |
2840 | VX-661, VRT-893661 | - | - | - | - | 1件: 299 299 💬 |
2841 | VX-661/Ivacaftor | 1件: Ivacaftor Ivacaftor | 1件: Ivacaftor
Ivacaftor
💬 | 1件: CFTR CFTR 💬 | 8件: ABC transporters ABC transporters, AMPK signaling pathway, Bile secretion, Gastric acid secretion, Pancreatic secretion, Tight junction, Vibrio cholerae infection, cAMP signaling pathway 💬 | 1件: 299 299 💬 |
2842 | VX-661/ivacaftor (VX-770) 100mg/150 mg | 1件: Ivacaftor Ivacaftor | 1件: Ivacaftor
Ivacaftor
💬 | 1件: CFTR CFTR 💬 | 8件: ABC transporters ABC transporters, AMPK signaling pathway, Bile secretion, Gastric acid secretion, Pancreatic secretion, Tight junction, Vibrio cholerae infection, cAMP signaling pathway 💬 | 1件: 299 299 💬 |
2843 | VX-661/ivacaftor 100 mg/ 150 mg | 1件: Ivacaftor Ivacaftor | 1件: Ivacaftor
Ivacaftor
💬 | 1件: CFTR CFTR 💬 | 8件: ABC transporters ABC transporters, AMPK signaling pathway, Bile secretion, Gastric acid secretion, Pancreatic secretion, Tight junction, Vibrio cholerae infection, cAMP signaling pathway 💬 | 1件: 299 299 💬 |
2844 | VX-661/ivacaftor 100mg/150 mg | 1件: Ivacaftor Ivacaftor | 1件: Ivacaftor
Ivacaftor
💬 | 1件: CFTR CFTR 💬 | 8件: ABC transporters ABC transporters, AMPK signaling pathway, Bile secretion, Gastric acid secretion, Pancreatic secretion, Tight junction, Vibrio cholerae infection, cAMP signaling pathway 💬 | 1件: 299 299 💬 |
2845 | VX-661/ivacaftor 100mg/150mg | 1件: Ivacaftor Ivacaftor | 1件: Ivacaftor
Ivacaftor
💬 | 1件: CFTR CFTR 💬 | 8件: ABC transporters ABC transporters, AMPK signaling pathway, Bile secretion, Gastric acid secretion, Pancreatic secretion, Tight junction, Vibrio cholerae infection, cAMP signaling pathway 💬 | 1件: 299 299 💬 |
2846 | VX-661/ivacaftor 50 mg/ 75 mg | 1件: Ivacaftor Ivacaftor | 1件: Ivacaftor
Ivacaftor
💬 | 1件: CFTR CFTR 💬 | 8件: ABC transporters ABC transporters, AMPK signaling pathway, Bile secretion, Gastric acid secretion, Pancreatic secretion, Tight junction, Vibrio cholerae infection, cAMP signaling pathway 💬 | 1件: 299 299 💬 |
2847 | VX-661/VX-770 | - | - | - | - | 1件: 299 299 💬 |
2848 | VX-661/VX-770 (TEZ/IVA) | - | - | - | - | 1件: 299 299 💬 |
2849 | VX-668 | - | - | - | - | 1件: 231 231 💬 |
2850 | VX-770, VRT-8130077 | - | - | - | - | 1件: 299 299 💬 |
2851 | VX-770, VRT-813077 | - | - | - | - | 1件: 299 299 💬 |
2852 | VX-809 | - | - | - | - | 1件: 299 299 💬 |
2853 | VX-809 & VX-770 | - | - | - | - | 1件: 299 299 💬 |
2854 | VX-809 / VX-770 | - | - | - | - | 1件: 299 299 💬 |
2855 | VX-809, VRT-826809 | - | - | - | - | 1件: 299 299 💬 |
2856 | VX-809/VX-770 | - | - | - | - | 1件: 299 299 💬 |
2857 | VX-814 | - | - | - | - | 1件: 231 231 💬 |
2858 | VX-864 | - | - | - | - | 1件: 231 231 💬 |
2859 | VYNT-0126 | - | - | - | - | 1件: 156 156 💬 |
2860 | White chocolate (0% cocoa) | 1件: Cocoa Cocoa | - | - | - | 1件: 6 6 💬 |
2861 | WILATE 450 | 2件: Antihemophilic factor human Antihemophilic factor human, Von Willebrand factor human | - | - | - | 1件: 288 288 💬 |
2862 | WILATE® 450 | 1件: Von Willebrand factor human Von Willebrand factor human | - | - | - | 1件: 288 288 💬 |
2863 | WVE-003 | - | - | - | - | 1件: 8 8 💬 |
2864 | WVE-004 | - | - | - | - | 2件: 2 2, 127 💬 |
2865 | X4P-001 | - | - | - | - | 1件: 65 65 💬 |
2866 | XGEVA - 120 MG - SOLUZIONE INIETTABILE - USO SOTTOCUTANEO - FLACONCINO (VETRO) - 1.7 ML 4 FLACONCINI | 1件: Denosumab Denosumab | 1件: Denosumab
Denosumab
💬 | 1件: TNFSF11 TNFSF11 💬 | 8件: Breast cancer Breast cancer, Chemical carcinogenesis - receptor activation, Cytokine-cytokine receptor interaction, NF-kappa B signaling pathway, Osteoclast differentiation, Parathyroid hormone synthesis, secretion and action, Prolactin signaling pathway, Rheumatoid arthritis 💬 | 1件: 274 274 💬 |
2867 | XmAb5871_1.0MG | - | - | - | - | 1件: 46 46 💬 |
2868 | XmAb5871_10.0MG | - | - | - | - | 1件: 46 46 💬 |
2869 | XmAb5871_3.0MG | - | - | - | - | 1件: 46 46 💬 |
2870 | XOMA 052 | - | - | - | - | 5件: 41 41, 46, 50, 56, 106 💬 |
2871 | YONDELIS 0,25 mg polvo para concentrado para solución para perfusión | 1件: Trabectedin Trabectedin | 1件: Trabectedin
Trabectedin
💬 | - | - | 1件: 159 159 💬 |
2872 | Yondelis 0.25 mg powder for concentrate for solution for infusion. | 1件: Trabectedin Trabectedin | 1件: Trabectedin
Trabectedin
💬 | - | - | 1件: 159 159 💬 |
2873 | YONDELIS 1 mg polvo para concentrado para solución para perfusión | 1件: Trabectedin Trabectedin | 1件: Trabectedin
Trabectedin
💬 | - | - | 1件: 159 159 💬 |
2874 | Zanubrutinib 80 MG | 1件: Zanubrutinib Zanubrutinib | 1件: Zanubrutinib
Zanubrutinib
💬 | 1件: BTK BTK 💬 | 7件: B cell receptor signaling pathway B cell receptor signaling pathway, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, NF-kappa B signaling pathway, Osteoclast differentiation, Platelet activation, Primary immunodeficiency 💬 | 1件: 300 300 💬 |
2875 | ZAVESCA 84CPS 100MG | 1件: Miglustat Miglustat | 1件: Miglustat
Miglustat
💬 | 1件: UGCG UGCG 💬 | 2件: Metabolic pathways Metabolic pathways, Sphingolipid metabolism 💬 | 1件: 19 19 💬 |
2876 | ZD 4522 | - | - | - | - | 1件: 46 46 💬 |
2877 | ZGN-440 | - | - | - | - | 1件: 193 193 💬 |
2878 | ZGN-440 for Injectable Suspension | - | - | - | - | 1件: 193 193 💬 |
2879 | ZGN-440 sterile diluent | - | - | - | - | 1件: 193 193 💬 |
2880 | Zink Natur-Drogeriet | - | - | - | - | 1件: 171 171 💬 |
2881 | ZITHOMAX 40 mg/ml ENFANTS | - | - | - | - | 1件: 299 299 💬 |
2882 | Zoenasa-1:4 | - | - | - | - | 1件: 97 97 💬 |
2883 | Zofran - no intubation | - | - | - | - | 1件: 98 98 💬 |
2884 | Zoledronic Acid Kern Pharma 4 mg/100 mL solution for infusion, generic medicinal product | 1件: Zoledronic acid Zoledronic acid | 2件: Zoledronic acid
Zoledronic acid
,
Zoledronic acid
💬 | 1件: FDPS FDPS 💬 | 4件: Human T-cell leukemia virus 1 infection Human T-cell leukemia virus 1 infection, Influenza A, Metabolic pathways, Terpenoid backbone biosynthesis 💬 | 1件: 274 274 💬 |
2885 | Zoledronic Acid Kern Pharma 4 mg/100 mL solution for infusion, generic medicinal product. | 1件: Zoledronic acid Zoledronic acid | 2件: Zoledronic acid
Zoledronic acid
,
Zoledronic acid
💬 | 1件: FDPS FDPS 💬 | 4件: Human T-cell leukemia virus 1 infection Human T-cell leukemia virus 1 infection, Influenza A, Metabolic pathways, Terpenoid backbone biosynthesis 💬 | 1件: 274 274 💬 |
2886 | Zoledronic Acid Kern Pharma 4 mg/100 mL solution for infusion,generic medicinal product | 1件: Zoledronic acid Zoledronic acid | 2件: Zoledronic acid
Zoledronic acid
,
Zoledronic acid
💬 | 1件: FDPS FDPS 💬 | 4件: Human T-cell leukemia virus 1 infection Human T-cell leukemia virus 1 infection, Influenza A, Metabolic pathways, Terpenoid backbone biosynthesis 💬 | 1件: 274 274 💬 |
2887 | ZX008 - 0.2 mg/kg/day | - | - | - | - | 1件: 140 140 💬 |
2888 | ZX008 - 0.8 mg/kg/day | - | - | - | - | 1件: 140 140 💬 |
2889 | ZX008 0.2 or 0.8 mg/kg/day | - | - | - | - | 1件: 144 144 💬 |
2890 | ZX008 0.2 to 0.8 mg/kg/day | - | - | - | - | 2件: 140 140, 144 💬 |
2891 | ÁCIDO GADOBÉNICO | - | - | - | - | 1件: 96 96 💬 |
2892 | Ácido risedrónico | - | - | - | - | 1件: 274 274 💬 |